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ABSTRACT 
Phenylpropanolamine (PPA), a synthetic sympathomimetic amine, is widely 
used as a nasal decongestant and as an appetite suppressant. Much 
controversy ex i sts regard i ng the eff i cacy of the drug as an anorect i c 
agent, the related adverse reactions caused by the relatively high doses 
required for appetite suppression and the potential of this drug for abuse. 
Whilst numerous studies have been carried out to assess the central and 
cardiovascular safety of PPA and many investigations have been performed 
to evaluate efficacy in terms of weight loss in humans, there is a relative 
paucity of information regarding the effects of PPA on appetite and food 
intake. 
A pilot trial was conducted to determine the feasiblility of a 
multidimensional approach to evaluate the safety and efficacy of PPA as an 
anorect i c agent in humans. Eight normotens i ve caucas i an women who were 
overweight participated in a randomised double-blind cross-over comparison 
of PPA (75 mg) and placebo and were dosed to steady-state on a 12-hour 
fixed-dose schedule for a period of eleven weeks. Aspects of efficacy 
evaluated included the effects of PPA on hunger, appetite and satiety, 
salivation, macro-nutrient food intake and body weight. Standardised scales 
were used to quantitatively assess the possible subjective mood and 
behavioural reinforcing effects of PPA. Supine systolic and diastolic blood 
pressures were monitored continually throughout the trial. 
I n add it; on, peak and trough blood samp 1 es were taken to mon; tor serum 
concentrations of PPA reached at steady-state and patient compliance with 
xiv 
the dosing schedule. An adaptation of a published reverse-phase high-
performance liquid chromatographic (HPLC) assay for PPA in serum using U.V. 
detection at 210 nm is presented. 
A significant decrease in body weight, salivation, total food intake and 
carbohydrate consl1mption was demonstrated following PPA administration. 
Phenylpropanolamine produced significant decrements in subjective reports 
of hunger and appetite, whilst apparently having little effect on satiety. 
No significant changes were observed for blood pressures and PPA did not 
produce significant mood alterations or behavioural reinforcing effects. 
The study demonstrates the feasibility of using this muti-faceted approach, 
with certain design modifications, to evaluate the overall safety and 
efficacy of PPA as an appetite suppressant. 
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CHAPTER 1 
GENERAL INTRODUCTION 
Phenylpropanolamine hydrochloride is a synthetic member of the extensive 
class of sympathomimetic amines and is structurally and pharmacologically 
related to amphetamine and ephedrine. Phenylpropanolamine, however, 
produces similar but not equipotent biochemical and central effects (1). 
Phenylpropanolamine (PPA) ;s widely employed as the active component of 
over-the-counter (OTC) nasal decongestant and appetite suppressant 
preparations. More recently, PPA has begun to emerge in a multitude of 
street-stimulants (2). 
The most frequently reported adverse reaction associated with the use of 
phenylpropanolamine is increased blood pressure but other reactions such 
as psychotic disturbances have also occurred (3). 
1.1 PHYSICO-CHEMICAL PROPERTIES OF PHENYLPROPANOLAMINE 
1.1.1 Description 
Phenylpropanolamine hydrochloride or d7-norephedrine can be named in 
various ways (4): 
(a) ~-{l-aminoethyl)benzenemethanol hydrochloride 
(b) ~-(l-am;noethyl)benzyl alcohol hydrochloride 
(c) (±)-2-amino-phenylpropan-l-ol hydrochloride 
(d) 2-amino-l-phenyl-l-propanol hydrochloride 
(e) ~-hydroxy-~-am;nopropylbenzene hydrochloride 
(f) I-phenyl-2-amino-1-propanol hydrochloride 
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FIGURE 1.1 Chemical structure of phenylpropanolamine hydrochloride 
OH H 
0\ I I -C-C-NH 2,HCl 
- ! I 
H CH3 
MM 187.67 
1.1.2 Synthesis 
Phenylpropanolamine hydrochloride ;s prepared by reacting benzaldehyde in 
95% ethanol in the presence of sodium hydroxide to form a-(l-
nitroethyl)benzyl alcohol with subsequent reduction of this nitro-alcohol 
to the corresponding amino compound. A stream of hydrogen chloride passed 
into a suitable solution of the base yields the hydrochloride (5). 
1.1.3 Physical Properties 
1.1.3.1 Solubi lity 
Phenylpropanolamine hydrochloride is soluble in 2.5 parts of water and in 
9 parts of 95% alcohol and insoluble in chloroform and solvent ether (4). 
1.1.3.2 Specific Rotation 
The specific rotation [a]25D1 of phenylpropanolamine hydrochloride in water 
is 0°(6), 
1.1.3.3 Dissociation Constant 
The pKa of phenylpropanolamine hydrochloride determined potentiometrically 
at 20°C ;s 9.44 ± 0.04 (7). 
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1.1.3.4 Ultraviolet Spectrum 
The ultraviolet spectrum of phenylpropanolamine hydrochloride in methanol 
at a concentration of 1 mg/ml was obtained with a Beckman Acta MVI 
ultraviolet spectrophotometer. The spectrum obtained in methanol is shown 
in Figure 1.2 and depicts shoulders at 267) 248 and 243 nm (8). 
FIGURE 1.2 
210 
Ultraviolet spectrum 
hydrochloride in methanol 
240 ao 
WAYfLE)lOTH. 0", 
laO 
of phenylpropanolamine 
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1.2 STEREOCHEMISTRY OF PHENYLPROPANOLAMINE 
Simplified line drawings of phenylpropanolamine or d, I-norephedrine as it 
is chemically known, reveal that both the ct- and ~-carbon atoms are 
asymmetric or chiral (Figure 1.3). It is clear that around each of these 
carbon atoms four spatial arrangements occur and thus four stereoisomers 
of PPA exist. Evidence of confusion about and a nonchalant approach to the 
distinctions between the isomers of PPA abounds in the literature. In many 
reports, part of this confusion has resulted due to the presumptive, non-
probative nature of urine drug screening tests using immunoassays, which 
depend on a relatively nonspecific antibody. Most of the 
phenylisopropylamines will cross react and a IIpositive ll result may reflect 
the presence of a norephedrine, amphetamine or ephedrine isomer; or even 
similar compounds such as phentermine or diethylpropion (9). 
FIGURE 1.3 Chiral (asymmetrical) carbon atoms 
* = asymmetrical carbons 
A synthetic reaction essentially yields a racemic mixture composed of equal 
parts of the (+) and (-) isomers. Phenylpropanolamine, widely marketed and 
used clinically, consists of a racemic mixture of (+)- and (-)-norephedrine 
enantiomers (Fig 1.4). Isomeric distinction ;s of great importance, as 
enantiomers and diastereomers are not interchangeable and have different 
pharmacodynamic properties and effects (la, 24). 
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Numerous reviews of chiral drug action greatly clarify this issue. Results 
show that (+)-norpseudoephedrine is a potent stimulator of locomotor 
activity, whilst corresponding isomers of PPA produce stimulation only at 
doses approaching the lethal range (11). In other studies, results suggest 
that 7-norephedrine and d, 7-norephedrine are capable of direct activation 
of vasopressor a-adrenoreceptors, while d-norephedrine has a non-
significant effect (12,48). 
FIGURE 1.4 Configurational characteristics of PPA isomers 
CH3 
J 
NH 2-C-H 
J 
OH-C-H 
o A 
L-norepnedrine 
(t)- nor ephedrine 
CH3 I 
NH2-C-H 
J 
H-C-OH 
o c 
o -norpseudoephedrine 
H-norpseudoephedrine 
CH3 
I 
H-C-NH2 
I 
H-C-OH 
A V 
8 
0- norephedrine 
(-)- noreph ed rine 
CH3 I 
H-C-NH2 
I 
OH-C-H 
o o 
L -norpseudoephedrine 
( "')-norps€udoephedrine 
Analytical methods to quantitatively assess norephedrine enantiomers using 
indirect (diastereomers) and direct (chiral staitionary phases) approaches 
have been published (13-16) and several researchers have reported 
norephedrine resolution (17/ 18). A direct enantiomeric high-performance 
liquid chromatographic separation of PPA has recently been reported by 
Wainer et al (19). 
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1.3 PHARMACODYNAMIC PROPERTIES OF PHENYLPROPANOLAMINE 
1.3.1 Mechanism of Pharmacologic Action 
Phenylpropanolamine hydrochloride (PPA.HC1) belongs to the ~-
phenylethylamine class of drugs, called sympathomimetics, whose actions 
closely mimic sympathetic responses. The primary pharmacologic effects of 
sympathomimetics such as phenylpropanolamine are summarised in Table 1.1. 
The main neurotransmitter of the sympathomimetic adrenergic fibres is the 
catecholamine, norepinephrine (NE), the others being epinephrine and 
dopamine. Sympathomimetic amines cross the cell membrane of the adrenergic 
neurones, usua lly through an active transport process. Within the axon 
varicosity, the drug crosses the storage vesicle membrane and displaces NE 
in the intragranular pools which may then act at the adrenoreceptor sites 
of effector cells, undergo enzyme deactivation by catechol-O-
methyl transferase (COMT), or reaccummulate in the cytoplasm of the neuronal 
axon (20). 
Systems 
Central nervous system 
Cardiovascular system 
Metabol ic 
Other 
Effects 
Stimulant (psychomotor, locomotor) 
AnalgesiC 
Drugseeking ("addicting") 
Anorexiant 
Vasoconstriction 
Increased blood pressure, heart rate, cardiac output, etc. 
Arrhythmias 
Hypertensive crisis 
Tachycardia 
Increased basal metabolic rate 
Accelerated blood sugar/carbohydrate metabolism 
Accelerated blood lipids/fat metabolism 
Accelerated gastrointestinal mobility/secretions 
Decreased weight 
Mydiras;s 
Decreased uterine contractility 
TABLE 1.1 Pharmacologic actions of sympathomimetic agents 
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The classic studies of Liebman and Tredelenberg (21) established that PPA 
exerts its sympathomimetic effects via a combination of direct and indirect 
actions with relatively low potency in this respect. Indirectly-acting 
amines typically exhibit tachyphylaxis, that is, a decrease in the 
intensity of drug response as the releasable stores of noradrenaline are 
depleted following repeated administration of the amine (20). 
Phenylpropanolamine is absorbed systemically after oral administration, 
crosses the blood-brain barrier and acts as a central nervous system (eNS) 
stimulant via its sympathomimetic activity (22). This activity is related 
primarily to the blockade of presynaptic neuronal catecholamine uptake, 
increased release of norepinephrine, inhibition of monoamine oxidase and 
stimulation of post-synaptic alpha receptors (23). Phenylpropanolamine has 
a low potency for producing central stimulation and increased locomotor 
activity (9). 
Investigations by Levitt et al (25) showed that PPA causes negligible 
effects on endogenous norepinephrine release, even at toxic doses. In 
contrast, several studies have demonstrated that PPA inhibits re-uptake of 
radio-labelled NE via the high-affinity uptake1 mechanism. There is no 
direct evidence that PPA causes depletion of NE in the adrenergic terminals 
and no studies have tested whether PPA could be taken up into the amine 
storage granules and released as a false transmitter (25). 
Phenylpropanolamine possesses both ct1- and ~l- adrenergic agonist properties 
and as such has been labelled a partial agonist. The alpha effects are 
predominantly vasoconstrictive in nature although urethral and uterine 
smooth muscle are also affected. The beta effects are occasionally seen as 
increased heart rate although tachycardia is seldom noted in humans or 
animals with intact cholinergic mechanisms (26). Published reports lack 
clarity with regard to possible PPA ~2-agonist activity. 
1.3.2 Mechanism of Anorectic Action 
The mechan i sm by wh i ch PPA exerts its anorect i c act ion is uncerta in, 
despite the numerous central and peripheral theories that have been 
proposed. 
8 
It has been established that the anorexic effects of PPA are not mediated 
by ventromedial hypothalamic effects and that local application to the 
lateral hypothalamus selectively suppresses food, but not water intake 
(97). It has been suggested that the anorectic effects of PPA are mediated 
by NE release or by direct noradrenergic effects in the prefornical region 
of the lateral hypothalamus (27). Although this explanation does not seem 
feasible as PPA does not cause significant release of noradrenaline from 
the noradrenergic neurons (31), it has been shown by Cairns et al that PPA 
may produce anorexia via catecholaminergic mechanisms (28). A recent study 
by Wellman (166) suggests that although PPA has weak actions on 
dopaminergic neurons, its anorexic activity, in contrast to that of 
amphetamine, ;s not mediated via a dopaminergic system. 
Phenylpropanolamine may cause weight loss, in part, from an excitatory 
action on brown adipose tissue thermogenesis which is regulated by the 
sympathetic nervous system and stimulated by ~-agonists (29). This 
suggestion is partly supported by the absence of effects of ~-adrenergic 
blockade on PPA-induced thermogenesis (31). Phenylpropanolamine causes a 
dose-dependent release of free fatty acids from adipose tissue in vitro. 
It has been shown that phenylpropanolamine increases the gastric transport 
time in rats and produces a dose-dependent increase in the gastric 
retention of food (30). 
Although numerous animal studies have investigated the effects of PPA on 
blood glucose and glucose utilization, in attempts to determine whether 
PPA's anorexic action is mediated by a possible glucostatic mechanism, no 
consistent data have been produced (31). Altered physiological states may 
influence the effects of PPA. In a study by Resnick et a 7 (32), PPA 
produced greater hypoglycaemic effects in diabetic as compared with control 
rats. Another postulated mechanism of the peripheral effects of PPA is 
conditioned taste aversion, as PPA has been shown to be an aversive 
stimulus when administered to rats on this paradigm (33). 
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1.3.3 Structure-Activity Relationships 
The functional groups attached to a drug can greatly affect its physico-
chemical properties, which can significantly modify both receptor activity 
and distribution to the biophase. 
FIGURE 1.5 Sites of potential structural variance of 
sympathomimetic phenylethylamines 
Phenylpropanolamine contains a two-carbon chain separating the phenyl group 
and the amino nitrogen. Phenylpropanolamine contains no substitution on the 
aromatic 3/4-dihydroxyphenyl ring and therefore exhibits relatively low 
potency as a sympathomimetic amine. The lack of substitution of the 
catechol nucleus increases the oral effectiveness of PPA and renders it 
insens it ive to cat echo l-O-methyl transferase. Non-catecho 1 ami nes can 
manifest both a- and ~-effects, mainly by indirect mechanisms. The methyl 
group attached to the a-carbon of PPA renders it insensitive to oxidation 
by monoamine oxidase (MAO) thus greatly prolonging the duration of action 
of the compound (34). 
Phenylpropanolamine contains no substitution on the amino nitrogen and 
hence has relatively little selectivity for ~-adrenergic activity. Beta-
hydroxyl substitution markedly reduces distribution of PPA in the central 
nervous system, decreases the lipid solubility and increases the polarity. 
For example, the chlorform/water partition coefficients for 
dextroamphetamine, ephedrine and PPA are 146, 0.015 and 0.001, respectively 
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(35). Hydroxyl substitution on the beta-carbon may sometimes be accompanied 
by an enhancement of peripheral a- and ~ -effects. Beta-hydroxyl 
substituted compounds are considered indirect agonists (20, 30), that act 
by enhancing the release of stored catecholamines and/or by inhibiting the 
uptake of catecholamines (37). 
1.4 PHARMACOKINETIC PROPERTIES OF PHENYLPROPANOLAMINE 
1.4.1 Absorption and Distribution 
Following oral ingestion of an aqueous solution of PPA, absorption is 
rapid, being completed in less than 2.5 hours (4, 170). However, absorption 
can be altered by various factors, particularly the presence of absorbents 
such as activated charcoal (38). Phenylpropanolamine, being a weak base, 
will not be readily absorbed from an acidic stomach because of ionization. 
However, in the more a 1 ka 1 i ne stomach, absorpt i on does occur at rates 
determined by the dissociation constant and the lipid solubility of the 
unionized form. Although the pKa of PPA is 9.4, it is almost completely 
absorbed in the small intestine due to the large surface area available for 
absorption (7). 
Phenylpropanolamine is not highly bound to proteins in the blood (4, 10). 
As large differences in pH between the blood and gastric contents exist, 
weak bases such as PPA are, to a small extent, passively concentrated in 
the stomach. PPA is highly distributed in organ tissues with negligible 
body fat localization, as evidenced by its tissue distribution in dogs 2 
hours after administration; kidney> lung> liver> spleen> brain> heart 
> muscle> plasma> fat> cerobrospinal fluid (4). Water soluble forms that 
are metabolically stable, poorly penetrate cellular barriers to reach 
further sites of metabolism, or central sites of action. PPA has been found 
to have an apparent volume of distribution of 300 litres (8). 
1.4.2 Metabolism 
Comparatively little information is available concerning PPA metabolism and 
excretion. The drug is referred to by Axelrod as a II metabolically stable 
entityll (39). Considerable species variation has been reported in the 
metabolism of PPA. In studies with humans, it was found that approximately 
90% of the drug was excreted in urine over a 24 hour period, predominantly 
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unchanged. (40). Sinsheimer et al (41) found that, in humans, 86% of a dose 
of PPA was excreted unchanged with only 4% occuring as transformation 
products, the major biotransformations being parahydroxylation to 4-
hydroxynorephedrine and oxidative side chain deamination to hippuric acid. 
Phenyl propano 1 ami ne is a 1 so metabo 1 i sed by pheny 1 ethano 1 ami ne-N-transferase 
to the corresponding N-methylated metabolite. 
In the rabbit and rat, 80-90% of [14CJ of small oral doses of [14CJ-PPA is 
excreted in the urine within 24 hours, with 1-2% of the dose being detected 
in the faeces. In the rat, 60% occurs as the unchanged drug and 35% as 4-
hydroxynorephedrine. Small amounts of 4-hydroxyhippuric acid and 1,2-
dihydroxy-1-phenylpropane were also detected. In the rabbit, however, 76% 
is excreted as deamination products consisting of 31% 1,2-dihydroxy-1-
phenyl propane, 27% 1-hydroxy-2-oxa-1-phenyl propane and 24% benzo i c ac i d 
(4). Phenylpropanolamine appears as a major metabolite of cathinone (44) 
and as a minor metabolite of amphetamine, methamphetamine (42) and 
ephedrine (43). 
1.4.3 Excretion 
The elimination half-life of PPA.HCl in humans has been reported as 3.9 
hours and the elimination rate constant as 0.18 hr-1 (8, 10, 45, 170). In 
a study with humans under controlled urinary pH conditions, acidification 
of the urine resulted in the excretion of largely unchanged PPA.HCl (46). 
Conversely, basic urine conditions resulted in a lower fraction of 
unionized drug causing extreme tubular reabsorption with little influence 
on metabolism and the renal clearance of PPA decreased by 33.5% (167, 168). 
Phenylpropanolamine is excreted by glomerular filtration (47). 
1.5 USES OF PHENYLPROPANOLAMINE 
Phenylpropanolamine hydrochloride is widely used as an over-the-counter 
(OTC) nasal decongestant and weight control aid and has been the focus of 
continual debate for many years. Independent FDA advisory panels have 
reviewed the clinical evidence of PPA as an OTC drug and found it to be 
safe and effective at appropriate doses in approved formulations (2). 
Numerous clinical studies have been performed that support the conclusions 
of these government reviews (51-61). Nevertheless, much controversy exists 
regarding the safety of PPA (49) and the potential of this drug for abuse 
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( vide infra section 1.6) (50). 
Phenylpropanolamine, first synthesized in 1910 (4), was developed and used 
as an alternative to ephedrine, with significantly fewer side effects, for 
parenteral maintenance of blood pressure in hypotensive patients. However, 
with the advent of more effective pressor medicat ions, PPA has become 
obsolete in this respect. One of the earliest clinical uses of PPA was as 
a nasal decongestant and it is still used in this regard for the treatment 
of colds and sinusitis and for symptomatic relief of allergic conditions 
caused by hayfever, allergic rhinitis, urticaria, angioneurotic oedema and 
bronchospastic conditions accompanying allergic asthma (64, 81, 82). 
Phenylpropanolamine is often used in combination with analgeSics, 
antihistamines, anticholinergics, caffeine, atropine-like drugs and other 
products to reduce the di scomforts of upper respiratory tract symptoms 
(65). PPA is present in numerous solid and liquid oral formulations (66), 
and is administered in doses of 12.5 to 50 mg every 3 to 8 hours. Although 
oral administration may provide a longer duration of action, systemic use 
may be complicated by undesirable sympathomimetic effects such as 
agitation, insomnia, increased blood pressure, blurred vision, nausea and 
epigastric pain, for example (67). Topical nasal solutions and gels 
containing PPA in concentrations of 1% to 3% are also available (fi8). While 
topical application has the advantage of more rapid onset of action, 
prolonged use causes rebound vasodilation or rhinitis medicamentosa, 
thereby limiting the usefulness of this route (69). 
By a direct stimulatory action on the a-adrenoreceptors, PPA causes 
constriction of the microvasculature of the edematous nasal mucosa which 
reduces the blood flow to the tubinates, resulting in shrinkage of the 
swo 11 en mucosa and promot i ng re 1 i ef from nasa 1 stuff i ness (70) . 
Phenylpropanolamine has an anti-allergic effect (76), moderately inhibits 
mucosal secretion (71, 72) and is useful in improving air flow in the nasal 
passages (75). PPA has been used with some success for the symptomatic 
treatment of perennial rhinitis (73, 74). Decongestant-antihistamine 
preparations incorporating PPA to partially counteract the drowsiness 
caused by antihistamines have been found to be efficacious in treating 
nasal congestion frequently accompanying acute otitis media with effusion 
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in children (77). 
Phenylpropanolamine in dosages of 50 mg twice daily seems to be of some use 
in relieving stress during incontinence by stimulating the alpha-
adrenoreceptors at the proximal urethra, resulting in sphincter 
contract i on, increased bladder out 1 et tone and improved bladder storage 
(78, 79, 143). It has been reported that PPA, when administered in 
conjunction with oestrogens, causes a more effective elevation of the 
urethral pressure in elderly women with urinary incontinence (80). 
The usefulness of sympathomimetic agents such as PPA in correcting, at 
least partially, retrograde ejaculation in the presence (82-84) or absence 
(85) of neurogenic dysfunction, has been demonstrated in occassional 
reports. Phenylpropanolamine, in doses of 25-75 mg, has recently been 
indicated to alleviate symptoms in patients with orthostatic hypotension 
after general treatment measures have failed (86). PPA has been reported 
to be of some benefit for adults who suffer from mild or sporadic snoring 
(87) and in combination with paracetamol and phenyltoxamine citrate, may 
be useful in cluster headache (Harton1s Headache) (88). 
In a recent report (89) 1 PPA was found to be beneficial in antagonizing 
several, mainly unwanted, effects of diazepam, without diminishing the 
tranquilizing properties of the anxiolytic. 
Clinically, PPA has been used for over 40 years as an appetite suppressant, 
following the appearance of an article by Hirsch (52), in which he 
concluded that PPA was effective in controlling the appetite of patients 
on an anti-obesity diet. 
The first controlled clinical trial of PPA as an appetite suppressant was 
published by Fazeekas et al in 1959 (90), in which the authors intimated 
that PPA did not possess significant anorexiant potential. However, the 
study was severely critised as the result of several basic flaws in the 
experimental design (91). The critisisms raised included: The study 
population consisted of mentallly deficient individuals whose diets were 
not restricted during the study and who were not necessarily motivated to 
lose weight, and therefore may not be directly indicative of a normal 
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population. The design of the trial was questioned in terms of the "double-
bl indo conditions imposed and because spontaneous weight loss was not 
estimated. In addition, compliance was impossible to verify as some 
patients went home on weekends and blood levels of the drug were not 
monitored. Finally, there appeared to be an interaction between IQ and drug 
effectiveness (2,91). 
Numerous animal studies have demonstrated that PPA significantly reduces 
body weight and food intake (92, 95, 96, 169). In a systematic study using 
rats, Tainter (93) found that PPA caused loss of body weight that was not 
due to changes in energy output or metabolism. However, PPA slowed the rate 
of passage of food through the gastrointestinal tract. Food intake was 
reduced, but after approximately one week, tolerance to PPA developed and 
food intake returned to normal (93). More recently, phenylpropanolamine was 
found by Rosofsky et al (94) to disrupt postprandial satiety in rats as 
evidenced by changes in behavioural sequence. 
Much research has gone into the evaluation of the use of PPA as an appetite 
suppresant. One problem in assessing the efficacy of an anorectic agent is 
quantitation of the response. In numerous studies, weight loss and degree 
of appetite suppresion have been used as measures of anorectic efficacy 
(55-63). However, although weight reduction was the major criterion for 
proving efficacy, very little emphasis was placed on the effects of PPA on 
appetite, and the methods used to monitor appetite except in one study by 
Hoebel et a 1 (62). 
Two reports have appeared in the literature concerning the effects of PPA 
on food intake. Hoebel et al (62,63) reported that subjects taking PPA 
experienced a suppression in liquid food intake and noted a significant 
reduction in supper s ;ze and the total amount of snacks eaten 1 when 
compared to placebo. Recently, Klesges et al (98) reported that PPA (in 
chewing-gum form) caused a significant reduction in total caloric, fat, 
carbohydrate and protein intake from baseline to subsequent weeks following 
a cessation of smoking. 
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Objective assessment of the safety and efficacy of PPA as an appetite 
suppressant has been difficult as clinical trials have not always been 
convincing. Weintraub (99) reviewed a number of PPA clinical trials, 
published and unpublished. His criticisms related primarily to those 
des i gns intended to show eff icacy, and did not cite ev i dence of bias 
regarding safety data. Concerns raised by the author included design 
defects, failure to include a run-in period, inconsistent handling of 
treatment group comparability and IIdrop-outs ll , inclusion criteria, problems 
with ancillary therapy and improper approaches to caloric restriction. 
Several appetite suppressant products are currently available in the United 
States and include traditional dosage forms such as tablets and capsules, 
as well as novel dosage forms such as chewing-gum and breath-mints. Smaller 
dose products are usually contained in immediate release formulations, 
while those containing higher doses are available only as sustained release 
preparations. Recommended daily dosages vary, but none exceed 75 mg. 
As with other medications, some adverse drug reactions attributed to PPA 
may be related to its serum concentration. Pharmaceutical scientists, in 
an attempt to decrease the incidence of concentration-dependent adverse 
reactions have developed an osmotically controlled drug delivery system for 
PPA, called OROS (Osmotic Release Oral System) and this formulation is 
marketed as Acutrim. OROS tablets release medication, following zero order 
kinetics, from a core of active PPA within a semi-permeable membrane. 
Recently, in a controlled clinical trial Acutrim did not produce any 
serious cardiovascular effects and in combination with individual ised 
caloric restriction and physician-managed behaviour modification was found 
to be more effective than placebo in reducing body weight in overweight 
women (59). 
1.6 SIDE EFFECTS OF PHENYLPROPANOLAMINE 
In evaluating reports of adverse drug reactions, it is often difficult to 
identify the contribution of a specific substance, as drug interactions, 
pre-existing disease conditions and the possibility of overdoses may, 
individually or jointly, come into play. In addition, accepting patient 
drug identification without analytical verification of the drug in question 
in body fluids, is fraught with problems. 
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Numerous reports of adverse reactions to products containing PPA have been 
cited in the literature, the most frequently documented reaction being an 
increase in blood pressure. On the basis of chemical structure and 
pharmacologic activity, there is no doubt that PPA in sufficient doses is 
capable of a- and ~ -agonist action, with potential for evoking 
hypertension, tachycardia, headaches, arrhythmias and encephalopathy. 
Hypertensive responses have been reported after ingestion of single doses 
of PPA in previously normotensive subjects (100-102), and in patients with 
special sensitivity to adrenergic pressor agents (103, 104). In a 
controlled clinical trial, patients taking a double dose of PPA experienced 
transient hypertension (105). Tachyphylaxis to the blood pressure elevating 
effects of PPA has been suggested as a possible explanation for the adverse 
reactions occuring after a single dose of this drug (106), There is 
evidence that a strong dose-response relationship exists for PPA's 
hypertensive effect (106-108), as most cases of ad hoc blood pressure 
increases occur following the ingestion of more than 50 mg of PPA (106). 
However, there have been sporadic reports of increased BP after doses lower 
than 50 mg (100). In a recent study by Dowse et al (l09L which detailed 
the effects of 3 different dosages of racemic PPA as single doses on BP in 
normotensive human subjects, it was found that no significant changes in 
BP occured following the 25 mg dose, whereas statistically significant 
increases in BP occured following the 50 and 100 mg doses. However, 
although serum concentrations of PPA increased linearly with increasing 
doses of PPA, the authors concluded that no clear-cut correlation could be 
found between serum concentrations and BP effects. 
The reports by Horowitz et al (103, 107) which detailed elevated BP's and 
adverse reactions emulating eNS stimulation in healthy subjects receiving 
a single dose of Trimolets (an Australian 85 mg IR product) have been 
widely discussed. There appears some confusion regarding whether the active 
ingredient contained in this preparation was PPA or {+)-norspeudoephedrine, 
one of its most centrally active isomers (2). 
Additional evidence suggests that PPA-induced hypertension may result in 
cerebrovascular haemorrhage (lID, Ill), myocardial injury (112) and cardiac 
arrhythmias (113, 114). A number of cases of adverse cardiovascular events 
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have been reported (lIS). While some case reports fail to specify the exact 
dose of PPA consumed, most indicate that patients took overdoses of either 
cough-cold or diet-aid products containing PPA. Three cases of raised blood 
pressure accompanied by elevated levels of serum creatinine kinase and 
cardiac-iso-enzymes associated with myocardial infarction have been 
reported (112). Excessive adrenergic stimulation has been suggested as a 
causative factor in myocardial necrosis (112). 
The increased blood pressure associated with ingestion of therapeutic (116) 
and excessive doses (117, 118) of PPA has been implicated in causing 
cerebrovascular haemorrhage with angiographically defined vasculitis, and 
deaths resulting from these conditions have been ascribed to PPA (114, 116, 
118, 119). Although four published case reports (Ill, 116, 119, 120) have 
cited a relationship between the ingestion of products containing PPA and 
subsequent occurence of stroke related symptoms, the number of cases was 
small and none could confirm any association between PPA and intra-cranial 
haemorrhage. 
Although blood pressure increased significantly following a single 
intravenous dose of PPA (0.44 mg/kg), these increases did not correlate 
with serum concentrations of the drug (121). In controlled repeated-dose 
trials of sustained release (SR) and immediate release (IR) PPA 
formulations, in healthy (53, 60, 61) and hypertensive (55, 122, 131) 
subjects, no clinically significant pressor responses were observed. A 
similar scenario was demonstrated in a one-day dosage regime comparison of 
either 25 mg IR tds or 75 mg SR, in normotensive volunteers (51). However, 
in a similar study by Blackburn et al, a clinically unimportant but 
statistically significant pressor effect occured in the first 6 hours after 
ingestion and was greater in the sustained release group (123). 
Several case reports (124-129, 142) of psychiatric or affective disorders 
related to the ingestion of nasal decongestants, appetite suppressants, or 
1I1ook-alikes ll (vide infra) containing PPA are cited in the literature. 
Symptoms of psychotic episodes include auditory and visual hallucinations, 
confusion, disorientation, delusions, aggression, bizarre and impulsive 
behaviour, mania, paranoia, agitation, anxiety and depression. 
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In one report by Dietz (130) acute CNS effects also included 
hyperventilation, which was probably the result of stimulation of the 
medullary respiration centre. The most consistent characteristic shared by 
many of these patients is a positive past psychiatric record. The products 
containing PPA more than likely exacerbated trait-related symptoms in 
patients presenting these histories and caused acute drug-induced brain 
syndromes in those with no psychiatric history. All cases required medical 
attention and hospitil ization was necessary in cases where combination 
products, in particular those containing caffeine, had been taken. 
Presumably because the legal manufacture and availability of amphetamines 
was severely limited following the passage of the Controlled Substances Act 
of 1970 , a new source of stimulant drug abuse emerged and continues to the 
present time. Phenylpropanolamine (in combination with caffeine and 
ephedrine) began to appear in a multitude of amphetamine "look-likes" or 
"street" stimulants, which were not controlled by prescription. Associated 
with the abuse of these 1I1 00k-alike ll combination products there have, quite 
predicitably, been reports of amphetamine-like reactions, CNS toxicity and 
overdose cases (130). PPA has often been implicated as the culprit in such 
reports, presumably due to its structural similarity to amphetamine. 
However, there is ev i dence that the pharmaco 1 og i ca 1 act i v i ty of PPA is 
markedly distinct from that of amphetamine (AMP) (165), that PPA does not 
possess AMP-like euphorogenic or dependence potential (135) and that animal 
models and epidemological studies have shown PPA to have a low potential 
for abuse (132-137). The sale of these combination products was, however, 
banned in the United States in 1983 (2). 
Acute renal failure with tubular necrosis (138) and non-traumatic 
rhabdomyolosis (139) have been reported following PPA overdose. Caperton 
(140) reported alleviation of significant complications of Raynaud1s 
phenomenon in three young women following discontinuation of PPA-containing 
products. He speculated however, that caffeine may have augmented possible 
vasospastic effects. 
PPA has been implicated in causing blurring of eyesight in susceptible 
people. A recent report suggests that PPA was the precipitating factor in 
causing bilateral acute angle closure glaucoma through pupil dilation in 
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a hypermetropic woman (141). 
1.7 INTERACTIONS OF PHENYLPROPANOLAMINE WITH OTHER DRUGS 
With any widely used drug, it is of major medical importance to establish 
the effect of its concommitant use in the presence of pre-existing disease 
states or with other medications. Many reports of adverse drug reactions 
following the use of PPA are attributed to circumstances in which numerous 
other drugs, in addition to PPA, were used. 
Other sympathomimetic agents should not, even in acceptable doses, be used 
concurrently with PPA as summation of adrenergic effects is likely to cause 
adverse reactions (144). A number of reports of interactions occuring 
between monoamine oxidase inhibitors (MAOI) and sympathomimetic amines/ 
including PPA, appear in the literature (145-148). Concommitant 
administration of an indirectly acting sympathomimetic amine and a MAOI is 
likely to cause a sharp increase in blood pressure, accompanied by 
tachycardia, chest pains and severe occipital headache I and may result in 
intracranial haemorrhage, cardiac arrythmias, circulatory failure and 
death. The results of a controlled clinical study have demonstrated 
concordance of the adverse pressor effects caused by MAOI-PPA interactions 
(149) . 
The inhibition of monoamine oxidase (MAO) in the terminal axon by MAOI 
causes an increase in levels of norepinephrine at the storage site, which 
when released by sympathomimetic amines, causes extensive excitation of the 
receptor neurones resulting in hypertensive crisis (150). However the 
results of a study performed by D1Mello (151) show that PPA is a poor 
substrate for MAO and suggest that other enzymes are involved in its 
metabolism. 
A case has been cited of a subject who consumed cheese prior to ingestion 
of PPA and experienced a hypertensive episode/ which could have been due 
to tyramine present in the cheese acting synergistically with the effect 
of the sympathomimetic amine (152). Other foods rich in tyramine include 
red wine l beer, pickled herrings l chocolate and others may act conjointly 
with PPA to produce an adverse cardiovascular event (148). 
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Phenylpropanolamine provoked a hypertensive episode in a patient who was 
taking methyldopa and oxprenolol. Methyldopa is known to potentiate the 
pressor effects of sympathomimetic amines and it has been postulated that 
beta-blockade may produce similar effects by permitting unopposed 
vasconstriction to adrenergic stimulation (153). The mechanism was, 
however, not supported as the beta-blocker propranolol, blocked PPA-induced 
cardiovascular responses (108). 
The hypotensive effect of guanethidine may be blocked by PPA (154), and 
sensitization to the effects of sympathomimetic agents may occur following 
the administration of bethanidine 1 whose action is analogous to 
guanethidine in hypertensive crisis (ISS). It has been proposed that PPA 
and hypotensive agents 1 including debr;soquine 1 and tricyclic 
antidepressants may compete for neural reuptake (106). 
An unexplained death1 attributed to ventricular arrythmia, occurred in a 
woman taking thioridazine and a PPA-containing product. However 1 this 
profound effect may have been coincidental, as the patient had shown T-wave 
abnormalities while taking chlorpromazine 1 suggesting a predisposition to 
adverse effects from the phenothiazine class of drugs (114). 
Reports have appeared in the literature of hypertensive reactions occurring 
when PPA is taken concurrently with indomethacin (156). The authors 
concluded that cyclooxygenase inhibitors 1 such as indomethacin and aspirin, 
influence the prostaglandins system by reducing the prostaglandin-
controlled negative feedback mechanism of catecholamine release at 
sympathetic nerve endings. 
There is evidence that the administration of general anaesthetics may 
sensitize the myodardium to the potential for PPA-induced cardiac 
arrythmias (154). 
Two reports have been published of women taking oral contraceptives, who 
experienced hypertensive episodes following PPA ingestion (157, 158). 
Factors that can induce hypertension following oral contraceptive use can 
also increase sensitivity to the pressor effects of PPA. 
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Individuals who consume large amounts of caffeine-containing products such 
as coffee, chocolate and cola are at a greater risk of suffering adverse 
reactions to phenylpropanolamine. 80th PPA and the trimethylated xanthine, 
caffeine, have different, but synergistic mechanisms of action, although 
caffeine causes more potent CNS stimulatory effects (159). These two drugs 
in combination have the potential to cause psychotic episodes, cardiac 
arrythmias (119, 120L as well as cardiovascular accidents. In a recent 
study (160), it was shown that PPA administered concurrently with caffeine, 
caused an increase in the plasma caffeine concentrations, r.esulting in 
elevated blood pressures. The authors suggest that PPA either enhances 
absorption or inhibits elimination of caffeine which may explain increased 
reports of side effects after their combined use. 
In a recent study by Zimmerman et al (167), urinary alkalinization with 
sodium bicarbonate depressed the renal clearance of PPA producing higher 
post-absorptive plasma concentrations and a small but significant increase 
in diastolic blood pressure. 
1.8 CONTRAINDICATIONS OF PHENYLPROPANOLAMINE 
Phenylpropanolamine is contraindicated in pregnancy as it could affect the 
foetus indirectly through effects on uterine blood flow or uterine 
contractility during labour (161). It has also been shown that drugs with 
alpha-adrenergic agonist activity are associated with increased risk of 
malformations (162). 
Expectant and postpartum mothers shou 1 d be adv i sed aga i nst tak i ng any 
sympathomimetic agent, including PPA, as they may be most susceptible to 
major affective disorders during these periods (163). Psychotic episodes 
were experienced by two women who ingested diet aids while pregnant (128). 
Phenylpropanolamine is contraindicated in patients who have a familial 
history of psychosis, as susceptible subjects may develop psychiatric 
complications following the use of PPA-containing products (128). 
Conditions that impair the balance and control of the sympathetic nervous 
system such as autonomic dysfunction, may increase vulnerability to the 
hypertensive effects of PPA (164). There is also evidence to suggest that 
individuals with genetically low MAO levels may be more liable to 
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experience the blood pressure elevating effects of PPA (106). 
Phenylpropanolamine is contraindicated in patients with cardiovascular or 
gastro-intestinal disease, hepatic or renal dysfunction, thyroid or 
endocrine disorders, hypertension and asthma. The adrenergic properties of 
PPA may lead to elevated glucose levels and is thus contraindicated in 
diabetes (165). 
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CHAPTER 2 
EVALUATION AND TREAHIENT OF OBESITY 
2.1 ETIOLOGY OF OBESITY 
Many view obesity, at best, as a set of bad habits and at worst, as an 
extreme flaw or evidence of moral depravity in the form of gluttony or 
sloth. The d i 1 emma of obes ity is of great concern to the popu 1 at i on at 
large as well as to the medical profession and the treatment of obesity has 
become the focus of increasing scientific scrutiny. 
The etiology of obesity is unknown but the mechanism is simple. The 
condition develops when energy intake exceeds energy expenditure and an 
individual1s body weight significantly exceeds the norm or ideal body 
weight (65, 172). Obesity is best viewed as a multifactorial problem 
i nvo 1 vi ng met abo 1 i c , neuro 1 og; ca 1, psycho 1 og i ca 1 and soc i o-economi c 
factors, some of which may be genetically determined. Obesity is generally 
defined as the excessive accummulation of fat in the storage regions of the 
body. Excess calories are stored in the form of triglycerides in a cellular 
unit called an adipocyte. Anatomically, the triglycerides may be stored in 
pre-existing adipose cells resulting in an increased cell size, or new 
ad i pocytes may be formed produc i ng an increase in ce 11 number (172). 
Functionally, adipose tissue synthesizes and stores fatty acids in triacyl-
glycerols and releases these fatty acids as a source of metabolic fuel 
(178) . 
Obesity can be classified according to the age of onset, by etiologic 
causes and by the anatomic and regional distribution of adipose tissue. 
When hypercellularity occurs in childhood (Dearly-onset obesityD), there 
is an increased number of fat cells and in adulthood (ll maturity-onset 
obesityll), as the number of fat cells is usually fixed, the adipose tissue 
is enlarged (173). Etiologic causes of obesity include hyperinsulinism, 
Cushing1s syndrome, hypothyroidism and hypogonadism. In addition, obesity 
can be induced by dietary changes (178). 
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2.2 BIOLOGICAL ALTERATIONS IN OBESE INDIVIDUALS 
The topographical differences in adipose tissue distribution in obesity are 
well known. Android obesity is characteristically displayed by obese men 
who typically show enlarged fat depots located on the upper part of the 
body. However j this type of obesity can be seen in women j particularly 
during menopause accompanied by other signs of virilization. Gynoid obesity 
is typical in women who display an excess accummulation of fat deposits in 
the lower parts of the body and can be seen in men (173 1 174). It has been 
shown that adipocytes localised in the femoral and gluteal regions in women 
are larger than those in the abdominal areas. Recent functional studies 
indicate that the specific metabolic pattern of adipocytes in these two 
regions is regulated by female sex hormones (173). These adipocytes tend 
to accummulate triglycerides by an increased lipoprotein lipase activity 
combined with a low lipolytic activity and mobilize fat less effectively 
than abdominal adipocytes. Consequently, it is extremely difficult to shift 
the excess weight in the form of adipose tissue in gynoid obesity. The male 
type of fat distribution, with enlarged abdominal or truncal fat depots, 
involves fat that is easier to mobilize (173). 
There is a large body of evidence to suggest that the majority of obese 
people show some impairment of carbohydrate metabolism, which may be 
improved by substantial weight reduction. In addition, obese persons 
generally show glucose intolerance and an addiction to high carbohydrate 
diets (176) which would greatly augment insulin levels (177). Insulin has 
a stimulating effect on fat synthesis and the high blood levels often found 
in the obese and which are increased following a glucose pre-load may cause 
rapid accummulation of fat stores (175). 
A consistent correlation has been found between the concentration of very 
low-density lipoproteins (VLDl) and obesitYI and that weight reduction is 
the best treatment for hypertriglyceridemia resulting from the elevated 
leve 1 s of hepat ica l1y synthes ized VLDL. In contrast, the high-dens ity 
lipoproteins (HDl cholesterol) are consistently reduced in obese males and 
females. The concentration of HDl cholesterol is inversely related to the 
incidence of cardiovascular risks associated with obesity. In general I HDL 
cholesterol increases with weight loss while the ratio of total cholesterol 
to HDl cholesterol decreases (175). 
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The concentration of free fatty acids (FFA) and their turnover are 
increased in obese subjects. There is enhanced basal lipolysis in large fat 
cells and an increased response of large fat cells to lipolytic agents. It 
has been reported that obese persons tend to have lower concentrations of 
fat-mobilizing substance (FMS) in urine during fasting as opposed to normal 
control subjects similarly treated. FMS appears to be of pituitary origin 
and present in man during active fat catabolism and periods of severe 
carbohydrate deprivation. It is known, in addition, that obese people 
usually have low levels of growth hormone (GH) which has fat mobilizing and 
anti-lipogenic effects (173, 175). 
In obese men and women the concentration of serum testosterone is decreased 
probably due to the reduction of sex hormone binding globulin (SHBG), which 
transports the testosterone in the serum. Obese subjects also generally 
display an enhanced conversion of androstenedione to estrone in 
fibroblasts by the stromal elements in adipose tissue, and obese women 
exhibit a reduced turnover in estradiol (175). 
Adrenal secretion of cortisol and excretion of urinary cortisol metabolites 
are significantly increased in obesity. While the adjustments that occur 
in thyroid hormone function in obese subjects are complex, it is known that 
in obese fasting subjects, total thyroxine (T4) levels remain normal but 
serum triiodothyronine (T3) levels decline (175, 178). 
It is thus evident that differences in metabolic and hormonal balance do 
often exist between obese and non-obese individuals and that in some obese 
individuals there may be a relative defect in fat mobilisation and an 
increased tendency to fat synthesis as a consequence of these imbalances. 
Some of the alterations occur;ng in obese individuals, such as 
hyperinsulinemia, impaired GH response and hormonal changes are reversible 
with weight loss. However, the changes that occur in adrenal or thyroid 
function, may not change following weight loss (172, 173). 
2.3 REGULATION OF ENERGY BALANCE 
Because of the complex nature of the relationship between man and his diet, 
it is difficult to separate the physiological basis of human eating 
behaviour from the vast overlay of non-physiological factors that may 
26 
influence food intake (179, 180). For this reason, it has been difficult 
to carry out meaningful investigations of food intake regulation in human 
subjects and researchers have usually sought answers to questions relating 
to man by observing feeding behaviour in laboratory animals (180). 
Feeding behaviour is best viewed as an interaction between two domains: 
events conducted under the skin and events occuring beyond the skin. Figure 
2.1 lists some of the pertinent features of the external environment. 
Naturally, many of these are concerned with the nature of the food supply 
including its temperature, flavour, texture, composition and variety. 
Alterations in these parameters alone are often sufficient to cause large 
changes in food consumption and body weight (181). 
FIGURE 2.1 Feeding depicted as an interaction between two domains 
Reproduced from Hill and Blundell (250) 
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2.3.1 Physiological Factors Affecting Food Intake and Weight 
Table 2.1 depicts numerous physiological signals which may trigger the 
functioning of the complex system which tends to match nutritional input 
to bodily or somatic requirements. Some of the biological factors that must 
be considered include the role of taste! gastro-intestinal factors! 
hormonal and nutrient blood levels and the central nervous system (182). 
Genera 1 Type of Signa 1 ExalJ1) le 
Oropharyngeal Signals: depending on the taste, texture, 
temperature of food 
Gastro-intestinal events: stomach contractions and distension, 
intestinal distension 
Hormonal signals: insulin, prostaglandins, cholecystokinin 
Metabolites carried in blood: glucose, free fatty acids, amino acids, 
glycerol, lipid mobilising substance 
Factors associated with body weight: amount of fat tissue, number of fat 
cells, size of fat cells 
Factors influencing energy utilization: thyroxine, growth hormone, 
corticosteroids 
TABLE 2.1 Physiological signals believed to influence food consumption 
Reproduced from Blundell (182) 
2.3.2 Mechanisms of Food Intake Regulation 
The regulation of food intake is a complex biological process that involves 
regulatory mechanisms at biochemical j organic! behavioural! endocrinologic! 
social and even cultural levels. Obviously! any anorectic drug! could 
theoretically affect regulation of food intake at any of these levels and 
may well act at several to reduce hunger and decrease food intake. 
Several theories involving both central and peripheral sites have been 
proposed to explain the multifactorial mechanisms by which food intake and 
hence body weight is regulated. For many years research on energy 
regulation focused on the hypothalamus. This was seen as the loci of the 
brain where taste factors are integrated with glucostatic! thermostatic and 
1 i postat i c mechan isms to contro 1 both energy metabo li sm and the 
psychological aspects of eating (183). 
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2.3.2.1 Peripheral Theories 
Peripheral mechanism theories emphasize the role of peripheral factors such 
as taste 1 stomach distension 1 rate of stomach emptying l rate of nutrient 
absorption and the role of gastrointestinal hormones such as 
cholecystokinin1 glucagon 1 bombesin and somatostatin released during a 
meal. Alterations in concentrations of these hormones, or any of these 
factors, have been correlated with changes in eating behaviour induced by 
various experimental manoeuvres such as sham feeding, for example. The 
neuroendocrine and sensory aspects of the gut have been suggested as the 
major peripheral mechanisms that signal feelings of hunger or satiety to 
the central neural network (178, 184-186). 
2.3.2.2 Central Theories 
The central anatomical regions thought to regulate appetite occur mainly 
in the hypothalamus. The hypothalamus acts as a transducer by integrating 
the sensory inputs and maintaining nutritional homeostasis by activating 
or suppressing food-seeking behaviour. The hypothalamus fulfills its role 
through a complex pattern of monoamines and neuropeptides acting on 
hypothalamic interneurons (188). 
To date l a large portion of the research to elucidate basic hunger 
mechanisms has centred on electrical and chemical control of the 
hypothalamus. The ventromedial hypothalamus has been designated the satiety 
centre 1 since electrical stimulation of this area causes inhibition of 
feeding leading to aphagia, anorexia and weight loss. ConverselY1 bilateral 
electrolytic lesions placed in the ventromedial nucleus cause hyperphagia 
and obesity. The satiety centre is associated with the serotonergic pathway 
and the ventral adrenergic bundle (183 1 189). 
The ventrolateral hypothalamus is known as the feeding centre as it appears 
to be involved in eliciting feeding behaviour. Application of similar 
electrical treatments to this area produce essentially opposite effects as 
the medial hypothalamus. The feeding centre is associated with the 
dopaminergic nigrostriatal tract. Many of the anabol ic and catabol ic 
responses evoked after electrical stimulation or destruction of the 
hypothalamus are mediated by the autonomic nervous system (ANS) and the 
autonomic hypothesis suggests that obesity is caused by ~n imbalance in the 
ANS (183, 188). 
While regulation 
ventromedial and 
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of feeding behaviour is commonly attributed to 
lateral hypothalamic sites, evidence continues to 
accummulate to demonstrate that several extrahypothalamic structures such 
as the amygdala, the midbrain, the septum pellicudum and others are also 
involved in this complex regulatory system (183). 
As information is transmitted in the hypothalamus by the release of 
neurohumoral substances, one of the most vigorously investigated parts of 
central appetite regulation is the role of the monoamine neurotransmitters 
in the hypothalamus. By injecting various natural compounds, their 
analogues or drugs into specific regions of the brain, some of the basic 
neural systems controlling appetite, satiety and several aspects of 
behaviour reinforcement have been possible to outline (183). The 
phenylethylamines such as amphetamine (AMPH), phenylrpopanolamine (PPA) and 
fenfluramine (FEN) have similar basic structures to the monoamine 
neurotransmitters, dopamine (DA), epinephrine (E), norepinephrine (NE) and 
serotonin (5-HT), which are considered to play an important role in the 
regulation of various brain functions as well as in the mechanism of action 
of centrally acting drugs (97, 187). 
The pioneering research by Leibowitz (97) showed excitation of feeding by 
an alpha-adrenergic system in the paraventricular nucleus (PVN) by 
inhibition of part of the ventromedial hypothalamic satiety centre. Alpha-
adrenergic agonists, including AMPH, induce feeding in the medial portions 
of the hypothalamus probably by releasing NE or E, it is not clear which 
(97). Amphetamine-induced feeding may sound paradoxical, but is easily 
observed and explained when AMPH is locally applied to the PVN where it 
could inhibit satiety and aversion (183). The satiety centre ;s thought to 
be under positive serotonergic control as the usual effect of serotonin-
agonists, such as FEN, is the production of anorexia (183, 188). Injection 
of NE, DA and E into the perifornical region of the lateral hypothalamus 
feeding and reward system has an anti-feeding effect. Likewise the 
injection of drugs which release catecholamines, such as AMPH into the 
lateral hypothalamus (LH) suppresses feeding and the effect is beta-
adrenergic or dopaminergic (189). 
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Output from the PVN apparent 1 y f ac i 1 itates both sat i ety and the post-
absorptive energy-release phase of metabolism which are inhibited by NE in 
the PVN. The evidence to date suggests that serotonin counteracts NE in the 
PVN control of satiety and carbohydrate intake and metabolism. Most 
anorectic agents are known to act on brain monoamines and while most show 
a preferential action for a particular monoaminergic system, they can also 
affect other systems in the brain (183). 
More recently, research has focused on three interesting classes of 
compounds a) opiates such as enkephalin and dynorphin, b) brain-gut 
peptides such as cholecystokinin and neurotensin, and c) compounds related 
to phencyclidine (PCP) or angel dust (183). 
Various studies have shown that both exogenous and endogenous opiates can 
stimulate food intake (190), and appear to preferentially increase the 
intake of foods with a high energy content (188). Support for this role of 
the opioids is the ability of the opiate receptor antagonist, naloxone to 
inhibit the appetite in a variety of species, including man. More 
specifically, dynorphin, an endogenous opiate peptide that contains leucine 
enkephalin at its amino terminal apparently induces eating by stimulating 
kappa opiate receptors. Stress-induced eating may also relate to increased 
activity of the endogenous opioid system (185, 188). 
In contrast to the opioid peptides, the release of most other neuropeptides 
such as the ca 1 c i urn lower i ng hormone I ca 1 c iton i nand cort i cotroph i n-
releasing factor (CRF) appear to inhibit rather than stimulate feeding 
(185, 188). CRF is available in higher concentrations during stress, in 
some depressed patients and in some disease states such as anorexia nervosa 
(191, 192). Overactivity of CRF may playa role in the weight loss these 
patients may experience (185). 
It has been shown that the gut peptides cholecystokinin (CCK), neurotensin 
and bombesin can all cause malaise at high peripheral doses and that 
intrahypothalamic and intraventricular injection of these brain-gut 
peptides selectively inhibits food intake (184). Exogenous CCK has been 
shown to inhibit the size of a test meal in obese and lean subjects and to 
decrease appetite, in a dose-related fashion (193). The stimulant PCP is 
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known to act at sigma opiate receptors and acts as a reinforcer at the 
nucleus accumbens (183). 
2.3.2.3 IISet-Pointll Theories 
Obesity is regarded by many as a behavioural problem and is frequently 
treated with behavioural therapy in attempts to modify maladaptive eating 
patterns. However, resistance of obesity to such treatment raises concerns 
that its origins may not be behavioural (194). The observation that body 
size remains fairly constant over long periods of time, following the 
period of rapid growth, has led some theorists to suppose that body size 
or some aspect of size such as weight is actively regulated (181). 
The Iiset point ll theory is supported by numerous researchers and suggests 
that biological constancy in body weight is maintained within a narrow 
range or level of adiposity, by reference to a set point embodied in 
physiological mechanisms I which in turn controls energy intake and 
expenditure. Other theorists have argued that features such as total body 
energy, body fat or weight are not actively regulated about prescribed set 
va 1 ues but that apparent constancy is rna i nta i ned by a natura 1 ba 1 ance 
between intake and output (194, 195). 
It has been demonstrated by Bray (196) that some obese people attempting 
to lose weight by drastic caloric dilution show a minimal (3%) weight loss 
and a large decline (17%) in the resting rate of oxygen consumption. This 
large decline in metabolic rate with so modest a weight loss suggests the 
participation of a physiological process actively resisting weight change. 
This type of obese person who displays a normal capacity to regulate and 
defend body weight physiologically, albeit at an elevated set point, is 
extremely difficult to treat as the chances of acheiving significant weight 
loss or of sustaining losses that do occur is greatly diminished. However! 
the growing evidence that set points can be altered by various 
neuroanatomical, physiological and pharmacological manipulations may! in 
time, offer a solution to physiologically regulated obesity (194, 195). 
However, some obese patients who lose weight fail to display these rapid 
adaptive adjustments in resting metabolism, suggesting that this type of 
obesity results from a regulatory dysfunction. It is likely that 
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conventional treatments such as dieting, behavioural modification of eating 
habits and increased expenditure through excercise might well be effective 
in this type of obesity (194). 
It is generally thought that changes in body weight set points can be 
induced by changes in diet, by drugs or toxic agents and by excercise. It 
remains uncertain whether the changes in body weight that accompany shifts 
in female hormones, onset or cessation of smoking and the metabolic changes 
in body composition associated ",lith aging occur because of a direct 
influence on intake or output, or because the set point has been changed 
(194, 195). 
2.3.2.4 Appetostat Theories 
The group of compounds that may serve as correlates between central and 
peripheral mechanisms are known as appetostats. Appetotstat theories 
suggest that eating behaviour is modulated by the concentrations of 
substances such as glucose 1 i nsu 1 in I ami no ac i ds, free fatty ac i ds and 
purines. The role of nutrients in appetite control and CNS sensors that 
regu 1 ate nutrient leve 1 s have been emphas ized by numerous researchers 
(188). 
The glucostatic theory was proposed by Carlson in 1916, modified by Mayer 
in 1955 (188) and suggests that appet i te and hunger are regu 1 ated by 
changes in blood glucose levels or related factors such as glucose 
utilization, insulin or glucose receptors. Glucoreceptors have been 
identified and located in the ventromedial hypothalamus and in more caudal 
regions of the brain, in the liver and in the gastro-intestinal tract. It 
has been shown that iontophoretic application of glucose and/or insulin 
increases firing of the medial hypothalamic neurons (188). 
The lipostatic theory was proposed by Le Magnen (198) who suggested that 
free fatty acids and triglycerides released during lipolysis could signal 
feeding behaviour. Iontophoretic application of free fatty acids caused 
firing of the lateral hypothalamic neurons (197). 
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The aminostatic theory proposes that changes in plasma amino acid levels 
may playa role in food intake regulation (188). Certain amino acids such 
as y-aminobutyric acid (GABA) have been shown to act as neurotransmitters 
and to alter feeding l whereas others such as tyrosine and tryptophan (199)1 
that serve as precursors for monoamines I have been shown to modu 1 ate 
feeding (200). 
The proliferation of theories of the control of food intake by nutrients 
suggests that the brain may possess mechanisms for modulating all of the 
essential nutrients. As macro-nutrients can be interconverted by cellular 
metabolism l several theories based on overall energy utilization have been 
proposed. Brobecks classic thermostatic theory suggests that body 
temperature and the heat generated by metabolic fuels is responsible for 
feeding regulation (188). 
It has been shown that a defect in brown adipose tissue of genetically 
obese mice accounts for their inability to increase metabolism in response 
to cold stress. In man l however l the evidence of thermogenic defects is 
equivocal and would be inadequate to explain the etiology or persistence 
of obesity (178/ 201). 
Miscellaneous factors thought to be important in the regulation of hunger 
and food intake include hormones I oral and GI factors, vagal influences l 
excercise and energy balance. Short-term and long-term regulation of food 
intake are generally considered to be controlled by independent mechanisms 
(97) • 
2.3.3 Psychological Factors in the Control of Appetite 
It is generally agreed that eating behaviour is controlled to a large 
extent by psychological factors. For example, taste preferences, time of 
eating and contents of a given meal show wide cultural variation l being 
influenced more by social and psychological factors than by physiological 
determinants. 
Psychological factors that affect eating include stress l palatabilty and 
salience of the food, social influences and cognitive decisions. These 
variables may operate to affect eating indirectly, by increasing or 
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decreasing hunger or satiety or directly, independent of the individual1s 
state of deprivation or repletion (202). 
2.3.3.1 The Externality Hypothesis 
It has been suggested that obese individuals are unable to differentiate 
between internal arousal states and frequently interpret such states as 
hunger. The interna 1 ity-externa 1 ity hypothes i s proposed that eat i ng by 
normal-weight persons was influenced by internal signals such as gastric 
motility and other peripheral and central cues signalling hunger and 
satiety. On the other hand, eating by obese people was thought to be 
influenced largely by external cues such as the taste and sight of food, 
and the number of highly palatable food cues present (180). It has been 
proposed that the external cue has two effects, a specific effect that 
elicits an anticipatory response such as salivation and a nonspecific one 
that arouses the individual and increases the chances of eating to occur 
(204). It is known that certain times of the day 1 as well as visual 1 
gustatory 1 olfactory and cognitive cues predict food availabi 1 ity and 
result in responses that characterize caloric depletion (205). 
There have been numerous reports of sign if i cant (206 1 207) and 
nonsignificant (208 1 209) interactions of body weight with variations in 
the visual and cognitive salience of food cues, and the perceived passage 
of time. It has also been established that normal-weight individuals 
compensate for changes in caloric density of meals incompletely and are 
often inaccurate in their perceptions of internal hunger and satiety cues 
(179, 210-212). Due to a variety of methodological and definitive problems 
it is difficult to analyse the studies on responses to external cues in 
obese and non-obese people. However, it is evident that overweight people 
are not necessarily more responsive to external cues than leaner controls 
but that external responsiveness is an individual difference factor that 
can be identified at birth1 or subsequently learned and does have the 
potential to produce weight gain (203). 
2.3.3.2 Palatability 
Although palatabilty was originally considered to be an external food-
related cue , it has been shown that this variable is not simply an 
intrinsic property of food. Hedonic judgements are strongly influenced by 
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physiological variables such as the individual1s acute state of energy 
excess or deprivation, amount of fat stored and metabolic status (213). 
Palatability is also related to the nutrient value of the food (214) and 
reflects the learned history of the person rating the food (215). 
Most studies on palatability show that both obese and normal-weight 
individuals consume more when the food is palatable (206, 207, 215, 216). 
However, in general, overweight subjects ingest more palatable food than 
normal-weight subjects and these findings are stronger than the findings 
that overweight subjects reduce their intake of a meal of low palatability. 
Studies have been performed to establish whether heightened taste 
responsiveness, and sweet tastes specifically, relates to the development 
and rna i ntenance of obes i ty. It has been demonstrated that subjects of 
different body weights do not differ in perceptions of taste intensity and 
that weight loss achieved through dieting increases the perceived intensity 
of sweet tasting solutions (203). 
The presentation of a variety of palatable foods augments intake and it has 
been postulated that the variety effect may be mediated by perceived 
changes in palatability. Reduction in palatabilty has been attributed to 
the mechanism of sensory-specific satiation, first postulated by Le Magnen 
(203) and which suggests that the oral satiety mechanism operates through 
stimulation of food passing through the mouth. Several studies demonstrate 
that the pleasantness ratings of foods consumed during a meal decrease more 
than the same ratings for foods not eaten. It has been argued by'Rolls et 
al that satiety relies on an interaction between internal satiety signals 
and sensory food cues such as texture, shape, smell, taste and temperature 
(203). 
2.3.3.3 Restrained Eating 
It has been suggested that the obesity-externality correlation is a 
phenomenon of the fact that obese people are always dieting or restricting 
their food intake in order to lose weight and that conscious restraint is 
responsible for externality (217). Early experiments showed that restrained 
eaters, but not unrestrained eaters, consumed more of a test meal following 
the ingestion of a high-calorie preload. This paradoxical behaviour, termed 
dcounter-regulationJl, was thought to occur from disruption of the control 
36 
dieters usually exert over their food intake (217). This disinhibition was 
observed by inducing arousal, administering alcohol or manipulating 
cognitive variables such as knowledge of the caloric content of the 
preload. It was also shown that unrestrained eaters eat less and lose more 
weight, and that the effect is reversed in restrained eaters in response 
to dysphoric emotions such as anxiety, depression or stress (219). 
Several studies have reported that restraint, as measured by a restraint 
sca 1 e or Eat i ng Hab its Quest i onna i re, is more common among obese we i ght 
individuals than among normal weight individuals (203, 217). However, the 
large number of obese persons who identified as restrained eaters may be 
related to the properties of the restraint scale. Studies suggest that 
counter-regulation may be most typical for normal-weight individuals (218), 
as obese restrained eaters ate considerably less than normal-weight 
restrained eaters following a preload aimed at inducing counter-regulation 
(203). Factor analyses of the restraint scale yielded two main factors, 
that is, a weight fluctuation factor and a dietary concern factor (219). 
The three-factor restraint questionnaire designed by Stunkard and Messick 
(219) proposes three discrete factors of the global construct of restraint 
that is, cognitive restraint of eating, disinhibition and hunger, which 
allow for the determination of how these aspects of restraint relate to 
binge eating, obesity and other eating disorders. 
2.3.3.4 Psychodynamic Hypothesis 
Psychoanalytic theories have led to two universal predictions about obese 
individuals. First, unconscious conflicts arising from disruptions in 
personality development that occur with a specific pattern of personality 
traits, leads to overeating. Several psychological disturbances have been 
postulated and include lack of emotional satisfaction leading to 
frustration, lIover-compensationll, increased drive for oral satisfaction, 
a true addiction to food, a sexual conflict situation, passive dependence 
and so on. Second, overeating is a response to emotional distress such as 
anxiety or depression. However, while it is true that psychodynamic 
mechanisms are important for some indivduals, current evidence suggests 
that obese persons do not, as a whole, differ from normal-weight 
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individuals on measures of global psychological adjustment and on standard 
measures of personality (202, 203, 220). 
It is well established that one of the effects of stress, anxiety and/or 
depression is a loss of, or a reduction in appetite. It is postulated that 
stress activates the sympathetic nervous system to release stored glucose 
into the bloodstream, which acts to suppress hunger. Although this is 
generally the case with normal-weight individuals, overweight subjects more 
often than not, do overeat in response to stress compared to when calm. It 
appears that stress appears to affect normal weight, non-dieting 
individuals by affecting hunger and that the effect of stress in obese, 
dieting individuals is not mediated physiologically (202). 
2.3.3.5 Eating Styles of the Obese 
Severa 1 researchers have invest i gated the assumpt i on that obese peop 1 e 
overeat. However/ a variety of methodological problems intrinsic to both 
laboratory and field studies have hindered the ability to interpret the 
data clearly. 
Most surveys suggest that energy intake is significantly lower in the 
overweight than in those of normal weight (221). However, one concern with 
these retrospective observations is that overweight subjects tend to be 
biased to the low side when using self-report programs (178). In field 
studies, measuring food intake is complex as subjects have access to many 
foods, the observer must remain inconspicuous and observational data are 
subject to observer bias (180, 203). In laboratory studies, although amount 
eaten is assessed objectively, subjects have fewer food choices and less 
control over their eating profile. In addition the fact that they are being 
observed may influence behaviour (222). If differences occur between obese 
and normal weight subjects in the amount of food eaten, it may be because 
they choose different types of food and may not necessarily correlate with 
degree of overweight or level of weight gain (203). 
Behaviour therapists have focussed on eating styles as potentially 
significant in the etiology and treatment of obesity. Empirical studies 
have evaluated aspects of the topography of eating such as meal duration, 
eating rate, and a variety of micro-elements of eating styles such as 
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choice of eating utensils and number of chews per meal (203, 216). 
Laboratory studies that have engaged subjects in some parallel activity 
during eating to ensure that they are unaware of being observed and more 
naturalistic studies without distraction have shown that meal duration of 
obese and nonobese subjects does not differ when all subjects are served 
identical meals (203). However, in a recent summary of research performed 
in this area, the authors concluded that the obese tend to eat at a more 
rapid rate than normal-weight individuals (178). 
Rate of eating has been studied with other measures of appetite such as 
perceived hunger and as an aspect of a stable eating style. Presumably 
eating faster permits a greater intake before post-ingestive satiety cues 
occur. Wooley et al found that the rate of eating one meal has a positive 
influence on salivation a putative measure of appetite, at a subsequent 
mea 1 (203). 
Most of the current data provide an inconsistent picture of differences in 
eating style or amount eaten between overweight and normal-weight subjects. 
Differences that do emerge may not be causally related to obesity since 
efforts to modify eating style in behaviour treatment programs have not 
shown substantial effects on weight loss for all over-weight patients 
(203). 
2.4 CLINICAL ASSESSMENT OF OBESE INDIVIDUALS 
Although the factors eliciting or contributing to obesity are numerous and 
not coherently illustrated as yet, sufficient information is available to 
demonstrate that the obese are a diverse group with many differences. One 
of the obstacles in the treatment of obesity is a tendency toward bias of 
recommendations according to the strengths or background of the clinician 
or counsellor. A comprehensive assessment of the factors contributing to 
the development of obesity is essential to allow adequate and pertinent 
treatment modalities to be instituted. 
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Clinical and biochemical evaluation of diabetes, hypertension and 
hyperlipidemia should be included as part of an overall assessment due to 
a high preva 1 ence of these diseases in obes i ty. Measurement of basa 1 
metabolic rate is of prime importance, as treatment measures will differ 
according to the individual rate. For example, an individual with a 
relatively low resting rate of metabolism will benefit more from increased 
physical activity or changes to abberant eating patterns than from caloric 
restriction 310ne. 
For obese persons with psychiatric disturbances such as depression or 
anxiety, treatment recommendations should be tempered so that the demands 
of the treatment are modest and achievable without undue stress. Based on 
clinical judgement of responsiveness to external cues, treatments will vary 
so that highly responsive people are taught stimulus control, for example. 
An awareness of the restrained eating phenomenon is useful to aid in 
alleviation of the concerns of individuals with this type of behaviour. 
Likewise it is of tantamount importance to assess the nutritional status 
of the individual in terms of eating frequency, variety and quantity of 
foods eaten as well as to evaluate the extent of an individual1s activity 
levels, in order to avoid unrealistic treatment demands (218). 
2.5 MEDICAL CONSEQUENCES AND TREATMENT OF OBESITY 
The medical consequences of obesity are well recognised. The incidence of 
cardiovascular, menstrual and reproductive disorders as well as arthritis, 
gout and hypertension is much higher among obese individuals than normal-
weight individuals. Obesity is associated with a number of established risk 
factors for ischaemic heart disease (IHO) and related conditions. These 
include hyperinsulinemia, diabetes mellitus, hyperlipidemia and 
hypertension. It has been established that men who show android fat 
patterning specifically localized abdominally are more prone to exhibit 
metabolic complications which may lead to hypertension and IHO (173, 175, 
223) . 
However, the treatment of obesity ;s a difficult medical problem. Since 
maintenance of body weight is determined by food intake and energy 
expenditure it would seem that decreasing body weight would be a simple 
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matter of reducing food intake l increasing energy output, or both. In 
practice, however, decreasing body weight is not a simple process; for 
example/ to lose 0.45 kg (1 lb) of body weight one must reduce one1s 
caloric intake by 3500 calories l or run 25 miles. Obviously for an 
individual who is even moderately overweight, a considerable amount of time 
and effort is required to effectively lose weight (223/224). 
Many traditional as well as novel approaches to weight reduction and weight 
loss maintenance have been proposed. The multiplicity of treatment 
approaches include psychotherapy, psychoanalysis, group therapy, behaviour 
modification/ repatterning/ surgical and pharmacologic therapy. 
Surgical procedures include various types of gastric bypass operations/ 
such as the ileojejunal bypass, for example, as well as horizontal and 
vertical gastroplasties. Despite numerous technical and medical 
complications and criticisms to the contrary, surgical procedures, when 
accompanied by post-surgical follow-up measures and sound treatment 
practices, remain an effective treatment in terms of both weight loss and 
weight maintenance in the morbidly obese (225). Mechanical treatments used 
in the treatment of obesity include jaw-'l'liring and intragastric balloon 
bezoars. While jaw-wiring produces clinically significant weight loss/ 
weight regain occurs following the removal of the wires (223, 226). Only 
a few studies have been performed with the relatively new nonsurgical 
technique of balloon bezoars (227). However/ gastric erosions have been 
noted in up to 50% of patients with these devices in place and studies in 
animals have indicated that weight regain occurs once the ballooons have 
been removed (228). 
Loca 1 fat depos its have also been a ltered for cosmet i c purposes, by a 
technique called liposuction or suction-assisted lipectomy. With the 
patient anaesthetised, a suction probe is inserted into an incision made 
in an area usually covered by clothing, and the tissue is then aspirated 
through a cannula. Successful operations have usually been performed on 
younger patients with limited quantities of fat to be removed. However/ 
seromas and infections and other complications such as dimpling and wavey 
contour have been observed (223). 
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Emetics and purgatives have been used to control body weight, particularly 
in eating disorders such as anorexia nervosa. However, the use of these 
agents should be discouraged as they are socially disruptive, medically 
dangerous and very resistant to treatment (226). 
Physical activity is perhaps the most effective and important intervention 
necessary for successful weight control. It has been shown that excercise 
may facilitate weight loss by increasing the metabolic rate, increasing 
energy expenditure and may decrease appetite resulting in a reduced caloric 
consumption. Excercise may also enhance the mobilization and utilization 
of free fatty acids from adipose tissue producing an increased fat weight 
loss while minimising lean mass loss (223, 226, 228). 
The most universally used intervention is that of dieting. Numerous IIfad ll 
diets such as liThe Beverly Hillsll diet and the IIScarsdale ll diet, to mention 
but two, have been and are, used by millions of people in attempts to lose 
weight rapidly. However, many of these diets are based on unsound 
nutritional principles and have a high failure rate as weight usually 
returns to normal following cessation of the diet (223, 226). Very low 
calorie diets (VLCD) are those which contain less than 800 calories per day 
and are typically composed of protein with smaller proportions of 
carbohydrate and fat. These diets frequently consist of smaller quantities 
of food or can be a pharmacologically manufactured formula; synonyms are 
Illiquid protein Jl diets or II protein-modifed ll fasts. When used with adequate 
patient selection, close medical supervision and a high quality diet, 
VLCD's produce cl inica lly significant weight loss with minima 1 
complications (228 , 229). 
A nutritionally balanced, calorically restricted diet may be essential for 
obesity treatment, but the success rate of even medically sound dieting, 
including the VLCD's is low when used alone. If used, a diet should be 
instituted as part of a comprehensive program of nutritional education and 
behaviour modification to ensure efficacy and maintenance of weight loss. 
Behaviour therapy or behaviour modification is employed in the treatment 
of obesity as a result of maladaptive learned behaviours that concern food 
intake, energy expenditure and habit control (223, 226, 228, 229). 
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Techniques used include: 
1) Control of environmental and intrapersonal stimuli that elicit 
excessive eating. 
2) Changes in eating behaviour such as slowing eating rate and 
increasing awareness of the amount eaten. 
3) Self-monitoring techniques for systematic recording of dietary intake 
and weight. 
4) Social support initiation and relapse prevention programs. 
More recently, two new areas, that is cognition and spouse support have 
been added to the list of factors deemed important in the treatment of 
obesity. The Master Questionnaire, an obesity assessment device, has been 
designed lito provide an outcome measure sensitive to the types of changes 
relevant to the cognitive-behavioural conceptualization of obesity 
treatment II and to serve as a predictor of changes in obesity status in such 
programs (230). 
It is generally perceived by many, that combining interventions such as 
behaviour modification, physical activity programs and diets based on sound 
nutritional practices , is of enormous value in effecting weight loss and 
sustaining the lost weight. 
Pharmacological treatments used to modify appetite have previously been 
confined to the administration of amphetamine and amphetamine-like 
compounds. The development of tolerance, potential abuse liability and side 
effects often outweigh their mild and transient appetite suppressant 
effects. Medical practitioners have often been either overzealous or 
totally reluctant in prescribing them. There has been considerable 
controversy about the value of pharmacological intervention in the 
treatment of obesity. Although the majority of anorectic prepartions on the 
market are not ideal, when used according to prescribed directions , they 
may be of great value in the treatment of overweight conditions, 
particularly when used as adjuncts to low calorie diets and in combination 
with behviour modification (188, 223,231). 
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It has been shown by Weintraub et al (232)1 that failure to consider such 
factors as a patient1s response to a diet-only period, motivation! eating 
habits, personality and obesity characteristics may partly explain the low 
discriminatory power of anorexiant clinical trials. The authors suggested 
that these factors I wh i ch were shown to be important determi nants of 
outcome, may help medical practitioners in treating patients in terms of 
drug selection and treatment strategy (232). 
Because conditions of obesity are complex and multifactorial} treatments 
must reflect individual differences with respect to physiological, 
psychological and social factors. 
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CHAPTER 3 
EVALUATION OF THE EFFICACY AND SAFETY OF ANORECTIC PREPARATIONS 
3.1 PHARMACOLOGICAL TREATMENT OF OBESITY 
Most of the appetite suppressant drugs on the market possess many of the 
pharmacological properties of the neurotransmitter, norepinephrine, and 
therefore many of these preparations can stimu 1 ate the eNS, increase 
locomotor activity and cause adverse cardiovascular reactions in the form 
of raised blood pressure and heart rate. It is thus of prime importance to 
determine the safety and efficacy of anorectic agents in order to establish 
whether they are clincially useful or not. An anorexiant is deemed 
efficacious if it reduces hunger and food intake consistently and produces 
a sustained reduction in body weight. Safety is inferred if the drug in 
question does not cause increased blood pressure or subjective mood or 
stimulant effects and shows low abuse liablility and little dependence 
potential (178,223). 
3.2 BEHAVIOURAL PHARMACOLOGY OF ANOREXIA 
The term behavioural pharmacology represents a union between two scientific 
disciplines, psychology and pharmacology. In general, the term can refer 
to any instance in which some aspect of behaviour is monitored in alliance 
with a pharmacological manipulation, and in the study of feeding the 
behavioural variable most frequently chosen has been the weight of food 
consumed (181). 
This field of study has expanded along with the increasing interest of 
pharmaceutical concerns in the development of anti-obesity agents. This 
venture has needed testing procedures to determine which of numerous new 
compounds produced, display clinically desirable behavioural activity. The 
second purpose of this field of study involves the use of detailed 
procedures for investigations of mechanisms of drug action, whilst the 
third is the use of drugs to explore the structure of complex behaviour in 
terms of the associations between physiological occurences and behavioural 
events (181). 
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3.2.1 The Structure of Eating and its Relationship to Behaviour 
Drugs are usually tested for their effects on appetite under restricted 
conditions, the most common of which involves adapting a rat to a feeding 
schedule. When the rat1s intake has stabilised on this schedule, the drug 
treatment begins. The effect of the drug treatment and hence anorexia is 
defined objectively by measuring the inhibition of the weight of food 
consumed by these experimental animals in a brief time interval (usually 
15 - 20 minutes) (233, 234). A similar paradigm is used for humans except 
that subjective reports are usually obtained in addition to changes in food 
intake. These methods are used to evaluate the acute effect of drugs on 
meals or short-term food intake and the drug effect is understood in terms 
of feeding as an episodic behaviour. Drugs are also administered daily for 
weeks to determine their therapeutic effect on body weight (234). 
Mammalian food intake comprises complex behaviour patterns and constitutes 
a discontinuous process in which periods of eating alternate with non-
feeding bouts. Accordingly, it is possible to measure feeding by assessing 
various parameters of meal patterns such as number of meals taken over a 
given period, meal sizes, meal duration, inter-meal intervals and certain 
relationships between these variables such as the ratio of meal size to the 
pre- or post-meal interval. These techniques draw attention to the 
distinction between food intake and feeding behaviour which can only be 
understood through a deta i 1 ed ana 1 ys i s of the topography of the eat i ng 
response (181). 
The simplicity of the notion of giving the unit of anorexia a fundamental 
and unequivocal identity may be contrasted with the complex interaction of 
processes which actually regulate feeding activities. These processes 
contro 1 the onset I rna i ntenance and termi nat i on of eat i ng ep i sodes, the 
selection of particular nutrients and food items, the expression of 
preferences and dislikes, the long-term temporal patterns of feeding and 
the relationship between feeding and other pertinent behaviours. In 
addition, in humans the act of eating is enveloped by economic variables 
and social influences pandered by beliefs, attributions and cognitions 
(233). 
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An examination of the structure of feeding activities reveals a highly 
organised sequence of actions which have a clearly defined beginning and 
end. There is a strong possibility that mechanisms responsible for the 
initiation of a feeding occasion (appetitive phase) may differ from the 
mechanisms which maintain the behaviour (consummatory phase) (181/ 182). 
3.2.2 Hunger and Appetite - Constructs in Search of Identities 
Hunger and appetite are considered to be two distinct physiological 
phenomena and the differences between them are important when designing and 
evaluating clinical studies. Hunger is defined as the physiological need 
for food occasioned by food deprivation (bodily sensations) and appetite 
is defined as the psychological motivation for food which ;s independent 
of the nutritional state of the individual (mental signals) (235/ 239/ 
243) • 
L ike many other behaviour sequences/ feeding ;s a periodic series of 
discrete events with a definite temporal structure. Human feeding ;s 
distributed in episodes which can be regarded as discrete meals. 
Consequently, the meal can be regarded as one basic unit of analysis of 
feeding behaviour. Although there ;s a great deal of controversy over the 
definition of a meal, meal pattern analysis provides one way of isolating 
events that occur at the initiation of an eating episode; during the 
maintenance of eating behaviour/ toward the close of a feeding period and 
which inhibit further eating following ingestion. The partitioning of 
eating into three basic phases - initiation, maintenance and termination -
suggests one way in which hunger/ appetite and satiety may be related to 
observed behaviour (182). 
Figure 3.1 represents the most significant motivational criteria which are 
likely to alter during the ingestion of food. At the initiation of a meal/ 
hunger is characterised by strong hunger sensations and a low fullness 
value, a high hedonic rating, a large score on the food preference 
checklist and a relative preference for protein. At the close of the meal/ 
satiation is characterised by low hunger but high fullness ratings/ a low 
checklist score 
preference for 
terminology). 
indicating sensory-specific satiety and a relative 
carbohydrate {vide infra 3.3.2 for discussion of 
FIGURE 3.1 
Pre-meal 
Hunger 
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Fluctuations in aspects of appetite which accomapny 
ingestion during the course of a meal 
Reproduced from Blundell and Hill (236) 
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When used in coalition with the technique of temporal tracking (vide infra 
3.3.2.1.2), the use of this system provides information that concerns the 
psychological state preceding the meal, accompanying eating and following 
consumption (199, 236). 
Hunger can be regarded as a process which indicates that eating is imminent 
and primarily determines the onset of eating while exerting a very small 
effect on the amount eaten (181). Appetite is intimately linked to the 
sensory qualities of food such as taste, texture and temperature, features 
which are commonly referred to as palatability. Appetite exerts a primary 
effect on the commodities selected, the rate of ingestion and the amount 
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consumed (181, 182). Food selection is a function of the appetite mechanism 
and this proposal ;s consistent with the concept of specific appetites for 
particular nutrients and food commodities (182). 
A further distinction that must be made for technical precision is that of 
satiation and satiety. Satiation refers to the process of bringing the meal 
to a close while satiety connotes the state of inhibition over further 
eating. Satiety is defined by feelings of disgust or surfeit caused by 
excess food, gratification beyond onels natural desire or by lassitude due 
to repletion (181, 182). 
The conceptualisation in Figure 3.2 represents a distinction between hunger 
and appetite and relates these terms to the structure of eating behaviour. 
One particular advantage of this scheme is the separation of the urge to 
eat from the amount of food consumed and more accurately suggests a 
dissension between those factors which influence the urge to begin eating 
and those wh i ch promote consumpt i on once eat i ng has begun. Th i s mode 1 
suggests a disengagement between hunger and appetite based on a 
distinction between willingness to obtain food and willingness to eat food 
once it has been obtained. This idea is consistent with the observation 
that the amount of food consumed frequently fails to correlate with the 
degree of experienced hunger, particularly if the food tastes bad (182). 
FIGURE 3.2 
Category of 
subleclive 
e"perience 
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feelings 
I Observed 
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Operations 
Postulated relationship between formal eating operations 
and the accompanying subjective experiences 
Reproduced from Blundell (182). 
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It is generally understood that states such as hunger and satiety bear some 
relation to food consumption. However, the terms cannot be defined by 
reference only to the bulk of food consumed. In an attempt to find 
identities for hunger and satiety it may be questioned whether an organism 
observed to be eating does so in response to the presence of hunger, or to 
the absence of satiety (181, 182). 
In studies on human feeding, the identification of hunger and satiety is 
sought in correlated sensations or physiological events. Initially it would 
be unwise to assume the source of i nformat ion of verbal reports of an 
experience such as hunger, as the person may be commenting on (181): 
(1) the presence of a true physiological need 
(2) the existence of physiological events or physical stimuli unrelated 
to bodily needs 
(3) the observation that other people have initiated consumption 
(4) stimulating effects of the presence of attractive foods 
(5) deprivation state since the previous meal, or 
(6) the appropriateness of remarks preceding the start of eating. 
3.3 EVALUATION OF ASPECTS OF EFFICACY 
There are three measurement criteria considered important when assessing 
the eff i cacy of an anorect i c agent in humans. Anorect i c eff i cacy is 
objectively measured in terms of (1) the amount of weight lost, (2) the 
extent of overall food intake reduction and (3) the degree of 
hunger/appetite suppression experienced. 
In the present context, it is important to measure the effect of a drug on 
subjective hunger, appetite, satiety and food consumption since these 
factors largely, if not entirely, determine how the drug in question 
influences body weight, and it is this drug-induced weight change which is 
generally the most clinically significant effect (239, 240). 
3.3.1 Measurement of Body Composition 
There are numerous methods available for the measurement of body fat or 
composition. A variety of sophisticated laboratory methods exist for 
obtaining direct and reliable estimates of body fat and include underwater 
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weighing, vo lume di sp lacement, radiograph i c ana lys is 1 ana lys is. of 
potassium-40, isotropic dilution and ultrasound techniques. While these 
techniques are certainly valid, they are time-consuming and costly in terms 
of equipment and trained technicians, and are therefore impractical (178, 
237). 
The most widely used indirect technique is to check an individual1s weight 
for their given height, frame size l age and sex against published desirable 
or ideal weight tables which are based on population averages 1 such as 
those prepared by the Metropolitan Life Insurance Company of America (255)1 
for example. 
Percentage overweight is then obtained from the following equation 
(Equ.3.1): 
% Overweight = Initial Body Weight - Ideal Body Weight 
X 100 
Ideal 80dy Weight 
Eqn 3.1 
Height-weight indices comprise essential baseline data, but may be poor 
indicators of obesity. The major deficiency of standard height and weight 
tables is the inability to differentiate lean body mass from fat weight, 
thus limiting their use for estimating fat proportions (175, 178). 
As opposed to reliance on these height-weight tables l the Quetelet Index 
or Body Mass Index (8MI) has been recommended (175). 8MI is calculated 
using the following formula (Equ. 3.2): 
80dy Weight (kg) 
[Height {m)J2 
Eqn 3.2 
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An individual with a BMI of 27 kg/m2 is roughly 20% overweight (228). An 
important distinction that must be made is that the term overweight refers 
to deviations in body weight from some standard weight related to height 
and may not necessarily mean obese (175). The definitions of these terms 
are as follows: 
Overweight! 
1. BMI of 25 to 30 kg/m2. 
2. Body weight between the upper limit of acceptable and 20% above that 
limit. 
Obese: 
1. BMI greater than 30 kg/m2. 
2. Body weight more than 20% above the upper limit for height. 
3. Body fat 25% of body weight in males or 30% in females. 
Skinfold fat and body circumference are the two anthropometric variables 
most commonly used in body density predictions. Using sound techniques, 
skinfold thickness measurements can be reliable predictors of percentage 
body fat if they are not used inter-rae; a lly or in the gross ly obese. 
However, skinfold measurements are not useful to assess slow, gradual 
weight loss and accurate measures are needed by trained personnel (175, 
237). 
Usually the sum of the skinfolds taken at seven anatomical locations are 
used as reliable measures of subcutaneous fat. Figure 3.3 is a 
diagrammatical representation of the location of these sites on the human 
body. 
However, it has been suggested that the age of the individual and sum of 
three skinfolds can be used to evaluate adult body composition and % body 
fat. These sums provide a good representation of the total body with regard 
to gender and are highly correlated (r > 0.97) with the sum of seven 
skinfolds. Percentage fat is estimated from the age of the subject and sum 
of their skinfolds using standard tables (237). 
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The preferred sum of three skinfolds are different for men and women and 
include: 
MEN: Sum of chest, abdomen and thigh skinfolds 
WOMEN: Sum of triceps, suprailiac (iliac crest) and thigh skinfolds 
FIGURE 3.3 Skinfold sites on the human body 
Reproduced from Ross and Marfell-Jones (238) 
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Anthropometric measurements and somatotyping may be useful in assessing the 
degree of obesity and identifying other characteristics, such as peripheral 
or central fat distribution, which can infer expected morbidity and 
prognosis (218). 
3.3.2 Measurement of Hunger, Appetite and Satiety 
Before a quantitative determination concerning the effects of drugs on 
subjective hunger can be made, a "measuring" instrument that is both valid 
and reliable is required, to allow the subjective sensations underlying 
hunger to be translated into aDjective data (239, 240). However, the 
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measurement of hunger and appetite in man, critical in the objective study 
of food regulation and obesity presents conceptual and methodological 
problems and is not a simple issue, as often presumed (245). 
The only means of IImeasuringll hunger and appetite is to ask a subject to 
compare one experience with another using a ranking procedure: that is, 
to ask the subject whether he or she was more or less hungry than on a 
previous occassion, and to assign numerical scores to these rankings. These 
numbers can then be manipulated using various statistical techniques (239). 
3.3.2.1 Ratings of Hunger Appetite and Satiety 
The two most comnmon rating methods used are fixed-point scales and visual 
analogue scales. 
3.3.2.1.1 Fixed-Point Scales 
Fixed-point scales, also known as multi-stem scales (241) are quick and 
simple to use, and the data that they provide are easy to analyze. Viewed 
simplistically, these scales are numerical indications of the absence or 
presence of hunger. However, the scales can vary greatly in complexity. 
Different research groups have tended to construct their own scales, which 
vary not only in the number of points used but also in the definition of 
the measured variable (242). Thus some researchers have used five-point 
(63, 243) and others seven-point scales (244, 245). For example, a seven-
point scale would contain the numbers 1 through to 7 and text assignment 
in terms of hunger would be of a similar order to 1 = not at all, 2 = a 
little, 3 = somewhat, 4 = moderately, 5 = quite a bit, 6 = very and 7 = 
extremely. 
3.3.2.1.2 Visual Analogue Scales 
One way of overcoming some of the disadvantages of fixed point scales is 
to abolish the points and bypass the numbering system completely. Visual-
analogue scales (VAS) are horizontal lines, usually 100 mm long, unbroken 
and unmarked except for word anchors at each end of the extremes of the 
subjective feelings to be quanitified. For use in experiments involving 
hunger and food intake, a hunger VAS, one end of which is labelled IINOT AT 
ALL HUNGRY II and the other end liAS HUNGRY AS YOU HAVE EVER FELTIl is used 
(246, 247). The user of the scale is instructed to mark the line at a point 
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that most accurately represents the intensity of the subjective feeling at 
that time (242, 239, 240). 
For analysis of the results l the answer mark on the line of the scale is 
measured to the nearest millimetre 1 producing a score of between 0 and 100 
for each determination (246/ 247). When subjects are presented with a 
succession of hunger VAS at fixed intervals/ the pattern of their hunger 
response to a drug or other experimental variable can be evaluated (246). 
Silverstone et al have found VAS to be both valid (239, 246) and reliable 
(239) in terms of between-subject reliability ((276) and test-retest 
reliability (239). 
The benefits of fixed-point scales have been retained by visual-analogue 
s~ales whilst the problematic effects associated with either comprehension 
of descriptive terms or number preference I have been avoided. In a direct 
comparison of the two methods, it was found that VAS were as accurate and 
reliable as a fixed-point scale but more sensitive in studies registering 
the effects (242). However, it was demonstrated in a recent study (241), 
that these two methods of presenting response opt ions show comparab le 
responsiveness and validity. Moreover, it was concluded that the ease of 
administration and interpretation of the seven-point scale recommneded its 
use. 
Visual-analogue scales do, however, contain some anomalies in their 
distribution of responses. Much of this deflection from a normal 
distribution is a consequence of using bipolar scales (eg. tired/alert, 
hungry/satiated) rather than using unipolar scales (eg. very tired/not at 
all tired, hungry/not at all hungry) (242). 
In studies of subjective experiences accompanying eating, VAS have been 
used to monitor changes in hunger ratings before, during and after 
ingest; on of a mea 1. Th i s method of II tempora 1 track i ng II has revea 1 ed 
hitherto unpredicted effects of physiological and sensory manipulations. 
In addition, this technique allows changes in subjective ratings to be 
related to different sections of the behavioural sequence (242, 250). It 
has been observed by Blundell et al (278) that although anorexic drugs 
suppress ratings of hunger prior to a meal, once eating begins these levels 
55 
are reinstated to control levels. 
The psychophysical technique of cross-modal matching has been used to scale 
perceived satiety (248). The technique requires a subject to adjust the 
length of a metal tape whose graduations are visible to the experimenter 
only, at two minute intervals while eating a fixed-amount meal. Although 
the validity of using the magnitude estimation method was confirmed, 
reliability of the technique was judged to be uncertain. 
Subjective ratings made on visual-analogue scales, fixed-point scales or 
by psychophysical techniques such as magnitude estimation, show subjective 
hunger to increase steadily as mealtime approaches and to decrease sharply 
after eating. Per~eived satiety rises steadily during the course of the 
meal and decreases steadily afterwards (199, 236). It is generally believed 
that the higher the hunger rat i ngs, the more food wi 11 be consumed. 
However, the correlation between pre-meal hunger ratings and the actual 
amount of food consumed varies from moderate (246) to weak (249). Also in 
pathological conditions such as anorexia nervosa or bulimia, ratings of 
hunger and satiety may not be correlated with consumption (250). 
One reason that ratings of conscious experiences of hunger and satiety may 
not successfully predict behaviour, is because they require each volunteer 
to describe all their experiences in a single continuum, or to select one 
sensation which is assumed to correlate highly with that category of 
subjective experience, to the exclusion of other sensations (250). 
The weaknesses associated with simple numerical rating scales have led to 
the development of a more complex formulation in which subjects can 
partition their subjective experiences into physical, emotional and 
cognitive aspects. Hill and Blundell (250) propose a multidimensional 
approach to hunger, which is founded upon an analysis of changes in bodily 
sensations and feelings which incorporates aspects of taste hedon;cs, food 
preference, stimulus-induced-salivation and patterns of eating. Figure 3.4 
outlines this strategy and depicts procedures for sequential monitoring of 
causal factors such as physiological state and environmental cues, which 
dictate factors such as food preferences and salivation to a stimulus 
(conceptua 1 i zed as med i at i ng mechan isms) wh i ch re 1 ate d; rect 1 y to the 
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observed outcome in terms of the behavioural feeding pattern. The authors 
postulate that this approach could make categorisation of hunger much more 
sensitive as an indicator of nutritional adjustments (250). 
FIGURE 3.4 Conceptualization of the procedure for measuring and monitoring 
hunger 
Reproduced from Hill and Blundell (250) 
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One technique widely employed to identify hunger and satiety experiences 
is a checklist of physical sensations, coupled with checks upon the 
intensity and duration of thoughts of food and the urge to begin eating or 
the resistance to stopping (182). 
In the study of feeding, subjective experiences are usually derived from 
certain physical sensations of which, the most widely acknowledged, occur 
in the stomach. Many people perceive that hunger is signalled by an empty 
or rumbling stomach sensation and interpret gastric fullness as satiation. 
There are however, other easily identifiable sensations associated with 
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eating whose location is in the head, mouth or throat, as well as less 
easily defined bodily feelings (242). 
Studies of bodily sensations often list the individual items in the form 
of a checklist. The subject1s place a mark next to any of the sensations 
or feelings that are being experienced at that time (251/252). The 
checklist may be scored as the total number of items checked or may be 
categorised according to location. The number of times a group of subjects 
mark any item may be compared before and after various treatments to 
indicate treatment-induced changes in subjective sensations. Factor 
ana 1ys i s of the data may then be performed to demonstrate the most 
significant effects (250). 
Clear differences in sensations have been detected between pre- and post 
prandial ratings (251) and between normal subjects and individual1s 
suffering from anorexia nervosa (252) thereby giving credence to the belief 
that these sensations do provide a source of information which is used 
during reports of hunger and satiety. The administration of drugs with 
markedly differing pharmacological profiles have been shown to adjust 
bodily sensations in a manner consistent with their neurochemical actions 
(247). This data shows that bodily sensations could provide a sensitive 
indicator of nutritional manipulations. 
3.3.2.3 Taste Hedonics 
Taste stimuli, like bodily sensations, have clearly distinguishable 
properties. A taste stimulus may be judged according to its intensity 
(strength) and to its hedonic (pleasantness) properties. It is known that 
people vary in their ability to perceive particular tastes. The reasons for 
th i s are var i ed and inc 1 ude adrena 1 cort i ca 1 ; nsuff i c i ency I diabetes I 
cancer, taste bud pathology, nutrition, and age (242). 
The usual way of evoking hedonic responses to a taste is to offer a range 
of concentrations of the taste stimulus and to plot hedonic appreciation 
as a function of increasing concentration. The concommitant measurement of 
intensity enables computation of detection and recognition limits and has 
shown taste stimuli to have unforseen hedonic properties even when they are 
apparently undetectable. Moreover these II expectancy ratings" differ 
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according to weight status (242). 
Using this method of data collection, three important properties of taste 
hedonics have been observed, as summarised by Blundell (242). Firstly, the 
relationship between pleasantness and the concentration of a solution is 
different to that of intensity. Secondly, inter-subject variablilty exists 
in this relationship, with two characteristic pleasantness-concentration 
profiles emerging. Type-I responders show a decrease in preference for 
sweet stimuli, while Type-II responders show a monotonic rise in 
pleasantness as sweetness increases. 80th types of responders are found in 
all weight categories. However, there is evidence that a greater proportion 
of the obese are type-I reponders (242, 250). 
Thirdly, subjects' hedonic response to a sweet stimulus depends in part on 
their physiological or nutritional state. Alliesthesia , a word coined by 
Cabanac (213) and meaning Uchanged sensation", describes the dependence of 
hedonic experience on the internal environment. It is best shown by the 
decrease in pleasantness of a sweet solution after ingestion of a nutritive 
glucose meal (242). 
The real importance of alliesthesia is likely its functional properties; 
that is, the decline in preference for a sweet taste leading to decreased 
food intake and so being part of the process of satiation (242, 250, 258). 
3.3.2.4 Food Preferences 
Apart from the total amount of food eaten, food preferences occupy an 
important position in the causal chain of mediating mechanisms underlying 
the consumpt ion of food. A bas i c assumpt i on is that food preferences 
determine food intake. The preference for one food is not simply the sum 
of preferences for that foods' associated tastes; other qualities may be 
important such as odour, texture, temperature, socio-cultural influences 
and metabo 1 i c and neuro-chem; ca 1 effects. As summar i sed by Hill and 
Blundell (250) IIfood preference is thus a multidimensional composite of all 
these factors, which may differ in their relative output" . 
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The most simple technique to assess changes in food preferences, is to 
construct a short checklist of food items. The subjects l task is to check 
the items that they would like to eat, considering each one independently 
of the others. The overall score constitutes a range of food preferences. 
Priority preference may be demonstrated by asking the subjects to rank the 
food items in order of preference. Alternatively, the frequency of checking 
food items may be compared between two or more predetermined categories 
such as high calorie-low calorie or high protein-high carbohydrate to 
reveal changes in macro-nutrient preference. Variants of this checklist 
method often include hedonic scales or visual-analogue scales associated 
with each item (242). 
Blundell and-Rogers (247) used a food preference check-list consisting of 
a II menu ll of 30 basic food commodities whose nutritional composition could 
be readily identified by the subjects, on which the subjects I indicated 
their preference at that moment. The list was divided into high-protein and 
high-carbohydrate items for the purpose of analysis. A relationship was 
found between the presumed neurotransmitter effects of various drugs and 
their effects on preferences for foods rich in proteins and carbohydrates. 
This type of checklist does not lack sensitivity as a low dose of 
fenfluramine did not effect food intake or hunger ratings, but selectively 
reduced preferences for carbohydrate-rich items (247 , 250). 
An alternate approach to quantifying food preference other than the check-
list or eating scale methods is the forced-choice procedure. Using this 
technique, the subjects are presented with the names of two food items on 
printed cards and are required to express a preference for one, allowing 
both relevant pref~rence scores and individual hierarchies of individual 
preferences to be assessed (242, 250). This procedure has provided 
unambiguous measures of individual food preferences in a study of anorexia 
nervosa patients (250). 
3.3.2.5 Salivation 
Pavlov (240) in his experiments on conditioned reflexes, used the salivary 
response to the sight of food as a measure of an animals l desire to eat. 
He noted that such salivation could be affected by the nature of the food 
present, and how long it had been since the dog had last eaten; the longer 
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the period of deprivation, the greater the 
basis of this and other reports, Wooley and 
salivation in response to the sight of food 
measure appetite in man. 
salivary response. On the 
Wooley (245) suggested that 
may be used to objectively 
The secretion of saliva is an involuntary accompaniment to eating and the 
salivatory response has the capacity to be conditioned to the arrival of 
food and to anticipate eating. These anticipatory repsonses are known as 
cephalic reflexes and are sensitive to the sight and. smell of food. 
Functionally they act to prepare the digestive system to receive food 
(242). 
A number of findings have motivated sal ivation to be envisaged as a 
reliable index of the quantitative measurement of appetite. Firstly, it is 
apparently uncontaminated by the cognitive and methodological variables 
that influence pen-and-paper ratings (242). Secondly, it has been shown by 
Wooley and Wooley (245) that anticipatory salivation is modulated by 
palatability and deprivation and correlates Significantly with ratings of 
hunger and food appeal. In addition, salivation is easily measured (242). 
There are three basic measurement techniques. The most widely used is the 
Strongin, Hinsie and Peck (SHP) method. This method consists of placing 
three preweighed 38 em cotton dental rolls in the subjects l mouth (one 
sublingual1y and two bucal1y), leaving them in place for a two-minute 
collection period, removing and reweighing them. The average weight of 
saliva collected in grams in the three 2-minute collection periods 
separated by a 2-minute rest period constitutes a single measure for a 
single subject. The dental rolls are packaged in polyethylene bags with 
twister seals and are weighed to the nearest milligram before and within 
one hour of use (245). 
An alternative to this procedure which requires very little specialized 
equipment, is the Lashley suction cup which monitors saliva flow rate from 
a single group of salivary glands. This device takes the form of a plastic 
cup positioned unilaterally or bilaterally over Stensen1s duct and held 
to the inside of the cheek by negative pressure, which draws the saliva to 
the recording device (242, 256). This method is very accurate and may be 
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used to provide continuous records of saliva flow over relatively long 
periods of time} such as an hour. 
In contrast to both of these methods, which are intrusive and somewhat 
uncomfortable, the total salivary output can be collected from the mouth. 
This may be done by suction using a dental fluid ejector continuously or 
at the end of a timed period 1 or by simply voiding the accummulated 
secretions into a pre-weighed container (242, 254). 
Comparisons of these methods have shown them to be significantly 
intercorrelated. An important consideration is the design of the 
experiment. There are two basic ways in which salivation is studied. The 
one way ;s to measure salivation in a range of subjects and to correlate 
it with another variable such as weight or dieting status (242). The other 
method which is used more frequently is to establish a baseline of 
salivatory response and to compare this with the level of salivation evoked 
by a food-related stimulus. The stimulus used in lIstimulus-induced 
salivation ll may be the sight or smell of real food, a food word or thinking 
about food (242, 245). 
Stimulus-induced salivation (SIS) has been shown to be a sensitive measure 
as a low dose (IO mg) of amphetamine reduced SIS before any effect could 
be seen on hunger ratings (257). In addition to deprivation and 
palatability (245L SIS has also been shown to be influenced by body 
weight, by dieting to lose weight and is even dependent on the time of day 
and it appears that salivation is a supersensitive response (242). These 
factors may account for the inconsistent relationship found between 
salivation and hunger ratings in studies varying in methodology and 
experimental design. Blundell and Rogers (247) observed pronounced 
decreases in baseline salivation following anorexic drug administration. 
The authors suggested that the timing of the salivation tests was most 
likely to have been the cause of this reduced salivatory response, as a 
sufficient interval was allowed to elapse enabling peak drug concentrations 
to be reached. 
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It has been suggested by Sahak ian (254) that more attent i on to the 
cognitive and sensory processes involved in both salivation and appetite 
ratings is needed to clarify the conditions under which ratings of hunger 
and food appeal are correlated with the size of the salivation response 
induced by food. He mentioned, in particular, that the effect of 
palatability on salivation will depend on the dieting status of the 
indivdual. 
However, Blundell (242) states, that llit remains to be confirmed whether 
sa 1 i vat i on represents a g 1 aba 1 index of hunger or appet i te 11. He a 1 so 
suggested that, on the basis of findings in other studies, SIS may be used 
as a measure of alliesthesia and of sensory-specific satiety. 
3.3.3 The Measurement of Food Intake 
From the dawn of time it has been evident that the acquisition and 
consumption of food is an essential factor, not only of health and welfare, 
but also of social life (259, 260). Due to recent interest in possible 
associations between diet and health, clinicians and nutritionists have 
realized a need for dietary methods to reliably assess the nutritional 
intake and status of individuals and population groups. These methods 
should be simple, accurate, cost-effective and above all, readily 
applicable in epidemiological investigations (259, 261). 
There are two approaches to measuring food intake in man, the indirect and 
the direct. 
3.3.3.1 Indirect Measures 
The methods used to indirectly survey individual and group dietary intake 
and practices are varied and include numerous forms of diet history 
questionnaires and recall techniques, which are used to obtain data on 
habitual quantitative intake of food items, and diet diaries which are used 
more frequently (259, 260, 262). Diet diaries are detailed records, kept 
by the subject, of foods consumed over a period of time and are 
particularly useful in the longer-term assessment of the effects of drugs 
on food intake, especially if such observations are extended over days or 
weeks (239, 240). 
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Individual dietary studies fall into two basic categories} that is} 
recording present intake and past intake. 
3.3.3.1.1 Recording Present Intake 
This method, used on an individual basis l requires the subject to maintain 
detailed dietary records of all foods and beverages ingested over a period 
of time. Portion sizes may be estimated using food models or photographs 
(262) and/or standard household measures, or alternativelYI all ingredients 
used in the preparation of the food may be precisely weighed (263) I 
together with the wastage at the end of the meal (259, 261, 264). 
OviouslYI while the latter is a more precise method I it requires frequent 
supervision by the clinician and a great deal of participant effort I 
motivation and cooperation. A problem indigenous to both methods is the 
constant focus of attention on food selection and consumption. Thus, high-
1 eve 1 se 1 f -man i tor i ng procedures may exert the i r own i nf 1 uence on the 
behaviour under investigation and alter normal eating habits (242). 
3.3.3.1.2 Recording Past Intake 
The methods used to aid the subjects to remember and describe their 
retrospective intake differ largely in the duration of the recall period. 
The method of choice for collecting dietary data has been the 24-hour 
recall, which elicits an inventory of the food intake for the previous day. 
The subjects are asked by the interviewer to note the foods eaten on a 
checklist or short questionnaire (262) or to detail their meals using 
estimated amounts of food. AlternatelYI a diet history of usual dietary 
intake may be obtained and supplemented by the 24-hour recall (242). 
A major drawback of 24-hour recall techniques is the questionable 
reliability of using a single daysl intake as a measure of habitual 
consumption (259). However, on the whole, recall procedures are quick and 
relatively inexpensive and require little specialist supervision. An added 
advantage of this technique is that limited time and effort is required on 
behalf of the participant (242). 
64 
Following its collection, dietary data are converted into caloric or 
nutritional information using standard tables of food composition. These 
tables contain lists of single food items and food dishes, both raw and 
cooked, describing the method of preparation. Details of caloric values 
(calories and kJ) and nutritional content (g, mg) per 100 g of edible food 
are given. Physiological values for the energy content of macronutrients 
are calculated using the Attwater factors, that is 4, 9, 4 cal/g for the 
energy available from protein, fat and carbohydrate respectively (265). 
However, there is some controversy about the accuracy of this procedure. 
Paul and Southgate (266) say of their own revision of McCance and 
Widdowson's, liThe Composition of Foods ll , the values are of IIrepresentative 
samples ll of the foods and as such may reflect the lIaverage composition ll of 
the food. Data from large population groups should exhibit intrinsic 
accuracy and the accuracy of studies on individuals may be improved by 
extending the size of the sample (242). 
3.3.3.1.3 Observational Studies 
The quantity of food consumed during a meal has been used as the dependent 
variable in many studies to determine human eating behaviour. However, 
careful observation of an individual while he is eating may permit the 
detection of certain subtle differences between drug actions that are not 
revealed by a simple measure of the amount of food consumed (181, 249). The 
classification and subsequent quantitation of the entire micro-structural 
sequence of eating behaviour is enabled by using data obtained from 
observational techniques. 
Behaviour may be monitored in naturalistic settings (cafeterias, 
restaurants or homes) or in the laboratory under controlled conditions. 
Analysis may be performed on IIlive " behaviour or carried out from video 
recordings. Generally, the observational method frequently employs some 
form of sampling. Event sampling requires that every occurence of a 
specific event is recorded, and time sampling indicates monitoring of 
events occuring at specific intervals during the observational period (216, 
240, 242). 
65 
For eating behaviour, which normally spans duration of a meal, a 
significant number of events (taking a bite, swallowing, etc.) are 
continuously recorded by an observer. In studies of eating behaviour, the 
main variables are extracted and calculated from various combinations of 
the rate and frequency of chews, mouthfuls and pauses between eating bouts, 
and are listed in Table 3.1. 
TABLE 3.1 Parameters of eating derived from the analysis of the micro-
structure of behaviour 
Reproduced from Blundell and Latham (181) 
1. Total food intake (g) 
2. Duration of time spent eating (minutes) 
3. Latency (time elapsed before onset of eating) (minutes) 
4. Number of eating bouts 
5. Size of bouts (g) 
6. Duration of bouts (minutes) 
7. Local rate of eating (g/minute) 
Observational techniques are time-consuming as close scrutiny of the video-
tapes is required by an independent observer to ensure that the data 
obtained is both accurate and reliable (239, 240, 242). 
Alterations in these variables have been used in attempts to detect 
differences between drugs with different neurochemical profiles (267), 
between foods of various preference values (216), between obese and normal 
weight individuals (268) and to assess the development of satiation during 
the course of a meal (249). 
3.3.3.2 Direct Measures 
Methods used to quantitate human food intake directly include various 
techniques of measuring the amount of a standardised liquid or solid meal 
consumed during an experimental test session. Over the past 20 years, 
numerous specialized devices have been developed and existing tools adapted 
to improve the sensitivity, accuracy and reliability of the measurement of 
food intake in humans. Most provide continuous intake monitoring, some are 
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designed for liquid nutrient rather than solid food 1 whilst others allow 
a degree of food choice. Some attempt to allow unobstructed eating to 
occur 1 while others demand an unnatural eating response. 
3.3.3.2.1 Liquid Nutrients 
Hashim and Van Italie (269) developed a technique to ensure accurate and 
continuous measures of caloric intake in man. The apparatus consisted of 
a mouthpiece connected 1 by means of flexible tubing 1 to a concealed 
reservoir containing liquid nutrient. The circuit was completed by the 
insertion of a valve and pump. As the subject depressed a button, the pump 
was activated and a measured quantity of liquid of pre-determined calorie 
content was delivered to the mouthpiece. It proved possible to monitor the 
intake of a subject per minute over several days by incorporating a timing 
device into the experimental apparatus (239, 240). 
Modifying this technique for experiments of 20 minute duration 1 Jordan et 
al (270). made use of a container of liquid nutrient, hidden from view, 
from which the subjects sucked ad libitum through a steel straw, under 
constant conditions. The volume of nutrient ingested was measured by the 
investigator who took readings from a graduated cylinder at fixed 
intervals. The device was modified in one experiment, so that the liquid 
was pumped into the subject's mouth (271). Using similar methodological 
approaches I numerous researchers were able to show that the ingestion of 
a liquid diet was sensitive to drug effects (63 1 180 1 272). 
A 1 though the consumption of 1 i qu i d foods can be recorded prec i se ly and 
measured with easel the use of such techniques to measure food intake is 
subject to significant limitations and hence far from optimal. In 
substituting liquid nutrient for solid food as the sole source of energy, 
one is effectively measuring drinking and not eating. It is clear that 
these methods do not emulate normal behaviour as the nutrient provided is 
monotonous and unusual, as no element of choice 1 nor opportunity to savour 
the various tastes and textures is possible (239, 240 1 273). 
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3.3.3.2.2 Solid Food 
A number of techniques have been devised to overcome the problem of direct 
measurement of the quantity of solid food eaten over a given period of 
time, in terms of actual caloric intake and mass of food consumed. As with 
many forms of clinical measurement, proposed methods are a compromise 
between measurement accuracy and ease of application. 
3.3.3.2.2.1 Bomb Calorimetry of Duplicate Meals 
Two identical duplicate meals are prepared with weighed and measured food 
constituents. The subject is requested to eat his fill from one of the two 
meals. The remaining food is placed in a bomb calorimeter, ignited by means 
of a small electric current and the heat of combustion calculated from the 
rise ;n temperature in the calorimeter. From these physical measurements 
the calorie content of the meal can be determined. The calorie content of 
the untouched duplicate is similarly measured, the difference between the 
two being equivalent to the calories consumed by the subject (274). 
This is the most accurate of all the available methods to determine calorie 
consumption at a given meal but it ;s limited to studies involving a small 
population of only one or two subjects at a time. The method requires 
detailed analysis by an expert dietician and is thus both time-consuming 
and expensive (239 1 240 1 242). 
3.3.3.2.2.2 Standardised Foods and Sandwich Meals 
A standardised sandwich meal was developed in an attempt to combine ease 
of measurement with a certain amount of variety in as naturalistic setting 
as possible (239, 240). At each meal subjects received a predetermined 
number of quartered crust less sandwiches. Each constituent was accurately 
weighed and the calorie content determined from standard food composition 
tables. Following meal cessation, the number of each sandwich variety and 
mass of constituent was recorded and the total calorie consumption 
calculated. This approach has been successfully applied in a study of the 
effects of dextro-amphetamine (242). 
More recently, methods have been developed and used whereby the intake of 
certain standard foods such as nuts, crackers and sausages of known calorie 
content is measured (240). However, while it is a relatively simple 
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procedure to count the number of crackers, nuts, sausages and sandwiches 
consumed, the foods ,themselves lack variety and'are more in the nature of 
snacks than complete meals. 
3.3.3.2.2.3 Automatic Monitoring via Eating Utensils (BITE) 
In order to gain more insight into the mechanisms controlling food intake, 
it ;s necessary to observe and measure eating parameters and to eastablish 
human eating patterns in the presence and absence of disease states. The 
Bite-Indicating Telemetering Eatometer (BITE) was developed by Moon (275) 
to continuously monitor the consumption of solid and semi-solid foods. The 
technique is based on the recognition that human eating is composed of a 
sequence of contacts between the mouth and the eating utensil and that the 
number of contacts is proportional to the amount of food consumed. 
Therefore, by continuously monitoring these utensil-to-mouth contacts, it 
becomes possible to track the temporal course of food consumption. 
The BITE apparatus records the rate and frequency at which a subject 
deposits food orally using specially constructed spoons and forks with 
handles containing telemetering equipment (275). Mouth contact permits the 
passage of current from the utensil to the handle, which constitutes a 
signal that is telemetered to recording devices by a battery-powered 
transmitter within the utensil handle. 
Studies using the BITE apparatus have shown that a continuous record of all 
utensil-to-mouth contacts can be obtained over a set period of time. The 
value of such measures may be augmented with the addition of a weighing 
cell, which would provide a continuous measure of total food and calorie 
intake over the same time period (239, 242, 275). 
At the moment, the full potential of this system is unknown, as to date no 
drug stud i es have been undertaken us i ng these nove 1 e 1 ectro-mechan i ca 1 
methods. While they might allow an accurate representation to be made of 
the detailed micro-structure of eating, they do not allow more extended 
observations, nor can they furnish information about food choice (242). 
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3.3.3.2.2.4 Monitoring Intake via the Plate (UEM) 
Whi 1 st the BITE procedure attempts to ana lyze the structure of eating 
behaviour by monitoring intra-meal events such as mouthfuls and intervals, 
it falls short of the requirement to monitor changes in the actual weight 
of food consumed without the addition of a weighing cell. A device called 
the IIUniversal Eating Monitor ll (UEM) was developed to continuously measure 
alterations in the amount of normal chewable solid foods or liquids 
ingested (273). However, the disadvantage of this technique is that no 
measure ;s made of the physical elements of eating. 
A concealed electronic balance on which a plate containing the food rests, 
;s conncected to a specialized digital computer which automatically 
monitors the weight of food on the plate, producing a cummulative intake 
curve for the entire period of study. A pilot study utilizing this 
technique demonstrated that it could accurately and precisely temporally 
track the intake of 1 i qu i d and so 1 i d foods, and that the dev ice ; s 
sensitive to some of the factors influencing overall food consumption 
(273). The results obtained in a recent study to evaluate the effect of the 
gut hormone cholecystokinin {CCK-8) on eating illustrates the potential of 
the method for use in investigations of the effects of anorectic drugs on 
food intake (242). 
3.3.3.2.2.5 Food Dispensing Machines 
Many of the techniques used to study human eating behaviour have been 
improvised from tactics used to monitor animal feeding patterns. The 
principle of using pellet dispensers and eatometers to measure the effects 
of pharmacological manipulations on animal feeding patterns has recently 
been extended for studies of anorectic drug effects on human food intake 
patterns (276). 
The solid-food dispenser is a modified commercial food vending machine 
which provides quartered sandwiches as food units that are accurately 
controlled with regard to weight/ nutrient content and calorific value. The 
removal of each food unit from the apparatus is monitored and a cummulative 
record of the caloric intake and behaviour of the subject ;s obtained. The 
use of this technique has been shown to detect alterations in eating 
profiles induced by anorectic drugs and to compare temporal patterns of 
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hunger ratings and food intake (242, 276). 
An advantage of this type of device is that by stocking it with food items 
of different macro-nutrient composition, it is possible to measure protein 
and carbohydrate intakes separately and to assess particular nutrient or 
taste preferences (276). 
3.3.3.2.2.6 Monitoring of Chewing and Swallowing - The Edogram 
The methods described thus far have attempted to trace human eating in two 
ways, either by monitoring the volume or weight of food consumed or by 
recording the behviour of the subjects as they eat. Observational methods 
have been used to record and ana lyse the structure of eat i ng behav i our 
(216) and finer units of behaviour such as salivation (245) have been used 
as objective measures to quantitate both the internal state of depletion 
and the sensory qualities of foods. 
Pierson and Le Magnen (222 1 277) initiated an automated and objective 
method for describing the micro-structure of eating and established the 
edogram. The edogram was composed from precise oscillating eletromyographic 
recordings of the fine motor sequences of the masseter muscles during the 
mast icatory movements known as chewing 1 in conjunction with para 11e 1 
records of deglutition or swallowing movements. 
More recently chewing has been measured by a strain gauge that monitors jaw 
movements wh i 1 e swa 11 owi ng has been measured by pressure changes ina 
balloon resting on the Adam1s apple and kept in place by an elastic collar 
(222 , 277). Figure 3.5 depicts a photograph of the equipment used for the 
recording of chewing and swallowing activity, where A is the head set with 
strain gauge, B is the balloon and liquid pressure transducer and C is the 
elastic collar. 
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FIGURE 3.5 Equipment for the monitoring of chewing and swallowing activity 
Reproduced from 8e11;s1e and Le Magnen (222) 
Head set with strain gauge (chewing) (A) 
Balloon and liquid pressure transducer (swallowing) (8) 
Elastic collar for maintaining the balloon on the subjects throat (C) 
c 
A 
The edogram represented in Figure 3.6 allows a fine temporal analysis of 
the chewi ng time per food un it, the number and frequency of chewi ng 
movements, the swa 11 owi ng i nterva 1 and the number and d i str; but i on of 
deglutitions per food unit (222, 277), This procedure provides a sensitive 
technique for the continuous tracking of calorie intake and for the 
detection of changes in important eating parameters affecting eating 
behaviour, as the standardised test foods used in these studies are 
normally a number of small distinctly flavoured sand¥,iches of known 
calorie content. With this device, it becomes possible to describe how 
eating behaviour and food intake is influenced by variables such as 
palatability of the food, level of deprivation and body weight of the 
subjects (242, 277). 
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FIGURE 3.6 The edogram 
Reproduced from Bellisle and Le Magnen (222) 
r-
PV 
10 sec. 
c 
3.4 EVALUATION OF ASPECTS OF SAFETY 
Deglutition movements (A) 
Swallowing movement (8) 
Chewing T.Ovements (C) 
As already mentioned in section 3.1, most of the appetite suppressant drugs 
on the market, due to their structural similarity to norepinephrine and 
their mechanisms of action, may cause adverse cardiovascular reactions 
manifest as increased blood pressure and heart rate, 'l'Ihich may lead to 
hypertensive crisis. In addition, these compounds may show abuse liability 
and dependence potential as a direct consequence of eNS stimulation. 
Although appetite suppressants differ in their relative potencies for these 
effects, it must established to what degree. if any, these agents can cause 
adverse effects. 
Abused substances share two primary measurable properties. Firstly they 
serve as reinforcers ("rewards" that contribute to compulsive drug-seeking 
behaviour), as determined from animal and human studies of drug 
administration and secondly they serve as euphorogenics that produce 
subjective feelings of euphoria and well-being, as determined from human 
self-report data. Additionally, abused drugs may be categorized on the 
basis of their interoceptive stimulus effects, measured using psychometric 
instruments in humans or drug discrimination trials in animals. Methods 
:'1ave been deve loped that re 1 i ab 1 y measure these or:Jpert i as of var i ous 
SUDS!anC2S ;n Joth anima:s ana numans and that a110w for comoarison wlth 
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the profiles of other drugs of known abuse potential (280-282). 
Abused substances produce behavioural (cognitive and emotive), 
physiological and subjective effects, of which subjective effects are 
crucial to predict abuse liablility. The basic technique is the single-dose 
drug administration procedure, which employs subjects who have previously 
used and abused psychoactive substances. Typically, double-blind procedures 
are i nst ituted and the test compound is compared with placebo and an 
appropriate positive control such as amphetamine in a study of anorectic 
agents, for example. Following administration of the drug, a variety of 
signs (observer reported) and symptoms (subject reported) are assessed at 
periodic intervals dependent on the time action of the drug (282). 
3.4.1 Measurement of Abuse Liability and Stimulant Effects 
Self-report measures of subjective drug effects are collected from the 
volunteers using structured questionnaires. The "Single-Dose Questionnaire" 
is the simplest psychometric instrument and contains four scales: the first 
determines psychoactivity of the drug, the second permits classification, 
the third permits characterization and quantitation of symptoms, whilst the 
fourth is a measure of euphoria (280). 
Another self-report measure is the Addiction Research Centre Inventory 
(ARCI) pioneered by Haertzen et al in 1963 (283). The ARCI questions were 
sampled from the responses made to sentence completion sterns by opiate 
addicts while they were under no-drug or various-drug states. The items so 
se 1 ected were cons; dered to be usefu 1 for the quant i tat i on of ord i nary 
states of being as well as for altered states of consciousness (284). The 
ARCI is a self-report true-false questionnaire with 550 empirically derived 
scales sensitive to various classes of psychoactive substances. 
Martin et al (281) sampled various items from several of the orginal ARC! 
scales which yielded a 49 item ARCI scale. The authors concluded from their 
investigations using this 49 item scale "that it would appear that the 
constellation of subjective and physiological responses herein described 
provides a valid measure of the abuse potentiality of amphetamine-like 
drugs ll • 
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Short forms of the ARCI, of which there are many, can be administered 
quickly and are especially useful for demonstrating potency, time actions 
of drugs and whether or not a drug effect is present. However, none of the 
short forms contain any estimate of possible subject carelessness in form 
completion (280). 
3.4.1.1 The Addiction Research Centre Inventory (ARCl) 
The 49-item version of the ARCI commonly used for the assessment of 
anorectic drug effects contains subsets from 5 scales: 
(1) The Morphine-Benzedrine Group (MBG) which is a general measure of 
drug-induced euphoria and well-being. 
(2) Amphetamine (A) which is a measure specific for dose-related effects 
of d-amphetamine. 
(3) The Benzedrine Group (BG) which is an amphetamine scale consisting 
mainly of items relating to intellectual efficacy and energy. 
(4) The Pentobarb i ta l-Ch 1 orpromaz i ne-A 1 coho 1 Group (PCAG) wh i ch is a 
measure of sedation and intoxication. 
(5) The Lysergic Acid Diethylamide Specific Scale (LSD) which is a 
measure of dysphoria and somatic symptoms. 
The 49 statements are presented in the form of a true-false questionnaire 
and the subjects are instructed to indicate whether each question is true 
or false as they go through the scale. 
3.4.1.1.1 ARCI Item Data Capture and Analysis 
The data processing program was written in Digital Equipment Corporation 
(DEC) BASIC and was kindly supplied by Dr L.D. Chait l Department of 
Psychiatry, University of Chicag0 1 Illinois (285). This program was 
converted to Microsoft GW-BASIC by Mr A.G. Soper, School of Pharmaceutical 
Sciences l Rhodes UniversitY1 Grahamstown l South Africa. In addition, Mr 
Soper added a data capture program. 
The data capture program, ARCICAP allows the responses to the 49 statements 
(items) to be entered from the ARCI questionnaire. The user is prompted 
with the relevant statement for each response 1 thus permitting ARCICAP to 
replace the ARCI form if so desired. A 11111 is recorded for a IITrue 
repsonse and a 110 11 for a IIFalse ll response. Captured data are replaced in 
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a fi le with a user selected name and the extension II .CAPII. ARCICAP performs 
some error checking and allows the user to make corrections. 
For data processing, a set of 49 responses is read from the data (.CAP) 
file. Eight primary scores [S(I) - S(8)J are computed from 8 subsets of the 
responses to the item numbers relevant to that score. These scores are 
allocated to the eight scales, that is, S(I) = PCAG neg, S(2) = 8G pos, ... , 
S(8) = LSD neg., etc. 
In the primary processing phase, the first 5 scores [S(I) - S(5)J receive 
ONE point for each TRUE response in the appropriate subset, with the 
remaining 3 scores [S(6) - S(8)J receiving ONE point for each FALSE 
response in the appropriate subset. The item number allocation relevant to 
the 8 primary scores and hence the 8 scales is listed below: 
SCORE 
5(1) Items 
S(2) Items 
5(3) Items 
S( 4) Items 
5(5) Items 
S( 6) Items 
5(7) Items 
S(8) items 
ITEM NUMBER ALLOCATION (Subset) SCALE 
1,2,3,4,5,6,7,8,9,10,11 ...•......• PCAG pas 
23,26,28,30,31,32,34,36,37 ...•...• 8G pas 
34,35,41,42,43,44,45,46,47,48 ..... LSD pos 
13,14,15/16/17,18,19,20,21,22,23, 
24,25,26,27 ...•................••. MBG pos 
24,25,26,27,29,30,31,32,33,34,35 .. A pos 
12,23,29,48 .............•......... PCAG neg 
10,38,39,40 ....................... 8G neg 
11,22,33,49 ....................... LSD neg 
In the secondary phase of processing, the 8 primary scores are combined as 
follows to yield the secondary scores which relate to the final scales: 
FINAL SCALf FINAL SCALE 
5(1) becomes 5(1) + S(6) PCAG 
S(2) becomes S(2) + S(7) BG 
5(3) becomes S(3) +S(8) LSD 
S(4) remains 5(4) MBG 
S(5) remains 5(5) A 
5(6) becomes 5(1) + 5(2) + 5(3) + 5(4) + 5(5) 
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As a check, if 5(6) now equals zero, scores 5(1) to 5(5) are each set to 
99 to indicate a condition of error. 5(6) is not used in the final result 
set. The final result set pertaining to the 5 ARCI scales is scores 5(1) 
to 5(5). 
Figure 3.7 shows a typically completed ARCI questionnaire. 
FIGURE 3.7 Typical Completed ARC! Questionnaire 
THE ADDICTION CENTRE RESEftRCH INVENTORY 
I NSTRUCTI OrJS 
These 119 i terns mayor 1l'<1Y not descr i be how yeu fee 1. C ire lethe T next to ea::h item nun:be; that 
describe how you feel. and ci;cle the F next to each item that does not describe hew you feel. 
'I 1. ,~ F 2. T F 3. T F 4. T ~ 5. T 0 6. 
:w, 7. 8. ~~ 9. 10. 11. ~~ 12. 13. I F 14. 
T F 15. TCD 16. 
F 17. 
F 13. 
F 19. 
F 20. 
F 21-
F 22. 
F 23. 
F ZJ 
F 25. 
F 26. 
F 27. 
F 28. 
F 29. 
F 30. 
F 31. 
F 32. 
T t:' 33. f~ JL 35. 36. 
fas 37. 33. 39. 
T 40. 
T 41-
T 42. 
T 43. 
.. 44. , 
T 45. , 
T 46. 
$ el7 • 48. , 49. 
~l a:r:e fE/canor 
My speech is slurred. 
I am root as active as usual. 
I h3ve a feeling of just dragging along rather than coasting. 
I feel sluggish. 
My head feels heavy. 
I feel like avoiding people although I usually do not feel this way. 
I feel dizzy. 
It seems harder than usual to move around. 
I am !!'Oody. 
People might say I am a little moody today. 
I feel drowsy. 
I am full of energy. 
Today r say things in the easiest possible way. 
Thi:1gs around me seem nore pleasing than usual. 
I ha'le a pleasant feeling in my stomach. 
1 feel I wi 1 1 lose the contentment that I have now. 
I feel in complete harmony with the world and those around ~e. 
I can co~~letely appreciate what others others are saying when I am in this mood. 
I would be happy all the time if I felt as good as I feel now. 
feel so good that I know other people can tell it. 
feel as if something pleasant had just happened to me. 
'",ould be happy all the time if I felt as I do now. 
feel more clear headed than dreamy. 
feel as if I would be more popular '.vith people today. 
feel a I}ery pleasant emptiness. 
My tr!'Jughts CCHx:! n'Ore eas i ly than usua 1. 
I feel less discouraged than usual. 
I am in the mood to talk aJ:out the feelings I have. 
r feel more excited than dreamy. 
Answering these questions was very "asy today. 
My "emory seems sharper to me than usual. 
I feel as if I could write for hours. 
r feel very patient. 
Some parts of my body are tingling. 
I ha'/e a weird feel ing. 
~ly mov"rents seem fas'cer tr.an usual. 
I ha"le better can tro lover myse If than usua 1 . 
My movements seem slower than usual. 
I find it hard to keep my mind on a task or job. 
I ~on·t feel like reading anything right now. 
It seems! am spending longer than r should on each of these questions. 
My nand fee:s clumsy. 
I notice my hand shakes when I write. 
I have a disturbance in my stomach . 
I hav" an increasing awareness of bodily sensations. 
I feel anxious and uoset. 
have ;Jf1USUd! ',y'eak n~ss of ~ny :nusc: es. 
thrlll has~on" thr::ugh :r.e one or :nore times since 
My movements are free. relaxed, and pieasuraole. 
star:ed :his :est. 
OJ" ."f Tin:e pm 
J 
dces 
'
i .. 
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The response data obtained from this questionnaire was subjected to the 
ARCI computer data capture program ARCICAP to yi e 1 d the fo llowing data 
fi le: 
0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0, 
1,0,0,0,0,0,0,0,0,0,0,1,1, Date:wk2dy7, Time:pm, User:Laur;, 
Volunteer:Eleanor 
The text footer is self-explanatory with the user being the person who 
entered the data into the computer program. 
This file was processed using the computer program to yield the following 
results: 
Date: wk2dy7, Time: pm, User: Lauri, Volunteer: Eleanor 
Final Score Final Scale 
S(1) = 
° 
PCAG 
S(2) = 11 8G 
S(3) = 2 LSD 
S(4) = 14 M8G 
5(5) = 9 A 
This set of results (scores) was manua 11y checked against the software 
supplied by Dr Chait and Mr Soper, and was found to be identical, as 
fo l1ows: 
Hwmer Final Final 
of Items Phase One Scorn Phase Two Score Score Scale 
l's O'S l's O'S 
11 S(1) a 11 S(1)=S(1)+S(6) a 11 a PCAG 
9 S(2) 7 2 S(2)=S(2)+S(7) 11 2 11 BG 
10 S(3) 1 9 S(3)=S(3)+S(8) 2 12 2 LSO 
15 S(4) 14 1 S(4)=S(4) 14 0 14 MBG 
11 S(5) 9 2 S(5)=S(5) 9 0 9 A 
4 S(6) a 4 
4 S(7) 4 a 
4 Sea) 1 3 
78 
3.4.1.2 The Profile of Mood States (POMS) 
An experimental version of the POMS described by McNair et al in 1971 (133-
137, 285, 286) is used, which consists of 72 adjectives commonly used to 
describe momentary mood states. Subjects indicate how they feel at the 
moment in relation to each of the adjectives on a 5-point scale ranging 
from IINOT AT ALLII (0) to II EXTREMELY u (4). There are eight clusters or 
scales of items (anxiety, depression, anger, vigour, fatigue, confusion, 
friendliness and elation) that have been separated empirically using factor 
analysis. The value of each scale is determined by adding the numbers 
checked for each adjective in the cluster and dividing the total by the 
number of adjectives in that cluster. 
Two additional, unvalidated scales (arousal and positive mood) that are 
derived from the other scales are commonly used. The two additioonal scales 
are calculated as follows: 
Arousal = (Anxiety + Vigour) - (Fatigue + Confusion) 
Positive Mood = Elation - Depression 
3.4.1.2.1 POMS Item Data Capture and Analysis 
The data processing program was written in Digital Equipment Corporation 
(DEC) BASIC and was supplied by Dr L.D. Chait, Department of Psychiatry, 
University of Chicago, Illinois (285). Dr Chait also supplied a copy of the 
POMS questionnaire. This program was converted to Microsoft GW-BASIC by Mr 
A.G. Soper, School of Pharmaceutical Sciences, Rhodes University, 
Grahamstown, South Africa. In addition, Mr Soper added a data capture 
program. 
The data capture program (POMSCAP) allows the answers to the 72 adjectives 
and the date/t ime/name data to be entered from the POMS quest ionna ire, 
edited and written to disk in the format required by the data processing 
program, POMS. Seventy two answers plus the date/t ime/name compri se a 
single record. 
POMS reads one complete record from the input file and some error checking 
is performed. Two answers receive extra processing, thus: 
If the response value is < or = 4 then the value becomes 4 - value .... (;) 
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The values which are treated in this manner are: 
Repsonse 36 liRe 1 axed II (used in score 1) 
Response 43 IIEfficient ll (used in score 6) 
Eight scores [5(1) - 5(8)J which relate to the 8 scales are then computed 
by averaging the elements of each subset (item number) of the 72 answers, 
as follows: 
i=n 
Score = Sum (A ;=1 ;) ......................... " .. " ......... " ... ( i i ) 
n 
Where Ai = responses (i.e. a value of either 0, I, 2, 3, or 4) 
allocated to each item in that subset 
n = number of items in that subset 
Each item expressed as an adjective is allocated to the eight clusters 
(scales) as follows (285): 
ITEM NUMBER ALLOCATION (Subsets) 
Items 2,11,18,27,36,39,48,53,65 ................ . 
Items 6,10,16,22,25,29,35,41,42,50,51,54,64,67,69 . 
Items 4,14,19,24,30,33,44,47,52,58,62,71 ........ . 
Items 8/17,23,31,46,59,61,66 ................... . 
Items 5,12,20,32,38,55,70 
Items 7,9,21,37,43,57,63 
SCALE 
(3a) Anxiety 
(3b) Depression 
(3c) Anger 
(3d) Vigour 
(3e) Fatigue 
(3f) Confusion 
SCORES 
SO) : 
5(2): 
5(3): 
5(4): 
5(5): 
5(6): 
5( 7): 
5(8) : 
Items 1,15,28,34,40,49,60,68 .................... (3g) Friendliness 
Items 3,13,26,45,56,72 .......................... (3h) Elation 
Two further scores are computed from the previous 8 scores. 
S(9) = [S(l) + S(4)] - [S(5) + S{6)] ............•.....•.... (9) Arousal 
S(10) = S(8) - S(2) ...................................... (10) Positive Mood 
Figure 3.8 shows a typically completed POMS questionnaire. The response 
data obtained from this questionnaire was subjected to the POMS computer 
data capture program to yield the following data file: 
3,0,3,0,1,0,0,2,0,0,0,0,1,0,3,0,2,0,0,0,0,0,3,0,0,2,0,3,0,0,3,0,0,2,0,3, 
0,0,0,2,0,0,2,0,3,2,0,0,2,0,0,1/0,0,0,1,0,0,1,3,1,0,1/0,0,0,0,3,0,0,0,1, 
Date:wk2dy7, Time:pm, User:Lauri, Volunteer:Eleanor 
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FIGURE 3.8 Typical Completed POMS Questionnaire 
THE PROFILE OF MOOO STATES 
fNSTRUCTfONS 
Here is a list of ~ords and phrases that describe different feelings people have. Please read each ~ord and 
dec~de how much you are feeling that 'tIay right now: not at all, a little, iTXlderately, quite a bit, or 
ex trerr€ly. Circle a number next to the word to show your answer. 
P I ease be sure to c i rc I e ONE number - and ONLY ONE number - nex t to e'Jery word on the sheet. Examp Ie: The 
first \'/ord is "Friendly". Consider how friendly you have been feeling. If you have :lot been feeling friendly 
at all, circle the number "0" to the left of the 'tIord "Friendly": 
0 1 Z 3 4 Friendly 
. . 
. ... = ..... 
~ >, 
'>, 
~ >, 
~ . .Q .Q >, 
"" 
CLI 2 "" CLI CLI 
"" ~ ..... "" ~ ..... -' 
"" 
..... ..... 
"" 
"" 
..... t.. CLI C) 
"" 
.... t.. 2 C) CLI ..... t.. ~ t.. 
..... "0 ..... ..... "0 .... 
a Q ::J >< 0 Q ::J x c: 
'" 
c r::r QJ c 
"" .= 
.CT QJ 
t.. t.. t.. t.. t.. t.. ~ t.. t.. t.. 0 0 0 0 0 0 
-2 0 c 
'- .... 4- .... 4- 4- "- '- '-
0 
'" 
..., ..,. 0 
'" 
<"'"l 
.". 
0 1 2 6) 4 Friendly ~ 1 CD 3 4 Relaxed o<p 2 3 4 Tense 1 2 3 4 Sewi ldered 2 CD 4 Happy 1 2 3 4 Sluggish ~1 2 3 4 Angry 1 ~d 4 Uneasy Q) 2 3 4 \~orn out 0 1 4 Kindly 
<p 1 2 3 4 Unhappy ~ 2 3 4 Lonely CD 2 3 4 Confused @~ 4 Nise,able o 1 2 cp 4 Lively 0 4 Efficient (jiJ 1 2 4 Unable to concentrate ® 2 cb 4 Bitter 
o CD 2 3 4 Sorry for things done 0 234 Pleased 
@1 2 3 4 Shaky o 1 2 CP: Alert oeD 2 3 4 Listless ~i 2 Ready to fight 0 1 2 <p 4 Overjoyed 2 ~: Restless ~q; 2 <1 Peeved &>i 2 Good-natured 2 3 (D Agreeab Ie 2 3 4 Gloomy 
(§)1 2 3 4 Sad 
'i 
2 3 4 Desperate 
o 1 CD 3 4 Active 2 3 4 Rebellious 
~ 1 2 3 4 On edge 2 3 4 Nervous o 123 4 Grouchy 2 3 4 Helpless 
123 4 Fatiqued 2 3 4 Weary 
~ 1 2 3 4 Muddled 0 cp 3 4 Elated 1 2 3 4 Blue ~ 1 3 4 Forgetful o cD 2 3 4 Energetic 1 2 3 4 Deceived ~ 1 2 3 4 Spiteful 0 1(2)~4 Full of pep 012 3 4 Hopeless 0 1 234 Warm-heal'ted 
o 1 (y 3 4 Satisfied 0 1 2 0)4 Carefree 
@ 1 2 3 4 Panicky ~ 1 2 3 4 Furious $12(1)4 Helpful 1 2 3 4 Uncertain about things 1 2 3 4 Unworthy 1 2 3 4 Worthless 01234 Annoyed 1 2 3 4 Anxious 
012d)4 Cheerful o 1(£)3 4 Vigorous 
$1 Z 3 4 Exhausted cp i ~ ~ 4 Terrified o 123 4 Resentful 4 Good-tempered 
Old) 3 4 Forgiving ~ 1 2 3 4 Gu i lty ® l Z 3 .j Jisc::Juraged 
v ~ ~ 3 .1 3usned 1 , 3ad- cemoered ~ ~ 3 4 Refreshed 
~jame J2/earar '-leek ~ ..., frY"> Jav I T i:re 
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This file was processed using the computer program producing the following 
results in the output file: 
Date: wk2dy4, Time: pm, User: Lauri, Volunteer: Eleanor 
final Score final Scale 
S(1) = 0.111 
S(2) = 0.000 
S(3) :> 0.083 
S( 4) ::: 1. 750 
S(5) = 0.143 
S(6) = 0.429 
S(7) = 2.625 
S(8) = 1.833 
S(9) = 1. 290 
S(10) = 1.833 
Anxiety ----------------------------------> Note i) 
Depression 
Note i) 
Note ii) 
Note iii) 
Note iv) 
Anger 
Vigor 
Fatique 
Confusion ---~----------------------------> Note ii) Friendliness 
Elation 
Arousal ----------------------------------> Note iii) 
Positive Mood ----------------------------> Note iv) 
Computed using subset (3a). Since repsonse 36 is an element of 
this set and since response 36 is processed by (I), response 
36 becomes 4-3=1 and the average becomes: 
(0 + 0 + 0 + 0 + 1 + 0 + 0 + 0 + 0) / 9 = 0.000 
As for Note i) above except this value is computed using (3f). 
In this case response 43 is present resulting in an average of 
3 / 7 = 0.429 
Score 9 computed using (4) 
Score 10 computed using (5) 
This set of results was manually checked against the software supplied by 
Dr Chait and Mr Soper and was found to be identical, as follows. 
Response / Number Final Final 
Value of Items Score Scale 
S(1) = 1 / 9 = 0.111 Anxiety (Note: response 36 is present,thus value = 4 - 3 = 1) 
5(2) = 0 I 15 = 0.000 Depression 
5(3) = 1 I 12 = 0.083 Anger 
5( 4) = 14 I 8 = 1. 750 Vigor 
5(5) = 1 / 7 = 0.143 Fatique 
5(6) = 3 I 7 = 0.429 Confusion (Note: response 43 is present, thus value = 4 - 2 = 2) 
5{7) = 21 I 8 = 2.625 Friendliness 
5(8) = 11 / 6 = 1.833 Elation 
5(9) = 1.861-0.572 = 1.290 Arousal (Note: 5(9) = [5(1)+5(4)J - [5(5)+S(6)J 
5 (10) = 1.833-0.000 ::: 1.833 Positive Mood 
(Note: S(10)= [5(8) - 5(2)J 
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3.4.1.3 Visual Analogue Scales (VAS) 
The VAS form consists of six horizontal 100 mm line, each labelled with an 
adjective (ll stimulated ll , IIhighll, lIanxious ll , IIsedated ll , II down II and 
II hungryll ). The 1 eft ends are 1 abe 11 ed II NOT AT ALL II and the right ends 
IIEXTREMELY II . Subjects place a mark on each line to indicate how they feel 
at the moment they are completing the scale (133-137, 285). 
The 49-item ARCI, 72-item POMS and 6-item VAS have been used in studies to 
determine whether PPA 1 in various dosages exhibits abuse liability and/or 
dependence potential (133-137). 
3.4.2 Cardiovascular Measurements 
Sytemic arterial blood pressure is a physiologic variable which reflects 
the effects of cardiac output, peripheral vascular resistance and other 
hemodynamic variables (287). 
3.4.2.1 Equipment used for Blood Pressure Determinations 
Direct intra-arterial measurements of blood pressure are more precise than 
indirect measures using a sphygmomanometer. Nevertheless, properly 
measured, elevated indirect blood pressure readings are an important sign 
of vascular disease. Manual and automated mechanical devices are used for 
the indirect measurement of blood pressure (287). 
3.4.2.1.1 Manual Mechanical Devices 
The sphygmomanometer consists of a compression bladder of rubber enclosed 
in an unyielding cuff covered with nondistensible material of the contact 
closure (velcro), hook or bandage type. The bladder is connected by tubing 
to an inflating bulb or pump by which the pressure is increased! a 
manometer from which the applied pressure is read and a controlled exhaust 
valve to deflate the system. 
The inflatable bladders and cuff are usually standardised with regard to 
length and width. The correct bladder size must be chosen in relation to 
the arm circumference to ensure measurement accuracy. The manometers used 
may be of two types, that is a mercury manometer or a manual aneroi d 
consisting of a rotating needle to indicate blood pressure changes. When 
used with a stethoscope of standard variety, this technique is known as the 
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auscultatory method of blood pressure determination (287). 
3.4.2.1.2 Automated Devices 
The term automated can refer to various characteristics of the device. Most 
types of automated equipment have (288): 
1) an electronic aneroid containing a microphone in the cuff for the 
detection of the Korotkoff sounds 
2) digital or automatic displays for the blood pressure readings 
3) a bush-button feature for the automatic inflation or deflation of the 
cuff. 
3.4.2.2 The Determination of Blood Pressure 
The deflated cuff is attached to the sphygmomanometer around the subject1s 
right or left arm at the level of the heart or phlebostatic axis, as it is 
medically known. The cuff bladder is positioned over the brachial artery, 
with the lower margin about 2.5 cm above the antecubital fossa which lies 
medially in front of the elbow. A preliminary palpatory determination of 
the systolic blood pressure should be performed to enable the investigator 
to estimate the maximal pressure to which the system needs to be elevated 
in subsequent determinations (287). Figure 3.9 ;s a graphic representation 
of the anatomical positioning of the cuff for blood pressure measurements. 
FIGURE 3.9 The placement of the cuff bladder on the arm for blood pressure 
determinations 
Reproduced from Schmidt et al (290) 
\ Bicep 
~ Ulnar groove 
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A bell stethoscope is firmly applied to the antecubital space over the 
brachial artery! and the cuff inflated with the bulb! to occlude the artery 
and raise the pressure to approximately 30 mmHg above the point at which 
the radial pulse disappears. Thereafter, the pressure should be released 
at a rate of 2 to 3 mmHg/second to exclude the possibility of systematic 
error (287). 
As the pressure . dec 1 i nes I the Korotkoff sounds become aud i b 1 e over the 
artery below the cuff and pass through five phases as the pressure 
decreases and the sounds disappear (289). 
Phase I: 
Phase II: 
Phase III: 
Phase IV: 
Phase V: 
The period marked by the first appearance of faint clear 
tapping sounds which gradually diminish in intensitYI 
which corresponds to the systolic pressure. 
The period during which a murmur or swishing quality is 
heard. 
The period during which the sounds are crisper and 
increase in intensity. 
The period marked by the distinct l abrupt muffling sound 
so that a softl blowing quality is heard. 
The point at which the sounds disappear, which 
corresponds with the diastolic pressure. 
When all sounds have disappeared, the cuff should be deflated rapidly and 
completely. One to two minutes should be allowed to elapse for the release 
of blood trapped in the veins before further determinations are made. Blood 
prassure determinations can be performed with the subject seated l standing 
or supine. 
The American Heart Association recommends the use of the following guide-
lines to ensure accurate blood pressure readings (287, 290): 
1) The observer should be trained in performing blood pressure 
measurements and be uninhibited by sensory impairment. 
2) During the pressure observation l the eyes should be level with the 
meniscus of the mercury column or centred on the gauge. 
3) All observations should be performed by the same independent 
observer. 
4) The subject should be accommodated in a quiet room at a comfortable 
temperature with the arm unrestricted by clothing or other material . 
. , 
.•. 
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5) The subject should avoid exertion, exposure to cold, eating or 
smoking for half an hour prior to the measurements. 
6) There should be no postural change in the subject for 5 minutes 
before the recording of blood pressure. 
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CHAPTER 4 
CLINICAL STUDY - EVALUATION OF SAFETY AND EFFICACY 
A clinical trial was performed in order to supplement the vast amount of 
data available concerning the safety and efficacy of PPA. Whilst much 
research has been carried out to assess the central and cardiovascular 
safety of PPA (with the majority of these studies being carried out over 
short periods of time) and numerous reports attest to the efficacy of PPA 
in causing weight loss in humans, there is a paucity of information 
regarding its effects on appetite and food intake. 
As mentioned in section 1.5, some researchers (56,57) have reported that 
PPA causes appetite suppression. However, only in one study by Hoebel et 
al (62) were the effects of PPA on hunger/appetite emphasized. Following 
on from the discussion in section 3.2.2 and 3.3.2.5, respectively, it would 
be of interest to determine the effect of PPA on the satiety sequence and 
on salivation (a putative measure of appetite), as no published data are 
available in this regard. 
Only two reports, in which the subjects were not placed on a caloric-
restricted diet, of the effects of PPA on food intake have appeared in the 
literature, one in which the intake of a liquid lunch was measured (63), 
and the other which employed diet diaries to indirectly monitor overall 
food intake and the elective consumption of macro-nutrients (98). 
It is clear that more research is needed to extend the available data 
concerning the effects of PPA on overall food intake, the elective 
consumption of macro-nutrients and on the 3 basic phases of eating i.e. 
initiation (hunger), maintenance (appetite) and termination (satiety). 
The primary objective of the clinical study was to initialise a 
multidimensional approach to evaluate the efficacy and safety of PPA as an 
appetite suppressant in humans, using standardised methods and procedures. 
Aspects of efficacy assessed were broad and included the effects of PPA on 
subjective hunger, appetite and satiety, salivation, body weight, food 
intake and the elective consumption of macro-nutrients. In addition, the 
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safety of PPA was evaluated in terms of blood pressure influences, changes 
in subjective mood and abuse potential. The subjects were dosed to steady-
state for 4 weeks and peak and trough serum levels were analysed to enable 
possible correlations of these variables with serum levels of PPA. 
A pilot feas ibil ity tria 1 was conducted to determine whether such an 
approach was possible. 8ecause of the extremely subjective nature of such 
an approach and hence the reality of Jarge inter-subject variablility, a 
crossover design was implemented to enable each subject to serve as his/her 
own control. 
In a cross-over design, typically, two treatments are compared, with each 
subject or patient taking each treatment in turn. The patients are 
allocated to two groups and receive treatments on two different occasions 
called periods or legs. The order of treatment is random;sed, with the 
first group receiving the treatments in the order A8 and the second group 
in the order BA, where A and 8 are the two treatments. The balancing of 
order (A8 or 8A) takes care of time trends or other lIperiod ll effects, if 
present. A period effect is defined as a difference in response due to the 
occasion on which the treatment is given, independent of the effect of the 
treatment (291, 292). 
One of the most appealing factors associated with the crossover design, is 
that each subject acts as his or her own control. This feature enables 
direct comparison of drug treatments and is particularly efficient in the 
presence of large inter-subject variation. Since each subject takes both 
of the treatments, the comparison is based on the relative magnitude of the 
within-subject variation to between-subject variation. Thus, given an equal 
number of observations, crossover experiments are more powerful and usually 
result in greater precision than the parallel-groups design, where 
different subjects comprise the two groups (291). 
However, there are some problems associated with crossover designs (291). 
A crossover study may take longer to complete than a parallel study because 
of the additional testing period required. In the crossover design, missing 
data pose a more serious problem than in a parallel design. Since each 
subject must supply data on two occasions, the chances of observations 
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being lost are greater in the crossover design. In addition, if one subject 
defaults from a study phase, not only their data but data from another 
subject being administered the opposite sequence, is lost. 
Perhaps the most serious problem associated with the use of crossover 
designs is the possibility of interactions (292). The most common 
interaction that may be present in crossover studies is a differential 
carryover or sequential effect. This effect occurs when the response during 
the second period is dependent on the response in the first period, and 
this dependency differs depending on which of the two treatments is given 
during the first period. In bioequivalence studies, differential carryover 
usually oocurs if the washout period between administration of dosage forms 
is of insufficient duration to allow the body to eliminate the first dosage 
form completely. 
However/ this example only illustrates the problem; often carryover effects 
are not as obvious. The effects can be caused by uncontrolled factors such 
as psychological or physiological states of the subjects, or by external 
factors such as the weather, clinical setting, and so on. When carryover 
effects are present, the usual interpretation and statistical analysis of 
crossover studies are invalid. Only the first period results can be used, 
resulting in a smaller} less sensitive experiment (292). 
4.1 PILOT STEADY-STATE TRIAL 
A pilot steady-state trial was conducted using one female volunteer to 
establish various conditions such as frequency and times of blood sampling 
as well as the PPA concentrations which could be expected in serum after 
the ingestion of seven doses of a sustained release capsule containing 75 
mg of PPA.HC1/ administered at 12 hourly intervals. 
The volunteer was a smoker and had no previous history of hypertension. 
Blood and urine samples collected prior to the trial were subjected to 
eli n i ca 1 chern; stry tests and were found to be norma 1. The vo 1 unteer 
received a copy of the trial protocol and signed a consent form (Appendix 
1). She received an honorarium for participating in the trial and practised 
similar standardisation procedures as described in section 4.2.4. 
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The subject ingested one capsule of PPA.HCl with 200 ml of tap water at 
08hOO and 20hOO each day for three days prior to the trial day (day 4). A 
10 ml blood sample was withdrawn 5 minutes prior to the first (blank 0.0 
hr sample) and subsequent doses. The subject began fasting at 22hOO on day 
3 and a blood sample was withdrawn prior to the 7th and final dose at 08hOO 
on day 4. Thereafter I the subject was gi ven a standard i sed breakfast 
consisting of 2 slices of toast with margarine and jam and 250 ml orange 
juice. Blood samples were collected at 0.5, 1, 2, 3, 4, 5, 6, 8, 9, 10, and 
12 hours after ingestion of the 7th dose of the drug. The subject received 
a low fat standardised lunch at 13hOO and a standardised snack at 17hOO. 
4.2 CLINICAL EFFICACY AND SAFETY TRIAL: METHOD AND DESIGN 
4.2.1 Study Population 
Subjects were volunteers from the Grahamstown area who answered an 
advertisement placed in the local newspaper regarding people who wanted to 
lose weight. Prospective subjects were screened for their ability to 
participate in the study. At the initial visit, the investigator recorded 
the following variables: 
(a) Age in years, sex and race. 
(b) Occupation. 
(c) Height in metres and weight in kilograms. 
(d) Ideal body weight and % overweight according to the Metropolitan Life 
Insurance Company Tables of 1983 (255). 
(e) Body Mass Index described in section 3.3.1. 
The subjects then reported to the attending physician who performed the 
following examinations: 
(a) Body frame assessment as small, medium or large. 
(b) Medical history and vital signs physical examination. 
(c) Obtained sufficient blood and urine samples to allow for the 
determination of the following clinical laboratory values: 
Haematological status: Haemoglobin, haematocrit, leucocytes, red blood 
cell count, platelet and differential counts and 
sedimentation rates 
Clinical chemistry: 
Urinalysis: 
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SGOT (serum glutamic oxalacetic transaminase) I 
SGPT (serum glutamic pyruvic transaminase) I serum 
creatinine and ureal serum bilirubin and alkaline 
ophosphatase 1 glucose, cholesterol, triglycerides l 
sodium and potassium chlorides and total protein 
Specific gravity, pHI bile/ protein l glucose, 
ketones I blood and bilirubin 
Subjects were eligible for inclusion into the study programme if they were: 
(a) Male or female caucasians between 18 and 45 years old ; 
(b) Normotensive individuals in general good health; 
(c) Approximately 10 % above normal weight for their height and age; 
(d) Highly motivated to lose weight; 
(e) Normal in terms of medical historYI physical examination and if they 
presented normal clinical laboratory values. 
Prospective subjects were excluded from participating in the study 
programme if: 
(1) they had any significant clinical disease l overt illness or surgical 
condition such as cardiovascular or gastro-intestinal disease l 
hepatic or renal dysfunction, endocrine disorders, hypertension, 
asthma or diabetes mellitus; 
(2) they had a positive past history of psychiatric or affective 
disorders; 
(3) they were female who were/ or were apt to become pregnant l or if they 
were lactating or in the postpartum stage of motherhood; 
(4) they had an inability to communicate with the investigator; 
(5) they had any known or pre-existent sensitivity or intolerance to PPA; 
(6) they had been on any weight reduction programme for three weeks prior 
to the study; 
(7) they abused alcoholic beverages or had participated in another trial 
wihin 60 days preceding the study; 
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(8) they had a major illness during the 3 months preceding the study; 
(9) they had undergone treatment within the previous 3 months with any 
drug known to have a well-defined potential for toxicity to one of 
the major organs; 
(10) they required any concommitant medication (prescription legend or OTe 
preparation) such as tricyclic antidepressants, MAO-inhibitors, 
antihypertensives, other sympathomimetic agents, sodium bicarbonate 
or other antacids, aspirin, indomethacin or anticholinergic agents; 
(11) during the course of the trial, their blood pressure rose above 10 
mm Hg (diastolic) or above 30 mm Hg (systolic) and was sustained over 
three consecutive measurements of 30 minutes duration (10 mg 
Nifedipine was kept on hand for any hypertensive emergencies). 
Eight normal, healthy, caucasian women who conformed to the criteria set 
out above, were selected to participate in this trial. Individual details 
of these volunteers are depicted in Table 4.1. 
Subject Age InitiaJ Height Body Frame IdeaJ % 
Weight (em) Mass Size Weight Over-
(kg) Index (kg) weight 
SS (1) 38 70.67 175 23.08 M 66.00 7.08 
CA (2) 22 61.80 153 26.57 M 54.50 13.39 
LE (3) 36 77 .00 169 26.96 L 68.70 12.08 
EA (4) 37 65.73 160 25.68 S 58.05 13.23 
VW (5) 20 72.80 169 25.49 M 68.70 5.97 
LI (6) 32 81.20 168 28.94 L 68.05 19.32 
EG (7) 42 62.40 161 23.95 M 58.55 6.01 
CV (8) 32 66.60 165 24.46 M 60.70 9.72 
Mean 32.38 69.78 165 25.64 62.91 10.85 
:I: SD ± 7.70 ± 6.94 ± 6.82 ± 1.86 ± 5.62 ± 4.60 
TABLE 4.1 Demographic Details of Subject Population 
Each volunteer received a copy of the trial protocol and written informed 
consent (Appendix 2) was obtained. The selected volunteers indicated a 
willingness and good motivation to co-operate and were paid an honorarium 
for participating in the study. 
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4.2.2 Test Medication Dosage Forms 
The study compared the effects of PPA with a placebo control and 
identification parameters for both dosage forms are listed below: 
1) Test Medication A (TM A) 
Name: 
Dosage and Dosage Form: 
Identification: 
Manufacturer: 
Batch Number: 
Date of Manufacture: 
Supplier: 
Phenylpropanolamine Hydrochloride. 
75 mg Sustained Release (SR) capsule. 
Size 2 capsule (white body, green cap) containing 
white micro-encapsulated beads. 
Euderma, Italy. 
Lot S129/1 
19-09-1989 
Lennon Ltd, South Africa. 
2) Test Medication B (TM B) 
Name: 
Identification: 
Manufacturer: 
Batch Number: 
Date of Manufacture: 
Supplier: 
Pharmacologically Inert Placebo. 
Size 2 capsule (white body, green cap) containing 
white micro-encapsulated beads. 
Euderma, Italy. 
Lot S209/1 
20-09-1989 
Lennon Ltd, South Africa. 
Both test medications were formulated in identically appearing capsules and 
packaged in individual bottles. Each bottle of medication was labelled with 
the subject1s name and phase and contained 56 capsules, sufficient for each 
subject, for each phase of the trial. 
4.2.3 Experimental Design 
The study was carried out for a period of eleven weeks in a double-blind, 
randomised, placebo-controlled cross-over manner. Table 4.2 depicts the 
sequence of events for the trial. 
WEEK ONE 
WEEK TWO - FIVE 
WEEK SIX l 
WEEK SEVEN 
WEEK EIGHT - ELEVEN2 
Baseline evaluation period 
First phase of the study 
Wash-out period 
Re-establishment of baseline conditions 
Second phase of cross-over study 
1 The seventh week of the trial corresponds to the first week of the second phase. 
2 Weeks 8 - 11 of the trial correspond to weeks 2 - 5 of the second phase. 
TABLE 4.2 Study Plan for the Trial Summarising Weekly Events 
93 
As the cross-over design requires that equal numbers of subjects are 
allocated to each sequence or order of treatment, 4 subjects were allocated 
to the treatment in the order A (PPA) followed by B (placebo) and 4 
subjects in the order B followed by A using a randomisation schedule 
established by an independent colleague. Random assignment of subjects to 
PPA or placebo not only ensures complete double-blinding, but also 
eliminates a potential source of bias in comparison of treatment groups in 
baseline characteristics. Double-blind procedures infer that neither the 
subject nor the investigator knew which test medication was being 
administered during each phase. 
Each subject received one test medication for phase 1 (week 2-5) and was 
crossed over for phase 2 (week 8-11) receiving the test medication that was 
not used during the first phase. The subjects ingested the respective test 
medications twice daily on a 12-hour fixed-dose schedule, at 08hOO and 
20hOO hours for eight weeks according to the study design. Table 4.3 
depicts the random allocation of test medication to subjects per phase. 
Subject Test Medication 
Phase 1 Phase 2 
S5 (1) PPA Placebo 
CA (2) PPA Placebo 
LE (3) Placebo PPA 
EA (4) Placebo PPA 
VW (5) Placebo PPA 
LI (6) Placebo PPA 
EG (7) PPA Placebo 
CV (8) PPA Placebo 
TABLE 4.3 Test Medication A11ocation 
In an attempt to ensure patient compliance, the bottles containing the test 
med icat ions, labelled with subject I s name and phase were stored by the 
trial co-ordinator. The subjects were required to report each day during 
the week just prior to 08hOO and 20hOO to receive their medication. The 
weekend dose(s) were given to each subject in a bottle containing 4 doses 
of medication with instructions to ingest the doses at the specified times. 
It was hoped that the serum data obtained on the seventh day of every week 
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at 20hOO would indicate whether the subject1s had conformed to the weekend 
ingestion schedule instructions. 
During the first and seventh weeks of the trial the subjects did not 
receive any medication and baseline variables were established as detailed 
in the daily experimental schedule (Table 4.4). To facilitate subject 
handling, 4 women started the trial on a Monday and the other four on a 
Tuesday. Two women of the latter group began the trial two weeks later than 
the other six. 
4.2.4 Standardisation Procedure 
Identical test conditions were used for both treatments in order to prevent 
fluctuations in variables such as meal times, physical activity and 
caffeine and tyramine consumption across phases. 
1. The subjects were requested to fulfill the following requirements: 
(a) To refrain from ingesting alcohol, caffeine or xanthine containing 
beverages and food such as tea, coffee, chocolate and all cola-
flavoured soft drinks for 48 hours prior to and during both phases 
of the trial including the baseline weeks. 
(b) Subjects were allowed to consume caffeine-free coffee and tea. 
(c) To refrain from ingesting foods containing tyramine i.e. mature 
cheese, marmite, bovril, yeast, broad beans, beer, pickled herrings, 
hung game and foods containing the yellow food colour, tartrazine for 
14 days prior to the onset until study completion. 
(d) Not to take medications, including over-the-counter preparations for 
one week preceding the trial and for the duration of the trial and, 
if they needed concommitant medication to inform the investigator 
accordingly. 
(e) To maintain their usual state of physical activity across both 
phases. 
(f) To standardise their meal times for both phases when blood samples 
were taken. 
2. The subjects were encouraged to follow their usual dietary habits and 
not to follow any dieting practice for the duration of the trial. 
3. The subjects were requested to report any unusual effects that they 
experienced. 
.0 -
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4.2.5 Sampling Schedule for the Tria1 
The measurements] questionnaires and data collection format for the entire 
eleven week trial are detailed in the daily experimental schedule (Table 
4.4). 
WEEK ONE 
DAYl 07h30 
12h50 
13hOO 
13hlO 
DAY2 07h30 
19H50 
DAY 3 07h30 
19H50 
DAY4 07h30 
12h50 
13hOO 
13hlO 
DAY5 07h30 
DAY7 19h50 
WEEK TWO 
DAYl 07h30 
07h50 
08hOO 
12h50 
13hOO 
13hlO 
19h50 
20hOO 
DAY2 07h30 
& 3 07h50 
08hOO 
19h50 
20hOO 
DAY4 07h30 
07h50 
08hOO 
12h50 
13hOO 
13hl0 
20hOO 
DAY5 08hOO 
& 6 20hOO 
DAY7 08hOO 
19h50 
20hOO 
TABLE 4.4 
DAILY EXPERIMENTAL SCHEDULE 
\~EEKS THREE I FOUR AND FIVE 
Weight DAYl 07h30 Weight 
BP, MQ 08hOO Test Medication 
BP, BS, AHQ, BSQ 20hOO Test medication 
TEST MEAL PRESENTATION DAY2 08hOO BP, Test medication 
SIS, MQ &3 20hOO BP, Test medication 
TEST MEAL DAY4-7 As for WEEK TWO 
SQ, FPQ 
Weight, BP, MQ 
MQ WEEK SIX Washout period 
Weight, MQ 
MQ WEEK SEVEN As for WEEK ONE 
Weight, BP, MQ 
BP, BS, AHQ, BSQ WEEK EIGHT As for WEEK TWO 
TEST MEAL PRESENTATION 
SIS, MQ WEEKS NINE, As for WEEKS THREE, 
Test meal TEN & ELEVEN FOUR & FIVE 
SQ , FPQ 
Weight 
BP, MQ 
KEY TO THE ABBREVIATIONS USED 
Weight BP = Blood Pressure 
Blood sample, BP, MQ AHQ = Appetite and Hunger Questionnaire 
Test medication SQ = Satiety Questionnaire 
Blood sample, BP, BS, AHQ, BSQ SIS - Stimulus-Induced-Salivation 
TEST MEAL PRESENTED BS = Basline Salivation 
SIS, MQ MQ = Mood Questionnaire (ARCI. POMS. VAS) 
TEST MEAL BSQ = Bodily Sensation Questionnaire 
SQ. FPQ FPQ = Food Preference Questionnaire 
Blood sample, BP, MQ 
Test medication 
Weight, BP, MQ 
Blood sample 
Test medication 
Blood sample, BP, MQ 
Test medication 
Weight. BP, MQ 
Blood sample 
Test medication 
Blood sample, BP. BS, AHQ, BSQ 
TEST MEAL PRESENTED 
SIS, MQ 
TEST MEAL 
SQ. FPQ 
Test medication 
Test medication 
Test medication 
Test medication 
Blood sample, BP, MQ 
Test medication 
Experimental Schedule Indicating the Testing Procedures and 
Timing of Particular Events. 
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4.2.6 Collection and Storage of Blood Samples 
In accordance with the experimental schedule, a total of 38 blood samples 
for each subject per phase were withdrawn at the specified times. Table 4.5 
depicts a summary of the blood sampling times. 
Week 2 Day 1 07h50, 12h50 and 19h50 
Week 2 Day 2-3 07h50 and 19h50 
Week 2 Day 4 07h50 and 12h50 
Week 2 Day 7 19h50 
Week 3,4,5 Day 4 07h50 and 12h50 
Week 3,4,5 Day 7 19h50 
Week 8 Day 1 07h50, 12h50 and 19h50 
Week 8 Day 2-3 07h50 and 19h50 
Week 8 Day 4 07h50 and 12h50 
Week 8 Day 7 19h50 
Week 9,10,11 Day 4 07h50 and 12h50 
Week 9, 10 1 11 Day 7 19h50 
TABLE 4.5 Summarised Blood Sampling Schedule. 
A sterile hypodermic needle was inserted into a suitable vein in the 
forearm by a qualified nurse and ten millilitres of blood was withdrawn by 
syringe aspiration and collected into labelled Vacutest tubes. The samples 
were allowed to stand at room temperature for half an hour to allow the 
proteins to coagulate for serum separation. 
The blood samples were centrifuged at 3000 rpm for 10 minutes and serum 
ali quots from each sample were transferred to clean 1 abe 11 ed tubes and 
stored at -20°C until analysis. In a few cases, the serum contained fibrin 
clots, which were squeezed with the aid of an orange stick to free serum. 
These samples were re-centrifuged to separate the serum. 
The phenylpropanolamine concentrations in these serum samples were 
determined using a validated reverse-phase HPLC method of analysis, with 
UV detection at 210 nm (Section 5.5). 
4.2.7 Physical measurements 
4.2.7.1 Body mass measurements 
The subjects were weighed 25 times during each phase (5 measures per week). 
The measurements were performed on a calibrated portable digital balance 
accurate to 0.2 kg (Weigh-Less, Durban, South Africa). Three consecutive 
measures were made and an average weight recorded. To minimize the 
possibilty of instrumental or procedural error the subjects were weighed 
by the same person, at the same time each morning in their undergarments, 
without shoes. The weight of the undergarments was established and excluded 
in the subject's total weight. 
4.2.7.2 Skinfold Thickness Measurements 
Skinfold thickness was measured at three anatomical locations, one truncal 
site (supraspinale) and two extremity sites (triceps and front mid-thigh). 
The location of these sites on the human body is given in Figure 3.3. 
The triceps skinfold was measured from the back on the unclothed posterior 
surface of the pendant right arm at a level midway between the tip of the 
acromion and the tip of the elbow. The skinfold was lifted parallel to the 
long axis of the arm with the subject standing. 
The supraspinale skinfold was measured 3 cm from the iliac crest with the 
fold (taken at midline of the body) taken obliquely, descending medially 
and downwards at an angle of 45 degrees to the horizontal. Subject stands 
erect with arms pendant. 
The front-thigh skinfold was measured by raising a fold parallel along the 
long axis of the femur with the leg flexed at an angle of 90 degrees. 
Mid-thigh position is estimated half-distance between the inguinal crease 
and the anterior patella. 
A Harpenden skinfold caliper with a constant jaw pressure of ten grams per 
square centimetre was used for all of the above measurements. With the 
exception of the supraspinale measurements, all skinfolds were taken in the 
vertical plane. The following techniques were used: 
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(a) A fold of skin and subcutaneous tissue was picked up firmly between 
the thumb and forefinger 1 - 2 em above the area under consideration 
and pulled away from the underlying muscle. 
(b) The caliper jaws were placed 1 - 2 cm below the thumb and forefinger 
holding the skin and tissue, at a depth of approximately 1 em. 
(c) The skinfold was firmly held throughout the application of the 
caliper and the reading was taken when the needle became steady after 
full pressure of the jaws had been applied to the skinfold. The 
measurement was recorded to the nearest 0,1 millimetre. 
(d) The surface of the caliper jaws was parallel to the skinfold plane. 
(e) The accuracy of the measurement depends on the precise location of 
the skinfold site and standardisation of the skinfold crest 
alignment. 
(f) The measurement consists of an average of three readings. 
Skinfold thickness measurements were performed on the first day of week 1 
for both phases, during the trial and on the final day of each phase by the 
same anthropometric experimenter with the subjects in their undergarments. 
All bilateral measurements were made on the right side of the body. 
4.2.7.3 Cardiovascular measurements 
Supine systolic and diastolic blood pressures were measured with a mercury 
manometer using the ausculatory method throughout the entire study period 
in accordance with the experimenta 1 schedu 1 e. These measurements were 
performed using the recommendations of the American Heart Association 
detailed in section 3.4.2.2. 
Upon the initial examination, blood pressure was recorded in both arms and 
the arm found to have the higher pressure was used in subsequent 
examinations. Blood pressures were obtained 34 times during each phase (5 
measures during week I, 10 during week 2, 9 during ,,,leek 3 and 5 during 
weeks 4 and 5). 
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4.2.8 Behavioural Measurements 
4.2.8.1 Measurement of Subjective Mood and Stimulant Effects 
A Mood Questionnaire (MQ) was used to measure the possible behavioural 
reinforcing and subjective effects and was completed a total of 29 times 
during each phase by each subject, in accordance with the times indicated 
in the experimental schedule (Table 4.4). The MQ (Appendix 3) consisted of 
three subd i vis ions and inc 1 uded the 49 i tern Add i ct i on Research Centre 
Inventory (ARCI) (Table A3.1), the 72 item Profile of Mood States (POMS) 
(Table A3.2) and the 6 item Visual Analogue Scales (VAS) (Table A3.3). The 
ARC!, POMS and VAS item data are detailed in section 3.4.1.1-3. 
4.2.8.2 Ratings of Hunger, Appetite and Satiety 
Visual analogue scales as described in section 3.3.2.1.2 were used to 
measure subjective hunger, appetite and satiety (Appendix 4). The Appetite 
and Hunger Questionnaire (AHQ) was adapted from Silverstone et al (246) and 
contained 4 questions relating to hunger, appetite, preoccupation with 
thoughts of food and estimates of likely food consumption (Table A4.1). The 
Satiety Questionnaire (SQ) was adapted from Silverstone et al (246) and 
contained 6 questions relating to fullness, preoccupation with thoughts of 
food, food appeal, taste of the food, and estimates of consumption of a 
favourite food (Table A4.3). The results were analysed by measuring the 
answer mark on the line of the scale to the nearest millimetre. 
The Bodily Sensations Questionnaire (BSQ) discussed in section 3.3.2.2 and 
thought to be a means to measure feelings of hunger} was adapted from a 
questionnaire used by Monello and Mayer (251) and Garfinkel (252), and 
included checklists for mouth, throat, gastric and cerebral sensations 
(Table A4.2). The results of the BSQ were categorised according to location 
and the number of sujects and the number of times each sensat ion was 
recorded was compared after treatmnet with PPA (TM A) and placebo (TM B). 
The Food Preference Questionnaire (FPQ) discussed in section 3.3.2.4 and 
used to measure subjectively perceived preferences for particular foods, 
was in the form of a checklist and consisted of a list of 30 basic food 
commodities on which subjects indicated their preferences at that moment 
(Table A4.4). The FPQ incorporated 15 high protein and 15 high carbohydrate 
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items. 
These questionnaires were completed on the test meal days only, a total of 
seven times per subject for each phase. 
4.2.8.3 Measurement of Food Intake and Salivation 
Solid food intake was measured directly in the form of a standardised test 
meal. The freshly prepared food consisted of approximately 100g roast beef 
with 20g gravy, 200g boiled jacketed potato, 100g mixed steamed vegetables, 
2 slices of brown bread and 20g of margarine. Milk or water was also 
provided according to individual preference. Each food commodity was 
accurately weighed to 0.1 g (Sartorius 1213 MP, Optical Instruments) and 
placed sepa~atelyin a segmented stainless steel dish (the gravy was poured 
over the beef). Each segmented dish was then covered with a lid and kept 
warm on a Bain-Marie. 
On the test meal days, the subjects entered the clinic where a blood sample 
was withdrawn. Subjects were asked to clear their minds of thoughts of food 
and baseline salivation was measured. The experimenter instructed the 
subjects to complete a questionnaire booklet containing AHQ and BSQ before 
commencing their meal and the subjects were subsequently taken to the test 
room where the test meal was to be consumed. 
The room chosen was pleasantly comfortable and sufficiently neutral to 
prevent subjects from being in a rush to leave or from dawdling due to the 
attractive atmosphere. The room was furnished with four chairs and four 
tables and no clock was present. 
Each subject was invited to sit at an adjoining table where a second 
salivation test (stimulus-induced) was conducted in the presence of the 
food stimuli. During this time, the subjects completed the MQ. Subjects 
were told that they were free to eat as much or as little as they desired 
and that they could select freely among the food items. The subjects were 
also requested not to mix food items, to abstain from talking or reading 
during the session and to complete the SQ and FPQ after finishing their 
meal. The experimenter then left the room. 
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The subjects began eating at approximately 13h30 and left the room upon 
cessation of the meal, whereupon the remaining food items were re-weighed 
individually. From the amount of each food item eaten, total caloric (kJ), 
protein, carbohydrate and fat consumption was estimated using standard 
tables of food composition (265). In addition, protein, carbohydrate and 
fat energy percentages for each test meal were calculated according to the 
following equations: 
Protein Energy % = Total Protein Intake (kJ) X 100 
Total Food Intake (kJ) 
Fat Energy % = Total Fat Intake (kJ) X 100 
Total Food Intake (kJ) 
Carbohydrate Energy % = Total Carbohydrate Intake (kJ) X 100 
Eqn 4.1 
Eqn 4.2 
Total Food Intake (kJ) Eqn 4.3 
Salivation was measured using the Strongin-Hinsie-Peck (SHP) method 
reported in section 3.3.2.5. The average weight of saliva collected in 
grams in three 2-minute collection periods was taken as a single 
measurement. 
4.2.8.4 Additional Measurements - Observational Studies and Diaries 
In an attempt to gain some insight into whether or not PPA could, 
conceivab ly I affect the mi cro-structure of human eat ing behaviour, the 
subject1s eating patterns were observed during each test meal. The test 
meals were recorded on videotape for subsequent analysis of the parameters 
mentioned in Table 3.1 and monitored by means of a television camera. The 
camera unfortunately had to be visisble to the subjects, as it would have 
been impossible to relocate the subjects to another building containing an 
experimental room with a one-way screen behind which the camera could have 
been hidden. 
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In a further attempt to establish whether PPA exerted any effect on normal 
eating habits 1 in terms of quantities and types of food consumed 1 in 
addition to the test meals, the subjects were requested to complete a daily 
food intake diary (section 3.3.3.1). The diaries contained tabulated food 
intake columns for the three usual main meal and snack times as well as AHQ 
and SQ (Appendix 4, Tables A4.1 and A4.3, respectively), which the subjects 
were requested to complete. The diaries were kept by the subjects and were 
presented to the experimenter upon completion of the trial, for subsequent 
analysis of content. 
4.3 RESULTS - EVALUATION OF CLINICAL TRIAL EFFICACY AND SAFETY DATA 
4.3.1 Analysis of Serum Samples 
The method and results of the analysis of all serum samples obtained from 
the pilot steady-state and the clinical efficacy and safety trial will be 
discussed in Section 5.5. 
4.3.2 1I0rop-outsll and Subject Compliance with the Schedule 
Subject 5 developed a urinary tract infection on Day 41 week 2 of phase 2 
(PPA) and took Norfloxacin j Citrosoda and Paracetamol for the following 6 
days. She did not however, default from the study. Subject 7 developed a 
chest infection and was unable to complete weeks 4 and 5 of phase 1 (PPA) 
but returned after her illness to complete phase 2. Subject 8 developed 
measles during phase 2 (placebo) and was unable to complete weeks 2-5 of 
this phase. The remaining subjects completed both phases with no untoward 
medical complications. 
4.3.3 Reports of Adverse Reactions 
The incidence of side effects reported by the subjects was extremely low 
and sporadic. Subjects 1, 6 and 7 did not complain of any side effects 
during phase 1 or 2. Subject 2 reported experiencing an lIawareness of self ll 
at lunch time during the first day that she received PPA (Phase I), and 
complained of diarrhoea on the second day of phase 1. Subject 3 complained 
of nausea in the morning and at night for the entire first week that she 
was taking PPA (phase 2), and had a migraine during lunch time on the 
fourth day (week 3) of phase 2. Subject 4 reported feeling thirsty prior 
to the lunch time session on the first day that she took PPA (phase 2), and 
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was constipated on the second day of the same phase. Subject 5 was tired 
in the evening of the first day of the third week that she was taking PPA 
(phase 2). Subject 8 complained of tiredness in the evening of the first 
day that she took PPA (phase 1). 
Most of these reports of adverse reactions occured during the first or 
second day of the PPA phase l whilst no reports of side effects occured 
during the placebo phase. All subjects who complained of side effects only 
did so on one occasion, with the exception of subject 3 who experienced 
nausea for the entire first week that she took PPA. 
4.3.4 Statitistical Analysis of Data 
As discussed at the beginning of this chapter l in order to perform a 
crossover comparison of trial data, equal numbers of subjects assigned to 
test medication A (TM A) and test medication B (TM B) in the first phase 
and crossed over in the second phase] are needed. However, due to the 
unforseen complications of subject non-compliance with the biphasic trial 
schedule due to illness (see section 4.3.2)1 only 2 subjects were assigned 
to PPA in the first phase as opposed to 4 subjects assigned to placebo. 
Because the distribution of the order of assignment was unbalanced, that 
is, an unequal sample population was assigned to each test medication, it 
proved impossible to perform a crossover comparison of the trial data and 
thus no determination of possible sequence effects could be made. 
As six subjects completed the full crossover] i.e. 6 people took both PPA 
and placebo on two different occasions for the entire length of the trial 
{with an additional subject (Subject 7) completing only a portion of one 
phase of the trial), the only other option available was to conduct a 
parallel-groups comparison of the trial data. This method involves a 
comparison of the response data obtained from the subjects whilst they were 
taking PPA compared to when they were taking placebo, irrespective of which 
phase they were administered either test medication. 
Where appropriate, one-way and two-way analysis of variance (ANOVA) 
procedures for repeated measures were used to determine differences in 
response to PPA and placebo ingestion. Two-way analysis of variance was 
followed by Scheffels post hoc test for multiple range analysis with 
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factors in the analysis being drug condition [i.e. either PPA (TM A) or 
placebo (TM B)] and measurement occasion (weeks). The ANOVA technique 
compares the variation between the samples with the variation within the 
samples. A conservative F test was undertaken and a 5% level of 
significance was used to test for significant differences i.e. a P value 
< or equal to 0.05. 
These two ANOVA procedures were used to test the data in three ways: 
TEST 1) Baseline comparisons i.e. week 1 phase 1 with week 1 phase 2. 
TEST 2) 
TEST 3) 
Comparison of weeks on test medication (weeks 2-5) with 
baseline (week 1) for phase 1 and likewise for phase two (weeks 
8-11 compared with week 7). 
Comparison between test medication phases i.e. Week 2-5 (phase 
1) with week 8-11 (phase 2), excluding baseline data. 
Comparisons were performed on the mean data obtained from the sample of 7 
subjects (data obtained from subject 8 was excluded from the analyses for 
reasons given in section 4.3.2, but are reported in the appendix tables) 
and from individual subjects. It was decided, for the overall comparison 
of mean subject data, to include the data from subject 7 until the end of 
week 3 for both phases, whilst analyses of individual subjects were 
performed only on subjects 1-6. 
Separate analyses were undertaken for each of the dependent variables and 
ANOVA tests were performed on paired data only, that is, data present at 
any measurement occasion in either phase and absent at the same measurement 
occasion in the opposite phase, were omitted from the analyses. 
Two-way ana lys i s of var i ance was used to compare overall subject means 
between test med i cat i on phases as deta il ed in 3) above, except where 
indicated for specific variables. One-way analysis of variance procedures 
with drug condition (i.e. either TM A or TM B) as the factor were carried 
out on the remaining tests, for inidvidual and overall subject means. 
All results tabulated in the following section are the mean values ± the 
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standard error of the mean (SEM) obtained for the PPA (TM A) phase and the 
placebo (TM B) phase. The F ratios and P values are also given. In 
addition, where applicable, the two superscripted characters § and ~ 
indicate levels of statistical significance of the magnitude 0.015 < P < 
0.05 and P < 0.01, respectively. Bold, italicised F Ratios and P Values 
indicate the statistics for week 1 comparison across both drug treatment 
phases (Test 1). 
Where the statistical analysis of each variable for individual subjects is 
given I TM A corresponds to phase 1 for subjects 1 and 2, with TM B 
representing phase 2. The reverse applies for subjects 3 - 6, that is TM 
A corresponds to phase 2, with TM A representing phase 1. 
4.3.5 Physical Measurements 
4.3.5.1 Body Weight and Weight loss 
The daily body mass, weekly weight change and % weight change tables for 
each individual are shown in Appendix 5 (Tables A5.1.1-5.1.8 and A5.2.1-
A5.2.8, respectively). The average body mass data, F ratios and P values 
depicted in Table 4.6 were obtained from a two-way ANOVA test (TEST 3, 
section 4.3.4). Raw data was obtained from each daily weighing from week 
2 to 5 for each phase and the mean values for 7 subjects are reported. 
Weight loss and percentage weight loss were analysed using one-way ANOVA 
procedures with drug condition as the factor. Weight loss was calculated 
by subtracting the final weight (week 5 day 5) from the initial weight 
(week 2 day 1) for each phase. The final weight for subject 7 was taken on 
week 3 day 5, for reasons given in section 4.3.4. 
It is apparent from Table 4.6, that no statistically significant 
differences in the average body mass of seven subjects occured whilst the 
subjects were taking PPA or placebo. However, a statistically significant 
drug effect was observed for weight loss and percentage weight loss. The 
subjects had a mean weight loss of 2.05 kg and a mean percentage weight 
loss of 2.52 % whilst they were taking PPA, compared to a mean weight loss 
and percentage weight loss of 0.76 kg and 0.85 % respectively, on placebo. 
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Measure TM A :f: SEM TM B :f: SEM 
Average Body Mass 68.56 :f: 0.600 69.80 :f: 0.580 
Weight Loss -2.05 :f: 0.365 -0.76 :f: 0.339 
% Weight Loss -2.52 :f: 0.414 -0.85 :f: 0.345 
§ indicates a P value between 0.015 and 0.05. 
~ indicates a P value < 0.01 
F Ratio P n df 
2.16 0.1422 135 1.262 
6,22§ 0.0282 7 1.12 
9.5411 0.0094 7 1.12 
TABLE 4.6 Average Body Mass, Weight Loss and Percentage Loss (Mean values for 7 subjects) 
Table 4.7 depicts the initial and final weights of individual subjects and 
Table 4.8 shows the weight change and percentage weight change for each 
subject for weeks 1 and weeks 2-5 for each phase. Percentage weight loss 
was calculated using the following formula (Eqn 4.4): 
% Weight Loss = Initial Weight - Final Weight X 100 
Initial Weight Eqn 4.4 
It is evident from the run-in period data in Table 4.8 that 2 subjects (EA 
and EG) gained a small amount of weight, 2 subjects (VW and LI) maintained 
a constant weight whilst the remaining 4 subjects (55, CAl LE and CV) lost 
weight in anticipation of the study during the run-in period preceding 
phase 1. I n add i t i on lit can be seen that 1 dur i ng the second phase I 3 
subjects (CA, LI and EG) gained weight, whilst the remaining 5 subjects 
lost weight during the run-in period. 
Initial Weight Final Weight 
Week 2 Day 1 Week 5 Day 5 
Subject nlA TM B TM A TM B 
S5 (1) 70.20 68.87 68.80 68.60 
CA (2) 61.27 63.33 60.53 63.27 
LE (3) 76.20 76.40 73.27 75.20 
EA (4) 62.73 65.80 59.73 63.33 
VW (5) 71.53 71.93 69.53 70.67 
LI (6) 82.13 81.07 78.87 81.20 
EG (7) 62.00 60.80 61.27 60.87 
CV (8) 66.27 62.47 62.53 -
TABLE 4.7 Initial and Final Body Weights for Individual Subjects 
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From the weight change data depicted in Table 4.8, it can be seen that 
during the weeks that the subjects took the test medications (weeks 2 - 5), 
each subject lost more weight, with a higher percentage of weight lost 
whilst they were taking PPA (TM A) compared to placebo (TM B). Subjects 1 -
5 lost weight while they were taking placebo (TM 8), whilst subjects 6 and 
7 gained weight on placebo (TM B). During the phase that the subjects were 
taking PPA (TM A), 4 subjects (LE, EA, LI and CV) lost more than 2 kg, 2 
subjects (55, VW) lost between 1 and 2 kg, whilst the remaining 2 subjects 
(CA and EG) lost less than 1 kg. 
Week 1 (Run-in Period)3 Weeks 2-5 (Test Medication)4 
Weight Change (kg) Weight Change (%) Weight Change (kg) Weight Change (%) 
Subject Phase 1 Phase 2 Phase 1 Phase 2 TM A TM B TM A TM B 
SS (1) - 1.20 - 0.67 - 1. 70 - 0.97 - 1.40 - 0.27 - 1.99 - 0.39 
CA (2) - 0.33 + 0.54 - 0.53 + 0.87 - 0.74 - 0.06 - 1.21 - 0.09 
LE (3) - 0.87 - 0.40 - 1.13 - 0.52 - 2.93 - 1.20 - 3.85 - 1.57 
EA (4) + 0.07 - 0.93 + 0.11 - 1.45 - 3.00 - 2.38 - 4.78 - 3.63 
VW (5) 0.00 - 0.13 0.00 - 0.18 - 2.00 - 1.26 - 2.80 - 1.75 
LI (6) 0.00 + 0.33 0.00 + 0.40 - 3.26 + 0.13 - 3.97 + 0.16 
EG (7) + 0.33 + 0.13 + 0.53 + 0.21 - 0.73 + 0.07 - 1.18 + 0.12 
CV (8) - 0.07 - 0.67 - 0.11 - 1.07 - 3.74 
-
- 5.64 -
3 Indicates the run-in period (week 1 for each phase) preceeding phase 1 and 2 
4 Indicates the period (weeks 2 - 5 for each phase) that the subjects took TM A and TM B 
TABLE 4.8 Weight Cbange and Percentage Weight Change for Individual Subjects 
The data depicted in Appendix 5, Tables A5.3.1 - A5.3.3 are mean values for 
7 subjects for the average weekly body mass, weight loss and percent weight 
loss, respectively. The F ratios and P values were obtained from a one-way 
AN OVA test and show that no significant differences in treatment with PPA 
(TM A) or placebo (TM B) were observed for each week when compared to 
baseline weights (TEST 2, section 4.3.4). The bold italicised F ratios and 
P values indicate that baseline weights were comparable across test 
medication phases (TEST I, section 4.3.4). 
The average body mass for each individual subject during both treatments 
are shown in Table 4.9. It ;s apparent that subjects 2 - 6 had a lower 
average mass during the phase that they were taking PPA (TM A) compared to 
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the placebo (TM B) phase. The F ratios and P values are extremely 
significant due to a smaller within subject variation. However, although 
subject 1 had a higher average body mass on PPA (TM A) than on placebo (TM 
B), it can be seen from Table 4.B that she lost 1.40 kg on PPA (TM A) as 
opposed to a 0.27 kg loss on placebo (TM B). 
Subj TM A ± SEM TM B ± SEM F Ratio P 
1 69.41 ± 0.095 68.86 ± 0.101 15.33~ 0.0004 
2 60.83 ± 0.081 63.27 ± 0.090 407.56~ 0.0000 
3 74.76 ± 0.224 76.49 ± 0.126 45.33~ 0.0000 
4 61.12 ± 0.201 64.55 ± 0.200 147.66~ 0.0000 
5 70.54 ± 0.133 71.34 ± 0.103 22.72! 0.0000 
6 79.86 ± 0.196 80.96 ± 0.092 25.70' 0.0000 
n = 20 (i.e. 5 measures per week for 4 weeks for each subject), 
df = 1,38 . 
~ indicates a P value of less than 0.01 
TABLE 4.9 Average Mass per Individual Subject 
The average weekly mass for each volunteer is shown in Appendix 51 Table 
A5.3.4. The F ratios and P values were obtained using a one-way ANOVA test 
(TEST 1 and 2, section 4.3.4). The P values are again extremely significant 
due to a smaller within subject variation. Scheffe1s multiple range test 
(MRT) was performed to determine which weeks were significantly different. 
The asterisk in the MRT columns indicate where these differences occured. 
For example, during the phase that subject 1 was treated with PPA (TM A), 
her average body mass during weeks 3, 4 and 5 were significantly lower than 
during weeks 1 and 2, and her average mass was relatively constant during 
the placebo (TM B) phase. Subject 21s average mass during weeks 2, 3 and 
5 was significantly lower than during INeeks 1 and 41 for the phase that she 
took PPA (TM A), and her average mass during weeks 2, 4 and 5 was 
significantly higher than during weeks 1 and 3 for the placebo (TM 8) 
phase. During the phase that the remaining 4 subjects took PPA (TM A)1 the 
average mass of subjects 3, 4 and 6 was significantly lower during weeks 
2 - 5 when compared to week I, with week 5 being significantly lower than 
weeks 1 - 4 for subject 5. 
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During the placebo (TM 8) phase l subject 3 maintained a constant average 
weekly mass, and subject 4 experienced a significant reduction in weight 
during weeks 4 and 51 when compared to weeks 1 - 3. During the same phase 
(TM 8) subject 5 showed a significant decrease in average body mass during 
weeks 2 - 5 when compared to baseline (week 1)/ and the average body mass 
for subject 6 was statistically lower during week 4 when compared to weeks 
1-3 and 5. 
The bold italicised F ratios and P values corresponding to week 1 indicate 
the significance of the baseline (week 1) comparisons across treatment 
phases (TEST 11 section 4.3.4). It can be seen that of the two subjects (1 
and 2) treated in the order TM A followed by TM 8, subject 1 had a lower l 
and subject 2 had- a higher average body mass during the first week of the 
second phase (TM 8). The 4 remaining subjects were treated in the order TM 
B followed by TM AI and it can be seen that 2 (subjects 3 and 6) had 
comparable average masses across treatments I whilst subjects 4 and 5 had 
a lower average body mass in the first week of the second phase (TM A). 
4.3.5.3 Skinfold Thickness Measurements 
Individual weekly skinfold thickness measurements are given in Appendix 6 
(Tables A6.1 - 6.8). Table 4.10 gives the sum of three skinfolds and the 
percentage body fat determined from standard tables (237). 
Phase 1 Phase 2 
Skinfold % Body Fat Skinfold % Body Fat 
Thickness Thickness 
Subject Age (sum of 3) (sum of 3) 
Init Fin Init Fin Init Fin Init Fin 
SS (1) 38 74.00 75.50 28.50 29.40 70.17 69.00 28.30 27.60 
CA (2) 22 88.00 90.00 31.70 32.50 87.83 31.57 
LE (3) 36 83.00 31.70 82.67 78.83 30.90 29.80 
EA (4) 37 81.00 79.17 30.90 30.00 62.33 58.50 25.50 24.20 
VW (5) 20 81.00 83.50 30.10 30.90 10.83 66.50 26.60 25.70 
LI (6) 32 108.0 105.2 36.90 36.30 103.5 35.70 
EG (7) 42 77 .00 30.30 70.33 75.33 27.60 29.40 
CV (8) 32 64.00 52.33 25.20 21.10 51.00 51.10 
Init: Initial skinfolds taken on the first day of Week 2, for each phase. 
Fin: Final skinfolds taken on the final day of each phase. 
TABLE 4.10 Initial and Final Sum of Three SkinfoJds and % Body Fat for each Subject. 
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Statistical evaluation of the data was not performed as very little 
confidence could be placed in these results due to missing values and the 
inexperience of the experimenter in performing these measurements. In 
addition, as discussed in section 3.3.1, skinfold thickness measurements 
are not useful to assess the slow, gradual weight loss experienced by the 
given sample population. The reason for missing data sets in the individual 
skinfold thickness measurements tables in Appendix 6, was that the subjects 
complained that the measurements were extremely uncomfortable and 
intrusive, and to minimise the possiblity of subject IIdrop-outsll it was 
decided to reduce the number of observations. 
Assuming we were confident of the data however, the final vs initial and 
weekly % body fat could have been determined statistically and used as an 
additional measure of weight loss. 
4.3.5.2 Blood Pressure Measurements 
Individual daily supine systolic and diastolic blood pressures for each 
subject are given in Appendix 7 (Tables A7.1.1 - 7.1.8). Data depicted in 
Table 4.11 represent the mean supine systolic and diastolic blood pressures 
(Bp1s) for 7 subjects obtained throughout the trial and the F ratios and 
P values were obtained using a two-way ANOVA (TEST 3, section 4.3.4). From 
this table, it is evident that no significant differences in mean BP1s 
occured whilst the subjects were taking PPA (TM A) or placebo (TM B). 
Blood Pressure TM A :t SEM TM B :t SEM F P 
Systol ic 107.71 :t 0.56 109.04 :t 0.58 2.69 0.1019 
Diastolic 68.59 :t 0.45 68.87 :t 0.49 0.18 0.6782 
n = 193, df = 1,378 
TABLE 4.11 Average supine systolic and diastolic blood pressure {Mean 7 Subjects} 
The data depicted in Table A7.2.1 and A7.2.2 are the mean values for 7 
subjects for the average weekly systolic and diastolic blood pressures, 
respectively. The F ratios and P values were obtained from a one-way AN OVA 
test and show that no significant differences in treatment with PPA (TM A) 
or placebo (TM B) were observed for each week when compared to baseline 
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blood pressures (TEST 2, section 4.3.4). The bold italicised F ratios and 
P values indicate that basel ine blood pressures were comparable across 
phases (TEST I, section 4.3.4). 
Table 4.12 depicts the average weekly supine systolic blood pressure (8P) 
for each of the volunteers. The F ratios and P values were obtained from 
a one-way ANOVA test (TEST 1 and 2, section 4.3.4). The bold, italicised 
F ratios and P values indicate that baseline supine systolic blood 
pressures were comparable for each subject across both treatment phases 
(TEST 1), with the except ion of subject 5 whose systo 1 i c pressure was 
significantly higher during the first week (baseline, week 1) prior to 
receiving TM 8. 
Subj Week TM A :!: SEM MRT F Ratio P TM B :!: SEM MRT F Ratio P 
1 1 115.80 :!: 1.91 115.60 :!: 1.72 0.01 0.9407 
2 113.80 :!: 1.59 111.20 :!: 1.67 
3 113.22 :!: 1.20 2.31 0.0819 109.33 :!: 1.70 2.05 0.1140 
4 109.20 :!: 0.80 108.40 :!: 1. 72 
5 109.60 :!: 2.48 110.40 ± 0.75 
2 1 100.40 ± 1.29 96.20 :!: 2.06 2.99 0.1220 
2 98.60 ± 1.90 98.20 :!: 1.28 
3 97.44 :!: 2.22 O. 0.6036 102.00 ± 1.60 2.70 0.0500 
4 95.60 :!: 1.47 93.60 ± 3.87 
5 96.00 :!: 2.19 94.40 :!: 2.64 
3 1 114.40 :!: 0.98 112.40 :!: 1. 72 1.02 0.3420 
2 112.90 :!: 1.42 113.20 :!: 1.68 
3 108.89 :!: 1.67 1.54 0.2157 112.22 :!: 2.07 0.38 0.8198 
4 111.60 ± 1.17 114.80 :!: 1.96 
5 109.20 :!: 1.67 115.00 :!: 1.84 
4 1 112.60 :!: 1.08 113.60 ± 1.17 * 0.40 0.5528 
2 113.80 ± 2.15 120.00 ± 1.97 * 
3 112.22 ± 1.47 0.37 0.8256 114.78 ± 1.43 * 2.89§ 0.0398 
4 115.20 ± 2.06 112.40 :!: 2.23 * 
5 114.40 :!: 1.72 112.20 :!: 3.17 * 
5 1 113.20 ± 1.20 119.20 :!: 0.80 17.31' 0.0032 
2 108.90 :!: 2.79 113.20 ± 1.88 
3 108.44 :!: 1.82 0.97 0.4379 112.33 :!: 2.42 1.39 0.2618 
4 112.80 :!: 1.85 111.80 :!: 2.42 
5 107.20 ± 2.87 114.60 :!: 2.56 
6 1 103.80 ± 1.85 107.80 :!: 1.32 3.09 0.1169 
2 106.00 :!: 1.84 103.80 ± 2.15 
3 99.11 ± 2.77 1.80 0.1552 105.22 ± 1.60 0.58 0.6791 
4 103.60 ± 1.60 103.20 ± 3.14 
5 100.20 :!: 2.15 105.40 ± 1.60 
The mean systolic blood pressures for week 1 prior to both treatments are given in the body of the table. 
For baseline (week 1) comparisons across phases n = 5 for each subject per phase, df = 1,7. Bold 
italicised F ratios and P values indicate the significance for weeks 1. 
For the comparison of treatment weeks (2-5) with week 1, n = 34, df = 4,32 
The *'s in the MRT columns indicate where the differences in the weeks occured. 
§ indicates a P value of between 0.015 and 0.05. 
~ indicates a P value of less than 0.01. 
TABLE 4.12 Average Weekly Systolic Blood Pressures per Volunteer 
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It is evident from Table 4.12 1 that no statistically significant 
differences in average weekly systolic pressures occured during the weeks 
that each subject took PPA (TM A)I when compared to baseline. A similar 
scenario unfolds for each individual for the weeks that they were taking 
placebo (TM B)/ with the exception of subject 4. Application of Scheffe1s 
multiple range test to the systolic BP for subject 4 during treatment with 
placebo (TM B) revealed that her average systolic BP was significantly 
higher during the second week. 
Table 4.13 shows the individual average systolic BP for the weeks that each 
subject was administered PPA (TM A) and placebo (TM B). The F ratios and 
P values were obtained from a one-way ANOVA test (TEST 3/ section 4.3.4), 
with drug condition as the factor. 
From Table 4.13 it can be seen that, although subject 5 experienced a 
statistically significant lowering of systolic BP during the phase that she 
was taking PPA (TM A) I this ha-emodynamic variable remained relatively 
stable in the remaining 5 subjects during treatment with PPA (TM A) and 
placebo (TM 8). 
Subj TM A ± SEM TM 8 ± SEM F Ratio P 
1 112.10 ± 0.85 110.00 ± 0.83 3.15 0.0814 
2 97.28 ± 1.03 97.93 ± 1.51 0.18 0.6776 
3 110.79 ± 0.97 113.14 ± 0.96 3.89 0.0537 
4 113.66 ± 0.96 115.72 ± 1.17 1.87 0.1764 
5 109.14 ± 1.25 112.93 ± 1.12 5.14§ 0.0273 
6 102.45 ± 1.25 104.41 :l: 1.04 1.47 0.2300 
n = 29, df = 1,56 
§ indiciates a P value of between 0.015 and 0.05 
TABLE 4.13 Average Systolic Blood Pressure per Volunteer 
Table 4.14 depicts the average weekly supine diastolic blood pressure for 
each of the volunteers. The F ratios and P values were obtained from a one-
way ANOVA test (TEST 1 and 2, section 4.3.4). The bold, italicised F ratios 
indicate that baseline supine diastolic blood pressures were comparable for 
each subject across both treatment phases (TEST 1)1 with the exception of 
subject 1 whose diastolic pressure was significantly higher during the 
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first week prior to receiving TM B. 
It is evident from Table 4.14, that no statistically significant 
differences in average weekly diastolic pressures occured during the weeks 
that each subject took PPA (TM A) I when compared to the corresponding 
baseline week. The same non-significance is apparent for each individual 
for the weeks that the subjects were taking placebo (TM B). 
Subj Week TM A :t SEM MRT F Ratio P TM B :t SEM MRT F Ratio P 
1 1 67.00:t 0.45 73.60 :t 2.04 9.9!} 0.0134 
2 72.40 :t 2.11 71.30 :t 1.60 
3 67.67 :t 1.37 1.48 0.2378 71.56 :t 1.56 0.61 0.6572 
4 67.60 :t 1.94 67.20:t 3.44 
5 68.80 :t 3.01 71.60 :t 5.42 
2 1 59.60 :t 1.50 63.00 :t 2.83 1.13 0.3195 
2 62.60 :t 1.30 73.20 :t 1.47 
3 62.89 :t 1.38 1.53 0.2190 63.67 :t 1.45 0.85 0.5044 
4 61.00 :t 1.18 58.80 :t 2.87 
5 64.80 :t 0.97 61.60 :t 2.23 
3 1 67.60 :t 1.60 70.40 :t 2.48 0.90 0.3806 
2 68.60 :t 1.45 71.20 :t 1.01 
3 70.44 :t 2.40 0.42 0.7922 75.11 :t 0.81 2.72 0.0500 
4 71.60 :t 1.60 72.80 :t 1.02 
5 69.20 :t 3.67 70.20 :t 1.56 
4 1 70.40 :t 2.98 69.20 :t 0.80 0.15 0.7112 
2 73.30 :t 1.45 75.90 :t 1.93 
3 72.67 :t 1.86 0.78 0.5489 76.00 :t 1.76 2.69 0.0508 
4 72.80 :t 1.96 70.40 :t 0.40 
5 76.00 :t 1.79 72.80 :t 2.42 
5 1 75.60 :t 1.72 73.20 :t 2.73 0.55 0.4857 
2 70.10 :t 2.57 74.70 :t 1.62 
3 69,33 :t 1.29 1.40 0,2601 70.1l :t 0.98 2.36 0.0768 
4 73.20 :t 4.03 70.60 :t 1.17 
5 67.60 :t 1.47 76.00 :t 1.79 
6 1 62.80 :t 2.06 66,00 :t 2.53 0.96 0.3655 
2 69.40 :t 1.63 63.50 :t 1.56 
3 65.78 :t 2.61 1.84 0.1477 65.11 :t 1.53 0.33 0.8535 
4 65.40 :t 1.33 65.00 :t 1.34 
5 61.80 :t 2.76 63.60 :t 2.23 
The mean diastolic blood pressures for week 1 prior to both treatments are given in the body of the 
table. For baseline (week 1) comparisons across phases n = 5 for each subject per phase, df = 1,7. Bold 
italicised F ratios and P values indicate the significance for weeks 1. 
For the comparison of treatment weeks (2-5) with week 1, n = 34, df = 4,32 
§ indicates a P value of beh/een 0.015 and 0.05. 
TABLE 4.14 Average Weekly Diastolic Blood Pressures per Volunteer 
Table 4.15 shows the individual average diastolic BP for the weeks that 
each subject was administered PPA (TM A) and placebo (TM B). The F ratios 
and P values were obtained from a one-way ANOVA test "(TEST 3, section 
4.3.4). From this table it can be seen, that although subject 3 
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experienced a statistically significant lowering of systolic BP during the 
phase that she was taking PPA (TM AL no statistically significant 
fluctuations in diastolic BP occured in the remaining 5 subjects during 
treatment with PPA (TM A) and placebo (TM 8). 
Subj TM A :: SEM TM 8 :i: SEM F Ratio P 
1 69.48 :: 1.07 70.72 :: 1.27 0.56 0.4650 
2 62.79 :i: 0.68 62.31 :i: 0.93 I 0.18 0.6803 
3 69.79 :: 1.09 72.52 :l: 0.62 4.739 0.0339 
4 73.48 :l: 0.87 74.45 :: 1.00 0.53 I 0.4780 
5 69.97 t 1.20 72.79 :: 0.84 3.74 0.0583 
6 66.28 :l: 1.18 64.27 :l: 0.82 1.95 0.1678 
n • 29, df • 1.56 
§ indiciates a P value of between 0.015 and 0.05 
TABl.E 4.15 Average Weekly Diastolic Blood Pressure per Volunteer 
4.3.6 Behavioural Measurements 
4.3.0.1 Analysis of Mood Questionnaires 
The processed response data to each of the three subdivisions of the MQ, 
i.e., the ARC!, POMS and VAS for each subject per measurement occasion, are 
given in Appendices a (Tables A8.l.l - A8.l.a), 9 (Tables A9.l.l - A9.l.a) 
and 10 (Tables AIO.I.l - AIO.l.a), respectively. The ARC! raw data were 
processed using the ARCI data capture and processing program discussed in 
section 3.4.1.1 and the POMS raw data was processed using the corresponding 
POMS data capture and processing program explained in section 3.4.2.1. For 
analysis of the VAS response data, the answer mark on the line of each 
scale was measured to the nearest millimetre to produce a score of between 
o and 100 for each determination (section 3.3.2.1.2). 
4.3.6.1.1 The Addiction Research Centre Inventory (ARCI) Results 
The average responses for 7 subjects to each of the five ARCI scales i.e., 
the PCAG, BG, LSD, MBG and A scale, are given in Table 4.16. The mean 
response per test medication phase, F ratios and P values were obtained 
from a two-way ANOVA test (TEST 3, section 4.3.4). From this table it can 
be seen that no statistically significant effects for any of the 5 scales 
occured ac~oss the test medication Jhases. 
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The data depicted in Appendix B, Table AB.2.1 are the mean responses for 
7 subjects to each of the ARCI scales. The F ratios and P values were 
obtained using one-way ANOVA procedures and show that no significant 
differences in treatment with PPA (TM A) or placebo (TM B) were observed 
for each week when compared to baseline ARCI responses (TEST 2, section 
4.3.4). The bold, italicised F ratios and P values indicate that baseline 
responses to each of the ARCI variables were comparable across test 
medication phases (TEST 1). 
TABLE 4.16 
ARCI Scale TM A :l: SEM TM 8 :l: SEM F P 
PCAG 3.17 :I: 0.26 3.21 :I: 0.26 0.01 0.9279 
8G 6.18 :I: 0.31 5.99 :I: 0.27 0.29 0.5986 
LSD 3.45 :l: 0.17 3.79 :I: 0.15 2.42 0.1211 
MaG 5.83 :I: 0.49 4.76 :l: 0.44 2.63 0.1060 
A 3.45 :l: 0.36 3.28 :I: 0.31 0.13 0.7189 
n = 121, df = 1.234 
Average Addiction Research Centre Inventory Responses (Mean F ratios and ? values for 
7 Subjects) 
The average Pentobarbital-Chlorpromazine-Alcohol Group (PCAG), Benzedrine 
Group (BG), Lysergic Acid Diethylamide Group (LSD), Morphine-Benzedrine 
Group (MBG) and Amphetamine (A) responses are depicted in Tables AB.2.3 -
AB.2.6 respectively, for each test medication phase per volunteer. The mean 
response per test medication phase, F ratios and P values were obtained 
from a one-way ANOVA test (TEST 31 section 4.3.4), with drug condition as 
factor. From the mean individual PCAG response data shown in Table AB.2.2 
it can be seen that the degree of sedation experienced by each subject was 
not statistically different across test medication phases. 
Table AB.2.3 shows that 4 out of the 6 subjects did not experience any 
change in intellectual efficacy or energy (BG responses) across treatments. 
Of the two subjects who showed significantly altered responses to the BG 
scale across treatment phases, one (subject 1) showed an increased, whilst 
the other (subject 6) showed a decrease in intellectual efficacy and energy 
during the phase that they received PPA (TM A), compared to placebo (TM B). 
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Table AB.2.4 shows that 4 out of the 6 subjects did not experience any 
sign i f i cant a lterat i on in LSD response across treatment phases. Of the 
remaining two, subject 1 showed a significant lowering of dysphoric 
response during the phase that she received PPA (TM A), whilst subject 3 
exhibited a pronounced equality in LSD response during both test medication 
phases. 
Table AB.2.S shows that 4 out of the 6 subjects did not experience any 
significant change in MBG response across test medication phases. Both of 
the remaining two subjects (subject 1 and 4) showed a significant elevation 
of euphoric response and well-being during the phase that they received PPA 
(TM A) compared to placebo (TM B). Subject 3 again showed marked similarity 
in response to the MBG scale across treatments, although this anomalous 
reponse was not statistically significant. 
Table AB.2.6 shows that 3 out of the 6 subjects did not experience any 
significant change in A response across test medication phases. Subjects 
1 and 2 showed a significant elevation in amphetamine-like response, during 
the phase that they received PPA (TM A), whilst subject 3 exhibited a 
remarkable parity in response to the amphetamine scale during both test 
medication phases. 
4.3.6.1.2 The Profile of Mood States (POMS) Results 
The average responses for 7 subjects to each of the ten POMS scales 
(anxiety, depression, anger, vigour, fatigue, confusion, friendliness, 
elation, arousal and positive mood) are given in Table 4.17. The mean 
response per test medication phase, F ratios and P values were obtained 
from a two-way ANOVA test (TEST 3, section 4.3.4) with drug condition and 
weeks as factors in the analysis. From this table it can be seen that no 
statistically significant effects for any of the 10 scales occured across 
the test medication phases. 
The data depicted in Appendix 9, Table A9.2.1 are the mean weekly responses 
for 7 subjects to each of the POMS scales. The F ratios and P values were 
obtained using one-way ANOVA procedures and show that with the exception 
of the "depression° reponse no significant differences in treatment with 
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PPA (TM A) or placebo (TM 8) were observed for each week when compared to 
baseline POMS responses (TEST 2, section 4.3.4). Application of Scheffe1s 
multiple range test (MRT) to the average weekly IIdepressionll responses for 
the PPA (TM A) phase showed that the subjects were significantly more 
depressed during the last 3 weeks when compared to the first 2 weeks. 
TABLE 4.17 
POMS Scale TM A :I: SEM TM 8 :I: SEM F P 
Anxiety 0.31 :I: 0.02 0.32 :I: 0.03 0.26 0.6142 
Depression 0.12 :I: 0.04 0.14 :I: 0.04 0.23 0.6407 
Anger 0.15 ± 0.03 0.15 :I: 0.04 0.06 0.9399 
Vigour 1.44 ± 0.09 1.29 :I: 0.07 1.69 0.1948 
Fatigue 0.20 :I: 0.05 0.16 :I: 0.04 0.39 0.5396 
Confusion 0.41 :I: 0.03 0.47 ± 0.04 2.15 0.1441 
Friendl iness 1.88 :I: 0.08 1.78 :I: 0.07 0.89 0.3560 
Elation 1.32 :I: 0.09 1.23 :I: 0.07 0.60 0.4481 
Arousal 1.14 :I: 0.12 0.97 :I: 0.10 1.11 0.2924 
Positive Mood 1.20 :I: 0.10 1.09 :l: 0.08 0.68 0.4188 
n = 119, df = 1,230 
Average Responses to the Profile of Mood States (Mean F ratios and P values for 7 
Subjects) 
The bold, italicised F ratios and P values in Table A9.2.1 indicate that 
baseline responses to each of the POMS scales were comparable across test 
medication phases (TEST I, section 4.3.4)' with the exception of the 
lI anx ietylll !Idepressionll and II confusion ll responses} which were signifcantly 
higher during the baseline week prior to treatment with placebo (TM B). 
The average responses to the individual POMS scales are depicted in 
Appendix 9, Tables A9.2.2 - A9.2.11 respectively, for each test medication 
phase per volunteer. The mean response per test medication phase, F ratios 
and P values were obtained from a one-way ANOVA test (TEST 31 section 
4.3.4). with drug condition as factor. 
Table A9.2.2 shows that 2 out of the 6 subjects showed a statistically 
significant change in lIanxietyll repsonses across treatment phases, with 
subject 1 being less anxious and subject 6 being more anxious during 
treatment with PPA (TM A), compared to treatment with placebo (TM 8). From 
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Table A9.2.3, it can be seen that the responses to the POMS IIdepression ll 
scale for each individual subject were not significantly different across 
test medication phases. 
Table A9.2.4 shows that while 4 out of the 6 subjects did not show any 
alteration in the POMS "angerll response across treatment phases, 2 subjects 
(subject 1 and 6) were significantly more angry during the phase that they 
received PPA (TM A). The average IIvigourli responses for each subject during 
both test medication phases are depicted in Table A9.2.S and show that 
while 2 subjects (1 and 2) IJ'Jere significantly more vigorous! 1 subject 
(subject 3) was significantly less vigorous during the phase that they were 
treated with PPA (TM A). 
Table A9.2.6 shows that only 1 subject (subject 4) experienced significant 
lowering in the lIfatigue ll response during the phase that she received PPA 
(TM A)I whilst the responses of the remaining 5 subjects to this scale were 
unaffected by the administration of PPA (TM A). 
Two subjects (subject 1 and 4) exhibited significantly lower responses to 
the lI confusion ll scale (Table A9.2.7) and significantly higher responses to 
the IIfriendl iness ll scale (Table A9.2.8) during the phase that they were 
treated with PPA (TM A)I while the responses of the remaining 4 subjects 
to both of these scales were unchanged across test medication phases. 
Table A9.2.9 shows that while 4 out of the 6 subjects did not esperience 
any change in the lI elation ll response across test medication phases, 2 
subjects exhibited opposing responses during the phase that they were 
treated with PPA (TM A), with subject 1 being more lI elated ll and subject 3 
being less lI elated ll during this phase. The same picture emerges for the 
IIpositive mood ll scale depicted in Table A9.2.11. 
Table A9.2.10 shows that whilst the lIarousaP responses of subjects 1 and 
4 were significantly higher during the phases that they were treated with 
PPA (TM A), subject 3 once again exhibited a negative response to this POMS 
variable during the same treatment. 
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4.3.6.1.3 The Visual Analogue Scales (VAS) Results 
The average responses for 7 subjects to each of the six visal analogue 
scales (stimulation, high, anxious, sedated, down and hungry) are given in 
Table 4.18. The mean response per test medication phase, F ratios and P 
values were obtained from a two-way ANOVA test (TEST 3, section 4.3.4) with 
drug condition and weeks as factors in the analysis. From this table it can 
be seen that whilst both the II stimulation ll and IIhighll scales were 
significantly lower during treatment with PPA (TM A), no statistically 
significant effects for for the remaining 4 scales occured across the test 
medication phases. 
The data depicted in Appendix 10, Table A10.2.1 are the mean responses for 
7 subjects to each of the 6 VAS scales. The F ratios and P values were 
obtained using one-way AN OVA procedures and show that with the exeption of 
the IIstimulated ll and IIhighll reponses during the PPA (TM A) phase and the 
II stimulated ll responses during the placebo (TM 8) phase, no significant 
differences in treatment with PPA or placebo for the remaining VAS 
variables were observed for each week when compared to baseline responses 
(TEST 2, section 4.3.4). 
Measure TM A ± SEM TM B ± SEM F P 
Stimulation 8.86 ± 0.73 19.27 ± 1.66 33.43 0.0000 
High 8.03 ± 0.89 15.78 ± 1.69 16.63 0.0000 
Anxious 9.56 ::I: 1.25 11.89 ::I: 1.41 1.52 0.2187 
Sedated 8.06 ::I: 1.18 7.61 ::I: 0.83 0.10 0.7602 
Down 12.67 ::I: 1.94 11.89 ± 1.68 0.09 0.7631 
Hungry 13.37 ::I: l.62 17.69 :I: 2.06 2.66 0.1042 
n = 122, df = 1.236 
TABLE 4.18 Average Responses to Visual Analogue Scales (Mean F ratios and P values for 7 Subjects) 
Application of Scheffe's multiple range test (MRT) to the average weekly 
II stimulated ll responses for both the PPA (TM A) and placebo (TM B) phases 
showed that the subjects were significantly more II stimulated ll during the 
first week prior to receiving either TM A or TM 8 than during the four 
weeks that they received either test medication. The MRT applied to the 
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average weekly IIhighll responses for the PPA (TM A) phase revealed that the 
subjects were significantly less IIhighll during the 4 weeks that they took 
PPA (TM A) when compared to the baseline week. The bold, italicised F ratios 
and P values in Table A10.2.I indicate that whilst baseline responses to 
to the lIanxious ll and IIsedated ll scales were comparable across test 
medication phases (TEST I, section 4.3.4), the responses to the remaining 
4 scales (ll stimulated ll , "highll, II down II and IIhungryll) 1 were signifcantly 
lower during the baseline week prior to treatment with PPA (TM A). 
The average responses to the individual VAS scales are depicted in Appendix 
10 1 Tables AI0.2.2 - A10.2.7 respectively, for each test medication phase 
per volunteer. The mean response per test medication phase, F ratios and 
P values were obtained from a one-way ANOVA test (TEST 3, section 4.3.4). 
Table AIO.2.2 shows that subjects I, 4 and 5 exhibited a statistically 
significant lowering in the Iistimulation" repsonse during the phase that 
they were treated with PPA (TM A) when compared to treatment with placebo 
(TM 8), with the response differences from the remaining 3 subjects being 
statistically insignificant. 
From the average response data for the VAS Ilhighil scale depicted in Table 
AI0.2.3, it can be seen that the response from subject 2 was not 
significantly different across test medication phases, subjects I, 4, 5 and 
6 exhibited a lowered response and subject 3 showed an increased response 
to the Uhigh U VAS scale during the phase that they were treated with PPA 
(TM A), when compared to treatment with placebo (TM 8). 
Table AI0.2.4 shows that whilst the Ilanxious ll responses of subjects 1 and 
4 were significantly lower during the phase that they were treated with PPA 
(TM A), subject 3 exhibited the opposite (increased) response during this 
phase. The same is true for the II down II scale depicted in Table AIO.2.6. 
Table A10.2.5 shows that whilst the Ilsedated U responses of subjects 4 and 
6 were significantly lower during the phases that they were treated with 
PPA (TM A), subject 3 once again exhibited a negative response to this VAS 
variable during the same treatment. 
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Table A10.2.7 depicts the average IIhungryll responses for each test 
medication phase per volunteer. From this table it can be seen that the 
responses to this variable were only statistically significant in one 
subject (subject 4), who was significantly less hungry during the phase 
that she was treated with PPA (TM A). 
4.3.6.2 Problems Associated with Food Intake Data Collection and 
Subsequent Impact on Dependant Variables and Statistical 
Analysis 
One of the major problems with the trial, was that the food intake data 
from the test meals for the baseline period of the first phase i.e. week 
I, days 1 and 4 and for week 2 day 1 could not be used in the statistical 
analysis. During this time, the food items were prepared by the university 
canteen and the potatoes were of poor quality and badly cooked. Following 
the test meal on week 2 day I, the subjects complained that the potatoes 
were inedible and that the food had become cold whilst blood pressures and 
baseline salivation were being measured. A cursory glance at the amount of 
potato eaten by each subject confirmed these reports, as very little or 
none of the potato had been eaten. It could be seen that the carbohydrate 
ingested by the subjects was not representative of their usual intake. In 
order to enable the detection of possible differences in carbohydrate 
intake due to PPA (TM A) administration and to prevent subjects from 
IIdroppping outll of the trial, it was decided that a new approach was 
needed. 
Thus, from week 2 day 4 of phase 1 to the end of the trial, potatoes were 
hand-picked for quality and cooked in their jackets by the trial co-
ordinator. In addition, as temperature of the food plays an important role 
in palatability and hence food intake, once each subject1s test meal had 
been weighed and placed in a segmented dish, the dish was covered with a 
lid and kept warm on a Sain-maire type arrangement. 
However, although this alternate approach was instituted, the baseline food 
intake data was not comparable across phases and therefore could not be 
used for statistical analysis. Although this problem was inherent to food 
intake data only, the problem was extended to the the variables dependent 
on food intake, such as hunger and satiety ratings, SSQ, stimulus-induced 
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salivation and the food preference questionnaires. As a result, baseline 
data obtained from these parameters could not be statistically compared 
across phases (Test I, section 4.3.4), nor could the data obtained from 
weeks 2-5 of phase 1 be compared with data from week 1 (Test 2, section 
4.3.4). It followed that data obtained from weeks 7-11 of phase 2 was not 
analysed in the same manner. 
4.3.6.3 Analysis of the Appetite. Hunger (AHQ and SSQ) and the Sdtiety 
Questionnaire (SO and FPQ) 
The weekly response data for the 4 questions relating to the AHQ and the 
BSQ responses are given in Appendix 11 (Tables All.l.l -AIl.l.16) and the 
weekly response data for the 6 questions relating to the SQ and the FPQ 
responses for each subject per measurement occasion are given in Appendix 
11 (Tables All.2.1 - A11.2.16). 
The data in Table 4.19 depict the statistical results of the subjective 
ratings made on the Appetite and Hunger Questionnaires (AHQ). The mean 
rating for 7 subjects to each of the 4 questions per test medication phase, 
F ratios and P values were obtained from a two-way ANOVA test (TEST 3, 
section 4.3.4) with drug condition and weeks as factors in the analysis. 
Statistically significant drug treatment effects are apparent for the PPA 
(TM A) phase as opposed to the placebo (TM B) phase. A decrease in the mean 
hunger ratings, urge to eat or appetite, preoccupation with thoughts of 
food and estimates of likely food consumption occured when the subjects 
were taking active medication (TM A) as opposed to placebo (TM B). 
Subjective Ratings TM A ± SO TM B ± SO 
How hungry are you right now? 28.66 ± 2.68 41.10 ± 3.48 
NOT AT ALL EXTREMELY 
How strong is your urge to 28.19 ± 3.19 41.98 ± 3.64 
eat? 
NOT AT ALL EXTREMELY 
How preoccupied are you with 25.03 ± 2.77 37.24 ± 3.12 
thoughts of food? 
NOT AT ALL EXTREMELY 
How much food could you eat? 33.75 ± 3.29 45.55 ± 3.63 
NOTHING A LARGE AMOUNT 
§ indicates a P value between 0.015 and 0.05. 
~ indicates a P value < 0.01 
n = 31, df = 1,54 
TABLE 4.19 Subjective Ratings of Hunger and Appetite 
F P 
7.36' 0.0089 
7.68' 0.0076 
8.70' 0.0047 
5.83§ 0.0192 
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The average ratings to the AHQ questions are depicted in Table 4.20, for 
each test medication phase per volunteer. The mean rating per test 
medication phase, F ratios and P values were obtained from a one-way ANOVA 
test (TEST 3, section 4.3.4). It can be seen that out of the 6 subjects, 
only 1 (subject 4) experienced a statistically significant decrease in 
response to the first three questions of the AHQ (hunger, urge to eat and 
preoccupation with thoughts of food) when she was taking PPA (TM A) as 
opposed to placebo (TM 8). The lack of statistical significance as 
evidenced by higher P values for the remaining 5 subjects for questions 1-
3, and for subjects 1-6 for question 4 is mainly due to a large within 
subject variation. 
Subjective Ratings Subj TM A ± SEM 
How hungry are you right now? 1 39.00 ± 3.48 
NOT AT ALL EXTREMELY 2 28.00 ± 17.62 
3 37.25 ± 4.23 
4 8.33 :!: 2.60 
5 20.33 ± 6.44 
6 32.75 ± 6.68 
How strong is your urge to 1 45.25 ± 5.68 
eat? 2 26.67 :!: 20.51 
NOT AT ALL EXTREMELY 3 30.75 ± 5.14 
4 4.67 :!: 0.67 
5 20.33 ± 7.54 
6 35.50 ± 7.86 
How preoccupied are you with 1 26.50 ± 6.12 
thoughts of food? 2 26.33 :!: 15 30 
NOT AT ALL EXTREMELY 3 28.25 ± 2.43 
4 4.00 ± 0.00 
5 23.33 ± 9.06 
6 37.25 ± 8.31 
How much food could you eat 1 52.50 ± 7.98 
right now? 2 27.67 :!: 18.12 
NOTHING A LARGE AMOUNT 3 40.25 ± 3.20 
4 8.33 ± 3.67 
5 23.00 :!: 11.14 
6 36.25 ± 7.22 
§ indicates a P value between 0.015 and 0.05. 
~ indicates a P value < 0.01 
n = 4, df = 6, for subjects 1, 3 and 6 
n = 3, df = 4, for subjects 2, 4 and 5 
TM B :!: SEM F P 
54.50 :!: 7.32 3.65 0.1045 
31.67 :!: 14.50 0.03 0.8817 
44.00 ± 5.58 0.93 0.3823 
27.33 ± 5.04 11.2§ 0.0286 
53.00 ± 22.90 1.89 0.2416 
34.25 ± 2.39 0.05 0.8417 
59.00 ± 6.65 2.48 0.1667 
34.00 ± 15.89 0.04 0.8492 
40.25 :!: 6.56 1.30 0.2978 
29.67 ± 6.49 14.7§ 0.0186 
55.67 ± 22.36 2.24 0.2087 
36.25 :!: 4.59 0.01 0.9378 
36.75:!: 7.34 1.15 0.3247 
41.33 ± 2.03 0.94 0.3959 
39.00 ± 8.82 1.38 0.2846 
26.67 :!: 2.40 88.91 0.0007 
55.00 :!: 22.14 1. 75 0.2562 
31.00 ± 4.97 0.42 0.5491 
53.75 :!: 3.40 0.21 0.8917 
52.67 ± 5.49 1. 74 0.2572 
43.50:!: 7.66 0.15 0.7131 
35.67 ± 16.68 1.89 0.2416 
55.00 ± 23.29 1.54 0.2829 
35.25 :!: 5.33 0.01 0.9160 
TABLE 4.20 Average Subjective Ratings of Hunger and Appetite per Volunteer 
The results of the BSQ, divided into the number of subjects reporting a 
sensation and the number of times each sensation was recorded during 
treatment with PPA (TM A) and placebo (TM B) appear in Table A11.3.l. 
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From this table it appears that the only sensations possibly influenced by 
the treatments were rumbling of the stomach, nausea, no gastric sensations 
signalling hunger, salivation, headache, restlessness, warmth and 
contented. The data under interpretation in this discussion are from the 
number of times each particular sensation was recorded. It seems that PPA 
(TM A) reduced sensations of stomach rumbling, no gastric sensations, 
salivation, headache and restlessness, whilst sensations of nausea, warmth 
and contentment were heightened. 
The data in Table 4.21 depict the statistical results of the subjective 
ratings made on the Satiety Questionnaires (SQ). The mean rating for 7 
subjects to each of the 6 questions per test medication phase, F ratios and 
P values were obtained from a two-way AN OVA test (TEST 3, section 4.3.4) 
with drug condition and weeks as factors in the analysis. From this table 
it is evident that no statistically significant differences in the 
responses to the 6 questions of the SQ were observed across test medication 
phases. 
Subjective Ratings TM A :: SEM TM B ± SEM F P 
How sated / full are you right 59.27 ± 3.66 56.32 ± 3.11 0.35 0.5609 
now? 
NOT AT ALL EXTREMELY 
How strong is your urge to eat 12.73 :t 1.62 15.71 :t 1.62 1.63 0.2068 
after completing your meal? 
NOT AT ALL EXTREMELY 
How preoccupied are you with 10.11 ± 1.62 15.29 :t 2.77 2.43 0.1252 
thoughts of food? 
NOT AT ALL EXTREMELY 
How appealing was the food? 38.65 ± 4.07 37.79 ± 4.00 0.02 0.8856 
NOT AT ALL EXTREMELY 
How did the food taste? 41.68 :t 3.71 41.10 ± 3.61 0.01 0.9140 
VERY BAD VERY GOOD 
How much of your favourite 21.89 :t 3.75 26.84 ± 3.43 0.89 0.3604 
food could you eat right now? 
NOTHING A LARGE AMOUNT 
n = 31, df = 1,54 
TABLE 4.21 Average Subjective Ratings of Satiety (Mean 7 Subjects) 
The average ratings to the SQ questions are depicted in Table 4.22, for 
each test medication phase per volunteer. The mean rating per test 
medication phase, F ratios and P values were obtained from a one-way ANOVA 
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test (TEST 3, section 4.3.4), with drug condition as factor. It can be seen 
that out of the 6 subjects, only one (subject 3) experienced a 
statistically significant increase in response to question 3 of the SQ 
(preoccupation with thoughts of food)/ whilst another (subject 4) exhibited 
a significant decrease in response to questions 4-6 (appeal, taste and 
estimate of favourite food consumption) whilst they were taking PPA (TM A) 
as opposed to placebo (TM B). The responses of the remaining 4 subjects 
(subjects 1,2,5 and 6) to each of the 6 quest ions of the SQ were not 
significantly altered across treatment phases. 
Subjective Ratings Subj TM A ± SEM 
How sated / full are you right 1 61.25 ± 3.42 
now? 2 82.00 ± 8.33 
NOT AT ALL EXTREMELY 3 60.00 :l: 1.78 
4 34.00 ± 4.04 
5 78.33 ± 4.91 
6 49.50 :l: 1.04 
How strong is your urge to eat 1 14.50 ± 5.17 
after completing your meal? 2 0.00 ± 0.00 
NOT AT ALL EXTREMELY 3 18.25 ± 0.48 
4 10.00 ± 2.89 
5 2.67 ± 0.67 
6 20.50 ± 1.50 
How preoccupied are you with 1 9.50 ± 2.63 
thoughts of food? 2 0.00 :l: 0.00 
NOT AT ALL EXTREMELY 3 16.75 ± 1.11 
4 9.00 ± 2.08 
5 1.33 ± 0.67 
6 18.00 ± 3.12 
How appealing was the food? 1 60.00 ± 6.28 
NOTHING A LARGE AMOUNT 2 71.33 ± 13.97 
3 27.75 ± 6.84 
4 32.22 :l: 5.61 
5 17.67 ± 8.84 
6 38.50 ± 8.93 
How did the food taste? 1 63.50 ± 4.09 
VERY BAD VERY GOOD 2 65.67 :I: 14.86 
3 29.25 ± 6.56 
4 36.67 ± 6.33 
5 25.00 ± 13.23 
6 43.25 ± 4.92 
How much of your favourite 1 20.50 ± 5.27 
food could you eat right now? 2 1.33 ± 0.67 
NOTHING A LARGE AMOUNT 3 26.75 ± 4.27 
4 10.33 ± 3.84 
5 2.33 ± 0.33 
6 59.00 ± 6.10 
§ indicates a P value between 0.015 and 0.05. 
n = 4, df = 6, for subjects 1, 3 and 6 
n = 3, df = 4, for subjects 2, 4 and 5 
TM B ± SEM F P 
58.25 ± 2.87 0.45 0.5338 
50.67 ± 22.40 1.72 0.2600 
57.00 ± 4.49 0.39 0.5638 
42.33 ± 8.41 0.80 0.4314 
78.00 :I: 22.90 0.00 0.9702 
54.25 ± 3.30 1.88 0.2190 
15.25 ± 3.07 0.02 0.9061 
6.67 ± 4.06 2.70 0.1755 
16.00 ± 1.47 2.11 0.1963 
22.00 :l: 6.08 3.18 0.1493 
1.00 ± 0.58 3.57 0.1318 
19.13 ± 2.76 0.19 0.6811 
15.25 :I: 8.94 0.38 0.5662 
6.67 ± 6.67 1.00 0.3739 
l3.00 ± 0.91 6.829 0.0401 
25.67 :l: 6.57 5.96 0.0728 
1.00 ± 1.00 0.08 0.7980 
18.25 ± 3.30 0.00 0.9589 
57.50 :I: 7.67 0.05 0.8278 
37.00 ± 18.77 2.15 0.2162 
31.00 ± 1.58 0.22 0.6643 
59.33 ± 5.81 11.29 0.0287 
27.33 ± 4.81 0.92 0.4007 
30.00 ± 8.15 0.49 0.5157 
60.75 ± 8.01 0.09 0.7734 
35.00 ± 17.60 1.78 0.2533 
30.75 ± 1.97 0.05 0.8362 
62.33 ± 3.76 12.2§ 0.0252 
30.67 :l: 1.76 0.18 0.6872 
41.25 ± 9.20 0.04 0.8562 
25.50 :l: 0.50 0.89 0.3909 
47.00 :I: 26.58 2.95 0.1610 
20.25 ± 1.93 1.92 0.2147 
33.00 ± 5.03 12.89 0.0232 
1.67 ± 0.88 0.50 0.5256 
43.00 ± 4.14 4.71 0.0730 
TABLE 4.22 Average Subjective Ratings of Satiety per Volunteer. 
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The results of the FPQ, divided into the numbers of total food, protein and 
carbohydrate items checked during treatment with PPA (TM A) and placebo (TM 
B) appear in Table 4.23. 
MEASURE TM A TM B 
Total Food Items 9.28 8.40 
High Protein Items 4.36 4.16 
High Carbohydrate Items 4.92 4.24 
TABLE 4.23 Effect of Treatments on the FPQ 
From this table it appears that treatment with PPA (TM A) resulted in a 
slight increase in the number of preferred food items checked, as well as 
preferences for protein and carbohydrate items. 
4.3.6.4 Analysis of Food Intake Data 
Quantities of each food commodity presented, remalnlng and eaten at each 
test meal and the processed total food intake and macro-nutrient 
consumption data for each subject are given in Appendix 121 Tables A12.1.1 
- A12.1.8 and Tables A12.2.1 - A12.2.8, respectively. 
The data in Table 4.24 depict the results of the amount (g and kJ) and type 
(macro-nutrient breakdown) of particular foods consumed at the test meals. 
The mean intakes for 7 subjects per test medication phase, F ratios and P 
values were obtained from a two-way ANOVA test (TEST 3, section 4.3.4) with 
drug condition and weeks as factors in the analysis. It is apparent from 
this table that statistically significant decrements occured in total food 
and carbohydrate intake whilst the subjects were taking PPA (TM A) as 
opposed to placebo (TM B). Although total protein and fat intake appeared 
to be reduced during the PPA (TM A) phase compared to the placebo (TM B) 
phase, this difference was not statistically significant. In addition, 
prote i n I carbo hydra te and fat enegy percentages were not sign if i cant 1 y 
different across treatment phases. 
The average amount and type of food eaten at the test meals are depicted 
in Table A12.3.1, for each test medication phase per volunteer. The mean 
intake per test medication phase, F ratios and P values were obtained from 
a one-way ANOVA test (TEST 3, section 4.3.4)/ with drug condition as the 
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factor. It can be seen that when they were taking PPA (TM A) as opposed to 
placebo (TM B), 4 (subjects 1 and 4-6) experienced a statistically 
significant decrease in total food intake (g), whilst only 2 (subjects 4 
and 6) having significantly reduced total kilojoule intakes. Two subjects 
(3 and 4) experienced significantly reduced total protein intake (g and kJ) 
and 4 (subjects 1,3,4 and 6) experienced a significant decrease in total 
carbohydrate intake (g and kJ) during the PPA (TM A) phase compared to the 
placebo (TM B) phase. No significant effects occured for total fat intake 
and protein, carbohydrate and fat energy percentages across treatment 
phases. 
Measure TM A :J: SEM 
Total Food Intake (g) 297.64:J: 19.32 
Total Food Intake (kJ) 2251.68 :J: 156.78 
Total Protein Intake (g) 22.41 :J: 1.64 
Total Protein Intake (kJ) 376.46:J: 27.59 
Total Carbohydrate Intake (g) 49.41 :J: 4.65 
Total Carbohydrate Intake (kJ) 830.06 :J: 78.19 
Total Fat Intake (g) 27.65 :J: 1.70 
Total Fat Intake (kJ) 1045.15 :J: 64.43 
Protein Energy % 16.85 :J: 0.87 
Carbohydrate Energy % 36.05 :J: 1.92 
Fat Energy % 47.10 :J: 1.28 
§ indicates a P value between 0.015 and 0.05. 
n = 24, df = 1.40 
TM B :J: SEM F P 
359.47 :J: 14.53 5.91§ 0.0196 
2734.86 :J: 115.91 5.69§ 0.0219 
26.44 :J: 1.12 4.03 0.0514 
444.17 :J: 19.66 
65.97 :J: 4.08 6.49§ 0.0148 
1108.32 :J: 68.58 
31.29 :J: 1.28 2.84 0.1000 
1182.37 :J: 48.38 
16.51 :J: 0.70 0.09 0.7703 
39.69 :J: 1.35 2.43 0.1272 
43.79 :J: 1.06 4.05 0.0512 
TABLE 4. 24 Tota 1 Food I ntaka and the Elect i va Consumpt i on of Macro-
nutrients (Mean 7 Subjects). 
4.3.6.5 Analysis of Salivation Data 
The weight of saliva recorded in grammes before (baseline) and after 
(stimulus-induced) presentation of each test meal appear in Appendix 13 1 
Tables A13.1.1 - A13.1.8. The statistical results of the effects of PPA (TM 
A) and placebo (TM B) on baseline and stimulus-induced salivation are 
depicted in Table 4.25. The average salivation response of the subjects per 
test medication phase, F ratios and P values were obtained from a two-way 
ANOVA test (TEST 3, section 4.3.4) with drug condition and weeks as factors 
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in the analysis. It is apparent from this table that statistically 
significant decreases in both baseline (P < 0.005) and stimulus-induced (P 
< 0.001) salivation occured when the subjects were taking PPA (TM A) as 
opposed to placebo (TM B). 
Sa 1 ivation TM A :I: SEM 
Baseline 1.15 :I: 0.10 
Stimulus-induced 1.28 :I: 0.09 
~ indicates a P value < 0.01 
n = 93, df = 1,178 
TM B :I: SEM F P 
1.67 :I: 0.14 8.96' 0.0032 
1.88 :I: 0.15 1l.85~ 0.0007 
TABLE 4.25 Average Baseline and Stimulus-induced Salivation Measurements 
(Mean 7 Subjects) 
The average baseline and stimulus-induced salivation responses are depicted 
in Table 4.26, for each test medication phase per volunteer. The mean 
response per test medication phase, F ratios and P values were obtained 
from a one-way ANOVA test (TEST 3, section 4.3.4), with drug condition as 
factor. It can be seen that when they were taking PPA (TM A) as opposed to 
placebo (TM B), all of the subjects except 1 (subject 5) experienced a 
statistically significant decrease in baseline salivation, whilst only 2 
(subjects 1 and 2) experienced a significant reduction in stimulus-induced 
salivation. 
Sub 
1 
2 
3 
4 
5 
6 
Baseline Salivation 
TM A :I: SEM TM B :I: SEM F P 
1.69 :I: 0.18 3.83 :I: 3.83 38.1' 0.0000 
0.86 :I: 0.07 1.23 :I: 0.10 8.60' 0.0097 
0.65 :I: 0.07 1.03 :i: 0.10 50.2~ 0.0050 
0.33 :I: 0.03 0.50 :I: 0.04 11.09 0.0044 
1.30 :I: 0.12 1.17 :I: 0.09 0.75 0.4090 
0.62 :I: 0.07 0.96 :I: 0.08 9.06' 0.0064 
.~ indicates a P value < 0.01 
n = 12, df = 1,22 for subjects 1, 3 and 6 
n = 9, df = 1,16 for subjects 2, 4 and 5 
Stimulus-Induced Salivation 
TMA:l:SEM TM B :I: SEM F P 
2.07 :I: 0.24 4.34 :I: 0.22 50.2' 0.0000 
1.07 :I: 0.14 1.86 :I: 0.13 16.3' 0.0010 
0.86 :I: 0.05 1.07 :I: 0.09 4.11 0.0550 
0.49 :I: 0.06 0.61 :I: 0.06 2.19 0.1584 
1.64 :I: 0.10 1.72 :I: 0.18 0.18 0.6818 
0.72 :I: 0.08 0.74 :I: 0.06 0.04 0.8442 
TABLE 4.26 Average Baseline and Stimulus-induced Salivation Responses per 
Volunteer 
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4.3.6.6 Observational Studies and Diet Diaries 
As the trial was conducted under double-blind conditions, the processing 
and analysis of the preceding data was carried out after completion of the 
entire trial and proved to be an extremely lengthy procedure. Due to the 
limited period of time left to complete the clinical study, it was felt 
that processing the observational and diet diary data was beyond the scope 
of this trial. These data, however, remain on file at the School of 
Pharmaceutical Sciences, Rhodes University, Grahamstown, South Africa. 
4.4 DISCUSSION 
The primary objective of performing a pilot feasibility trial is to expose 
the possible problems that can be encountered with design, approach and 
methods used in the trial and indeed, in this study, this objective was 
realised. 
The clinical trial was restricted in terms of available facilities and 
number of trial monitors, which governed the small number of subjects used. 
In addition the longer testing period required to perform a cross-over 
comparison of the two treatments caused additional problems in terms of 
subject II drop-outs II due to illness. Because the cross-over broke down, the 
only way in which the trial data could be salvaged was to perform a 
parallel-groups comparison of the data which resulted in a smaller and less 
powerful study. As the presence of period effects was unfortunately 
impossible to ascertain, the parallel-groups analysis was performed on the 
assumption that if period effects were indeed present, these effects would 
be our least important concern. 
As the ethical requirements for using humans in a clinical study insist 
that volunteers are well-informed and aware of the nature of the trial, 
classic double-blind conditions were not actually imposed during this trial 
as the subjects knew that they would receive an active medication (PPA) and 
a placebo on two different occasions, although they were unaware of which 
phase they would receive each treatment. 
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Body mass and blood pressure, being objective measures, were easy to 
monitor. The average weight loss experienced by the subjects for the 4 
weeks that they were taking PPA was significantly greater (2.05 kg ± 0.37) 
than whilst they were taking placebo (0.76 kg ± 0.34), and ;s comparable 
to publ ished data (59). Although the weight loss experienced by each 
subject varied greatly (0.73 - 3.26 kg) following treatment with PPA, all 
the subjects lost more weight on PPA than placebo. 
The supine diastolic and systolic blood pressures of the subjects remained 
relatively stable during both treatment with PPA and placebo. Although some 
volunteers did show significant increases in BP during treatment with 
placebo, no significant rises in BP were encountered during treatment with 
PPA. 
The mood questionnaires were easy to administer, although the ARCI and POMS 
questionnaires were extremely time-consuming in terms of data capture and 
analysis. In addition, a possible short-coming of using these 
questionnaires and specifically as often as in this trial, is monotony and 
carelessness in completion. However, the validity of using these 
questionniares to illuminate possible stimulant effects and abuse potential 
of anorexiants has been proven repeatedly (133/ 134, 136, 137, 191, 282) 
and is necessary to assess the safety of this class of drugs. 
A lthough no significant differences in avera 11 response to the various 
scales of the ARCI, POMS and VAS questionnaires were seen following 
treatment with PPA or placebo, marked deviations in individual responses 
were apparent, with some subjects experiencing significant mood alterations 
following treatment with PPA. Generally, subjects 1 and 4 appeared to be 
more aroused and more influenced by the mood elevating effects of PPA, 
without experiencing negative effects, whilst the opposite was true for 
subject 3. However, because of the highly subjective nature of the 
responses under investigation, these effects could have been due to various 
factors such as the time that the questionniares were administered or 
extraneous cognitive variables, for example, and may not necessarily be 
drug-induced. In addition, it could well be likely that these effects were 
influenced by the order of drug treatment assignment. 
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The questionnaires (AHQ, BSQ, SQ and FPQ) used to monitor hunger and 
satiety were relatively quick and simple to administer and analyse. 
Significant decrements occured in the responses of the subjects to the 
hunger\appetite questionnaires whilst they were taking PPA as opposed to 
placebo, whilst no significant differences oocured in the responses to the 
satiety questionnaires across treatments. Although no definite statements 
can be made from the responses to the BSQ and FPQ due to the limited number 
of observations and small population studied, it appears that PPA reduced 
sensations of stomach rumbling and salivation (possibly indicating reduced 
hunger/appetite) and sl ightly increased the number of preferred foods 
chosen following meal completion (possibly indicating lack of effect on the 
satiety mechanism). These observations would appear to be consistent with 
the results obtained from the AHQ and the SQ. 
The composition of the test meal attempted to represent normal intake as 
far as possible and permitted calculation of the amounts of different 
macro-nutrients consumed following each treatment. Phenylpropanolamine 
significant ly reduced the total amount of food and carbohydrate items 
consumed by the subjects whilst exerting no significant effect on the 
amount of fat intake. In addition, although PPA appeared to reduce the 
amount of protein consumed at the test meals, this effect was not 
statistically significant. 
The SHP method of measuring salivation was relatively uncomplicated, 
although it required a great deal of subject participation and compliance, 
and the subjects complained that the method was uncomfortable. However, 
pronounced effects on baseline and stimulus-induced salivation were seen 
following treatment with PPA. Significant decreases in both salivation 
measures were observed whilst the subjects were taking PPA as opposed to 
placebo, with the effect on stimulus-induced salivation being more 
significant than on baseline salivation. These decreases in salivation are 
confirmed in the side-effect reports and the BSQ, as dry mouth was noted 
during treatment with PPA. 
It ;s well knowwn that one of the side-effects of the sympathomimetic class 
of drugs regularly encountered and reported, is dryness of the mouth. 
However, some researchers regard a reduct i on ; n sa 1 i vat i on, and 
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particularly stimulus-induced salivation, as a putative measure of appetite 
suppression. Indeed, one author (331) goes so far as to suggest that 
dryness of the mouth observed during treatment with sympathomimetic 
anorectics need not be a disadvantageous side effect, but by intensifying 
appetite suppression, is rather indicative of the effectiveness of the 
drug. 
The most elementary research on feeding is directed towards mechanisms 
responsible for initiation, maintenance and termination of eating and can 
be partitioned into studies of the control of caloric intake, selection of 
foods and nutrients· and the distribution of eating episodes. Such 
investigations are intended to provide explanations for disordered eating, 
whether represented by over- or underingest ion of calories 1 abnormal 
preferences and selection of foods, or aberrant sizes or patterns of eating 
episodes. 
In order to treat overweight patients successfully it is necessary to 
establish which factors contribute to abnormalities in the eating sequence 
(see section 2.4). Likewise, in order to institute efficacious 
pharmacological treatment of the overweight patient, it is vital to 
establish which variables in the eating response are affected by the 
anorectic agent. For example, if an overweight person has a penchant for 
carbohydrate food items, it would b~ advisable to recommend an anorexiant 
agent that would reduce, specifically, the amount of carbohydrate consumed 
by that patient. 
In the present study, various measures of safety and efficacy were 
monitored in an attempt to assess the global effect of PPA as an appetite 
suppressant. Although certain measures were time-consuming (ARCI, POMS, 
VAS) and intrusive (salivation measurements), their inclusion in the study 
was vital and elicited important information regarding the effects of PPA. 
While the present pilot study cannot irrevocably assure the safety and 
efficacy of PPA as an appetite suppressant due to the problems encountered 
with the design and methods used, the valuable data afforded by each of the 
measurements performed during the present trial demonstrate the feasibility 
of the multidimensional approach for evaluating the safety and efficacy of 
PPA. 
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CHAPTER 5 
ANALYTICAL METHODS 
5.1 INTRODUCTION 
High performance liquid chromatography (HPLC) has become universally 
popular as an analytical tool in a multitude of chemical 1 biochemical I 
pharmaceutical and clinical applications (293). Chromatography originated 
as a separation technique in 1903 1 when the Russian botanist Tswett 
separated plant pigments by adsorption chromatography (293). In 1941, 
Martin and Synge (296) established the groundwork for HPLC and introduced 
the concept of the "height equivalent to a theoretical plate" (HETP) which 
is now employed as a general measure of chromatographic efficiency. 
Since then many forms of liquid chromatography have been developed 
including partition , ion-exchange/ ion-pair and size exclusion 
chromatography. All 1 i qu i d chromatograph i c techn i ques are based on the 
prinCiple that solute separation results from different rates of zone 
migration caused by differences in relative affinities for a solid 
stationary phase and a liquid mobile phase. Modern HPLC is considerably 
versatile and is' characterised by precision, good sensitivity, short 
analysis times , high efficiency and continuous detection of eluting 
components (293 l 294 1 297). 
In reverse-phase (RP) chrom&tography, the stationary phase is made by 
covalently linking the silica support with a hydrocarbon chain such as an 
organochlorosilane or similar reagent to render a non-polar bonded 
stationary phase of varying degrees of 1 ipophil icity. The RP mode of 
chromatography is more suitable for analysis of aqueous samples as the 
mobile phase is aqueous. In addition RP chromatography is ideally suited 
to drug analysis in biological fluids, as the drug is likely to be one of 
the most lipophillic components of the sample and will thus be retained on 
the column longer than most endogenous substances due to interaction with 
the stationary phase (298). 
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In Paired-Ion Chromatography (PIC), a relatively new liquid chromatographic 
(LC) variation, addition of a suitable counter-ion to acidic or basic 
compounds results in the formation of an electrically neutral lipophillic 
ion-pair complex which greatly augments retention of these sample 
components on RP systems by hydrophobic interaction. Unlike conventional 
ion-exchange chromatographic techniques, PIC can be used to separate 
nonionic and ionic compounds in the same sample. Mobile phase composition 
can be adjusted to allow the separation of nonionic compounds to be 
optimized. If ionizable compounds are present, pH adjustment is required 
for the formation of the ion-pair complex (294, 295, 299). 
For basic samples, alkyl sulfonates (pKa<l) are used. The pKa of an alkyl 
sulfonic acid counter-ion should be less than pH 3 for ion-pair formation 
with bases to enable the sample to exist in its ionic form. In PIC, the 
var i ab 1 es inc 1 ude concentrat i on, type and size of the counter- ion, pH, 
solvent polarity, temperature and stationary phase, and enable additional 
possibilities for optimizing selectivity (299). 
5.2 ANALYSIS OF PHENYLPROPANOLAMINE RAW MATERIAL AND DOSAGE FORMS 
Numerous methods have been developed and used for the determination of PPA 
in pharmaceutical formulations and include UV spectrophotometric (300, 
302), colorimetric (302,303), spectroflourometric (304), titrimetrc (305) 
and Raman spectroscopic (306) analysis. While column (307, 308), paper 
(309) and thin-layer (310) chomatographic methods have been used, gas 
chromatography and HPLC (311) have been used extensively for the 
determination of PPA in pharmaceutical preparations and, to a lesser 
extent, for the determination of the drug in biological fluids. 
5.3 DEVELOPMENT OF AN HPLC METHOD FOR THE DETERMINATION OF 
PHENYLPROPANOLAMINE 
The HPLC method used to determine PPA concentrations in serum and to 
elucidate steady-state pharmacokinetic parameters was based on an 
adaptation by Scherzinger et al (10) of a published HPLC method of PPA 
assay (8, 170). 
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5.3.1 Experimental 
5.3.1.1 Reagents 
All reagents and chemicals were used without further purification and were 
of at least analytical grade. The HPLC grade water used in the preparation 
of the standards and the mobile phase was purified through a Mi 11 i-Q 
purification system (Waters Associates). Phenylpropanolamine 
hydrochloride1 , ephedrine hydrochloride2 , hydrochloric acid3 , the sodium 
salt of I-heptane sulphonic acid4 and distilled-in-glass grade acetonitrile5 
were obtained commercially. The mobile phases were filtered through 0,6 ~ 
m cellulose acetate filters6 and deaerated under vacuum. 
1. Aldrich Chemical Co., Milwaukee, Wis., United States of America. 
2. Holpro Analytics (Pty) Ltd., Johannesburg, South Africa. 
3. BDH Chemicals Ltd., Poole, England. 
4. Sigma Chemical Co., St Louis, United States of America. 
5. Burdick and Jackson Lab. Inc., Muskegon, Mich., United States of 
America. 
6. Type BD, Millipore Corp., Bedford, Mass., United States of America. 
The drug sample solutions were prepared in A-grade volumetric flasks by the 
addition of HPLC grade water. 
5.3.1.2 The High-Performance Liguid Chromatographic System 
The HPLC system used throughout analysis of dosage form purity and 
biological samples consisted of: 
1) Model 510 solvent delivery system (Millipore-Waters). 
2) Model 7125 20 ~L liquid sampling unit (Rheodyne). 
3) Model 481 Lambda-Max LC spectrophotometer (Millipore-Waters). 
4) Model 561 chart recorder (Perkin Elmer). 
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Separation was achieved on a custom-packed 25 em x 3.9 i.d. Techsil C1S (5 
~m) reverse phase column (HPLC Technology) which was encased by a Model LC-
22 temperature controller (Bioanalytical Systems Inc.) to allow the desired 
temperature to be maintained. 
5.3.1.3 Ultraviolet (UV) Detector 
The liquid chromatographic detector provides the informative nucleus for 
the quantitative and qualitative assessment of the compounds of interest. 
UV absorption detectors are the most widely employed detectors in HPLC as 
they are relatively insensitive to both flow rate and temperature changes 
and are highly sensitive, stable and have a wide linear range (312). 
The Lambda-Max Model 481 LC spectrophotometer ;s a solid-state 
continuously-variable modular instrument especially designed for HPLC 
app 1; cat ions. A true dua 1 beam ; s produced through fibre opt i cs for 
sensitivity detection and stability and can be placed in any order when run 
in series due to the high pressure capactiy (1000 psi) of the analytical 
cell. The detector was operated at 210 nm at a sensitivity setting of 0.005 
absorbance units full scale (AUFS) for analysis of biological samples and 
at 0.5 AUFS for dissolution and dosage form purity analysis. 
5.3.1.4 Columns and Mobile Phase 
The column used throughout the entire standardization and analytical 
procedures was a 25 cm x 3.9 mm i.d. steel column packed with Techsil 5 ~m 
octadecylsilane (CIS) material (HPLC Technology) by the method described in 
section 5.3.1.7. The optimum operating conditions for this column are 
summarised in section 5.5.2.2. When the formation of a top-end void became 
evident, it was repaired by the application of a paste of 5 ~m C1S Techsil 
in methano 1 . 
5.3.1.5 Guard Column 
A 10 ~m CIS cartridge guard column (HPLC Technology Ltd) housed in a 
cartridge holder (HPLC Technology) was employed during analysis of 
biological samples to protect the analytical column and to prevent the non-
eluting samples from accummulating on the analytical column. The guard 
column serves as a buffer, protecting the HPLC column against the negative 
influences of the sample and the chromatographic system. In addition, the 
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guard column absorbs the pressure surges of the solvent delivery system 
wh; ch cou 1 d damage the co 1 umn pack i ng bed. The guard co 1 umn did not 
demonstrate any contribution to dead volume or extra-column effects. When 
the guard column cartridge lost efficiency or caused double peaks it was 
discarded and replaced by a new cartridge which was obtained commercially. 
5.3.1.6 Mobile Phase Preparation 
The mobile phase was prepared oy mixing a 0.005 M 1-heptanesulfonate (HSS) 
solution (750 ml) with acetonitrile (224 ml) and adding 1 M Hel solution 
(1.5 ml). The 0.005 M HSS solution was prepared by dissolving 1.011 g of 
the sodium salt in 1.0 1 of HPLC grade water. The resultant mobile phase 
(pH 2.67) was filtered under vacuum (Eyela Aspirator l Tokyo) to expel 
dissolved gases. The system was allowed to equilibrate for one hour before 
commencement of analysis. The mobile phase was recycled I resulting in a 
stable baseline with minimal drift. Upon completion of the analysis, the 
column was flushed with 100 ml of water l followed by 100 ml of methanol to 
remove any residues or halides that are detrimental to the stainless steel 
HPLC components. 
5.3.1.7 Column Packing Procedure 
Columns were packed as follows using a pneumatic column packing pump. The 
packing material from a used 25 cm x 3.9 mm i.d. steel casing ( ~Bondapakl 
Waters Associates) was removed and the column thoroughly rinsed with 
methanol. The column end-frits and sieves were sonicated in an ultrasonic 
cleaner (Cole-Parmer Instrument CompanYI Chicago) for 20 minutes in 
methanol. Three grams of packing material (5 ~m C18 Techsil) were slurried 
in 30.0 ml HPlC-grade carbon tetrachloride and sonicated to enable 
dispersion of the agglomerates. After rapidly loading the carbon 
tetrachloride slurry into the column packing reservoir l 250.0 ml of 
degassed and filterd HPLC-grade methanol was pumped through the column at 
a pressure of 5000 ps;. Thereafter I the co 1 umn was inverted wi thout 
interruption of flow and a further 250.0 ml methanol was pumped through the 
column before removal from the column packer. The column was then removed 
from the packing system and washed with 50.0 ml of a degassed 
acetonitrile/water (75/25) solution and tested using this mobile phase and 
a C18 column test mixture prepared as follows: 
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Ten micrograms of benzamide, benzophenone and biphenyl, plus 0.5 ml of a 
1 in 50 solution of benzene were made up to 20.0 ml with acetonitrile. 
Twenty microlitres of this solution was injected onto the column at a flow 
rate of 1.0 ml/min with UV detection at 254 nm, a sensitivity setting of 
0.2 AUFS and a chart speed of 6 cm/min. The number of theoretical plates 
(N) was calculated for each column packed (Equation 5.1) to measure column 
efficiency. Column performance was measured periodicly as part of the HPLC 
method protocol to minimize instrument error. 
N = 5,54 
t 2 
1 
Where tl = retention time of peak 
wI = width at half peak height 
5.3.2 Results and Discussion 
Eqn 5.1 
Phenylpropanolamine hydrochloride absorbs in the low ultraviolet range but 
its intrinsic molar absorptivity is low (3l3). The need to detect low 
concentrations of PPA in biological fluids (12.5 ng/ml) necessitated the 
choice of a wavelength where the absorbance was relatively high. A 
wavelength of 210 nm has been shown by Dowse et a 1 (8) to provide 
sufficient sensitivity when monitoring PPA concentrations of 10 ng/ml and 
more. 
The compound chosen as the internal standard should preferably have 
physico-chemical properties similar to the analyte and homologous or 
analogous compounds and isomers are preferred to other substances (297). 
Ephedrine hydrochloride (EPH. HC1) was chosen as the internal standard as 
it was readily detectable at 210 nm and eluted after PPA. Peak shape was 
sharp and symmetrical and resolution between PPA and EPH peaks was 
satisfactory on the chromatographic system used. 
The necessity of having an ion-pairing agent in the mobile phase for the 
elution of PPA from a CI8 column has been established in two previous 
studies (8, 10). A 0.005 M sodium 1-heptanesulfonate (HSS) solution in the 
mobile phase yielded satisfactory retention time and good baseline 
resolution. 
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As it was necessary to decrease the pH of the mobile phase to reduce 
tailing of the analytes separated, hydrochloric acid was included since it 
did not interfere with detection at 210 nm. However I for monomeric C18 
columns a pH range of 3-7 is recommended and therefore only 0.15% 1 M HCl 
was used in the mobile phase. 
The mobile phase consisting of 23% acetonitrile/ 77% HSS solution (0.005 
M) with 0.15% 1 M HCl afforded satisfactory baseline resolution at 35°C 
and was used for the determination of all serum determinations. The 5 ~m 
C18 Techsil column could be operated at modest back pressures (2.75 kpsi) 
and yielded good separation efficiency. 
5.4 ANALYSIS OF PHENYLPROPANOLAMINE IN SERUM 
Quantitative analysis of phenylpropanolamine in biological fluids is 
necessary for the investigation of pharmacokinetics and to correlate toxic 
effects with drug levels. Since many of these studies are performed with 
very low doses, the requirements on determination limits are demanding and 
may be in the lower nanogram range. 
Over the last few years, HPLC has become a popular and widely used method 
for the determination of drugs in biological fluids. The methods used to 
treat biological samples prior to their introduction onto an HPLC column 
generally fall into two categories - extraction or direct injection. With 
the extraction method, the analyte of interest is removed from the 
biological matrix such as serum or urine using a suitable solvent and pH 
which enables undesirable material to be left behind. Although the direct-
inject i on techn i que is the simp 1 est and most rap i d of the two methods I 
rapid increase in back-pressure and deterioration of column performance 
occurs (314, 315) due to the precipitation of plasma proteins. 
Numerous HPLC methods have been developed that involve derivatisation of 
the extract (316 - 319), which are relatively time-consuming, or involve 
post-column manipulations (320, 321). Determination of PPA in serum and 
urine without prior derivitisation has been desribed by Scherzinger et al 
(10). The method is an adaptation of the method reported by Dowse et al (8, 
171) and involves extraction at a basic pH with methylene chloride 
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(dichloromethane) , a single back extraction into acid followed by 
chromatographic analysis on a reverse-phase column. The resulting 
chromatograms were devoid of interfering endogenous contaminants with 
detection limits for PPA in serum of 5 ng/ml and 5 ~g/ml in urine. 
5.4.1 Experimental 
5.4.1.1 Reagents 
The potassium hydroxide1 , hydrochloric acid1 and the HPLC-grade methylene 
choride2 were obtained commercially. 
1. B.D.H. Chemicals Ltd.,Poole. England. 
2. Burdick and Jackson Laboratories, Muskegon, Mich., United States of 
America. 
5.4.1.2 Sample Preparation 
5.4.1.2.1 Phenylpropanolamine hydrochloride serum stock solution 
Twenty five milligrams of PPA.HCl was accurately weighed, dissolved in 50 
ml water and 1 ml of this solution was diluted to 20 ml with water. One 
millilitre of this solution was made up to volume with blank serum to yield 
a resultant concentration in serum of 500 ng/ml. The stock solution was 
mixed slowly to ensure sample homogenity. Appropriate dilutions were then 
made. 
5.4.1.2.2 Internal standard stock solution 
Twenty milligrams of EPH.HCl was weighed and dissolved in 50 ml of water. 
One millilitre of this solution was made up to 20 ml with water to yield 
a concentration of 2 ~g/ml. This was used as the internal stock solution. 
The serum used to prepare the serum stock so 1 ut i on was obta i ned from 
Settlers l Hospital, Grahamstown, South Africa. Before the serum was used, 
blank serum samp le extracts were subjected to HPLC ana lys i s to ensure 
freedom from interfering contaminants. 
5.4.1.3 
5.4.1.4 
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Chromatographic Conditions 
HPLC system: Section 5.3.1.2 
Co 1 umn: CI8 5J.Lm Techs i 1 
Flow rate: 1.3 ml.min-1 
Pressure: 2750 psi 
Detection wavelength: 210 nm 
Attenuation: 0.005 AUFS 
Temperature: 
Recorder input: 
Chart speed: 
Mobile phase: 
35°C 
10 mV 
5 mm.min-1 
0.005 M HSS solution/acetonitrile 
(77/23) with 0.15% 
1 M HCl pH = 2.65 
Extraction Procedure 
One millilitre of serum, 100 J.Ll EPH.HCl solution (2 J.Lg/ml) and 100 J.Ll of 
a 10% potassium hydroxide solution, which adjusted the pH of the mixture 
to 12.25, were vortexed (Vortex-Genie l Scientific Industries Inc.! United 
States of America) for 20 seconds in a centrifuge tube. Eight millilitres 
of methylene ch lor; de were added, the tube stoppered I vortexed for 15 
seconds and centrifuged (IEC Centrifuge, Model HN-SII, Damon/IEC Division, 
Mass.) at 3500 rpm for 2 min. A further 2 ml increment of methylene 
chloride was added and the tube re-centrifuged for 3 min at 3500 rpm. A 
disc formed between the aqueous organic phases and the aqueous layer above 
this disc was removed by aspiration and discarded. A pasteur pipette was 
used to transfer the methylene chloride layer to a tapered centrifuge tube 
containing 120 J.Ll of a 0.1 M HCl solution. Care was taken to ensure that 
no serum was transferred. The tube was vortexed for 30 seconds and 
centrifuged (BAS Microfiltration Centrifuge , Bioanalytical Systems Inc.) 
at 1500 rpm for 2 min. The methylene chloride layer was reduced by 
aspiration to approximately 200 J.Ll and the tube was re-centrifuged at 1500 
rpm for an additional 2 min. Twenty microlitre aliquots of the hydrochloric 
acid extract were injected directly onto the column. 
It is known that too vigorous shaking during the mixing of an alkaline 
aqueous phase and halogenated solvents results in emulsion formation. Care 
was thus taken to avoid too vigorous vortexing of the samples. 
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5.4.1.5 Calibration Curve 
The serum stock solution of 500 ng/ml was diluted to yield six different 
concentrations I the stock solution itself providing the seventh. 
Concentrations ranged from 12.5 to 500 ng/ml and each concentration was 
assayed in triplicate. The calibration curve was constructed by plotting 
the ratio of the peak height of PPA.HCl to that of the internal standard, 
EPH.HCl versus the respective PPA.HCl concentration. The data were fitted 
by least-squares linear regression analysis. 
54.1. 6 Precision 
With-in run precision was evaluated by extracting six spiked serum samples 
at the lower (12.5 ng/ml L middle (100 ng/m1) and upper (500 ng/ml) 
concentrations, and three spiked serum samples at the intermediate 
concentrations (25, 50, 200 and 300 ng/ml). 
5.4.1.7 Extraction Efficiency 
(i) For this study, in which the analytical recovery of PPA from serum 
was assessed, spiked serum samples were assayed six times at four different 
concentrations. A similar extraction procedure to the one described in 
section 5.4.1.4 was applied to all the samples with one modification. One 
hundred micro 1 itres of water was substituted for the internal standard 
solution at the start of the procedure. A 2 ~g/ml EPH.HCl solution was made 
up in hydrochloric acid (0.1 M), and as the internal standard was added at 
the end, it was thus not carried through the initial stages of the 
extraction procedure. 
Standard aqueous solutions of PPA.HCl were made up and internal standard 
solution added in concentrations corresponding to those extracted above. 
The internal standard therefore accounted for variations in sample volumes 
injected. To determine the percentage recovery of analyte from serum, the 
ratios obtained from the serum extracts were compared to those resulting 
from the relevant standard solutions of equivalent concentrations. 
(ii) Analytical recovery of PPA.HCl from serum was also evaluated 
excluding the addition of EPH.HCl at any stage during the extraction 
procedure described in i) above. This assessment proved possible with the 
use of the Rheodyne injector with a fixed 20 ~1 loop, as there is 
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negligible variation (0.01%) in sample volumes injected. Spiked serum 
samples were assayed six times at four concentrations. 
Standard aqueous solutions of PPA.HCl were made up in concentrations 
correspond i ng to the serum samp 1 es extracted. To determi ne percentage 
recovery, the peak heights obtained from the serum extracts were compared 
to those resulting from relevant aqueous standard solutions of equivalent 
concentrations. 
5.4.2 Results and Discussion 
5.4.2.2 Linearity and Calibration 
Linearity was established for the range of concentrations studied (12.5-
500.0 ng/ml). The line had a slope of 0.007451, a y-intercept of -0.01824 
and a corre 1 at ion coeff i c; ent of of 0.9996. The ca 1 i brat i on curve for 
phenylpropanolamine in serum is shown in Figure 5.1. Chromatograms of a 
blank serum extract and a spiked serum extract containing 
phenylpropanolamine and ephedrine as internal standard are depicted in 
Figure 5.2. The retention time of PPA was 5.2 min and that of EPH was 6.1 
min. 
FIGURE 5.1 Calibration Curve of PPA in Serum 
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Chromatograms of (A) a blank serum extract and (8) a 
serum extract containing PPA (50 ng/ml) (1) and EPH (2) 
A B 
2 
5 )J.m Techs i1 
Acetonitrile/HSS solution (0.005 M) (23/77) with 0.15% 
1M HCl 
5.4.2.3 Precision 
Results of the with-in run preclslon study are depicted in Table 5.1. The 
method was found to be highly reproducible with R.S.D. values less that 5% 
at all concentrations. 
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TABLE 5 1 . Within-run precision study on PPA Hel serum assay . 
Spiked Concentration measured (ng/ml) 
Cone Replicate number Mean ± SO RSO % 
(ng/ml) 1 2 3 4 5 6 
12.5 15.48 14.53 14.18 14.20 14.08 14.53 14.50 ± 0.52 3.55 
25 26.72 26.97 27.61 27.10 ± 0.46 1.69 
50 52.25 52.10 52.10 52.15 ± 0.09 0.16 
100 103.43 103.27 100.41 99.44 104.11 98.12 101.46 ± 2.47 2.44 
200 199.79 200.48 215.26 205.18 ± 8.74 4.26 
300 310.30 301.81 308.11 306.74 ± 4.41 1.44 
500 516.43 518.58 526.79 515.99 511.88 515.99 517.61 ± 4.99 0.97 
5.4.2.4 Extraction Efficiency 
Table 5.2 (a) and (b) depict the analytical recoveries of PPA from serum 
for methods A and 8, respectively. Results indicate that the recovery of 
PPA from serum is constant and quantitative over the concentration range 
(25-500 ng/ml) studied. The mean recovery was 72.76% and 72.39% for methods 
A and 8, respectively. 
TABLE 5.2 (al 
Serum 
Conc 
(ng/m]) 
25 
100 
250 
500 
TABLE 5.2 (b) 
Serum 
Conc 
( ng/m]) 
25 
100 
250 
500 
Analytical recoveries of analyte from serum 
(Method A) 
Extraction Efficiency 
Replicate numbers 
1 2 3 4 5 
74.10 76.85 78.67 75.10 72.20 
66.80 66.11 68.69 66.48 66.48 
76.07 76.07 68.29 76.32 71.93 
78.47 73.14 75.09 78.85 76.15 
Mean percentage recovery (n = 24) 
Analytical recoveries of analyte from serum 
(Method B) 
Extraction Efficiency 
Replicate numbers 
1 2 3 4 5 
65.72 65.72 65.72 71.19 65.72 
71.12 71.12 76.81 78.24 68.28 
71.89 73.03 74.17 76.45 77 .59 
74.49 78.70 78.12 76.96 75.81 
Mean percentage recovery (n = 24) 
Mean ± SD RSO % 
6 
75.96 75.48 ± 2.24 2.97 
62.84 66.23 ± 1.90 2.87 
67.49 72.70 ± 4.07 5.60 
78.17 76.65 ± 2.26 2.94 
72.76 ± 4.86 6.67 
Mean ± SO RSD % 
6 
65.72 66.63 ± 2.23 3.36 
66.86 72.07 ± 4.56 6.32 
71.89 74.17 ± 2.39 3.23 
75.81 76.65 ± 1.58 2.07 
72.38 ± 4.65 6.43 
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5.4.2.5 Sensitivity and Detection Limits 
Under the conditions of this assay and based on a minimum signal to noise 
ratio Of 10:1 the detection 1 imit for PPA in serum was 5.0 ng/ml. A 
chromatogram of a serum extract containing PPA (5 ng/ml) is shwon in Figure 
5.3. 
FIGURE 5.3 
Column: 
Mobile Phase: 
Chromatograms of (e) a serum extract containing PPA (5 
ng/ml) (1) and EPH (2). 
c 
5 jJ.m Techs i1 
Acetonitrile/HSS solution (0.005 M) (23/77) with 0.15% 
1M Hel 
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5.4.2.6 Background Interference 
The technique of back-extraction eliminated a significant amount of 
interferring endogenous compounds which had been co-extracted with 
methylene chloride. The hydrochloric acid eluted at the void volume and 
peaks from serum constituents did not interfere with the analytes of 
interest. The 1 arge peak at 10 minutes was due to a trace amount of 
methylene chloride which partitioned into the hydrochloric acid. 
5.5 ANALYSIS OF BIOLOGICAL SAMPLES 
5.5.1 The Analysis of Serum 
Serum samples were analysed in ransomised order to avoid sequential 
effects. The two millilitre aliquots were brought to room temperature and 
were thoroughly mixed by slow vortexing before analysis. The method of 
sample preparation and the chromatographic conditions used for analysis are 
described in section 5.4. In order to assess method reproducibility, both 
in vitro and ex vivo serum standards were prepared and analysed under blind 
conditions. All test and reference preparations obtained from serum samples 
were stored under identical conditions and assayed by the same method. 
5.5.2 In vitro Quality Control for Phenylpropanolamine 
The performance of the assay technique was monitored continuously during 
the entire period of biological sample assay by including quality control 
specimens containing known concentrations of the analyte. 
5.5.3 Ex vivo Quality Control for Phenylpropanolamine 
Additional blood was collected from trial subjects at randomised times 
during the pilot clinical trial and analysed. 
5.5.4 RESULTS AND DISCUSSION 
5.5.4.1 Pilot Steady-State Trial 
The serum concentrations from the pilot steady-state trial are presented 
in Appendix 14, Table A14.1 and the final (7th) dose serum concentration 
profile is shown in Figure 5.4. The concentrations observed were within the 
quantitative range of the described method. The fitted curve was obtained 
from inputting observed data into the PC NONLIN Ver 3.0 computer modelling 
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program (332). Model 3 of this program was chosen (1 Body Compartmental 
Model (1 BCM) , first order input and output, no lag time) as it gave the 
best fit to the data. 
FIGURE 5.4 Observed Vs Fitted Data for the Steady-State Trial 
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The PC NONLIN program provided estimated primary parameters of vol 
(volume), ka (absorption rate constant), kel (elimination rate constant)1 
and secondary parameters of AUC (area under the curve), t~x (time to reach 
maximum concentration) and C~x (maximum concentration) 1 to the fitted data. 
Table 5.3 depicts these estimated parameters. 
Parameter Esti~te Std Error 
VO 1 (1) 163,110 20.876 
ka (hr") 1.018 0.253 
kel (hr") 0.190 0.036 
AUC (ng/ml.h) 2420.693 208.448 
troW! (h) 2.027 0.221 
Cmax (ng/m 1 ) 312.863 16.129 
TABLE 5.3 Parameter Estimates for Fitted Data 
From Table A14.1, it can be seen that for the multiple dose steady-state 
pilot trial, serum concentration trough values varied between 61.11 and 
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92.67 ng/ml. In addition, absorption was relatively rapid, with the peak 
serum concentration of 336.52 nglml occuring 2 hours after ingestion of the 
final test dose. 
Table 5.4 depicts the inter-day precision of the analytical method at two 
concentrations using spiked in vitro serum standards. The method of 
extraction and subsequent determination of PPA from serum was found to be 
sensitive and precise. The method does not netessitate derivatization , and 
extraction was relatively simple. The back-extraction step eliminates the 
need for organic solvent evaporation, thus reducing total sample 
preparation time significantly. 
TABLE 5.4 Inter-day precision for phenylpropanolamine in serum 
1 I 2 I 3 I 4 I Mean (SO) I RSO 
Low concentration (spiked: 83.14 ng/ml) 
85.46 J 86.01 J 88.69 I 77.25 I 84.35 (4.94) I 5.86% 
High concentration (spiked: 519.60 ng/ml) 
515.65 I 524.04 I 517.19 I 529.81 I 521.67 (6.54) I 1.25% 
Although the multiple venipuncture method of blood withdrawal is generally 
associated with more trauma than withdrawa 1 us ing butterfly sets, the 
method was convenient as each subject only had a maximum of 3 blood samples 
withdrawn in anyone day. 
5.5.4.2 Clinical Tria1 
Analysis of the blood samples taken during the phase that each subject took 
placebo revealed an absence of PPA.HCL in the blood, confirming that each 
subject took the correct dosage form during the placebo phase. The serum 
concentrations for each individual subject for the phase of the clinical 
trial that they were administered active medication are shown in Appendix 
14, Tables A14.2 - AI4.9. The mean trough level of PPA attained was 122.98 
± 43.76 nglml and the average peak PPA level was 255.75 ± 71.08 ng/ml. 
The fitted vs observed serum concentration profiles for each subject for 
the clinical trial are presented in Appendix 14, Figures A14.1 - AI4.8. 
These diagrammatical representations were generated using the PC NONLIN 
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program discussed in the previous section. The estimated parameters 
obtained from the last dosing interval of the steady-state data were used 
to produce the back-ground steady-state profiles onto which individual 
subject data were overlayed to produce each subject1s final serum 
concentration-time profile. 
From these serum concentration-time profiles it can be seen that the 
experimental data obtained for the subjects were in excellent agreement 
with the predicted data obtained using the 18CM model, as the majority of 
observed data points fell within the predicted steady-state peak and trough 
levels. 
From Figure A14.1, it appears that subject 1 (55) reached steady-state and 
complied with the dosing schedule as she exhibited a relatively constant 
profile for the duration of the PPA phase. Similar profiles are apparent 
for subjects 4 (Figure A14.4) and 8 (Figure A14.8). 
Subject 21s profile (Figure A14.2) reveals conformity with the dosing 
schedule until the final week (week 5) of the PPA phase, where the peak PPA 
serum concentration increased dramatically, possibly due to non-compliance 
with the dosing schedule. 
The serum concentration profiles of subject 3 (Figure A14.3), 6 (Figure 
A14.6) and 7 (Figure A14.7) appeared to be relatively stable during the 
first two weeks of dosing. However, erratic serum levels were displayed by 
the former two subjects (3 and 6) from day 7, week 4 until the end of the 
PPA phase, possibly indicating non-compliance. In addition, these two 
subjects were administered PPA during the second phase of the trial and 
appeared to be bored and frustrated at the s low weight loss that they 
experienced. Subject 7 developed a chest infection during the last two 
weeks of dosing with PPA and defaulted for the rest of the PPA phase. 
As mentioned previously, subject 5 was ill during the 2nd week that she was 
administered PPA (third week of the PPA phase), and presented considerably 
irregular serum levels of PPA (Figure A14.5). In particular, no PPA.HCl was 
present ;n the two trough serum samples taken during that week. It was 
uncertain if this was due to concommitant medication (urinary alkaliser) 
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or patient non-compliance. However, the former reason can possibly be 
discounted on the basis that urinary alkalinization has been shown to 
increase post-absorptive plasma concentrations of PPA (167). 
In controlled clinical trials (and particularly for safety and efficacy 
trials performed over extended periods of time) it is essential to measure 
serum drug concentrations in order to monitor compliance once correlated 
with pharmacodynamic effects. In addition, serum drug concentration levels 
are useful in determining the dosing regimen required to produce the 
desired effects. 
5.6 IN VITRO DISSOLUTION RATE DETERMINATIONS 
It is well established that the determination of dissolution rates plays 
an important part in the design, evaluation and control of solid dosage 
forms. It has been stated by Parrott et al (326) that lithe release of drug 
from the primary particle and its subsequent availability to the body is 
governed by the dissolution rate of the particle ll • Numerous methods to 
determine in vitro dissolution rates of oral, solid dosage forms exist and 
techniques differ in hydronamic properties, agitating intensities and 
mechanical destructive forces to the intact dosage form. There are three 
basic dissolution testing devices: the stirred tank reactor with a 
mechanical agitator such as Levy1s beaker method or the rotating basket 
method, the rotating vessel reactor such as the rotating flask or the 
solubil ity simulator and the stream reactor method such as the column 
method (327). 
In vitro dissolution rate determinations were carried out on two extended-
release capsules to determine comparative release rates of the two 
formulations. 
5.6.1 Experimental 
5.6.1.1 Chromatographic Methods 
The conditions were the same as described in section 5.4.1.3, except that 
the sensitivity setting of the UV detector was set to 0.5 AUF5 instead of 
0.005 AUF5 and a 10 ~l 55I injector was used in place of the 20 ~l Rheodyne 
injector. 
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5.6.1.2 Dosage Form Purity 
Two sustained release (SR) forms containing 75 mg PPA.HCl were tested for 
their dissolution characteristic. 
(i) Product LE - a capsule containing micro-encapsulated particles (the 
product used for the clinical trials) 
(ii) Product RD - a capsule containing micro-encapsulated particles 
The official USP monograph specifications for SR PPA.HCl dosage forms was 
used for the analysis. For product LE, the accurately weighed contents of 
the capsule, equivalent to 75 mg of PPA.HCl was transferred to a 100 ml 
volumetric flask. Fifty milliltres of water was added/ mixed and the 
contents of the flask sonicated for half an hour. Thereafter, the solution 
was made up to 100 ml with water. Approximately 1.5 ml of this solution was 
centrifuged for 5 minutes () and 1 ml of this solution plus 1 ml of EPH.Cl 
solution (530 ~g/ml) was made to volume in a 10 ml volumetric flask. A 10 
~1 sample of this filtrate was injected onto the HPLC column. The assay was 
conducted on six capsules. 
5.6.1.3 In Vitro Dissolution Study 
A type PTWS dissolution apparatus (Pharmatest, Hainburg] W. Germany)was 
used for th i s study. The vesse 1 was mounted ina clear perspex bath, in 
which water was heated by a pump mounted in such way that the vibrations 
were not transmitted to the rest of the apparatus. The vessel was covered 
with a perspex lid containing three apertures, a central one for the shaft 
and 2 peripheral openings for sampling and fluid replacement. The rotating 
basket method was used for all dissolution rate determinations. 
Each beaker held 1000 ml of the dissolution fluid which was maintained at 
37°C ± 0.5. One capsule was placed in each of the six dry 40-mesh baskets 
which were then immersed into the dissolution medium to a depth of 2 cm 
from the bottom of the vessel. Rotation at 100 rpm was initiated 
immediately. 
For dissolution testing using this apparatus, aliquot withdrawal was 
acheived with a clean 10 ml syringe, attached to which was a stainless 
steel cannula. A filter was attached to this cannula during the withdrawal 
of approximately 2 ml of sample. Thereafter 1 the filter was removed and the 
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2 ml sample was inserted into a clean 5 ml vessel. A 250 ~l aliquot of this 
sample was removed and 10 ~1 injected onto the HPLC column, the remainder 
of the 2 ml sample was returned to the dissolution vessel. 
As such small volumes were removed (0.6%), no replacement of dissolution 
medium was necessary. Sampling times were I, 2, 4, 6, 8, 10, 12.5, 15, 20, 
25, 30 and 45 minutes, and then 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 hours 
after initiation of rotation. Samples were stored in the refridgerator 
until analysis. 
5.6.1.4 Standard calibrators 
Twenty mg of PPA.HCl was accurately weighed into a 50 ml volumetric flask, 
and made to volume with EPH.HCl (100 ~g/ml). Subsequent dilutions in the 
concentration range 20 - 120 ~g/ml were made using EPH.HCl (100 ~g/ml) as 
the diluent. Each standard calibrator was injected onto the HPLC column six 
times, to monitor stability and reproducibility of the system. 
5.6.1.5 Dissolution Media 
Simulated intestinal fluid, was evaluated for its effect on the release of 
PPA.HCl from products LE and RD. Simulated intestinal fluid was prepared 
according to USP specifications, with the exception that pancreatin was 
excluded, as follows: 125 ml of monobasic potassium phosphate (6.96g/ 200 
m 1) was measured into a 5 7 vo 1 umetr i c flask. One hundred and ninety 
milliltres of NaOH (1M) was added and the solution diluted to approximately 
4000 ml with HPLC-grade water. Twenty five millilitres of EPH.HCl solution 
(20 mg/ml) was pipetted into the flask and the pH of the solution adjusted 
to 7.2 with 1 M HC1. The final solution was made up to 57 with water. 
5.6.2 Results and Discussion 
Analysis of dissolution by HPLC was rapid, accurate and precise. The HPLC 
column remained stable throughout the analysis and no increase in back-
pressure was observed. The PPA.HCl content for Product LE was found to be 
94.83% (71.12 mg/capsule) of the label claim of 75 mg/capsule. 
The incorporation of the internal standard into the dissolution medium had 
many associated advantages. The same internal standard solution was used 
for the standards for the calibration curve and for the dissolution medium. 
(; 
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The presence of the internal standard compensated for the loss in total 
volume of the dissolution medium due to evaporation during the dissolution 
test and evaporation from the aliquot removed for analysis. In addition, 
it has been reported by Dowse (8) that greater accuracy is associated with 
the incorporation of the internal standard in the dissolution fluid than 
with the addition of the internal standard following sample withdrawal. 
The supplement to the 8th USP (330) gives the following limits for the 
dissolution profiles of extended-release PPA.HCl capsules: 
Time Hours Amount Dissolved 
0.125 D 1.5 Between 15% and 45% 
0.250 D 3.0 Between 40% and 70% 
0.500 D 6.0 Not Less Than 70% 
where D = Dosing interval (12 hours) 
The individual results for the dissolution of PPA.HCl from Products LE and 
RD are listed in Appendix IS, Tables AlS.1 and Al5.2 respectively, and the 
dissolution profiles for product RD and product LE are depicted in Figure 
5.5. 
FIGURE 5.5 
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It can be seen from Table 5.5 that the release of PPA.HCl from Product LE 
proceeded more rapidly than for Product RD. Product RD exhibited conformity 
with the USP 1 imits for rates of release of drug from the dosage form 
matrix and is a good example of an extended, controlled-release formulation 
showing linearity within the first three hours. Product LEI on the other 
hand, did not conform to USP limits, with 60.60% of drug being released in 
the first 1.5 hours. 
TABLE 5.4 Comparative release rates for Product RD and Product LE. 
'% 
• PPA.HCl dissolved 
Time (Hrs) Prod RD :: SO Prod LE :: SO 
1.5 24.01 :: 0.04 60.60 :: 0.05 
3.0 43.64 :: 0.04 76.30 ± 0.06 
6.0 63.67 :: 0.04 90.67 :: 0.05 
10.0 80.61 ± 0.04 96.96 = 0.04 
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CHAPTER 6 
CONCLUSIONS 
Although extensively used, there is little information in the literature 
regarding the effects of PPA on appetite and food intake, and no study has 
been undertaken to determine the global safety and efficacy of PPA as an 
appet ite suppressant over a pro longed period of time, poss ib ly due to 
methodological and conceptual difficulties. The multi-dimensional approach 
and standard, validated methods described in this study, whilst certainly 
being feasible with a few design alterations, revealed certain short-
comings. The major restriction of performing such a clinical trial ;s that 
frequent supervision by the trial monitor and an enormous amount of 
participant effort, motivation and cooperation is required. In addition, 
the method requires detailed organisation and analysis by clinicians and 
statisticians and is thus both extremely time-consuming and expensive. 
In light of the difficulties encountered in data analysis due to the length 
of the trial, subject IIdrop-outs Jl and hence the cross-over breaking down, 
it is recommended that a parallel-groups study be performed, if a 
comprehensive trial is to be undertaken. However, due to the highly 
subjective character of the variables, it would be wise to increase the 
number of participating subjects and to establish base-line comparability 
between subject groups in all parameters under investigation before 
embarking on the study. 
Over the years, the potent i a 1 for adverse hypertens i ve and st imu 1 ant 
effects following the use of PPA, has been the topic of sporadic case 
reports and clinical studies. Whilst some of these reports are anecdotal, 
others refer to instances where gross overdoses and/or concomitant 
medications and combination products (including caffeine) were used (100, 
103, 107, 108). However, our findings were consistent with other reports 
and controlled clinical trials in the literature that found no significant 
stimulant or behavioural reinforcing effects (136, 282) or changes in blood 
pressure (36, 51, 53] 54, 59, 102) in normal individuals receiving PPA. 
Although some volunteers reported side-effects, these were considered by 
the investigator to be minor. 
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Whilst no absolute statements can be made concerning the efficacy of PPA 
due to the sma 11 number of subjects studied and the 1 imited number of 
observations, it appeared that treatment with PPA resulted in a significant 
weight loss, suppression of hunger and appetite and a reduction in 
salivation, whilst apparently exerting little or no effect on satiety. In 
a recent study (98) which used a validated 1-week food frequency 
questionnaire to indirectly monitor intake, treatment with PPA was shown 
to decrease total food intake, carbohydrate, protein and fat consumption. 
In the present study, the lack of significant differences in protein and 
fat intake following treatment with PPA, could have been due to the direct 
method used to measure dietary intake. 
One objective of the study, was to attempt to correlate serum levels of PPA 
with the subjective and objective variables under consideration. 
Unfortunately, due to the limited number of observations recorded for the 
AHQI SQ, salivation and food intake, it proved impossible to attempt such 
a correlation of these parameters. Due to large intra-subject variability 
in responses, and the reality of extraneous environmental influences no 
correlations of serum levels with BP and the various scales of the ARCI, 
POMS and VAS data could be found. 
Whilst the estimated steady-state pharmacokinetic parameter of kel is in 
good agreement with those previously reported (171, 325), the rest of the 
parameters showed discordance with previous results. Numerous reasons are 
possible and include differences in formulation, dosing interval (12-
hour ly) and i nterpersona 1 var; at i on. Some subjects d i sp 1 ayed i rregu 1 ar 
profiles of drug concentration serum profiles which were difficult to 
describe and interpret. 
Phenylpropanolamine is marketed as a racemic mixture of two enantiomers, 
and in this study, the pharmacodynamic properties of the racemic mixture 
were studied. To pursue the possibility of steroselective differences in 
safety and efficacy of PPA, further studies could be performed to examine 
the pharmacodynamic properties of d- and 7-norephedrine. In addition, the 
method of temporal tracking could be used to monitor the safety and 
eff; cacy of PPA cont i nua 11 y over a per i od of time. Indeed, a serum 
concentration-time comparison of the pharmacodynamic effects of PPA could 
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be performed if blood levels of PPA were monitored simultaneously. 
As mentioned in section 3.1 , an anorectic agent is seen as efficacious if 
it reduces hunger and food intake and produces a reduction in body weight. 
In addition, safety is inferred if the drug does not elevate blood pressure 
and shows little abuse potential. 
The present study demonstrates the utility of the standardised methods and 
procedures used, and the feasibility of the multidimensional approach for 
the assessment of the efficacy and safety of PPA as an appetite 
suppressant. However, in order to validate the data found in this study, 
it is recommended that a full-scale trial be undertaken, using the design 
modifications previously discussed. 
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APPENDIX 1 
VOLUNTEER INFORMATION 
CONSENT TO ACT AS A RESEARCH SUBJECT - STEADY STATE SEVEN DOSE PILOT TRIAl 
1. Phenylpropanolamine hydrochloride (PPA. Hel) has been widely used for decades as a nasal decongestant 
and appetite suppressant. The purpose of this study is to determine the serum concentrations and steady 
state pharmacokinetics of PPA. HCl following the administration of seven doses of a sustained release 
capsule containing 75 mg of PPA. Hel, given at 12 hourly intervals. 
2. To participate in this trial I must fulfill the following requirements: 
(a) must be in good health - established on the basis of an interview, physical examination, urine and 
blood analysis. (b) must have no prior history of gastrointestinal, cardiovascular, hepatic, renaJ, respiratory or 
endocrine disease. (c) must not take any medication for one week preceding the trial and for the duration of the trial. 
Cd) must not have had any major illnesses for three months preceding the trial. (e) must refrain from ingesting alcohol, caffeine or xanthine containing beverages and food for 48 hours 
prior to and during the trial period (day 1 - day 4). This includes tea, coffee, chocolate and all 
cola-flavoured drinks. (f) must not ingest foods containing tyramine i.e. mature cheese, marmite, bovril, yeast, broad beans, 
beer, pickled herrings and hung game and foods containing the yellow food colour, tartrazine for 14 days 
prior to the onset until study completion. (g) must refrain from doing any strenuous excercise for 24 hours prior to, and during the trial. 
(h) must follow all instructions concerning my diet before and during the trial. 
If I agree to be a subject, the following will occur. I will report to the clinic at the School of 
Pharmaceutical Sciences at 07h45 and 19h45 each day for three days prior to the trial day (day 4). I will 
receive one capsule of PPA. He1 with 200 ml of tap water at 08hOO and 20hOO. A 10 ml blood sample will 
be drawn prior to the first and subsequent doses. I will begin fasting at 22hOO on day 3 and report to 
the clinic at 07h30 on the trial day. 
After arrival, a hypodermic needle will be inserted into a suitable arm vein by a registered nurse and 
a zero-time blood sample collected at 07h45. I will receive a standard breakfast and at 08hOO I will be 
given the seventh and final dose with 200 ml of water. I will be served a standard lunch at 13hOO and 
a standard snack at 16hOO. I will remain in the clinic for the entire day of the trial (i.e. 07h45 -
20hOO). 
Blood samples (10 ml) will be collected according to the following schedule: 0,5; I,D; 2,0; 3,0; 4,0; 
5.0; 6,0; 7,0: 8,0; 9,0: 10,0; 11,0; and 12,0 hours after the final dose (a totaJ of 13 samples). 
3. The incidence of untoward effects associated with the use of PPA. HCl is low. Phenylpropanolamine 
hydroch loride has been reported to cause some mild and trans ient s ide effects such as headaches, 
tiredness I lightheadedness, anxiety, insomnia, dry mouth, nausea I vomiting, cramps, heartburn I 
epigastric pain, frequent urination and in susceptible subjects, to cause an increase in blood pressure, 
arrythmias, tachycardia and awareness of heartbeat. The risk of these side effects occuring does increase 
with the administration of multiple doses. 
The insertion of the needle for drawing blood can be painful and a small bruise ~ay develop on my arm 
and, very rarely a a localised infection may occur. 
4. These procedures have no direct benefit to me but information may be obtained concerning PPA. He1 
concentrations in the human body. 
5. This information was explained to me by Miss L. Petrie. I understand that she will answer any 
questions I may have concerning this investigation. If I have any other questions I may ask Professor 
Kanfer. 
6. I will be paid for participating in this study. 
7. Participation in this study is voluntary. I have the right to refuse to partiCipate or may withdraw 
at any time without jeopardy to my standing whatsoever. 
Volunteer Name ••••••••••.•••••• S ignature ••••.•••••••••••• Date ••••••••••••••• 
Witness Name ••.•.•..•...•••.. Signature ••••.••..••••..•. Date .............. . 
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APPENDIX 2 
VOLUNTEER INFORMATION 
CONSENT TO ACT AS A RESEARCH SUBJECT - STEADY STATE PILOT TRIAL 
1. Phenylpropanolamine hydrochloride (PPA. HC1) has been widely used for decades as a nasal decongestant 
and appetite suppressant. The purpose of this study is to evaluate the efficacy of PPA.HCL in terms of 
the degree of satiety or appetite suppression induced by this agent. The effects of PPA.HCL on changes 
in body weight, food consumption, blood pressure, skinfold thickness and salivation will be monitored. 
Adverse drug reactions and changes in psychological mood states will also be assessed. The study will 
take place for a period of eleven weeks. 
WEEK ONE : 
WEEK TWO - FIVE 
WEEK SIX : 
WEEK SEVEN 
WEEK EIGHT ELEVEN 
Baseline evaluation period 
First phase of the study 
Wash-out period 
Restablishment of baseline conditions 
Second phase of cross-over study 
2. To participate in this trial I must fulfill the following requirements: 
(a) be in good health - established on the basis of an interview, physical examination, urine and blood 
analysis. 
(b) have no prior history of gastrointestinal, cardiovascular, hepatic, renal, respiratory or endocrine 
disease. 
(c) not take any medication for one week preceding the trial and for the duration of the trial. 
(d) not have had any major illnesses for three months preceding the trial. 
(e) refrain from ingesting alcohol, caffeine or xanthine containing beverages and food for 48 hours prior 
to and during the trial period. This includes tea, coffee, chocolate and all cola-flavoured drinks. 
(f) not ingest foods containing tyramine i.e. mature cheese, marmite, bovril, yeast, broad beans, beer, 
pickled herrings and hung game and foods containing the yellow food colour, tartrazine for 14 days prior 
to the onset until study completion. 
(h) follow all instructions concerning my diet and phYSical activity before and during the trial. 
If I agree to be a subject, the following will occur. I will report to the clinic at the School of 
Pharmaceutical Sciences at the allocated times on each day of the first and seventh week. I will not 
receive any medication during these periods, but various tests will be performed according to the 
experimental schedule to establish my baseline variables. Week six will be a washout period in which I 
will receive no medication and no tests will be performed on me. 
During weeks two to five, and weeks eight to eleven I will report to the clinic at the allocated time 
each day and after arrival, a hypodermic needle will be inserted into a suitable arm vein by a registered 
nurse or medical practitioner and a zero-time blood sample collected at 07h45. At 08hOO I will receive 
one capsule of PPA. HC] or placebo (according to the randomisation schedule) with 200 ml of tap water 
at 08hOO and at 20hOO. A 10 ml blood sample will be drawn prior to the first and subsequent doses of PPA 
according to the experimental schedule. 
It is clear to me that for four weeks I will be taking an active capsule of PPA.HCL and for a further 
four weeks I will be taking an inactive placebo capsule identical to the PPA.HCL capsule in appearance. 
I will not be told during which phase I will be receiving the active or the placebo capsule. 
Blood samples (10 ml) will be collected according to the following schedule 
Week two (day 1) : 
Week two (day 2-3) 
Week two (day 4) : 
Week two (day 7) : 
Week three, four and five (day 4) 
Week three, four and five (day 7) 
Week eight (day 1) : 
Week eight (day 2-3) 
Week eight (day 4) : 
Week eight (day 7) : 
Week nine, ten and eleven (day 4) : 
Week nine, ten and eleven (day 7) : 
07h50, 12h50 and 19h50 
07h50 and 19h50 
07h50 and 12h50 
19h50 
07h50 and 12h50 
19h50 
07h50, 12h50 and 19h50 
07h50 and 19h50 
07h50 and 12h50 
19h50 
07h50 and 12h50 
19h50 
A TOTAL OF 38 BLOOD SAMPLES FOR THE ENTIRE TRIAL PERIOD. 
Note: The procedures for measuring all of the other variables (i.e blood pressure, skinfold thickness, 
appetite, food intake and salivation) have been explained to me by Miss L.R. Petrie. The sampling times 
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for the measurement of all of these variables appear in the daily experimental schedule of which I have 
a copy. 
3. The incidence of untoward effects associated with the use of PPA. HCl is low. Phenylpropanolamine 
hydroch loride has been reported to cause some mi ld and trans ient s ide effects such as headaches, 
tiredness / lightheadedness, anxiety, insomnia, dry routh, nausea / vomiting, cramps, heartburn / 
epigastric pain, frequent urination and in susceptible subjects, to cause an increase in blood pressure, 
arrythmias, tachycardia and awareness of heartbeat. The risk of these side effects occuring does increase 
with the administration of multiple doses. 
The insertion of the needle for drawing blood can be painful and a small bruise may develop on my arm 
and, very rarely a localised infection may occur. 
If I do experience any side-effects, I will report them to Miss L. Petrie. If my blood pressure rises 
above 10 ITJIlHg (diastolic) or above 30 mmHg (systolic) and is sustained over three consecutive 
measurements of 30 mins, the medicial practitioner may decide to withdraw me from the study, or 
administer a dose of Adalat (lOmg) in order to lower my blood pressure. 
4. These procedures have no direct benefit to me but information may be obtained concerning the safety 
and efficacy of PPA. HCl in humans. 
5. This information was explained to me by Miss L. Petrie. I understand that she wi 11 answer any 
questions I may have concerning this investigation. If I have any other questions I may ask Or A. Kench. 
6. I will be paid for partiCipating in this study. 
7. Participation in this study is voluntary. I have the right to refuse to participate or may withdraw 
at any time without jeopardy to my standing whatsoever. 
Volunteer 
Supervisor 
Witness 
Name •..•..••..•••.••.•••. S ignature •..•..••..•...•..•... Date •.••..••.•• 
Name •.•.•••••.••••••••••• Signature ••••..••......•..•.•. Date ..•.••••• , • 
Name •.•••.••••••• , ••• , .•• Signature •.....•.........•••.. Date .•...•..... 
TABLE A3.1 
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APPENDIX 3 
MOOD QUESTIONNAIRES 
The Addiction Research Centre Inventory (ARCl) 
INSTRUCTIONS 
These 49 items mayor may not describe how you feel. Circle the T next to each item number that does 
describe how you feel, and circle the F next to each item that does not describe how you feel. 
T F l. 
T F 2. 
T F 3. 
T F 4. 
T F 5. 
T F 6. 
T F 7. 
T F 8. 
T F 9. 
T FlO. 
T F 11. 
T F 12. 
T F 13. 
T F 14. 
T F 15. 
T F 16. 
T F 17. 
T F 18. 
T F 19. 
T F 20. 
T F 21. 
T F 22. 
T F 23. 
T F 24. 
T F 25. 
T F 26. 
T F 27. 
T F 28. 
T F 29. 
T F 30. 
T F 31. 
T F 32. 
T F 33. 
T F 34. 
T F 35. 
T F 36. 
T F 37. 
T F 38. 
T F 39. 
T F 40. 
T F 41. 
T F 42. 
T F 43. 
T F 44. 
T F 45. 
T F 46. 
T F 47. 
T F 48. 
T F 49. 
Name 
My speech is slurred. 
I am not as active as usual. 
I have a feeling of just dragging along rather than coasting. 
I feel sluggish. 
My head feels heavy. 
I fee] like avoiding people although I usually do not feel this way. 
I feel dizzy. 
It seems harder than usual to move around. 
I am moody. 
People might say I am a little moody today. 
I feel drowsy. 
I am full of energy. 
Today I say things in the easiest possible way. 
Things around me seem nore pleasing than usual. 
I have a pleasant feeling in my stomach. 
I feel I will lose the contentment that I have now. 
I feel in complete harmony with the world and those around me. 
I can completely appreciate what others others are saying when I am in this mood. 
I would be happy all the time if I felt as good as I feel now. 
I feel so good that I know other people can tell it. 
I feel as if sorrething pleasant had just happened to me. 
I would be happy all the time if I felt as I do now. 
I feel more clear headed than dreamy. 
I feel as if I would be more popular with people today. 
I feel a very pleasant emptiness. 
My thoughts come more easily than usual. 
I feel less discouraged than usual. 
I am in the mood to talk about the feelings I have. 
I feel more excited than dreamy. 
Answering these questions was very easy today. 
My memory seems sharper to me than usual. 
I feel as if I could write for hours. 
I feel very patient. 
Some parts of my body are tingling. 
I have a weird feeling. 
My movements seem faster than usual. 
I have better control over myself than usual. 
My movements seem slower than usual. 
I find it hard to keep my mind on a task or job. 
I don't feel like reading anything right now. 
It seems I am spending longer than I should on each of these questions. 
My hand feels clumsy. 
I notice my hand shakes when I write. 
I have a disturbance in my stomach. 
I have an increasing awareness of bodily sensations. 
I feel anxious and upset. 
I have unusual weakness of my muscles. 
I thrill has gone through me one or more times since I started this test. 
My movements are free, relaxed, and pleasurable. 
Week Day Time 
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TABLE A3.2 The Profile of Mood States (POMSj 
INSTRUCTIONS 
Here is a list of words and phrases that describe different feelings people have. Please read each word 
and decide how much you are feeling that way right now: not at all, a little, moderately, quite a bit, 
or extremely. Circle a number next to the word to show your answer. 
Please be sure to circle ONE number - and ONLY ONE number - next to every word on the sheet. Example: 
The first word is "Friendly". Consider how friendly you have been feeling. If you have not been feeling 
friendly at all, circle the number "0" to the left of the word "Friendly": 
0 1 2 3 4 Friendly 
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0 1 2 3 4 Friendly 0 1 2 3 4 Relaxed 
0 1 2 3 4 Tense 0 1 2 3 4 Bewi ldered 
0 1 2 3 4 Happy 0 1 2 3 4 Sluggish 
0 1 2 3 4 Angry 0 1 2 3 4 Uneasy 
0 1 2 3 4 Worn out 0 1 2 3 4 Kindly 
0 1 2 3 4 Unhappy 0 1 2 3 4 Lonely 
0 1 2 3 4 Confused 0 1 2 3 4 Miserable 
0 1 2 3 4 Lively 0 1 2 3 4 Efficient 
0 1 2 3 4 Unable to concentrate 0 1 2 3 4 Bitter 
0 1 2 3 4 Sorry for things done 0 1 2 3 4 Pleased 
0 1 2 3 4 Shaky 0 1 2 3 4 Alert 
0 1 2 3 4 Listless 0 1 2 3 4 Ready to fight 
0 1 2 3 4 Overjoyed 0 1 2 3 4 Restless 
0 1 2 3 4 Peeved 0 1 2 3 4 GOOd-natured 
0 1 2 3 4 Agreeable 0 1 2 3 4 Gloomy 
0 1 2 3 4 Sad 0 1 2 3 4 Desperate 
0 1 2 3 4 Active 0 1 2 3 4 Rebellious 
0 1 2 3 4 On edge 0 1 2 3 4 Nervous 
0 1 2 3 4 Grouchy 0 1 2 3 4 Helpless 
0 1 2 3 4 Fatigued 0 1 2 3 4 Weary 
0 1 2 3 4 Muddled 0 1 2 3 4 Elated 
0 1 2 3 4 Blue 0 1 2 3 4 Forgetful 
0 1 2 3 4 Energetic 0 1 2 3 4 Deceived 
0 1 2 3 4 Spiteful 0 1 2 3 4 Fu 11 of pep 
0 1 2 3 4 Hopeless 0 1 2 3 4 Warm-hearted 
0 1 2 3 4 Satisfied 0 1 2 3 4 Carefree 
0 1 2 3 4 Panicky 0 1 2 3 4 Furious 
0 1 2 3 4 Helpful 0 1 2 3 4 Uncertain about things 
0 1 2 3 4 Unworthy 0 1 2 3 4 Worthless 
0 1 2 3 4 Annoyed 0 1 2 3 4 Anxious 
0 1 2 3 4 Cheerful 0 1 2 3 4 Vigorous 
0 1 2 3 4 Exhausted 0 1 2 3 4 Terrified 
0 1 2 3 4 Resentful 0 1 2 3 4 Good-tempered 
0 1 2 3 4 Forgiving 0 1 2 3 4 Gui lty 
0 1 2 3 4 Discouraged 0 1 2 3 4 Bushed 
0 1 2 3 4 Bad-tempered 
0 1 2 3 4 Refreshed 
Name Week Day Time 
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TABLE A3.3 Visual Analogue Scales (VAS) 
I NSTRUCTI ONS 
On this sheet are a series of lines labelled with a mood or feeling And measuring along a continuum from 
"NOT AT ALL" (on the left) to"EXTREMELY" (on the right). Please make a mark on each line indicating how 
you feel RIGHT NOW. 
NOT AT ALL EXTREMELY 
Stimulated 
High 
Anxious 
Sedated 
Down 
Hungry 
Name Week Day Time 
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APPENDIX 4 
HUNGER. APPETITE AND SATIETY QUESTIONNAIRES 
TABLE M.l Appetite and Hunger Questionnaire (AHQ) 
INSTRUCTIONS 
The following seales are about hunger and appetite. Each scale has a question that must be answered. To 
answer, place a mark on the line at a point that you consider to be appropriate to the way you feel at the 
moment. You must answer all of the questions. 
1. How hungry do you feel right now? 
NOT AT ALL HUNGRY AS HUNGRY AS YOU HAVE EVER FELT 
2. How strong is your urge to eat? 
VERY WEAK VERY STRONG 
3. How preoccupied are you with thoughts of food? 
NOT AT ALL EXTREMELY 
4. How much food do you think you could eat right now? 
NOTHING AT ALL A LARGE A!'10UNT 
TABLE M.2 Bodily Sensations Questionnaire (BSQ) 
INSTRUCTIONS 
The following questionnaire is about hunger and appetite. For each heading circle as many answers that you 
consider to be appropriate to the way you feel at the moment. You may leave out a section, or answer more 
than once. At the end add any general comments about your usual feelings of hunger and the desire to eat. 
1. GASTRIC SENSATIONS 
1. feeling of emptiness 
2. rumbling 
3. ache 
4. pain 
5. tenseness 
6. nausea 
7. no gastric sensations signalling hunger 
2. MOUTH AND THROAT SENSATIONS 
1. emptiness 
2. dryness 
3. salivation 
4. unpleasant taste or sensation 
5. pleasant 
6. tightness 
3. CEREBRAL SENSATIONS 
1. headache 
2. dizziness 
3. faintness 
4. spots before the eyes 
5. ringing in the ears 
4. GENERAL SENSATIONS 
1. weakness 
2. tiredness 
3. restlessness 
4. cold 
5. warmth 
6. muscular spasms 
5. MOOD WHEN EATING 
1. nervous 
2. irritable 
3. tense 
4. depressed 
5. apathetic 
6. cheerful 
7. excited 
8. calm 
9. relaxed 
10. contented 
166 
TABLE M.3 Satiety Questionnaire (SQ) 
I NSTRUCTI ONS 
The following scales are about satiety. Each scale has a question that must be answered. To answer, pJace 
a mark on the line at a point that you consider to be appropriate to the way you feel at the moment. You 
must answer all of the questions. 
1. How satiated / full do you feel right now? 
NOT AT ALL FULL UNCOMFORTABLY FUll 
2. How strong is your urge to eat after completion of your meal? 
VERY WEAK VERY STRONG 
3. How preoccupied are you with thoughts of food? 
NOT AT ALL EXTREMELY 
4. How appealing was the food? 
NOT AT All EXTREMELY 
5. How did the food taste? 
VERY BAD VERY GOOD 
6. How much of your favourite food do you think you eat right now? 
NOTHING AT All A LARGE AMOUNT 
TABLE M.4 Food Preferenee Questionnaire (FPQ) 
INSTRUCTIONS 
This questionnaire is about food preference. The following is a list of common food commodities. Please 
indicate your preferences by circling the number next to each food item. You may select as many items as 
you wish. At the end add any additional comments about your food preferences that you feel may be applicable 
right now. 
1. cheddar cheese 16. turkey, goose or duck 
2. dried apples 17. cornflakes 
3. white or brown rice 18. honey 
4. roast leg of lamb 19. veal cutlet 
5. doughnut 20. macaroni 
6. canned tuna fish 21. fried bacon 
7. baked potato 22. mince pie 
8. cooked halibut fish 23. plain chocolate 
9. waffles 24. dried prunes 
10. fried or boiled egg 25. porterhouse steak 
11. raisin bread 26. fried beef liver 
12. kippered herring 27. canned sardines 
13. muffins 28. sturgeon caviar 
14. chicken 29. kidney beans 
15. cane sugar 30. pork sausage 
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J . 61.~O , 0.000 62.60 , 0.000 
4 IlI.H.0.1I5 61.00 , 0.000 
5 61.41 • 0.115 62.60 , 0.200 
1"0 I 61.21 ,0.11' 61.B • O.IIS 
2 60.20 • 0.200 61.n .0.115 
1 60.~1 • 0.115 61.~0 ,0.200 
-,-~- ~...!~~5 __ ~~...!..Q.,ill........_ 
5 60.80 • 0.000 6~~~_~ ___ CXJ 
a 
Ulrt!~ I 61.13 , 0.11' ___ 6_3.~~~ __ 0 
-< 
2 60.11 • 0.115 61.10 • 0.000 
-
1 60.61 , 0.115 62.81 ,0.11. 
3: 
l> 
I 60.13 • 0.115 62.HO • 0.000 
----_. 
VI 
VI 
5 60.9] • 0.11. 62.61 , 0.1l!> l> 
fOUl' I 61.00.0.200 61.11 , O.IlS Z l> 0 '"0 
2 61.33 • 0.11. b3.41 ,0.115 -0 
:£ ,.." ...... 
J 61.40 • 0.200 62.~1 , 0.115 ,.." z m 
H 0 ........ 
1 61.31,0.115 61.01 , 0.11. G> H 
::l: X 
S 61.20 , 0.200 6J.UO • 0.000 
-J 
f Iv. 
-
I 60.60 , 0.000 61.61 ,0.115 01 n 
2 60./J ,~~ ____ 6_.~~:_II .. S__ ::l: l> 
] ciO.40 , 0.000 ~60'0.~ __ Z G> 
~ 60.11 , O.IIS 6J.60 • 0.000 M 
----
5 60.51 • 0.115 63.21 ,0.115 0 
------- l> 
!~dd WC'ilk Iy W61Ubt Cholllle ond ~.rc."t'y6 Wulght Choll!l" (Subject 2 (CA)] -l l> 
Wed 
(uay 5 - UdY 1, -----w .. ·~(r"Je ~--.. -t Percentilljd uel~~hQlIlJe (\) 
~~_A_)_ PI •• s. 2 (1M 61_ ~_1!~L~_ PhdS. 2 (1M 0) 
- O.H t· 0.54 l -0.5] 1-----!-1.61 
O. 4/ ___ .:...'!.:1~ ___ . ____ ....:.J!:.! .. 1 __ 1_---=-__ -_0_'_'11 ___ _ 2 
-"------
_________ ... __ ... ____ -_o_.~ ___ _ 
- 0.40 ____ :...'!:1L.-_L __ ..:...!!.·bl ___ _ 
___ ~ __ J. __ ~~Q.. __ I __ ~'!..:.:!_' ___ J __ ..'...!!~ __ I ___ ~_4 __ _ 
-_-2 .. -_-... J -0.0/ -I - 0.40 - 0.12 - 0.6J 
Overdll 0 •• 1190' - 0.14 --.-l - 0.06 .-l ___ -_I_.2_1 ___ L_...:..~_.J 
UVCI',3 J I O~4lltJe ... Week 5 Day ~ - Wet" 2 04Y l 
llilll_6hU 0. tI~ Body H ... 1I", .. u ........ " .. (Subject 1 (If)) 
Ph.,. I (lK 8) 
,---
Pha,. 2 (IK A) 
llct:& Oa, Mean Mass I. SO Hean iiass t SO 
(kg) (kg) 
1---
On~ I 11.00 , 0.000 16.,3 , 0.115 
11.00,0.200 15.6 , O.I1S 
1 11.00 , 0.000 16.5 • O.IIS 
4 16.73 • O.I1S 16.60 • 0.000 
5 /6.11 • 0.115 ]6.13 • 0.231 
I.u I lb.40 • 0.200 /6.20 • 0.000 
2 /6.6/ • 0.115 15.61 .0.115 
3 16.13 .0.115 15.60 • 0.000 
4 15.91.0.115 16.33 • 0.115 
; IS.OO • 0.200 15.73 • 0.115 
-----
JtlfCt: __ I 11.20.0.000 15.20 • 0.000 
2 1/.01 .0.115 16.21 • 0.115 
I 
1 II.Jl ,0.115 15.H • 0.115 
4 16.80 , 0.000 15.11.0.115 
5 15.80 • 0.200 14.60 • 0.000 1 
--,------
tour I 16.21 • 0.30, 14.11.0.115 
2 11.00.0.000 14.00 • 0.000 
1 J7.0] J. 0.115 /l.bl • 0.115 
4 16.13 • 0.115 Il.60 • 0.000 
5 76.40 • 0.000 14.21 • 0.115 
ti\lt! I 11.01 • 0.115 14.21 • 0.115 
2 16.20 , 0.000 14.H.0.I1S 
J 16.1] , 0.115 14.00 • 0.000 
4 16.'] , 0.1!5 1 J. 40 • 0.000 
----.- - ~--- 15.20 • 0.000 13.21 • 0.115 
IAlIIL~,ld. Weekly Weight ChA''il. And fercenUlg. Wolghl ChAngo (Subject 1 (LEIl 
i ______ W~"~I~~f~.( CI~'~C (L21 kccl( 
(Ila, ~~~~_-I~~~_ 
1-- _ O.HI 
- 0.60 
1.40 
4 • 0.)) 
Ph",~~ 
- 0.40 
.041 
1.61 
• 0.14 
Pcro.:ut~tj~ ~t: 11j~!.!. ChdflgC:..· ..l(":'\<-) __ 
Pha,. I (lK 8) fhas. 2 (TM A) 
I.ll 0.52 
0.19 0.62 
I.HI ---~---
0.11 • 0.19 
_. ____ S-----I--..:i.-OI--l . ,-,1.",00,-___ ~_ ---'-!..;.~--
O\lcr" II Chd'llJe" - 1.20 2 .9) I. 51 - ].B5 
O .... Cl'.i II U".Inyc ~ Ucck. f» DI1Y ~ - ked 2 04iY 1 
IAllLE A5.I.i o.lIy Body lIou lIe .. u ...... nu (Subject 4 (EAIl 
PMS. I (lK 8) Pllase 2 (1M Al 
Week 04, Kedn fuss a; SO Hean ttdss J; SO 
(kg) (kg) 
0 ... I 65.11 • 0.115 6j.9] .0.115 
2 6~.61 • 0.115 61.1l • 0.115 
1 65.61 , 0.2ll 62.13 • 0.115 
4 65.61 • O.IIS 61.11 • 0.115 
5 65.60 • 0.000 63.00 • 0.000 
1.0 I 65.60 • 0.000 62./3 • 0.115 
2 65.53 • 0.115 62.51.0.llS 
1 65.60 • 0.000 62.ll • O.lIS 
4 65.20 • 0.200 62.33.0.115 
~ 65.00 • 0.008 61.61 • 0.115 
Ihree I 65./3 • 0.ll5 61.93.0.115 
2 1------'-- 65.11.0.115 61.20 • 0.000 
3 65.01 • 0.ll5 60.9] • 0.115 
4 64.60 • 0.000 61.00 • 0.000 
5 64.40 • 0.000 60.1l .0.115 
four I M.OO • 0.000 60.~1 .0.llS 
2 M.41 .0.ll5 ,--.61.13 • .!:.!.!2. _____ 
1 64.01 • 0.115 60.51.8.115 
4 63.60 • 0.200 60.20 , 0.000 
5 61.81 • 0.ll5 60.U J; O.II!t 
fh/e I 64 .40 • 0.000 60.80 • 0.000 
2 61.61 • 0.115 61.01 • 0.115 
1 63.21 • O.ll~ ~~o~~_ 
~ 62.91.0.ll5 60,20'0~ 
_._ .... _.-
,_ ... ~ 
--
6l.33 • 0.115 59.}] • 0.ll5 
r.@!J ... 6H~ W ... kly W61uht Chong • ... a Percentog" Wuluht ChAngc (Subject 4 (EAlI 
WcitJ,.t qliUljJC (kY). ____ ~ PCf'centagc \t~l~ ChdflljC (%) Week 
(Ddy 5 - Do, II 
Phdso;..!...!.!!!..!L... PI, ... 2 (IK A) _ Ph.,. 1.. (1M 6) Phd'. 2 !..!~_ 
• 0.01 
- 0.93 • 0.11 - 1.45 
- 0.80 - 0.86 __ - 1.22 ___ . ___ - !.J!. 
!..;.]_1 ___ 
___ -_I:~. __ - - 2.02 1.94 
- 0.93 - o.ao - 1.44 l. JI 
-----I-- 1-
~--- - 1.01 1.66 1.6b 
Ovcrd t I Ch.:wgc· 2.lU 
- 1.00 l.63 - 4.16 
.. Ovel'" I I ChdlUje .. Week !J Ooly !l ~ Week 2 Doy 1 
I-' 
CJ) 
(Xl 
JABI E ...M~La o.lIy IIod.y 110 .. lIe .. ur&:wo:nh (Subject 5 (IIV) J 
._---
Ph.,. I (111 0) Pha'e 2 (1M A) 
Wed O.y HeaR f1Q)~ J: 50 Hean tld~!i .t. SO 
(kgl (kgl 
Uut: I 12 .80 , 0.000 /O.BO • 0.000 
2 /l.00 • 0.200 /0.80 , 0.000 
) I2.B/ • 0.115 10.61 • 0.115 
4 12 .80 • 0.200 11.21 • 0.115 
5 12 .80 • 0.000 10.01 ,0.115 
-----' 
1.0 I 11.9} • 0.115 11-5} • 0.115 
f--2 11.40 , 0.000 /1.20 • 0.000 
) 11.21 , 0.115 10.ao , 0.000 
4 11.60 , 0.000 10.BO , 0.200 
5 11.80 , 0.000 11.00 , 0.200 
.-------
'hree I 11.40 • 0.000 10.6} • 0.115 
2 11.60 , 0.000 10.60 , 0.000 
} 11.60 , 0.000 10.n • 0.115 
4 11.40 • 0.000 II.Il , O.IIS 
_._----- !-' 5 11.20 • 0.000 /0.80 , 0.000 
four I 11.13, O.IIS 11.00 • 0.200 
2 11.61 , 0.115 10.ao • 0.200 
1 11.81 , 0.115 10.13 • 0.115 
4 11.40 , 0.000 IO.ao , 0.200 
5 11.00 , 0.000 10.40 , 0.000 
-
f Ivt! I 11.41 , 0.115 69. /) , 0.115 
2 }0.40 , 0.000 69.60 , 0.000 
1 10.n , 0.115 69.41 , 0.115 
4 10.81 , 0.115 10.01 • 0.115 
5 10.61 • 0.115 69.5} , 0.115 
--------
TAIllfA5-Ll! Weekly WelUht o.0lli.l0 00<1 'ercentage Weight Ch0lli.le [Subject 5 (IIV)] 
Ut!lght Cht~e (kg) Pe,"ct:ntdlJe \Ie Ifh' (hdllgU (\) 
Phd'. I (1M Bl 
Wtt:k 
(O.Y 5 . Udy II 
Ph., • .2 (lH A) Phase I (III H) Phase 2 (III A) 
. ___ l __ ,~ 0.00 " ~- - O.W 
--C~_·IB - 0.14 
- 0.28 ' 0.18 1
----
2
-.----t ,0.11 I 
_____ l ____ . ____ ,~.20 __ + _ ____'_"_'_'" 
1---- -~ 0.61 __ ~_O __ I ___ ' 0.~4 ___ L __ '~ __ 
0.80 I ~I - 1.12 _~ __ ---..: 0.29 
_.~~!~~.["·~~~I 1.26. ___ '_I'~_~~ __ J 
• OVt:l'd II (hdU'J!.: .. Weck ~ OdY 5 - Ut:ck 2 OdY 1 
TABU A5.1.6 
Ueuk Oay 
0 •• I 
2 
3 
4 
5 
1 .. 0 I 
2 
) 
f--~ 
5 
rhrt:~ I 
2 
J 
4 1----' 
5 
,--
fout' I 
1--. 2 
} 
4 
5 
f he I 
2 
} 
4 
, 
~,u 
\I.:.::i. 
(Day. - o.y I) 
(}ally IIod.y /10>$ /Ieo,,,,,,,,,,,nh (Subject 6 (1I)) 
PhdS. I (III H) PhdS. 2 (III Al 
'-
tre311 MaSS. & SO I1tHIU JidS!I ~ SO 
(kgl (kgl 
--
81.20 , 0.000 HI.tiO , 0.000 
UI.5J , 0.115 81.41'0~ 
81.41 • 0.115 80.~0 • 0.000 . 
81.69 • 0.231 60.60 , 0.000 i 
BI.20 , 0.211 81.91 • 0.11. i 
81.01 • O.II~ 82.11 , 0.115 
80.87 • 0.115 81.07 • 0.11. 
61.01 • 0.306 80.40 • 0.000 
BO.Y] , 0.11. 80.41 ,0.115 
al.OI.O.IIS 80.') • 0.11' 
81.00 • O. J46 80.60 • 0.000 
81.00 , O. ]46 80.20 • O.UOO 
81.01 • 0.115 80.00 • 0.008 
61.2/ • 0.2ll 80.01 • 0.115 
81.21 • 0.115 19.81 • 0.115 
BO.13 • 0.115 19.93 • 0.115 
80.13 , 0.115 19.5] • 0.11. 
UO.)l • 0.115 19.41 • 0.115 
19.81 .O.IIS 19.20 • 0.000 
60.61 • 0.115 18.41 , 0.211 
81.93 ,0.115 IB.1l .0.115 
81.40 • 0.000 19.40 • 0.000 
80.dO • 0.20U I~. 21 , 0, _"_5 __ 
80.9} , 0.115 19.00 • 0.000 
81.20 • .'l:OO(j .... 18.81 ,0.11' 
~ -~-- --- ---
Weekly WeIght OIOIli.lO 00<1 Perc.urou_ WeIght Ch'''Jo (Subject 6 (1I)] 
Wei9hl (/1d1l9" (kg) 
Pha,. I (III B) Ph ••• 2 (III Al 
___ ~tayc YI!!ght ChdllY~ (\) 
• 
~!J.. (III U) Ph.,. 2 (III &_ 
i---~--t 0.00 • O,~ __ . __ -'0"'.0::.:0'- ' 0.40 
0.00 - 1.60 0.00 - 1.95 
• 0.21 D./} • O.ll , 0.91 
--------
_~.:...!!~~--I--....:...!"~-.--I---.:...~--I---.' .1.8J I 
- 0.11 _ .O.H _____ ' _O.!!L. _____ .:.~L_ 
OVI::.·"II Ch.aUlJ'=· • 0.11 - J.26 .1.Y/ t O.l~ __ ~. __ ._ __ 
G Ovt:ra II Cl!.iIIYC .. Hcel\, ~ tJ4Y ) • Week l U.:.y 
..... 
rn 
lD 
TAlllE .... jd Do lIy Body /Iou "" ••• .....,.,,,t. (Subject 1 lEG)) 
,--
Pha.e I (1M A) Phase 2 (1M H) 
\led. O.y Mean ttdss .t. SO Hean Has'S .t; SO (kg) (kg) 
0"0 I 62.40 • 0.000 60.80 • 0.000 
t-. 2 62.40 • 0.000 60.87 • 0.115 
) 62.5] • 0.115 60.13 • 0.115 
4 62.80 • 0.000 60.40 • 0.000 
5 62.1l.0.115 DO.9} • O.l1S 
1\10 I 62.00 • 0.200 60.80 • 0.000 
2 61.D} • 0.115 60.9] • 0.1l5 
3 ti1.8} • O.llS 60.80 • 0.000 
4 62.20.0.000 60.00 • 0.000 
5 61.80 • 0.000 01.40 • 0.000 1-----
HI,Ott I 61.93 .0.115 00.93 • 0.115 
2 62.00 • 0.000 61.20 • 0.000 
3 61.00 • 0.000 61.13 .0.115 
4 01.40 • 0.200 .60.QHi 
S 61.21 t 0.115 60.81 t 0.115 
tour I 60.60 • 0.000 
2 61.0} t 0.115 
] 60.13 • 0.11. 
r--' 
4 60.61 • 0.115 
5 60.53.0.115 
f t\le I 60.93.0.115 
2 60.00 t 0.000 
1 61.40 • 0.000 
4 60.93 t 0.115 
5 oO.o} t 0.115 
~------
TAlliE A5.2.1 WC'flk Iy Holubt Ch.fllle 0,1<1 Per"""tag8 Welgllt Chonge [Subject 1 (EG)] 
,---
Heck Ue l~hI (hd~. (,g) Perce'".g_ We! ht Ch.~e (\) (OdY 5 - Gdy I) 
--
Ph.,. I (1M A) Ph.s. 2 (TIl 0) Phase I (/M A) Pha •• 2 (1M 8) 
I • o.n .- 0.11 • 0.5] 
• 0.21 
2 - 0.10 • 0.60 
- 0.]2 
• 0.99 
3 
- 0.66 - 0.06 
- 1.0} 
- 0.1 I 
"""1 
4 
- O.O} 
- 0.12 
5 
- 0.26 
___ -_O~~_ 
--
OV~fu l' (hdl~Jc 
- 0.1l • O.O} 
- 1.18 • 0.12 
• 0\1;';1'0 t I (Jldlllj<! w Weer. l UliY ~ - Week l Day 1 
TAIllE AS.I,!! Dolly Ilo4y /Iou """ •• .....,.1. (Subject 8 (OJ)) 
Phase I (lHA) Ph.,. 2 (1M 8) 
Ht!ck Oay Hedt) Mass. '" SO Hean Mass " SO (kg) (kg) 
O"e I 66.60 • 0.000 62.41 , 0.115 
2 66.31 • 0_115 61.80 • 0.000 
1 6bA} t 0.115 61./3 • 0.115 
4 66.60 , 0.200 61.80 • 0.000 
5 66.53 , 0.115 61.80 • 0.000 
lwo I 66.21 • 0.306 
2 65.21 • 0.115 
3 65.00 • 0.200 
4 64.53 .0.115 
5 04.07 • 0.115 
lhr~e I 64.11 t 0.115 
r----_2 64 .01 • 0.115 
-----------------
3 bl.60 • 0.000 
4 63.11 t 0.115 
S 62.80 • 0.000 
rour I 63.53 .0.115 
2 63.00 , 0.000 
3 61.40 • 0.000 
4 6].80 , 0.000 
5 63_40 t 0.000 
"lve I 6].00 • 0.000 
.. -
2 62.87 t 0.115 
3 62.93.0.115 
4 b2.60 , 0.000 
-
5 1i2.53 t 0.115 
TAllIE A5d,l! W""kly Weight (h'''Il" .,1<1 Percentoy" ~"Ight (hongo [Subjoct 11 (eV)] 
\leek Wclgllt Cha"ge (kg) Percenta.ge WeHJht ChiUltjc (\) 
(Day 5 - Oay I) 
Pha.. I (I" A) __ Yho,. 2 (1M 8) Ph ••• I (TN A) Ph.,. 2 (IN 6) 
I - 0.07 -0.61 __ - 0.11 - 1.01 
2 . 2.20 - 3.32 
3 - 1.1) - 2.07 
4 - O.ll - 0.21 
S - 0.41 - 0.1> 
Ovcra II (tl4ruje - ].H . 5.1i4 
----~----
• Ovura 11 Chanc.Ju .. Wt!ck ~ Day 5 - Week 2. Oay t 
I-' 
'---J 
a 
------
~. 1M A • ,I" f Rd( 10 P III 8 • Sfll f Rdt 10 ~ 
I 69.44 • 1.186 69.86 , 1.101 0.06 0.80g1 
1 68.91 • 1.223 69.59. 1.146 
J 68.41 • 1.210 0.19 0.9421 69.66 • 1.112 0.16 0.9562 
4 68.06 • 1.152 69.40 • 1.166 
; 68.18 • 1.250 10.66 • 1.1~5 
o • 65. of • 1.68 
~~ Ave,·3gu 600y K<u,s pcr Ut."Ci. (ltceUl IIdlucs lor I SubjccU) 
\Je~k I" A • Sf/I 1M 8 • SfN 
-0.31 • 0.22 
-0.11 • 0.18 0.58 0.4691 
-0.6/ • 0.11 
-0.20 • 0.11 
-0.ti9 • 0.21 0.51 0.126/ -0.5/ • 0.24 I. ~9 0.1241 
-0.45 • 0.26 
-0.11 • 0.28 
5 -0.46 • 0.20 
-0.83 • 0.25 >-----_. 
--
1\ • Il. 0' • 4.11 
IAllle AS.3.2 A •• ,·aye Weekly Weiyhl 10," (Hean V.lw. lor J Subjcch) 
WI.!cr. IH A • SfH 1M 8 • SfH 
-0.'19 • 0.12 
-0.02 • 0.34 1.0/ 0.JJ60 
·0.9l • 0.21 
·0.21 • 0.26 
-0.99 • 0.32 0.51 0.1320 -0.62 • 0.l4 2.11 0.0111 
·0.63 % O.3~ 
-0.11 • 0.42 
; -0.68. 0.11 
-1.2 •• 0.28 
---------
o-ll.df-4.31 
(AUlt A5.J.l Avcrdyt: Wed Iy Pt!rcl!nt Wl!h.Jht lo~s (ltcan \l4Jues tor} SUbjects) 
SUbj. Wt:'t:k III A • SUI 11111 f aallo p III 8 • Sfll lilt I f Rallo P 
I I 10.24 • 0.220 
· 
68.82 • 0.161 26.91' O. OIIOIJ 
2 69.91 • 0.106 
· 
68.84 • 0.115 
3 69.)2 • 0.1l1 
· 
12.0J' 0.0000 69.01 • 0.182 1.21 0.3290 
4 69.26 • 0.075 69.02 • 0.211 
S 69.08.0.146 
· 
68.53.0.112 
---
2 I 61.52 , 0.083 
· 
62.04 .0.158 
· 
JfUt 0.0001 
2 60.65 • 0.181 61.21 • 0.090 
) 60.88 • 0.014 
· 
15.11' 0.0000 62.96 .0.121 
· 
6.62' 0.0015 
4 61.25 • 0.0/1 
· 
63.24 • 0.213 
· 5 60.52 • 0.011 63.68 • 0.1l1 
· ,.------
3 I /6.29 • 0.116 /6. II • 0.169 J.OJ O. 0/J48 
2 15.91 • 0.149 16.19.0.158 
) 15.35 • 0.268 
· 
13.10' 0.0000 16.84 • 0.214 1.98 0.1J1l6 
4 1).94 .0.130 
· 
16.69.0.159 
5 )),84 • 0.220 16.21 • 0.106 
4 I 63.42 • 0.215 
· 
65.15 • 0.039 
· 
95.11 0.0000 
2 62.36 • 0.141 
· 
65.39.0.106 
· 1 61.16 • 0.201 
· 
31.91' 0.0000 65.15 • 0.131 
· 
22.15' 0.0000 
4 60.56.0.191 
· 
64.16.0.015 
· 5 60.36.0.250 63.52 • 0.146 
· .. _--
5 I 10.84 • 0.111 
· 
n .65 • 0.019 
· 
2fJl.l:i 0.0000 
2 11.01 , 0.138 
· 
11.60 • 0.122 
· 3 10.19 • 0.092 
· 
19.0'1- 0.0000 11.44 • 0.075 
· 
3,.01' 0.0000 
4 10.63 • 0.158 
· 
11.51 • 0.1l1 
5 69.68 • 0.101 10.15 , 0.205 
· 
------- ---
6 I 81.20 • 0.l91 
· 
81.H • 0.09) 
· 
0.41 O.o/af 
2 80.92 • 0.325 
· 
81.00 , 0.042 
· l 80.15 • 0.125 
· 
IS.N' 0.0000 81.12 • 0.062 
· 
} .99' 0.0005 
.. 19.32 • 0.242 80.41 • 0.166 
5 19.05 • 0.124 81.25 • 0.199 
Hie lI~dll mass I"or w&:~k 1 for both trt:dLlUtwts art: given in the budy of the tdO Ie. for week I, n .. !i for cacti 
subject per phase. df .. 1,89. For CO'iVdrison at lhe trCd.[llkHU ... eeb (2-5) with week I, Q .. 2~. ,j{ .. 1.23. 
Jhe ··S 10 the MR) columns Imhc"te whe,·e We ditten:llC~s in I~t:eks occured. 
t iwjlca(es d P value 01 less than 0.01 
~,U Aven:aye WLock hi H.).Si per voluutccr 
...... 
'-.I 
...... 
'!M!!.L&! SUntold 1I.ld""" &.,"rcu>t:1I15 {s..tajeCl I (SSl) IAlUf A6.} Sk Illfoid H.ld"" .. He"U"""""15 {Subject j (Ull 
Ph.," I (IH A) Pha,. 2 (IN H) I Ph ••• I (lit H) Ph ••• 2 (1M A) 
I Wed. Slo.iutohJ I 2 3 M •• n (mo) I 2 3 f1t!dn (al"lI) 
I Ihl/.;kues~ • SO ~ SO l1e4~llrefllCnt 
"eek Sk info Id I 2 J Ht:<ln (Dm) I 2 ) 11t:4n (11111) 
fhidncss i; SO %. SO 
Hedsurement 
I IrI(l!p~ 20.0 20.5 19.5 20.0 • 0.5 I Ir leeps 24.5 24.5 25.0 24.7 • 0.3 
S~d~IIid.~ 12.0 12.0 11.5 11.6,0.3 S"~rd·lliac 10.0 10.0 9.5 9.8 , 0.1 
___ lh_'_9h __ ~ 42.0 42.5 42.2 , 0.) --- r--- 1I.lgh 40.0 40.5 40.5 40.3.0.3 
2 Ir1eep!!; 24.0 24.0 24.5 24.2 , 0.) 24.0 24.0 25.0 24.3 ,0.6 2 rrlc~~ 26.0 26.0 25.5 25.8 • 0.3 to.O 25.5 25.0 25.5,0.5 
Suprd~ i I idC 8.5 8.5 9.0 8.1 , 0.3 1.0 1.5 1.5 1.2 , 0.3 Supra- illde 1l.5 14.0 14.5 14.0 • 0.5 12.5 12.5 U.5 12.8 • 0.6 
IlIlgh 41.0 40.5 40.5 40.1 • 0.) 38.0 36.5 39.0 18.5 , 0.5 Ihi9h n.o 32.0 43.5 43.2 , 0.3 44 .0 44.0 44.5 44.J • 0.1 
j 1 rlCCPS 24.0 24.0 24 5 24.2 , 0.3 25.0 24.5 24.0 24.5 • 0.5 3 Jr ieeps 24.0 24.0 24.5 24.2 • 0.3 26.0 25.5 26.0 25.8 • 0.3 
Suprd H iliac 10.0 10.5 11.5 10.5 , 0.5 8.0 8.0 8.5 8.8 , O. 1 
-
Supra. II lac 12.5 12.5 IJ.O 12.7 • 0.1 1l.0 11.0 1l.5 IJ.2 • 0.1 
Thigh 41.5 42.0 41.5 41., • 0.) 31.0 l8.0 l6.5 31.S • O.B 1I00gh 42.0 42.5 43.0 42.5.0.5 42.0 41.5 4).0 43.0 • 0.5 
4 Trlc'E:~s 4 Irlcep' 
Suprd- i) ide Supr.·lllde 
Haigh Ihlgh 
5 Jdeeps 24.0 24.5 24.5 24.3 • 0.3 25.0 24.5 24. , 24.1 • O. j 5 Jf ieeps 25.5 25.0 26.0 25.5 • 0.5 
SU}Jrd -,. ide 1.5 1.5 8.0 1.1 • 0.3 1.0 1.0 1.5 1.2 , 0.1 Supra. I II., 12.5 12.0 11.5 12.0 • O.S 
'----
III.gh 44.0 41.5 41.0 n.5 • 0.5 31.0 H.O JI.5 )1.2 • 0.3 Ihigh 41.5 41.5 41.0 41.l.0.l 
~l. Sklilloid H.I,k"",. He •• u"....:n" (Subject 2 (CAli 
.!M!!..UU Sklnfold n,l<knc" ""a'or""",,,ls {SuIojocl 4 (!:AlJ 
-I 
:x: 
....... 
1-1 
'-I 
N 
Plld •• I (TM A) Ph •• e 2 (TN 8) 
Wed; Sklnto I~ I Z 3 HedO (.1111) I 2 3 MedO ('II~) 
Jh,d,oe::.!t. , SO • 50 
Mt:~:iurel1r.:nt 
PlOd,. I (IN 8) Pha,. 2 (11\ A) 
\leek Sk Infold I 2 3 He.n (RIO) I 2 3 Hean (11111) 
lhlcknt:ss • SO ,SO 
n 
X 
Z 
m 
VI 
I fr Icevs 1J.0 21.0 23.0 21.0 • 0.0 
ftea~urelJlent VI 
Supra-II L:1C 19.0 19.0 20.5 19.5 , 0.3 
f--- IhlQh n.o 41.5 44.0 43.5 • 0.' 
2 I r1ceps 24.5 24.5 25.0 24. I , O. J 3~ 25.0 {S.U 25.0 • 0.0 
Su~rd· i I ide 20.0 20.0 19.0 19.6 , 0.3 20.5 20.5 21.0 20.1 • 0.3 
I r riceps 25.0 25.0 25.0 25.0 .0.5 
--
SUDra· I II., 11.0 17.5 11.5 11.3 • 0.3 
1I.lgh 36.0 36.5 l6.5 36.3 • 0.3 
2 lrleeps 27 .0 n.o 
.. ~ 27.2.0.3 17.5 16.0 16.5 16.7 • 0.8 
----
0 
» 
-i 
» 
f--. Ih'yh 43.0 H.O 44.5 H.8 , a.a U.O 42.0 42.5 42.2 .0.3 
1 II" I(~p!a 24.5 24.5 l5.0 24.7 , 0.3 25.0 25.5 25.0 25.2 • 0.3 
Supr.· I I Ide 16.5 16.0 16.0 16.2 • O. J t2 .0 12.0 12.5 12.2 • O. 1 
-----
Ihl"l. 3/.0 38.0 l8.0 37./ , 0.6 H,i... 34.0 ~ 29.2 .0.3 
.. ----
SUpCd -II tac 22.5 22 .0 n.o 22.2 , 0.3 21.5 22 .0 22.0 21.8 , 0.3 
1 Triceps 19.5 20.0 20.5 20.0 • 0.0 15.5 15.5 16.0 15.1 , 0.3 
. 
Hligh 46.0 46.0 46.5 46.2 , 0.3 H.O B.' 41.0 41.5 ,0.5 
SIJvr.l-lllae 15.5 16.0 16.5 16.0 • 0.5 I!..:l..- 11.5 ~ .!~ 
4 1--!l'iccPS 
Su~rd-Illac 
Ihlgh 37.0 3/.0 37.5 31.2 • 0.3 14.0 l4.0 14.5 14.2 , 0.1 
4 Irlc.p. 
Udgh 
)uera-II iac 
-. 
._-_. 
-' 
-
5 IrH.ep::. 24.5 25.0 25·L. 24.8 • 0.1 
)upfJ-1 tide 19.0 19.5 20.0 19.5 , 0.5 
IIllgh 
-
.---
--
5 ~~ !~ 24.0 ~. 24.l ,0.1 1;.0 ~ 15.5 1;.3 • 0.3 -----. -----
--
. 
Ihlg/I 45.5 45.' '6.0 45.7 • 0.3 
SUf::'"d -II idc 16.0 16.0 16.0 16.0 , 0.0 0.5 8.5 9.0 ~~:..L. 
Ihljjh 39.0 38.5 39.0 38.8 • 0.3 12.0 l2.0 12.5 l2.2 • O. 1 
----. 
IAlyl A6.~ Skin/old III"k"" .. "".'ureme." [Subject ~ (VIlli 
Ph.,. I (1M H) Ph .. e 2 (1M A) 
IJeck Sk 1010 hi 1 2 1 M.a. (urn) I 2 1 l1~dQ ('1.11) Jhldness , SO 
, SO MeaSl.ir~Qlent 
I lr leeps 21.0 21.0 22.5 n.8,0.1 
S~I~!"1.- II idC 21.0 11.0 12 .0 21.) • 0.1i 
t--- Ihlgll ]I .0 31.0 31.5 1I.1.0.1 
2 Jrlceps 25.0 15.0 25.0 25.0 • 0.0 20.0 20.0 20.5 20.2.0.3 
Supra-II idC 19.0 19.0 20.0 19.1 • 0.6 20.0 20.5 21.0 19.2 • O. J 
11'1 It h lO.5 41.5 42.0 16.8 , 0.1 lI.5 38.0 39.0 JI.5 • 0.5 
I Jr h.:eps 25.0 IS." 15.0 25.0 • 0.0 20.5 20.0 20.0 20.5 • O:~ 
Supra-II ide 19.5 lO.O 20.5 10.0 • 0.5 20.5 21.0 20.0 11.1 , 0.3 
JtllCJtI 3".5 35.0 14.5 14.1 • 0.1 30.5 10.5 lO.O 
, 
lO.3 • 0.) 
4 lrlc~V~ I 
, 
Supra-Illde 
fh Iyh 
5 Triceps 25.5 25.5 25.0 25.1 • 0.3 20.0 10.0 20.5 20.1 .0.) 
SUerd- i IldC 21.5 21.0 21.0 21.5 • 0.) 11.0 16.0 II. ~ 11.5 • 0.5 
L-. IhllJ/I 16.5 36.5 11.0 J6.1 • 0.1 10.5 10.0 10.0 10.1 • O. j 
l!!!J!.~.J! Skill/old Ihlek"" .. He.,un....,n!, [Subjeci 6 (1I)) 
---
Ph.:i::'c (IN H) Phd:" 2 (1M A) 
Wed. Sk lido!...! Mi:!dU (11111) I'ltdn (iI.tI) rtll(ilf'~!;iS , SO 
• SO t1ed5urefl~nt 
---r----
:---.!.!:.'lCP~ J6.0 10.0 36.5 ]6.1 • 0.) 
)upr.i-IIIJc 27.5 28.0 18.5 18.0.0.5 
f •• uh ~6. 5 l5.0 46.0 45.8 • 0.8 
---. '------ -
If Iceps 34.5 34.5 14.0 34.3 • 0.1 15.5 35.5 3 •. 0 35.5 • 0., 
Suprd- i I Ide 26.5 27 .0 21.0 16.8 • 0.1 14,0 24. , 25.0 14.5 • O.~ 
Ttl1iJ'l V., 41.0 41.5 41.2 , 0.1 41.0 14 .0 ll.5 ll.5 • 0.5 
I,-,(cps H.O 31.0 n.O n.o • 0.0 
~"ltldC /1.5 22.0 no 22.2 • 0.6 
Ihi\Jh ~1.0 41.5 41.5 41. 3 • 0.] 
rr l(cP~ 
$UP'"d-llloC 
III Ig" 
Ir iLCj.J~ l~. " 35.0 J6.0 J5.5 , 0.5 
Su~r4-llld( __ 1~.5 14.0 25.0 1'.8 • O.d 
___ ~~I 4~.0 H., '~.O H.8 • 0.1 
~ Sk illfold Ihickl"''' "'.'.r""""I, (Subject / (£G) I 
Ph ... I (IN A) Ph.,. 2 (1M 8) 
We~k Ski lifo Id I 2 1 hedn (IInI) I 2 1 MedII (Olll) 
Ih ickne .. , 50 , SIl 
HeQsur~ment 
I Tr":eps 14.0 24.0 2 •. 5 24.1 • 0.6 
Supra- i I Ide 19.0 18.0 le.5 18.5 • 0.5 
Ihigh )0.0 10.5 11.0 10.5 • 0.5 
2 Tr ieeps 22.0 21.5 22.0 21.8.0.1 22 .; no 23.0 22.6.0.1 
Suprd-iliae 16.5 11.0 11.5 16.5 , 0.5 13.5 14 .0 14.5 14.0 • 0.5 
f---- __ I_h~ 1/.5 18.0 16.5 18.0 • 0.5 U.S 14.0 1'.5 14.0 • 0.5 
1 Jr h:eps 21.0 23.5 24.0 21.5.0.5 21.5 2LO 2 •. 0 21.8 • 0.8 
Suprd~ I Ilee 16.0 16.0 16.5 16.2 , 0.1 14.0 14.0 1l.5 1J.8 , 0.1 
Ihigh 1/.0 17.5 36.0 37.5 • 0.5 17.5 1/.5 18.0 17.1 • 0.1 
4 Irleep' 
Supra-Iliac 
1I11qh I 
, 
5 Jr ictps 24.0 24.5 24.0 24.2 • 0.1 i 
SULlfd -II Ide 12.5 12.5 12.0 11.1.0.1 I 
flIIY~. L-_. 35.0 1~.0 H.5 34.8 , 0.1 I 
-
~ Skin/old Ihidlle .. He.sur_lllS (Subjeci 8 (CY)I 
Ucck Sk 1111010 
JhlcJweH 
tle4SUf"eIfk!nt 
PI •• ,. I (1M A) 
H~d.n (11.11) 
:; SO 
~(lM.~~C!.) ___ _ 
MCdn (/IUJ) 
• SO 
I .. ieep' 11.5 1~1"·7 .0.3 1'--1--1---1---
S"~r.-ili.c 14.0 H.5 14.j. 0.1 
1--_---1f--.......:lh~l_~ 19.5 30.~ 29.8.0.6.. I I 
rleeps 11.5 11.5 18.0 11.].0.1 12.5!--E2. 12.0 12.2 • 0.3 
I Supra-iliac 15.5 15.5 16.0 15.7. 0.1 I~ ~ 12.0 12.3.0.1 
Ihl<)ll 10.0 10.5 10.5 30.3.0.1 16.0 26.5 21.0 26.5,0.5 
Jdc~s 
Supra-Illde 
Ihlgh 
I SUPI·.-llia~ - - ------- --frieep, I I r= F ' ' 3 333 
Ihlgh ___ __ _ _ __ I 
~I(ep, ~l'O ~ ll.5 -!~.t--B'-f-----
5"("'0-11 i.e __ ~ _~.:L .. ~.~ . .!... . __ ._ ___ ____ ----j 
~~ 27.5 21~ 21.0 27.1, 0c.!... ____ . ______ _ L--
I--' 
'-.J 
W 
mll..uLL! Dolly Supille 8100.1 Pre .. u .... lIe ... u ...... nu (Subject I (SS)) TAllI,£ AI.1.2 Dolly Supl ... 81004 Pnouur. lleo,ur_nls (SubJoct Z (CAll 
fll ••• I ! "' A) fll.'. 2 liN 8) 
Pllase I (III A) PII.,.Z(IHO) 
Sy,tollc o 1.'lolic 5,>101 Ie Ol."ollc 
S,,,ollc Oi05tol ic 5"tol Ie Ol •• tol ic 
Pressure Pressure Prussure Pressurt 
Pressure Pressure PreS5,ure Pressure lIeek 0., r iUAe 
llct:L. OdY li." (.,"/lIg) (lIIulllg) ('"lI/lIg) (u'lI/llg) 
10,11/1101 (.,II/Ii"I ( • ."/IIQ\ ( ... IIIQI. 
On!:! I 011145 110 68 114 68 
Due I 011145 100 60 95 56 
- -------""---
2 011145 105 65 94 64 
2 011145 114 66 112 18 
4 011145 U5 oJ 116 14 
4 r---I!~ --~- 56 96 58 
111100 100 59 104 65 
131100 120 68 114 10 ---
I 191145 120 66 122 18 
I 191145 91 f--- 58 92 12 
------- Iwo I 011145 98 58 102 68 
Iwo I 011145 120 15 112 10 
UIIOO 100 10 90 60 
13,,00 110 10 110 00 ------
191145 110 10 110 12 
1911.5 ~--.!'!L-_ 6, '00 60 
------
2 011145 100 60 100 58 
2 01104, 112 12 114 16 
191145 112 65 102 65 
1%45 110 80 110 6b 
j 0/1145 118 10 roo 65 
1 ~~ 95 -~---~ ~--
191145 100 60 96 60 
191145 110 12 108 65 
4 011145 98 M 100 58 co 
4 011145 120 8, 112 15 
111100 95 60 100 10 
,.-
a 
131100 120 10 116 14 0 
I ~_19h45 108 00 120 10 
._"--
I 191145 88 60 92 64 
---------=.--
rhr~t! I 011145 90 60 9b 54 
0 
I line , f--- 011145 118 10 114 1·1 
------
~~ 114 64 106 68 
2 011145 116 64 112 ,. 
---- --------
19M5 96 ;U 104 __ 6_4 ___ 
2 011145 10} 66 ~!04 64 
t-~ 
'-J 
-J::> 
191145 112 62 114 82 
191145 102 
_ 6~_ 98 68 
------ -----
J f---~IM5 118 n 100 10 
3 __ O_I~ ~- 10 98 ,--------~ 
191145 9J 60 100 65 
......... 
CI 
19M; 113 10 10l 66 -- » 
4 011145 110 65 112 10 
131100 108 68 III 10 
4 011145 95 62 --.!!!~ 68 
------
I JhOO 88 __ 6_2 ___ 110 60 
-I 
:Po 
I 191145 110 14 110 10 
I ~~ 108 bO 100 b4 
-
fou,- I 011145 110 10 112 /4 
fOUl' I 011145 98 .~-- ---.--!~O 58 
2 011145 112 66 110 10 
l 011145 9? ;0 100 ___ 5_8 __ f-----=---
4 ~-'-- 108 10 10l '4 
131100 108 10 IOU 68 
4 011145 98 62 '----~ ___ 2!. __ 
- --------
131100 92 65 98 ~-------
-
-
I 191145 100 60 ____ I!.L_ 10 
------
five I 01114; 112 6b II? 18 
c---------- I ~i._ __ 9_8 ____ 60 90 ~---------
f lv~ I 011145 98 66 
-.!!!!-- 58 ------- ------
-
2 0lM5 Iii 68 110 6b 
2 O",~~ 98 -~--- 96 til -------
4 011145 102 62 100 58 
q f--- OIM,_ 112 12 108 56 
-- .--.---
~~ 110 18 ___ I!!. ____ 08 ---------
-----
I 191145 100 00 110 10 
----- ------- -------
1------ IlhOO ___ 9_0 __ b; au 00 ------- ----.---- -------- --~------
I 191145 ~ ~ % m 
-------- -------- '-------- ------ --------
------ ----------
------
M!!!.UU,1 l1li111 Supl"" 8100d P ..... u .... He ... u ...... nU (Subject 1 (Ull 
Phdse I (1M 6) PMs.2 (1M A) 
Systolic Ola'tollc S~'tol ic Otdostolic 
Pressure Pressure PreiSure Pressure 
Wtck Day lima 
'nlll/Hq\ (1I,"/lIu\ '"u/IIQ\ (n1O/llq) 
O'I~ I 011045 118 18 116 62 
2 011045 110 12 112 68 
4 011145 il2 64 lIb 12 
131100 106 66 116 66 I 
1 191045 114 12 112 66 
I .... I 0/1145 112 74 112 16 
131100 115 10 110 65 
191045 110 65 110 12 
I 2 011145 120 15 115 10 I 
191145 115 10 108 12 I 
l 01h4~ 120 10 116 60 
19h45 105 10 120 10 
4 0/1145 105 10 108 66 
I3hOO 114 16 118 10 
I 191145 116 12 110 6, 
Ihn:t: I 011045 114 16 112 66 
191,45 112 18 110 10 
2 011145 118 19 110 16 
191045 112 14 112 16 
1 011045 118 15 110 10 I 
191145 120 16 106 16 ~ 4 011145 110 15 110 60 
13hOO 102 10 96 60 
I 19h45 104 14 112 18 
fUUI" I 011145 116 12 112 10 
2 011145 110 14 110 10 
-
4 011045 110 10 110 101 
"1000 ~18 16 ~- 10 I 
I 191145 __ 118 12 116 g=J t Iv&: I 011045 118 12 112 Il ------1 011045 120 6b 111 Il 
4 01104~ __ 1_11 __ 68 --~- 50 ------
----
131000 _-'-l~ ___ 15 ___ ---'-~- ___ '_6 __ 1 
I 191145 110 10 100 ti8 
'--------- ------~ 
lABIE A7.J.4 IIIIlIy Supl"" Blood Pressun> 1I.,..u""""oU {Subject 4 (fA)] 
PI,.S. I (1M 8) PhdS. 2 (1M A) 
S~stollc Ol ... olle SystOliC Olastol Ie 
Pressure Pres~ure Press.ure Pn:ssure 
Week Day lime 
! .. n/II~1 ""n/II'11 (10'11/11'11 ( ... /lIq) 
On. I aIMS 110 68 110 64 
2 011145 116 n 114 68 
4 011145 114 10 114 II 
IlliOO 112 68 115 65 
I 191045 116 68 110 16 
Iwo I 011045 liS 15 115 12 
11hOO 130 80 115 10 
19M5 122 15 122 80 
2 011145 120 10 120 80 
191145 125 80 118 16 
] 01114. 115 80 106 10 
191145 110 82 110 10 
4 011145 115 IS 110 15 
11',00 120 80 100 68 
I 191145 106 62 120 10 
lhree I 0lM5 112 88 120 60 
191145 110 10 186 66 
2 011145 118 80 114 14 
191145 116 10 110 18 
] 011145 118 80 ~---1--__ 1_4 __ 
191145 109 10 110 10 
-
4 0/1145 112 n 118 18 
IJIIOO 116 15 110 10 
I 191045 122 111 112 M 
four I OIMS 116 10 IH 14 
-- ------
, ___ 2 __ 011145 104 10 110 IU 
4 011145 112 10 120 80 
------
I lloOO c----ill--- 11 r--~- 10 f---'--- f----- -----
1---- I r--_19M5 116 10 __ '_20 __ 10 -------- r-----
five I . __ O~_ --~- 12 __ -1~ __ r----! __ 6 _ ------ ------
2 011145 105 n 112 14 
-------
--
4 0/1,45 110 66 __ .l!!_ 18 
. ----~-.--
'31000 124 82 120 80 
------- ------ ------ ------ ----- ------
I l<Jh-It. 112 10 110 10 '---_____ ~___ f---. ___ 
---- ---------
........ 
'-J 
Ul 
IAllIE A}.l.~ Il4l1y SupltlO 6100d Pro .. u .... Iie •• u ...... /lt. (Subject 5 (YVll 
Plld'. I (IN 8) Plld'. 2 (IN A) 
SYS(ut 'c Oiaseolic SyHolic Ol.seollc 
,-- Prc:iisure Pressure P,-cssure Pressure 
Wcd Day It." 
J. .. ,n/!!llL J.'",I/Iigl !'''''/II~! (a'''/II'I) 
Olle 1 011145 116 16 112 80 
2 OIMS 120 66 112 16 
4 01MS 118 10 118 16 
131100 116 12 112 10 
/ 19h45 122 82 112 14 
I." I 0/1145 105 14 120 10 
IlhOO ItO 10 115 15 
191145 120 80 108 /0 
2 0/1145 116 10 98 52 
191145 110 16 90 62 
3 011145 110 /8 116 10 
19M5 112 /0 110 10 
4 0/1145 110 /0 110 80 
131100 125 8. 112 14 
I 19M. 112 14 110 10 
-----
HIf'~t: 1 O/MS 112 12 116 12 
191145 112 12 114 /0 
2 011145 111 09 100 00 
19M. 122 /4 108 66 
1 011145 118 68 110 10 
19104. 100 64 110 10 
4 OIIl4S lOS /0 106 14 
j----- iJIIOO 112 12 110 10 
I 
---
19M. 116 10 100 10 
four I 0/114. 110 /0 110 68 
2 011145 105 68 110 60 
4 011145 120 10 112 10 
------ ------
lJlIOO 112 I. 110 82 
I 191145 112 10 112 18 
five I 011045 116 14 100 10 
2 0lh45 114 16 96 j----- 62 j-------
4 011045 liS 18 11£- "6 
----
1)1100 100 10 110 06 
I 191145 122 80 110 10 
------ -----
-
!~U 
Uct:k 
One 
I , 
T.o 
Ihrt:c 
-. 
fOUf 
f 11.1(; 
O.lIy Supl"" 8100d P ....... ,. lie"U'CUlO"U [SubJ.ct 6 (1I)) 
Pt,ose I (IN 6) PII.,. 2 (IN A) 
Sy.lolle Old,eol ie Sy,eo I ie Olasto lie 
Pressure Prc!losure Prussure Pressure 
Ooy rime 
!"'"/II~! ('"lI/lIg) (u.lI/!!l!l (u .. I/llq) 
I 011145 112 10 104 62 
2 011145 108 6a 100 58 
4 07114. 10. 60 100 60 
I JiIOO 109 12 110 10 
7 19M5 105 60 10. 64 
I O/MS 10. 6S 98 64 
131100 96 60 tlO 18 
191145 110 70 100 68 
2 011145 100 60 106 10 
19M. 120 58 til 10 
1 01114' 105 60 102 ]0 
191145 100 60 tlO 68 
---'-
4 011145 IUO n 112 16 
111100 98 62 98 60 
I 191145 102 65 110 10 
1 011145 104 M 110 82 
191145 102 64 III 66 
2 071145 98 .8 98 58 
191.4. 106 10 92 60 
1 011145 110 10 86 58 
191145 112 10 90 60 
4 ~? 105 62 100 10 
111100 110 68 100 68 
7 19114. 100 ___ ~_ol __ 101 10 
I 071145 ---~-- 60 106 06 
___ 2 __ ~-- 108 66 1M 64 ------ -------- -------
4 071145 104 66 !~ 62 
- ------
1311UO 110 68 100 10 
I 19114S 102 6. 100 65 
I 011145 102 6l 100 6~~ 
2 01114; 102 60 96 54 
------ ------ ---'--- ------- -----_. 
4 ~~---~-- 6~ 9; 58 -----
111100 110 12 ---~- IU ------- ------
I 191145 108 60 IOU 65 
---
- '--------- ------- ------
I-' 
'-I 
0\ 
mlLULLl 1l411l/ Supl .. 8100d Pre .. u..., " ..... ' .... 010 [Subject 1 (EG)) 
Proa,. I 11K Al Ph.se 2 (III B) 
,y>lollc Did$(olic Systo II( Olaslollc 
Pressure Pressure Pressure Pressu.'c 
Wed O.y rlllW! 
r-- (1I,"/lIg) (,uVlIg) \lIllI/lIg) (lim/ug) 
Ufl\! I 011045 106 66 112 D, 
2 01/14. 112 62 114 61 
4 011045 112 64 112 6, 
131,00 116 66 106 62 
I 191045 III 62 112 66 
Iw" I 011045 100 10 100 58 
UnOO 110 12 108 65 
19M5 110 68 105 65 
2 071045 105 60 102 62 
--
19M, 110 10 112 60 
1 011145 100 62 115 62 
19M~ 100 68 110 ~~ 4 071045 108 10 110 60 
131100 110 66 106 64 
-
I 191145 110 10 100 60 
---~--- I--------=-
u.n:~ I DIM' 112 14 110 64 
191145 118 66 106 68 
2 DIMS 112 62 112 M 
19114. 112 66 108 62 
! 1 011045 110 12 110 6, i 
I 
19/145 110 68 110 68 I 
I 
4 011045 114 M 110 60 I ,---
131100 110 16 110 JO I 
----; 
I 191145 110 10 110 00 I 
------- , 
fout' I 0/1145 108 6b __ !!O __ ~---' 
2 011145 112 74 110 68 I 
4 011145 110 IS ----l!~ b8 
1]1100 112 68 110 10 
- -----
I 191145 110 60 110 10 
-------- -------
five: I 01104, 112 66 Il4 M 
l 011045 110 10 
4 011145 102 btl 
UIIOO 102 10 
-
-
1 19104' liD 10 
- -- --
~J..J! 
week 
--
Olle 
Iwo 
rhree 
flJur 
._--_ .. _-
f Iv(! 
Il4lly Supl .. 8100d Pre .. u .... lIe •• u .. "",,,U [Subject a (ev)) 
PI,.s. I (III A) Ph ... 2 (III 8) , 
Systolic Diastolic S)'5tol Ie: OSd~tollc 
Pres5ul'e Pn::asun: Pressure Pressul't~ 
O.y II." 
~L ("'o/II~1 (",u/llgl (",o/1191 
I 071045 110 76 108 16 
2 011045 116 68 112 __ 1_8 __ -
4 011145 114 14 110 82 
)3hOO 116 n IIJ 16 
1 19M5 108 aD 110 10 
I 011145 110 15 110 ___ 1_0 __ 
!JIIOO 109 14 116 /0 
19104, 100 10 112 10 
2 011045 110 14 
191045 105 /0 
] 011145 108 /4 
191045 110 68 
4 011045 112 68 
-< 
IlhOO 10] 
-
/8 c-----.~ 
I 191045 105 10 
I 
I 0/1045 10] 10 ! 
191045 114 15 
, 
2 011145 101 18 
19M. 108 14 
J 01104, 114 IS 
, 
-
191045 100 70 1------
4 011045 112 60 
I 
IJIoOO 110 12 j 
c------!-- 19,,4, 105 60 . r------------ -- I i 
r-------!--- 1---_ 0/104, 110 12 I I r--___ 2 __ ~- 108 --~-- 1 ----- -------
----] 4 ~? 110 14 
-------
----- --!l!!QL- ___ 1_12 __ n ----~ --=--- -----
I )9h4~ 108 10 I I 
------1 
I 0/1045 1----!!4 ___ 16 ! 
- -----
'-----~--- OJh45 114 64 i 
-I 
4 011045 110 ___ '_0 ___ 
131000 115 I, 
--= I ~~ IUD 16 --
I-' 
"--t 
"--t 
178 
'~eeJc TM ~ , SEM i F ~atlo I ~8 , 5EM , .~at10 i 
!10.~O , 1.07 0.08 OJ874 
108.51 
· 
~.9J 
:07.33 
· 
1.00 1.55 0.1896 0.04 1.3020 
t08.00 
· 
1.J5 
106.10 
· 
1.50 !08.S7 . I.S6 
, • 223. Jf • -.225 
TABLE U.2.! Average Systolic 3100<1 I'1"aSUI?I ;:er ~_ <_n ~aiues for 7 Subjects) 
i 
;~ A , SEH P ~at 1O I TM 8 , 5EM , ~atlO i 
;6.71 , 1.03 ;a.53 , J.99 1.18 I O.J.1J62 I 
59. " , 0.7~ 58.77 = 'J.34 
i 
" 
;:;8.21 , 0.7B 0.9' '1.~J91 59.50 • 0.77 1.57 I 1.Sd64 
58.50 
· 
l. 15 57.41 . 1. :4 ! 
5a.JJ , LZ2 ;9.30 , ! .13 
n • 228. Jf • -',225 
TABLE U.2 .2 A\lerage QiastoJ ie Bleed PT-s!ssures per ~ee!t; {~n 'Ja lues for 7 Subjec.ts} 
~! AddIction R.,earch Centra lnvonlory R •• pon.e. [SubJecl I (SS)] 
.. ---- . ... . " fl.a,. 2 (III 61 
"eeil. Oay Unit! COllllu(Cd Respoosi! RJ (Hlgs Week Oay lime CUII~utetJ R~sponsd R4t inj}~ 
HUG A 86 PCA6 LSO HUG A 8G PCAG LSil 
0"" I Olh,O 2 a I 12 I On. I 0lh50 1 4 2 4 .~ 
111150 2 6 I 10 4 12/.,0 3 4 J ___ 1-~I 
19"50 !~ I---i 
2 0711,0 1 1 I 6 I 2 011150 1 4 J 2 I 
191100 1 1 I 6 I 191150 J 4 I 2 I 
1 07h50 1 5 2 ) 2 J Olh,O 1 4 l 0 I 
191.50 l 5 I I 1 
- -
191150 J 4 2 I !----1--I » 
4 0lh50 J 4 I 6 2 4 07h50 1 4 2 I !---L- ::0 ("') 
121100 J 5 I 7 2 12h50 1 4 2 5 I H 
I 1%00 7 19/.50 1 4 
» 
1 I a ::0 "'0 
1.0 I 011100 J 4 I I 2 
121.50 J 5 I I 1 
191150 l 5 I I 2 
'wo I 0lh50 1 4 1 I I 
12h,0 1 4 1 2 2 
I-- 191150 J 4 2 2 - 2 
J"1'1 "'0 
Vl f11 .... 
"'0 ::::: 
'-I 0 0 lO Z I-i 
l/) >< 
2 011.00 J 4 I I 2 2 0/1150 1 4 I 1 
.t--!- J"1'1 CO 
191150 l 4 I 6 I 
1 07h50 1 5 I 6 2 
~O __ ) t---!- 2 J I ---" --I-~ 
J 0111,0 J 4 1 I 
0 
» 
-I 
191150 1 5 2 5 J 19h~O 2 1 1 4 1 :--!---j ~- » 
4 0]1100 J 1 j 5 2 4 0lh50 J 1 2 ~ __ I_-~i 
121150 J 5 I 5 1 121.50 4 ~- J I 2 i 
I 191150 J 4 2 6 2 7 191150 J __ 4 __ . 1 I I 
Jnree 4 ~!~ J 5 I _L.... 2 
Ilh50 1 4 ~- _-L- __ 2 __ 
I IYh50 l 4 I 4 2 
four 4 011.50 j 5 2 5 __ __ 1 __ 
"wee 4 011150 ) 4 3 I r.-1 121.50 J I-~- l 2 
7 191150 ) 4 J I -I~I 
fOUl- 4 ~- ) 4 1 0 _!. __ i 
1211,0 J 4 I r---!- __ 2 __ [-_ 121150 J 4 4 I o I .--- ---1 
7 19h50 J 4 1 __ 4 __ ~--1----'-----
f hie 4 l--.O/h~O _ J ~- 2 4 I 
Illi,O 1 4 I 1 2 
I 191150 
------
I 
---- -- -:~ five 4 011150 J 4 1 I Ill.50 "I 4 4 0 
I 1911~O J 4 l 1 I 
----- ----- .!..- ___ 19hW ________________ J 
~ 
flo.,. I (TH A) 
U~~k 
One 
1.0 
Ihrct: 
four 
----
five 
Oay 
I 
2 
1 
4 
1 
I 
2 
1 
4 
1 
4 
I 
4 
I 
4 
I 
Mdlet\QII R •• ""reh Centre Inventory R •• pon, •• [Subject l (CAl) 
II.", COOtluh:d Response Mat 'flgs. 
HUG A OG flAG I SO 
0lh50 1 J 10 2 2 
12h50 6 I 9 I 0 
191050 
-61 0lh50 I 8 I 12 
19h50 II 1 5 1 _o_~ 
0lh50 12 I 5 1 0 I ! 
19h50 5 6 1 6 
-W 
O/IoSO 4 8 4 9 6 
121050 II 1 1 1 1 
191050 Il 0 6 I 0 
0/1150 II I 5 2 0 
121150 I 12 I 
1 
Il 9 1 
191150 I 9 2 II ~I 
011050 6 2 6 0 0 I 
19h~O 1 1 8 8 1 i 
O]Il!JO I 8 J 9 
-8-1 
IYI150 I 1 
--I 
1 1 I 
i 0/1150 1 I 1 J 5 1 
12h50 1 6 4 1 2 ! 
191050 2 1 4 6 2 ~ 
0lh50 10 2 6 2 --;--] 
1 
121150 1 4 6 2 2 i 
---, 
191150 1 1 1 0 0 
1 
01t150 10 4 4 2 __ 0_
1 
121050 I 1 6 ___ 1_-t!=1 191150 9 l 4 __ 1_-
011150 5 4 I 2 1 1 
---1 
12h50 i 
19h50 i 
fll'" 2 (1M 0) 
Wel!k Oay 
0,,<> 1 
2 
1 
4 
I 
Iwo I 
2 
1 
4 
/ 
Hire&! 4 
I 
four 4 
(-----
I 
----
five 4 
1 
-
rime Cou(lutcd Re!)pun~e "ill hlfJS 
HOG A UG PCAG 1.50 
0/1150 II 1 5 2 0 
121150 II 4 8 2 0 
19h50 9 1 6 2 0 
011050 
191050 10 4 4 I 1 
011150 I 5 5 1 0 
191050 8 1 8 2 0 
011150 5 5 J 2 I 
121150 6 J / 2 I 
1%50 4 6 J I 1 
0lh50 8 2 I 0 0 
121050 I 4 6 __ 0 __ ~-
191150 1 1 5 I 0 
011150 2 5 4 1 1 
191050 4 1 I I I 
011,50 5 1 4 ___ 1_-1--0 __ 
19h50 8 4 f---!-- _1_-~-
011150 I~ 4 1-_1_ 1--0 I 
11h50 I 4 1 0 0 
19h50 Il 2 6 2 0 
1---0lh50 I 2 I I 2 
121050 6 5 6 
_L- 1--_0_ 
IYn50 14 4 9 I I 
0/1150 II 4 6 I 0 
I--~ __ 1_1-~ 1 1 ~-
1%50 ___ 1_- __ 1 _ ] 1-_8 __ 2 
-
011,50 2 1 1 9 1---4 __ 
121.50 3 1 I 9 2 
-~----- ------- -- ---
t--' 
CO 
a 
!AlIIU!U Addlcllon Re ••• rch C.nl .... Invonlory Re.ponses (Subject I (lEll 
~h ••• I (1M 8) ;'==-:--F-'--
I Week Uay i IUIt! (orl~l,ced Response Rdt lugs 
MUG A 66 P(AG LSO I 
---------, 
On~ I 01h50 I Ii 2 J J I 
121050 J Ii 2 I ----;-l 
191050 I 6 2 I J ! I 
2 011150 2 6 J I 2 
I 
19h,0 2 Ii J I 2 
, 
J 0lh50 2 5 J I I 
I 191050 I , 4 I I 
4 Ulh50 2 5 J I I ! 
12h50 I Ii 4 2 J 
I 191150 
----
1 .. 0 I 0lh50 4 6 ~ I 1 
121050 ] 5 __ 4 __ f---l- f--L-
191050 J Ii 4 I ~- I 
2 0lh50 J Ii 4 I r----!---
191150 I 5 4 I I 
J 0lh50 
_ -L-. 
--'-
__ 4 __ 
__ 1 __ - r------!-
19h50 I 5 4 I I 
----
4 01h50 J 5 4 I 0 
12/,50 2 5 4 I 0 
1---- 1 19h5U I 5 4 I I 
Itll't!t: 4 0lh50 I 5 4 I I~ 
121050 J , 4 I I_-
I 191050 2 , 4 1 I 
fout· 4 01h50 4 4 4 0 0 
12h50 4 4 4 0 0 
--- ------
I 191150 J 4 4 0 I 
----. 
----- -------
"I\lt! 4 0/1150 • 4 4 0 0 
12h50 4 4 4 0 0 
J I%~O 4 4 4 --~- 0 .----- ---- -----
TAlilE All,] 
Ph.se 2 (Iii A) 
\It!~k Oay 
Oue I 
2 
J 
4 
1 
I •• I 
2 
J 
4 
1 
Three 4 
---
} 
four 4 
---
1 
----
five 4 
-----
I..-.-~--
Addiction R .... rd. c.,lIlre Invontory R •• pon ••• (SnbJoct I (lE)] 
r Iiue (oo,)utell Rt!spouse Rat'"gs 
MBG A 6G PCAG ~-
01h50 J 4 4 0 ~ 
12h50 2 5 4 I 0 
----- r---"--
191050 
O}h50 J 5 4 I 0 
191050 2 5 4 1 1 I 
011,50 2 5 4 1 1 
19h50 
0lh50 J 5 4 I 0 
121150 J 5 4 1 .~ 
191050 4 4 
-
4 0 r-----Y-
011.50 J 5 -~ 1 0 
>----!2h50 __ 
_2._ 
--'--
4 I 0 
191050 4 
-----.!..- 4 0 ~ 
c-----2!h50 4 4 4 0 0 
191050 4 4 4 0 I~ 
0/1,50 4 4 4 __ 0 _ ~ 191050 J 5 4 I 0lh50 J 5 4 I 
121050 J 5 4 1 0 
191050 J 5 4 1 0 
011050 4 4 4 0 0 
_!21050 _ :1 5 4 1 ~ 
19h,0 J 5 4 I 0 
0110,0 J __ 5 __ 
'----! 1 0 
121150 ] 5 4 i-..L- 0 
191150 1--- --- ---- ---
0/1,50 J , 4 I ~ ---- 1-------
Ilh;O 1 , 4 I ~ 
_-.-!2~ J 
----..::........-.. L-~~ ~ I 0 
I--" 
();) 
I-' 
TABItl:!L1 Addiction Re''''lrch Ce"tro Inventory « •• pons .. (Subject 4 (EA)) 
fila •• I (1M U) 
Uct:k 03y f'lIIe ClHTf)uted l(espoos~ Rat togs j 
NUl; A 8G flAG I 50 I 
O'I<! I Olh~O j 10 4 Il 6 I 
----, 
121150 I 10 2 15 ~~ 
191150 0 10 2 II 1 i 
.- 2 011l~0 0 II 2 II I! 
191,50 , ij I 9 5 I 
3 011150 10 2 4 2 3 J 
19h50 2 1 2 Il 6 
4 011150 0 II 2 14 1 
12h50 0 II 2 II ~ 
1 191150 
1.0 I 0)h50 0 9 2 II 6 I 
1211;0 I 10 4 6 9 ! 
191150 I 10 2 10 6 I 
~ 
2 011150 0 II 2 13 8 i 
191150 0 10 __ 2 14 8 I 
3 07h50 0 II 2 __ 1_2 ____ "_! 
191150 0 10 2 12 __ 8 ___ 1 
4 071150 2 5 5 3 ~l I 
121150 1 6 4 4 6 
__ I 191050 0 II 2 14 9 
lloro. 4 011.50 0 II 2 14 9 
121150 0 II 2 14 9 
---, 
_____ I-_~ 19h50 0 II 2 II ___ 6_
' 
fou,- 4 071050 0 ~ __ 2___ ....lL_I--_8 __ 1 
f-----~~ 0 \l 1 14 __ 1_0_1 
f------- I 19",0 I 10 2 Il ~ 
five 4 011.50 0 _1_1 _ 2 1--__ 1_4 _ 9 I 
12,,50 0 10 2 Il I' 
'----_ I 19h50 0 10 2 I~_ L.._~ 
~ 
fila .. 2 (1M Al 
)It,:ck Oay 
One I 
2 
1 
4 
1 
r------
Iwo I 
2 
1 
4 
I 
Jhret! 4 
----
I 
four 4 
---
I 
five 4 
I 
Addiction ae.""rch Conlro Inventort Re,pon ••• (Subject 4 (EA)) 
HUll! (OII4.luted It~spouse Jtat lugs 
HU" A ijG feA. t SO 
011.50 0 II 2 14 6 
121150 I II 1 6 I 
191150 0 II 3 II a 
0111,0 0 II 2 14 6 
191150 
----
0lh50 9 2 6 1 I 
191150 0 10 2 14 6 
071150 0 II 2 14 8 
111150 0 II I 14 9 
~- 0 9 2 Il I 
0lh50 I II 2 14 9 
121150 0 9 2 II 1 
191050 0 10 2 II 8 
-
071150 0 
_--L-. __ 2 __ ~ -~ -----
19h50 0 10 -~ II ~ 
0/1150 0 12 2 1~_ ~--
191150 0 10 2 13 r---!--
_.!!.!!!50 0 12 1 r---1~ 9 
121150 0 10 2 14 .~ 
191150 0 10 2 13 ) 
071156 0 10 2 Il I 
121150 0 10 3 a 6 
191050 0 
" II 2 -~- 13 1 
--~ 0 10 2 IJ 1 
121150 
------
1%50 a 10 l __ 1_3_ ~ 
011110 0 10 2 13 8 
-----~ 
121.;0 0 II 2 Il 0 
l~hSO 0 II l L-~! __ ----~ 
....... 
CO 
N 
IM!.LM.,J! Addiction R •• ."reh CeIlC..., Inv.ntor~ n •• pon ••• [Subject 5 (VII)] 
Plldse I (IH 0) ~. 
Wcek Oay lilllt! (oCl~u,ed Response Ri1llng~ 
HOG A BG peAt lSD 
Ouc I 011,50 0 ] 2 9 5 
121150 0 10 6 II ~ 
19h50 
2 0lh50 I 1 5 9 I 
19h50 0 I 6 9 ] 
j 0lh50 0 10 6 II ~I 
19h50 5 4 l 4 ) 
4 0]1150 0 I 6 ] I 
I-- 121150 0 9 6 5 t-----l----i 
1 19,,50 4 I 4 5 5 
.-----
I"" I 011150 0 6 5 12 . ~ 
I-~ __ 0 __ II 6 12 9 
19h50 0 I I 1 ] 
2 011150 0 9 6 I I 
1911!:>O I __ ti 6 6 I 
J ~~i--- 5 4 6 } --]-_. 
I~~ ~- 6 6 6 ] 
4 011150 0 12 5 15 II 
121150 0 II 6 14 10 
I 191150 ] 4 6 6 6 
-----
lhrt:c: 4 011150 I 
i 
b I B I I 
f---- 121150 0 II 5 15 r---!!-
] 191150 9 I 6 0 0 
four 4 0]1150 I 5 ] ~-- _5_1 
121150 0 11 6 II 10 I 
-----I-~ 19h~O -.~ 
t ave 4 O}h~O 0 
. __ ll_ .. 6 9 10 I 
----
-10--1 1<1150 0 I} 6 6 
______ L __ ...!. __ ._ 191150 0 13 5 15 II I ____ L-____ I 
~ 
Pllas. 2 (1M AI 
Weck 
011. 
1.0 
Ihr •• 
Ooy 
I 
2 
l 
4 
I 
I 
2 
1 
4 
I 
4 
I--
I 
four 4 
f---. 
I 
f Iv. 4 
'----
I 
Addiction nc,eorcl, Cent..., In""nto~ n .. pon ... {Subject 5 (VII)) 
II ... C(U~uted Itesponse Alit inqs 
HUG A ot peAt lSD , 
011150 0 II 5 15 II 
121150 0 11 5 15 11 
191150 
071150 0 Il 4 15 ~ 
19h50 ~- 1l 4 15 II 
071150 0 I} 4 15 II 
191150 0 II 4 15 II 
-
0111;0 0 II 4 15 II 
12h50 0 1l 4 15 II 
191150 0 Il 4 15 __ 1_1_ 
071150 0 12 4 15 II 
12h50 0 Jj 4 15 II 
191150 0 II 4 I. II 
~!~ 0 lJ 4 15 \I 
191150 0 II 'I 15 II 
011150 0 13 4 IS __ 1_1_ 
191150 ~- 13 4 -~ \I 
071150 0 12 4 __ 1_5 _ __ 1_1_. 
121150 \I I 6 0 0 
-
191150 10 I 6 0 0 
011150 II I 6 0 0 
121150 to 2 S 0 
-r--!!--
19h50 0 12 2 15 9 
011150 0 1l 4 15 II 
12h50 0 1l J 15 10 
191150 0 II 4 I, II 
0111;0 I---~ IJ ~ .-~- II ------
121,;0 0 IJ 4 15 II 
I~II'O 
. __ ._--- --- _._--'--._-- ----
I-' 
(Xl 
W 
lAllH All.!! Addiction A ...... rch Ceotra Inventory R •• po05 .. (Subject 6 (L1)] 
~II.'. I {lH 6j 
llct:k u.y II." (on~uted Ae~ponse Rat 'figs 
HOG A 86 PeAG lSU 
Out: I 011150 I 11 2 15 8 
121150 2 11 ) 14 8 
191150 1 1 1 14 5 
2 071150 } 10 2 14 7 
191150 1 8 2 15 1 
} 011150 1 10 I 15 8 
191150 I 9 I 15 9 
4 011150 2 10 I 15 9 
121150 4 6 4 5 ~ 
1 191150 4 I 5 1 ~. 
1.0 I 071150 I 9 2 15 9 
121150 2 II 4 12 ~. 
191150 4 5 2 I 2 
2 071150 4 ___ 6 __ 2 2 3 
191150 4 8 2 11 8 
3 011150 I 9 I -~ __ 9 __ 
191150 3 10 1 12 .~ 
4 011150 4 5 1 4 2 
121150 J 10 4 14 8 
I 191150 5 4 J I 2 
-
Ihn:e 4 011150 4 6 1 1 ~ 
111150 ~- 6 4 J J 
I 1%50 6 1_- 4 I ,..--!--
-------
tour 4 011150 4 5 J 2 2 
--_. 
121150 1 ~- 2 ~ 2 
.~ ~O __ __ 4 __ J 'I 5 ~-
• iv~ 4 011150 4 5 1 0 ~ 
-----
121150 J 9 4 4 6 
I 191150 4 4 'I 0 0 
--
lADLE All.6 
Phose 2 (1M Aj 
week 
Olle 
hilo 
(hree 
fOUl" 
1-----
five 
Oay 
I 
2 
1 
4 
1 
1 
2 
1 
4 
I 
4 
1 
4 
I 
4 
I 
Addiction a .... rcll Centra Inventory A •• poo ... (Subject 6 (L1)) 
II ... COlilluted Re~ponse Rdl hUJ~ 
MOG A 8G PCAG LSD 
011150 5 } J 1 1 
121150 5 1 4 0 0 
191150 
011150 8 3 3 2 I 
191150 4 4 4 0 0 
011150 4 4 } 0 I 
191150 4 4 'I 0 0 
011150 4 4 4 1 0 
121150 4 4 5 0 0 
191150 5 1 4 0 0 
011,50 ~ 4 4 0 0 
121150 4 4 4 1 0 
191150 4 5 4 1 1 
-
011150 4 4 'I 0 0 
191150 'I 5 4 0 I 
011150 4 4 4 I 0 
191150 
~50 .• I 2 1 4 
121150 4 4 4 0 0 
191150 4 8 2 13 I 
07h50 4 4 4 1 • 
12h50 4 4 2 5 1 
191150 4 5 4 I I 
0lh50 4 5 'I __ 1 __ 2 
121150 4 4 'I 2 0 I 
19h50 'I 5 4 I 
_1_1 
----
01h50 j 8 2 II 9 
121150 2 a 2 10 I 
-191150 4 4 1 I I 
- ------ -- ----
...... 
en 
-t:. 
!~!!!.L~JLl Addiction n .... rch u:ntre Inllentory n •• po •••• (Subject 1 (EG)) 
PII.,. I (IN A) 
iJcck UaY J hue (ou~litel..l Response kat iogs 
/18G A 8G peA. 150 
Orlc I 0/1150 4 5 J 4 I 
121150 4 5 J 2 1 
191150 4 4 ) 4 I 
2 011,50 1 6 2 4 2 
191150 1 6 2 4 2 
1 011050 3 5 I 4 1 
191150 4 5 1 ) 2 
4 011150 1 5 2 2 1 
121150 4 5 1 1 2 
~-
7 191150 
--------------
Iwo I 071150 J 6 J 4 I 
121150 4 4 J 2 1 
191150 J 6 1 4 2 
2 __ ~11I50 3 6 1 ~ 
_L-
191150 J 6 2 4 2 
-
1 071150 1 5 } 1 ___ 1___ 
1%50 1 6 J 4 2 
-
4 0/1150 1 5 3 1 
----'-------
121150 r---2--- 6 1 2 ~ 
/ 191150 1 5 3 1 0 
-
Uu'cc 4 011150 ] 5 4 4 0 
----
~~ 1 6 4 2 1 
/ 1%,0 4 5 4 j 
_-'!..-
----
----
fOUl- 4 011,50 +--- --- ---- -
1211W 
~---- -~--
1 IlJh!lO 
------ ----- ---- ----
t Ive 4 011150 
-----
----
111150 
1 191,50 
'---._-
--
--- --- -
TABlE All.I 
Phase 2 (111 8) 
Week 
One 
Iwo 
OdY 
I 
2 
3 
4 
7 
1 
2 
) 
----
4 
I 
Jhn~t: 4 
I 
fOUl' 4 
/ 
----
five ~ 
I 
MdlcUon R •• earch Conlro Inventory A.'po .... [Subject I lEG)) 
II.Ie (Ofllput~tJ at:spolisc Rat ings 
--
MUG A 8. P(AG LSO 
-
071150 1 6 3 1 r---l---
121150 ) 5 ) ) I 
191150 ) b j 1 l 
-
07h50 3 6 3 ) 2 
191150 3 6 ) 1 2 
f---9 /115O j 6 ) ) 2 
I 
191150 1 5 1 ) I 
I 071150 1 6 3 1 2 
121150 3 5 } 3 1 I 
1%50 4 5 ) 2 2 
011150 1 Ii J 1 I 
121150 ) 6 j 2 __ 2_ 
191050 1 5 ) ) 1 
O/h!lO 1 5 ) j 1 
191150 ) 5 1 ) -1-1 
---I 
071150 1 5 1 1 
, 
I , 
-~ 1 5 -~ ) 
'-1-] 
071150 1 5 1---)-- r---2-- 1 , 
121150 1--_3 - 5 j r----!--- 1 -----1 
1%50 1 5 J 3 1 
-
0lh50 __ 3_ 5 1 ) 1 I 
121150 ) 5 __ 1_- _~l_ I 
191150 ) 5 ) 1 I , 
-----, 
071150 1 r---L- ---L_ --)--r---!-, 
121150 1 5 J 1 I ! 
-
~-- -~ 5 J 1 1 I 
1---_0 11I5~ __ 1 5 ) 1 ~-i 
121050 J 5 j 1 1 I 
191150 j 5 J 1 I I 
I--' 
()) 
Ul 
!AJIIE llU! Addlctlon R .. ""rel, c..nt", Invontory 1.'"".'.0 [Subject 8 (CY)) ~ 
PI .. ,. I (1M A) 
Wee.. 04Y J Ime ({jIl~lIted Response Rat ings i 
____ HUG A 8G PCAG ~ 
Ph, 2 (III 8) 
1I •• k O.y 
Ou. I 011150 3 II 2 14 9 1 
12h50 I II 1 Il 9! 
~
One I 
19h50 4 5 4 I ~, 
2 0lh50 I 2 4 8 4 
191150 5 2 6 I ~I 
3 0lh50 I 10 I 13 9 I 
2 
1 
191150 1 2 7 5 1 j 
4 0lh50 I _~ I I) 9 11 
12h50 I " I II f----'!----
I 191.50 I----
---;:-0-- I 01h50 6 2 6 4 I 'I 
4 
7 
Iwo I 
12h50 12 r-----'l- ___ 7__ I 2 J 
19h50 4 ) 5 b J 
---- 1 ~ 
2 07h50 4 4 4 4 4 i 
f--- 191150 2 12 I Il 8 I 2 
} 0lh50 4 10 1 5 5 ) 
1%50 I 12 I 12 8 I 
4 0lh50 + __ 1_ 12 I 13 ~1 4 
____ 12h50 I I-- 9 2 II _~ 
7 19h50 2 __ li__ r---!- 9 4 I 
1111'"" 4 0/1150 0 12 2 12 ~ n,rea 4 
12h50 0 _.-!_2_~_1--1_3_1--~ 
I 191150 0 12 2 11 ~ 7 
t oor 4 071.50 1 9 1 j 5 fOUl· 4 
I-- 121150 1 , __ 8 5 5 7 
__ I 191150 t II I 11 9 __ 
-----
-----1_ 
five 4 07h50 0 12 2 12 8 1---- F Iv. 4 
121150 0 10 2 13 9 
____ , ___ <----.!~h50 0 10 2 12 I i ~--~-
AddictIon R .... rch c..lltre Inventory R •• ""n ••• (Subject 8 (CY)) 
'hili! (ot.l~uted Rc~pon$e Rat ings 
MOG A 8G PCAG [SO 
0lh50 4 4 I 6 2 
12h50 4 8 5 4 4 
19h50 5 2 1 I 2 
07h50 I 12 J 8 6 
191150 
07h50 4 10 4 Ii 5 
191150 1-----
0lh50 2 II 1 10 I 
121150 0 II ) 12 9 
-
1%50 
,----
071150 5 3 8 9 } 
121.50 ___ L_ I 6 r---j-- __2_ 
191&50 5 Ii 5 J 1 
011150 
191,50 
-----
0/1150 
--- -
1911~~ 
~-
121150 
19h50 
--
0lh50 
121150 
----, 
19h50 
,--
---- ----
0/h50 
---- -----
121.50 
-----
191150 
----- -----
O/hSO 
---- ----
12h~O 
19h50 
-------
t--" 
CO 
0\ 
Subject TMAtSEM TM8.SEM 
1 3.00 t 0.00 3.06 • 0.06 
2 4.76 • 0.86 7.12 • 0.98 
3 3.28 • 0.11 2.83 • 0.26 
4 0.C6 • 0.06 0.47 • 0.21 
5 2.81 • 1.27 1.69 • 0.73 
6 3.89 • 0.14 3.44 = 0.28 
187 
MICI Week TMA%SEM I F :tatio I P I TMB%SEM F Ratio P Sea Te I 
PCAG ! 3.23 % 0.40 
I I 
3.06 t 0.34 0.10 0.7547 
2 2.69 % 0.28 2.94 t 0.29 
3 3.90 • 0.59 0.92 0.4539 3.67 • 0.73 1.31 0.2683 
4 3.54 % 0.87 4.14 • 1.02 
5 3.00 • 0.86 2.13 t 0.45 
BG 1 6.36 % 0.49 6.41 t 0.31 0.01 0.9295 
I 
2 6.56 % 0.41 6.09 % 0.31 
3 5.29 t 0.65 0.50 0.6636 5.76 • 0.68 1.19 0.3154 
4 6.29 % 0.96 5.43 : 0.94 
5 6.79 • 0.86 7.38 • 0.95 
LSD 1 3.43 • 0.23 3.32 • 0.22 0.12 0.7360 
2 3.21 • 0.17 3.54 % 0.18 
3 3.43 % 0.35 0.29 0.8667 4.14 % 0.41 1.34 0.2559 
4 3.36 % 0.34 4.07 • 0.47 
5 3.71 • 0.97 3.56 t 0.35 
MBG 1 6.25 • 0.72 5.81 • 0.66 O.ZO O.560Z 
2 6.25 • 0.57 4.97 t 0.58 
3 4.14 • 0.98 0.30 0.5241 4.24 t 1.08 0.57 0.6850 
4 5.57 • 1.54 4.64 • 1.32 
5 7.00 t 1.51 5.94 t 1.47 
A 1 3.56 • 0.52 I 
3.63 • 0.37 0.00 0.9742 
2 3.71 t 0.48 3.47 • 0.41 
3 2.14 t 0.64 '.n 0.3998 2.86 .O.H 0.73 0.5762 
4 3.15 • 1.14 I 2.64 • 0.92 5 4.54 • 1.13 4.38 • 1.06 
The rrean responses to each ARCr sea le for i'leek 1 for both treatments are given in the body of the table. 
For week. 1. n .. 61 for each phase, df ,. 1.120. Bold italicised F ratios and P values indicate significance 
for week.s 1. 
For the COfl1)aflson of the treatrrent weekS (2~5) with week 1. n,. 177 for each phase. df '" 4,172. 
TABLE AB.2.1 Average Weekly Respoos<>s to the S Scales of the ARCl Questionnaire (Ilean Values for 7 
Subjects) 
F P Subject TMA.SEM TMB.SEM F P 
1.00 0.3248 1 1.35 • 0.15 2.55 % 0.19 28.90' 0.0000 
3.17 0.0844 2 4.47 • 0.45 5.00 • 0.49 0.65 0.4364 
2.51 0.1226 3 4.00 t 0.00 4.00 • 0.00 100.0' 0.0000 
3.50 0.0705 4 2.12 • 0.08 2.~1 : 0.23 1.48 0.2324 
0.59 0.-1553 5 4.81 • 0.72 I 5.00 : 0.16 2.60 0.1177 
2.00 0.1664 5 3.22 • 0.25 3.00 t 0.23 0.43 0.5232 
n • 16 for each Test Me<! cation Phase for Subject 5, df ,.. 1.30 
n s 17 for each Test Med cation Phase for Subjects 1. 2. and 4, df • 1.32 
n ,. 18 for each Test Med cation Phase for Subjects;; and 6, df • 1,34 
n" 16 for each Test Medication Phase for Subject 5, df " 1.30 
n " 17 for each Test Medication Phase for Subjects 1. 2, and 4, df • 1.32 
n " 18 for each Test Medication Phase for Subjects 3 and 6, df • 1.34 
1 indicates a P value of less than 0.01 
TABLE AB.2.2 Average ·PCAG- Response for each Test Medication Phase per Volunteer TABLE AB.2.4 Average "LSD" Response for each Test /1edication Phase per Volunteer 
Subject TMA.SEM TMB.SEM F P Subject TMA.SEM TMB.SEM F P 
1 4.35 • 0.!5 4.00 • 0.00 5.76' 0.0224 1 5.41 • 0.31 1.29 • 0.19 129.4' 0.0000 
2 4.82 • 0.71 3.47 • 0.37 2.85 0.10ll 2 4.06 • 0.95 2.24 • 0.70 2.38 0.1327 
3 4.72 t 0.11 4.89 • 0.16 0.75 0.4029 l 0.72 • 0.11 0.72 • 0.11 0.00 1.0000 
4 10.35 t 0.21 9.86 • 0.44 0.95 0.3483 4 13.06 • 0.35 11.24 t 0.81 4.31' 0.0461 
5 10.06 • 1.22 8.56 • 0.93 0.96 0.3456 5 11.94 • 1.50 8.75 • 1.01 2.93 0.0972 
6 5.00 • 0.38 6.67 t 0.59 5.67' 0.0230 6 3.28 • 0.98 6.06 • 1.30 2.92 0.0966 
n .. 16 for each Test Medication Phase for Subject 5, df • 1.30 n " 16 for each Test Medication Phase for Subject 5. df • 1.30 
n • 17 for each Test Med icat ion Phase for Subjects 1. 2. and 4, df • 1.32 
n • 18 for each Test Medication Phase for Subjects 3 and 6. df • 1.34 
n • 17 for each Test Medication Phase for Subjects 1. 2. and 4. df • 1.32 
n ~ 18 for each Test Medication Phase for Subjects 3 and 6. df • 1.34 
§ indicates a P value of between 0.015 and 0.05 § ,"dicates a P value of between 0.015 and 0.05 
, indicates a P value of less than 0.01 
TABLE AB.2.3 Average -BG' Response for each Test Medication Phase per Volunteer 
TABLE AB.2.S Average "MIlS" Response for each Test /1edication Phase per Volunteer 
Subject TMA.SEM TM 8 • SEM F P 
1 2.12 • 0.15 1.06.0.13 28.48' 0.0000 
2 2.76 • 0.80 0.82 .0.30 5.14' 0.0303 
3 0.00 • 0.00 0.50. 0.12 17.00' 0.0002 
4 7.71 • 0.19 7.24 • 0.39 1.19 0.2833 
5 8.69 • 1.09 7.86 • 0.69 0.40 0.5391 
6 2.06 • 0.74 4.22 t 0.77 4.03 0.0533 
n " 16 for each Test Medication Phase for Subject 5, df • 1.30 
n· 17 for each Test Medication Phase for Subjects 1. 2, and 4, df • 1.32 
n • 18 for each Test Medication Phase for Subjects 3 and 6. df • 1.34 
§ indicates a P va lue of between 0.015 and 0.05 
1 indicates a P value of less than 0.01 
TABLE AB.2. 6 Average -A" Response for each Test Medication Phase per Volunteer 
TABLE M.l Protll. 01 Hood St.t •• a •• pon ••• (Subject 1 (55)) 
PI, 1 (1M A) ... -.- ..... .. ,
Heell. Uoy lure 
1- A«X 
One 1 01t.50 0.11 
121.50 0.00 
l~h~O 
-" 
2 011.;0 0.00 
191.:'0 0.11 
J 011150 0.00 
19h50 0.11 
4 011150 0.11 
f--. 121150 0.00 
I 19h50 
---
1..0 1 011150 0.00 
12h50 0.00 
191.:'0 0.11 
2 f-01l•5O 0.00 
l~h50 0.11 
3 ~ ~ 
191150 0.00 
. 
4 011150 0.11 
1- 121150 0.00 --
1 19h~O 0.11 
--_. 
Ihree 4 011150 0.11 
121150 0.11 
I 191150 ~ ---
fuur • 0/11110 _ 0.11 
--- -~-~. 
1 191150 o 11 
---
f ivt= 4 011.50 o II 
12h50 0.11 
1 l~fI~tJ 0.11 
~---
UL!!!.!!! AUIlHf V I A lli!!?..!!ill!; 
ANX. Aux icty 
Off; Ocpress lOU 
ANt: Angor 
VIG: Vh)Uur 
fAr: roily"" 
fOH: (on(u~iun 
fRI: ffH:flJI 'IlC~S 
[LA: f 13"011 
AAO: Arous41 
YOS: Po, It Ive I1uw 
(ulI\l'ut~d AesiJofls&: Rat 'fl'J5. 
O£P ANG VIG fAr CON fRI 
0.00 0.83 2.&1 0.00 0.29 1./5 
0.00 D.}) 3./5 0.00 0.14 3.88 
0.00 O.ll 3.00 0.00 0.00 4.00 
0.00 o.n 3.88 0.00 0.00 3.88 
0.00 0.31 4.00 0.00 0.00 4.00 
0.00 0.25 3.00 0.00 0.14 3.13 
0.00 0.25 1.25 0.00 0.14 1.50 
0.00 0.11 3.50 0.00 0.00 t--U~ 
0.00 0.11 1.15 0.00 0.14 1.15 
0.00 0.33 3.25 0.00 0.14 1.61 
0.00 O. Jl 1.61 0.00 0.14 1.50 
0.00 0.25 l.1l 0.00 0.14 1.50 
~ 0.11 1.11 0.29 0.14 3.11 
0.00 0.33 3.25 0.00 0.14 1.36 
0.00 0.25 1.25 0.00 0.14 3.38 
0.00 0.25 3.1l 0.43 0.14 3.13 
0.00 O. Jl 3.88 0.00 0.00 4.00 
0.00 -~. 3.00 1.14 0.14 l.ll 
0.00 O.lJ 1.1l 0.00 0.14 ~ 
0.00 0.25 1.11 0.00 0.14 1.13 
0.00 I-~ 3.00 0.00 ~~ 1.00 
~ ~~ J.OO 0.00 0.14 3.13 
0.00 G.n 3.11 0.00 
.!!.elL 2. " 
0.00 0.25 3.00 0.00 0.14 1.00 
0.00 0.25 3.00 0.00 0.14 1.1l 
0.00 0.25 1.00 0.00 0.14 ·l.00 
0.00 0.25 1.00 0.00 0.14 J.n 
, 
HA AIlO POS 
------, 
2.61 2./0 2.6/ 
3.11 3.61 4 
3.B 3.00 3.j) 
1.83 1.99 ].61 
4.00 4.00 4.00 
1.00 2.9/ 3.00 
I 
3.50 1.22 1.50 1 
1.50 3.50 1.50 
I 
1.50 1.61 1.50 I 
1.50 3.11 3.50 i 
1.00 1.59 1.00 
3.00 2.98 3.00 I 
1.00 2.81 3.00 I 
2.6/ 1.11 2.61 
3.50 1.11 3.50 I 
l.n 2.61 l.n 
3.61 3.88 3.61 I 
3.001 1.00 1.83 
1.00 1.09 1.00 
1.00 1.0~_ 1.00 I 
-I 1.00 2.9/ 3.00 . 
! 
1.11 2.91 J.t} i 
--1 
2:.~ ~L 2~1 
2.50 2.91 2.50 
'1 
1.00 2.91 ~j 
1.00 2.91 1.00 
2.61 2.91 2.61 
Ph.S. 2 (I" 0) 
licek Ooy rilllE;: 
ANX 
0 ... I 0/1150 0.11 
121150 0.11 
191150 
2 011150 0.11 
1911:'0 0.11 
J 0lh50 0.11 
191150 0.11 
4 011150 0.11 
121150 0.11 
I 191150 0.11 
Iwu I 0/1150 0.11 
121150 0.11 
191150 0.11 
2 011150 0.11 
19,,:'0 0.11 
1 011150 0.11 
191150 0.11 
4 011150 0.11 
121150 0.11 
1 191150 0.11 
Uaf&!t! 4 011150 0.11 
121,50 0.11 
1 191150 0.11 
four 4 ~ c-JW-
121>50 0.11 
1 ~----
f 'v.: 4 011150 0.11 
12h50 0.11 
1 191150 
ll!...!Q)II£ A81l11fV1AII0l/S U$[O: 
AHX AnxhHy 
O£P OIJPI'~SS ,on 
AUG AI'9b< 
VIC Vigour 
fAr fatigue 
(OU Confus 'on 
fRI fr hwdl illcSS 
EtA iI.tion 
AIlO Arousal 
.. as flo~ it ivt! 11000 
OfP 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.11 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
(on.Jutt:d He~J.lonse Rdt tlUJS 
AtIG VIG fAr (OU fRI 
O.ll 1.25 0.00 0.14 2.88 
0.25 2.6J 0.00 0.14 l.OO 
0.25 1.00 0.00 ~- 3.00 
0.25 1.00 0.00 0.14 2.6l 
0.25 ~ 0.00 0.14 3.00 
O.ll 1.00 0.00 0.14 2.63 
~ ~- .J!~ r1'.!.L .1~ 
0.25 3.00 0.00 0.14 ·J.n 
0.25 3.00 0.00 0.14 2.61 
0.25 3.00 0.00 0.14 1.00 
0.25 l.OO 0.00 0.14 l.ll 
0.25 1.00 0.00 0.14 l.OO 
0.25 2.61 0.00 0.14 3.00 
0.25 2.25 0.00 0.14 2.63 
0.25 2.25 0.00 O.H 3.00 
0.25 2.25 0.00 0.51 2.25 
0.50 2.25 0.00 0.29 3.00 
0.00 0.88 0.14 0.4> 2.6] 
0.25 1.00 0.00 
_!L!.L ~ 
0.25 2.63 0.00 O.q) 2.61 
0.25 2.ti3 --~ ~ 3.:1L 
0.00 1.88 0.00 0.51 2.6] 
0.25 1.00 0.00 I'...!!.:..'!.L 1.00 
~ I--~ 0.00 0.41 2.63 
r--- --_. r---
0.25 2.11 o.o~_ 0.41 3.00 
0.25 2.63 0.00 0.29 2.25 
--
flA AIlO POS 
2.61 U2 2.6/ 
2.:'0 2.59 2.50 
l.OO 2.YI 1.00 
1.00 2.91 l.OO 
2.50 2.59 2.50 
l.OO 2.91 1.00 
2.50 2.91 2.50 
1.11 2.91 ~ 
2.50 2.91 2.50 -0 a 
2.00 2.91 2.00 3'! tI) 
2.11 2.91 2.11 
-
» 
;;0 
-0 
2.00 2.91 2.00 
~. 2.'9 ~ 
2.00 2.22 2.00 
M 
" 
tI) ,.., 
........ 
-0 :z:: co 0 0 en z H 
2.00 
. 
2.n 2.00 
U) >< 
", 
2.00 1.19 2.00 \0 0 
2.00 2.08 ..lc~ » 
--I 
1.50 0.42 1.50 » 
~ r--UL ....!.:!L 
1.50 2. >1 1.50 
...!..:£... . 2.11 1.61 
-
,..!:~ I--! .~2 ~ 
2.00 2.66 
...l.c'!Q.... 
~ ~ 2.00 
--
2.00 1.81 2.00 
. 
2.00 2 .~5 2.00 
TABLE A9.2 frolH. 01 IIoocJ State. Ke.pon.es (Subject 1 (CA)) 
~".,. I (1M Al 
-
Ui:t.:k O.y liJl~ 
ANX Off 
---- ~--
Ollt.! I 011,;0 0.18 0.93 
1211,0 2.00 2 ~60 
191,,0 
2 0,"50 O~ 11 O·1.L 
191150 0~61 O~OO 
J 011,10 0.18 0.01 
191150 0.00 0.00 
4 OIt,IO o~ 22 o~oo 
12h50 0.56 O~ II 
I 19h!lO 0.44 O~OI 
--
rwu I O}II~O 0~a9 0.01 
121050 O. Jl 0.00 
----
~ O.H 0.00 
2 -~ ~ ~ 
1%;0 0.,6 0.21 
-. 
] OJh50 0.44 0.20 
191150 O.ll 0.00 
--
4 011150 0.11 0.21 
12h~U 0.44 0.00 
f---- 7 191150 0.44 0.2/ 
Jhn:c 4 07h50 0.78 2.B 
121150 0.33 0.40 
7 1%50 0.89 1.81 
---
fOl.lr 4 ~7h50 ~ --12!. 
121050 0.18 1.80 
7 19h~O 0.56 f-l.E.. ~~~- ~ 
fivt 4 ~~~- 0.61 I.lJ 
121,50 
_____ 1_.1-191050 --'---
B.U!!..ll1t AUlIl<tVIAIIO~S USEIl: 
AtU,; AUAlcly 
O(~: llt!~,.c!:.s.lon 
AUli Angtr 
VIG Vigour 
fAJ fdol hJut! 
COli (oo(us ion 
f~r f(l.:ndlilll!!Io~ 
U A t Llt Ion 
AHU Arou:l.:ll 
f'OS Pus.i t i VI! Muud 
~-
1.08 
3 ~03 
0.00 
0.08 
0.92 
0.00 
0.00 
o~n 
0~61 
0.25 
0.00 
0.00 
-~ 
0.17 
0.00 
0.08 
1.00 
0.00 
0.00 
2.08 
0.50 
1.08 
1.00 
~. 
.~ 
1.12 
COlftJuteQ fh:sponse Rat ings 
-~ fAr CON fRI ftA AHO fUS 
2.1l 1.11 1.00 2.25 I II ~ ~ 
1.36 1.41 2 ~oo 1.21 1.33 ~O ~ I -I.] 
--
1.15 0.29 o~ 51 2.38 ]~OO 1.00 2 ~81 
0.50 2.00 1.00 1.11 I. 50 -1.8 1. 50 
O~IO 2~41 1.00 o ~aa O~ 50 -2.2 o~ 4J 
1.00 1.11 0.41 1.63 1.11 -1.1 1.11 
1.38 o ~ 51 0~29 2 ~ 25 2.00 0.14 2.00 
0.63 0~86 0.11 0.15 O. J3 -0.4 0.20 
0.25 1.5} 1.00 o~ ]8 o~ ]] -1.9 0~21 
o~ 75 1.00 1.29 o.aa 0.50 ~O.6 0~4l 
~ i~O -~ 1. ]6 1.17 0.111 1.11 
2.25 O~OO 0.14 f~ 2.00 ~~ ~ 
0.63 0.14 0.86 0.75 ,..!!,£. ~!.!!... 0.07 
0.25 0.00 1.14 0.50 0.8] -0. j 0.51 
1.38 0.00 0.41 1.11 I~ .J..l.L }-'L!!!!.. 
I 38 0.00 0.29 1.25 1-0 . 61 -L£.. ~~ 
O.!lIl 0.00 0.11 0.75 0.61 O.~~ ~. 
1.}U 0.00 ~ 1.(l6 ~ ~ t-fL1!L 
1.00 0.14 0.41 1.38 1.11 0.87 0.90 
0.00 0.86 1.71 0.75 0.11 -1.8 -2.2 
0.75 0.00 0.51 1.1l 0.61 O. II o.n 
0.50 1. 17 ~ 0.08 0.50 -1.0 -1. 4 
0.18 0.51 2.00 ~ ..H.L. r:'L-L ~cL 
~ .!!~ t--!-:~ t--!-:~ 0.01 0.24 ~ 1. I 
-L~_ ~ ...LQ. ...!.1~_ 0.61 ...'L1L ~.:.!... 
0.75 0.51 I. I] ~ O.bl ~ 0.7 t--=l.J.--
'--- __ 1-- __ 
~h .. e 2 (III UI 
Ucek Oay TIDe 
AN~ 
00. I 0lh50 0.78 
~SO 1.56 
191050 1.22 
2 Olh~O 
19h50 3.11 
-
1 Olh50 1.67 
19h50 1.11 
4 071150 I.Jl 
121,50 1.33 
7 191&50 0.22 
rwo I 07h50 1.22 
12h50 1.]] 
1911;,0 I d.!.... 
2 0/1150 0.U9 
-----
19h50 0.22 
--
] 011150 0.12 
1911;,0 O. J] 
4 0/h50 0.44 
1211~0 0.56 
I 191150 1.78 
lhrce 4 011,50 0.22 
121.50 0.61 
7 1%50 0~89 
four 4 011,50 1.18 
1(1150 1.70 
I---- 7 ~ 0.22 
• iue 4 _~It'50 0.44 
121.50 0.~4 
I 191150 
!\!Ll~!llifVIAIIONS U'>W: 
ANJl Anll.lcty 
UfP Ol:!~f'ess ion 
AUG AOljcr 
VIC Vigour 
fAi fatiyu. 
(0" (ontrJs ion 
fRJ fr iClld Iillc~!I. 
EtA [Jdllofl 
AltO Al'ouscll 
J)05 Yo') it ivc HoolJ 
OEP AlIG 
1.81 2.06 
2.67 2.08 
1.9] 1.8] 
].41 1.25 
2.1l 2.42 
1.1l 0.15 
1.20 0.25 
I.Il 1.67 
0.60 O.H 
2.01 2.8] 
1.61 I.~L 
~ 1.11 
0.53 0.08 
0.5] 0.00 
0.80 O.O!!_ 
0.80 0.11 
0.60 0.00 
0.01 0.00 
1.01 1.91 
0.20 0.00 
0.20 0.00 
0.40 0.92 
0.67 0.58 
1.61 1.08 
0.11 r..!!.,00 
0.00 ~ 
0.00 0.00 
COIIVUtCtJ Uc:.punse Rdl intJ~ 
Viii fAJ (ON fHI 
0.50 0.4j 1.14 1.00 
1.00 O.-j] 1.11 1.57 
O.ll O.~I 2!i ~-
0.25 1.11 2.41 0.00 
0.00 0.71 1.51 o.aa 
0.50 ~~J 1.11 1.00 
0.25 0.14 -~- 2.1l 
1.1] 0.4> 
.....!..::.:!.! ...!.:l!!.... 
~ 0.29 1.14 2.00 
0.38 0.86 2.41 0.]5 
~ ~?!.. .!:.LL I-L!.L 
0.25 O.Ql _1:.'!~ 1.25 
.....!..:!L ....!U!.. ~:i!. .~ 
~ 0.00 0.57 1.15 
~ ..!!.~- ...!..:Q!L _1..:.lL 
0.10 0.14 0.11 1.00 
o.aa 0.14 0.66 1.15 
0.25 0.29 0.06 1.50 
-
0.25 2.43 1.14 0.63 
0.15 0.13 0.4] 1.75 
0.18 ~- 0.5] o.aa 
0.00 2.H 
,!.:1! 0.38 
0.11 0.U6 1.11 1.25 
0.00 rfLll- ..!,~ .....'LL. 
t-'L~. 0.00 ,..!!.,?!..- ..!.2L 
0.08 0.29 0.2~ rl.~ 
0.16 0.14 0.51 1.10 
--.-.~~ 
EtA AHO 
1.33 -0.3 
0.50 0.41 
0.50 .....:~ 
0.17 ·0.8 
0.61 -0.6 
0.]] -0.5 
1.00 0.44 
0.8] 0.60 
1.11 -0.1 
0.11 -1.1 
-.'L!Q- .....:'L!L. 
i-!..:~~ .....:!..:.! ~~ 
1.00 
.i.i!. 
1.00 0.40 
-~ _.:'LL 
0.0] 
....'L.2L 
1.00 0.]2 
0.6] -0.3 
0.11 -1.5 
1.50 0.12 
0.83 -~ 
0.00 -1.0 
0.50 -0.1 
~~ ...:.!!.:.!!..-
.Jl.J!!._. ...!!.:.:!!!. 
2.33 ~-
O.U] 0.11 
I 
! 
POS I 
~~! 
-2.2 ! 
~I 
I 
i 
-J.3 i 
-1.5 
-0.8 I 
-0.2 , 
-0.9 
0.57 
-1.1 
r--:-'L!!... 
. 
~ 
0.41 
.....:ll_ 
r-fL!!L 
~ 
0.60 
-0.9 
~ 
~ 
~ 
.....:.!:.~-
r---=!L 
~ 
2. ]j 
0.U3 
.~ 
Q::l 
lD 
TABLE A9.) Proflla of IIood Stot .. R.,p(lIl".~ (Subject 1 (LEll 
~I I (III Uj ---- - , . . -, 
Wed: 0.> lime 
f---1- AJlX 
Oll~ I 011.50 1.)] 
111.50 0.44 
1911;0 0.1l 
---
2 011150 0.22 
IlJtl)O 0.22 
1 011150 0.11 
19h50 0.22 
4 011150 0.22 
11h50 0.33 
--
I 19li50 
--.-
f"o 1 0lh50 O.ll 
12h50 0.44 
191.,0 O.ll 
-' 
2 011.50 0.22 
191150 0.22 
J 0lh50 o.n 
19h50 0.22 
4 0lh50 0.22 
1211:'0 O.ll 
----
I 191150 0.22 
---
Ihrc~ 4 011.50 0.22 
_!2h'Q_ 0.22 
I 19t.50 O. )) 
---
tour 4 ~~~~ 0.22 
'---. 
12h!.O ~£L 
I I~"!:IO 0.22 
-------
tivc: 4 Olh!>O 0.22 
121050 0.44 
} 19h~O 
-.- ... -.- .-,,-~"- 0.22 
~~!ill!.~IAflOII5 uSfO; 
AJU Anll. Ie (Y 
Off Ocpress lun 
AUt Anger 
VIC Vigour 
fAI f.1 ig". 
(011 (ooills hm 
flU fricnollllc~5 
HA tlo(IO'1 
AUO Arousa I 
IlOS .. O~ i t i vI! Muud 
COIl4Juted Respodse Adt'rlgs 
OE? ANG VIG fAr CON FRI 
0.21 0.42 U18 0.14 0.41 2.63 
0.01 0.08 2.11 0.41 0.41 I.B8 
0.00 0.00 2.63 0.00 0.29 1.25 
~ _~.OO 1.63 0.14 0.29 1.63 
0.00 0.00 2.00 0.00 0.19 1.15 
~ ~ 2.00 0.00 0.29 1.38 
0.00 0.00 2.ll 0.00 0.29 1.63 
0.00 0.00 1.63 0.14 0.29 1.25 
0.00 0.00 2.00 0.00 0.19 ~ 
0.00 0.11 0.15 0.71 ~ 0.50 
0.01 0.00 0.88 0.14 o.n 0.88 
- -
0.00 0.00 1.00 0.14 0.41 1.00 
0.00 0.00 2.25 0.00 0.14 1.15 
0.00 ~ _!.6J 0.00 0.14 1.5 
0.00 0.00 1.88 0.00 0.29 1.15 
0.00 0.00 1.63 0.00 0.43 1.50 
0.00 0.00 1.63 0.00 0.29 1.25 
0.00 0.08 1.15 0.00 0.29 1.25 
0.00 .~ 1.38 0.00 0.29 f.25 
O.ll 0.00 ~ 0.00 0.29 ~ 
~~O ~~ 1.50 0.00 0.41 1.2, 
0.00 0.00 2~. ~- 0.14 1.88 
0.00 0.00 
-.U'L 0.00_ ~ 1. JO 
~- 0.00 .~ ~ ~ .....!..1.L 
0.00 0.00 I. 50 ~~ ~ r-!~ 
~. 0.00 .~ ~ 0.29 1.15 
0.00 0.00 1.25 0.00 0.29 1.00 
0.00 0.00 
_.!c 6) 0.00 0.51 1.25 
EtA ARO POS 
l.33 3.64 2.01 
1.61 1.11 1.60 
2.ll 2.45 2. JJ 
f-!-61 1.42 1.61 
1.00 1.94 1.00 
1.61 1.83 I~~ 
2.00 2.06 2.00 
1. II 1. 42 1.11 
~ ~ -1~ 
a 50 I ~ ~ ~
O.H 0.15 0.21 
0.50 0.16 0.50 
1.6/ 2. ]] 1.61 
1.1/ 1.10 1.11 
I. 50 ~ 1.50 I 
1.61 1.42 -;:-;;;-1 
1.50 1.;6 1.50 i 
1.50 1.80 1.5 ! 
I.J] 1.11 I ~
-LE... ~ 1.03 ! 
1.61 1.29 J..bl I 
I.bl 2.19 1.61 I 
---j 
I. 50 I.2L ..!2Q...: 
...uL _.UL I ~j 
.J. .O~_ ~--~-: , 
I.)) r-!-:~9 rJ.2!..: 
1.3J 1.41 I. JJ 
...!..:.!..:... _!~_L!!...c 
~lId," 2 (I" A) 
Wet!k D.y I .... 
AUK 
One I 01h50 0.22 
121150 0.22 
191150 
2 011150 0.11 
191.50 0.22 
3 0lh50 0.22 
191150 
4 011.50 0.22 
121.50 0.22 
7 19h50 0.22 
1,,0 1 0lh50 0.22 
12h50 O.bl 
191150 0.22 
2 0lli50 0.44 
I--~ ~ 
] 011150 0.22 
19/150 
4 011150 0.22 
12h50 0.22 
I 19/150 0.12 
Jhrett 4 011150 0.22 
r- 121,50 0.22 
1----~ 191150 O.JJ 
four 4 O/h~O . J2E.. 
I--~~ 0.22 
--- r-l-- &tll,50 
f Iv. 4 011.50 0.22 
12h50 O.H 
I 
'----
1911,0 0.50 
K£V 10 lilt AHOHfVIAllO"~.J!~!!: 
AHX AillI.ll:ly 
OfP Oupress ion 
AUG Any", 
VIC V.qou, 
fAr fdtigu" 
CON (oniu~ ion 
fRI r .. i&:fI<J i illcss 
UA flJtlOIi 
AAO Arousd I 
PUS Pos i l i lit! Hood 
(olllpu(e(j Hcsponsl! Hal iogs 
OfP AUC VIG fAT COU fHI 
O.OU 0.00 I.IllI 0.00 0.14 1.50 
0.00 0.00 1.50 0.00 0.29 1.50 
0.00 0.00 LiS 0.00 ~. ~ 
O.O~_ 0.00 2.00 0.00 0.29 1.50 
0.00 0.00 -.!.:.~  ~ .....!.:J!!.... 
----
0.00 ".~ ~ --,!.OO _ 0.29 1.6) 
0.00 0.00 ~ 0.00 0.29 1.11 
0.00 0.00 ~ 0.14 0.51 1.38 
0.00 0.00 1.25 0.00 0.29 0.75 
-
0.00 0.00 1.1l 
_'!.:lL ~1L ~ 
0.00 0.00 I.l8 ~~O 0.5/ 1.50 
~ 0.00 ~ -~ I~ 1.25 
0.00 0.00 1.2~ 0.00 0.29 ~. 
0.00 0.00 0.63 o .~!!- 0.29 1.25 
1- ---- --- --
0.00 0.00 0.88 0.00 0.29 1.1l 
0.00 0.00 1.50 0.00 0.14 1.38 
0.00 0.00 1.00 ~.OO_ ~:29 1.00 
0.00 0.00 1.6) 0.00 0.5/ 1.38 
-
0.00 0.00 1.00 0.00 0.29 1.25 
1-.0.00. 0.00 0.15 0.1l0 0.14 1.13 
~ ~ ~l. .JL~ ....!1L I-L.!.L 
0.00 0.00 ~£. I-.'!~~--~ ...llL 
--------
~. 0.00 ~-~.OO_ 0.29 ~ 
0.00 0.00 0.15 0.00 o.n 1.ll 
0.00 .~ ~-~~~ 0.61 0.1llI 
fLA ARO 
1.00 1.95 
1.6J 1.44 
....L~ .....!.:.?L. 
1.50 1.94 
-LE... ~ 
I----
1.11 1.44 
!~ ...uL 
1.67 1.26 
.~E.... 1.19 
.J!:1L ...llL 
1.00 1.0) 
0.61 1.51 
1.00 1.68 
1.00 0.56 
f-- --
0.83 0.81 
I.)j f-,!~ 
0.83 0.94 
0.6!_ .~ 
~~ 0.94 
O. )) 0.9.:!_ 
0.61_ ~ 
~ ~ 
0.8J 1.19 
1.1 I 0./1 
0.50 O.d] 
1'05 
1.00 
I. til 
-
~ 
~ 
1.11 
1.11 , , 
~ 
c--!-:~J 
~ 
O.H 1 
~I 
0.61 
1.00 I 
~ 
I--
~ 
 
0.8] 
~-
0.50 
0.3l 
0.61 
0.50 
0.8l 
1.11 
O.~O 
....... 
lD 
o 
TABLE A9.4 Protlle 0' Hood Stol .. H.,pon ••• (Subject 4 (fA)] 
PI,.," I ,1M 0) r==-
We~" Oay I ink! 
f- NIX O[P 
One 1 0lh50 
12h50 
191050 
l 0lh50 
f-- 19h~0 0.11 0.01 
3 011,50 0.56 0.21 
191,50 0.11 0.00 
4 OJh~O 0.22 0.00 
--
-..!~ ~ ~ 
I 19h50 
----
lwo 1 0/1,50 0.22 0.01 
121050 0.56 0.00 
f---- 191,50 0.22 0.00 
2 0lh50 0.11 0.00 
l~h50 0.22 0.00 
1 0lh50 0.22 0.00 
-
1911~O 0.11 0.00 
---
4 I-~Ih~~ -~ ~ 
121l~O 0.44 0.21 
--
I 19 .. 50 0.11 0.00 
---
Hire/! 4 0/1050 0.11 0.00 
Uh50 0.11 0.00 
---
1 ~ r--~.11 0.00 
-.--
fuur 4 0/h50 0.11 0.00 
121050 0.22 0.00 
I 191050 0.11 0.00 
---
five: 4 0lh50 o.n 0.00 
Jlh!lO 0.11 0.00 
I l~ht!O 0.11 0.00 
--- -.-~.---- -- .--
ill.JJUj!!.~':'!m~ill: 
AUX A/l)lICI), 
lJff Deprcs.s IOU 
ANt Anger 
VIG VIQuuf 
fAI f..It !!Jut! 
tOn (onl u~ iou 
fAI fr iew11 I lit.:::. s 
llA [1.1(101. 
NW ArouSJ I 
1'05 Pus i' ivc Mllt)d 
(on~uled Response Rdot iogs 
AUG VIG fAr COu fHI 
0.08 1.50 0.86 0.86 1.15 
~ 1.15 1.14 0.5] 1.88 
~ 0.88 0.11 0.71 2.00 
0.00 2.n 0.00 0.29 1.88 
0.08 1.18 0.00 0.29 2.00 
._-I--- ---I---
0.00 1.00 0.00 0.29 2.11 
0.08 0.6J 0.00 0.86 1.50 
0.00 1.11 0.00 0.29 1.88 
0.00 1.25 0.00 0.29 2.00 
0.00 1.88 0.00 0.29 1.88 
0.00 1.15 ~ ~ 1.811 
0.00 1.25 0.00 0.29 1.!l8 
0.00 1.00 0.14 O. )J 1.88 
0.81 0.88 0.14 0.86 0.15 
~- 1.15 0.14 0.41 2.61 
0.00 1.25 0.00 0.29 2.15 
0.00 1.7> 0.00 0.51 2.18 
0.00 2.38 0.00 0.29 2. J8 
0.00 2.11 0.00 0.29 ~. 
0.00 I~ 0.00 0.29 1.86 
0.00 f--L!-L O.I!_ ~ 2.00 
0.00 1.25 0.00 0.29 1.15 
0.00 2.00 0.00 0.29 2.25 
0.00 1.6) 0.00 ".29 2.~~ 
--
HA AlIO POS 
1----1 
.1----1 
I.lI -0.1 1.l0 
1. 50 0.59 1.21 
1.11 -0.4 1.11 
1.50 2.06 1.50 
1.11 1.65 1.11 
1.11 0.94 1.10 
0.81 0.12 O.Bl 
1.11 1.06 1.11 
I.ll 1.06 l.ll ' 
1.63 1.81 1.81 
I.H 1.69 I.Jl 
.-!.~ ~ I.)] : 
1.11 0.51 ~ 
O"~ 0.12 ~, 
1.81 1.29 -L~ 
~ 1.08 ~i 
1.61 1. 51 l.til ' 
~ 2.20 1.83 i 
1-.2.6/ _ 1.95 2.61 I 
1. iii 1. 56 1.61 i 
1.11 1.4J i-J..J!.. 
1.1) 1.19 I. )) 
I. jJ 1.8) I. )J 
I. JJ 1.'" 1.)1 
Ph ... 2 (lH A) 
Wee. Oay II .. " 
NIX 
One 1 011,50 0.11 
121,50 0.22 
19h,0 0.11 
2 0/1,50 0.11 
19h50 
1 011150 0.1) 
191150 0.11 
4 071050 0.22 
121150 0.22 
I 191150 0.11 
Iwo 1 Olh,O 0.22 
~ 0.22 
191150 0.11 
2 0lh50 0.22 
1910,0 0.22 
1 O/h~O 0.22 
19/050 0.22 
4 ~~ ~ 
121150 0.11 
--
I 191150 0.22 
. 
rhret! 4 ~!"50 
....!2L 
121o~0 0.22 
I 191150 0.22 
four 4 ~ _ !UL 
r--- 12h50 
} 19h50 0.11 
fl •• 4 011,50 0.22 
121150 0.22 
'----
I 191150 0.11 
KO 10 lilt AUUlI£VIAIIOIIS USlD; 
AltX Aux h: t y 
Uf P O~J.lrt: ~ S 100 
Atd~ A'}(Jer 
VIG Vigour 
fAJ fot igut: 
cou (o"t us ion 
fR. fc' H:fldllnc~~ 
II A Elot ,on 
AAO At'OU'Sd I 
!lOS Po ~ it i ve Hooa 
OfP 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
~ 
0.00 
~ 
0.00 
0.00 
0.00 
0.00 
0.01 
~ 
0.00 
0.00 
0.00 
0.00 
-
(ofl(lu(cd Ht!~P(}11S.C RJ( lOljs 
MIG VIG fAI CON fRI <LA AAO 
0.00 2.11 0.00 0.14 ,.11 1.61 2.09 
0.15 1.6) 0.00 0.29 1.11 1.11 1.56 
0.00 2.00 0.00 0.14 ~- ~ 1.91 
0.00 1.88 0.00 O. '9 ~ ~ ..ll!!... 
--
0.00 1.00 1.00 0.29 1.63 O.til 0.05 
0.00 1.25 0.14 0.29 1.88 1.00 0.93 
0.00 1.6) 0.00 0.29 2.25 I. J1 1.56 
0.00 U8 0.00 0.29 2.18 1.11 
. ....!.:!L 
0.00 1.16 0.00 0.29 I-~ ~ f--~ 
0.00 1.l8 0.00 ~~ 2.25 ~ ....!.:2L 
0.00 1.18 0.00 0.29 r1~ ~. ....!.:2L 
0.00 1.88 0.00 0.14 2.38 1.61 1.81 
0.00 1.50 0.00 0.29 2.25 1.]) 1.44 
0.00 2.00 0.00 0.29 2.16 2.11 1.94 
-' 
0.00 1.16 0.00 ....!:~ ...L.~L .l2L r---!-:1L 
~-~ 0.00 0.29 ~. ~ r-!-,61 _ 
0.00 i....!.£.. 0.00 ...!!~ 2.25 1.50 1.45 
0.00 1.88 0.00 ~~ 2.25 .J..J!.. ~ 
0.00 ~ ~ 0.29 2.25 !2i.. -D!... 
~- -~. J!;~ 0.29 ~. 1.11 1.56 
0.00 ~ 0.00 -..!!~ ,.25 ~ 1.56 
0.00 1.50 0.00 0.29 2.11 I.Jj -.-!.:.~-
.....2J!CL ....!..:1l. -~. _!!.,!L . .1:.!L ....!.J.L. i~ 
r-
0.00 1.15 0.00 0.29 2.25 1.6/ .-!.:.~ 
0.00 1.15 0.00 0.29 2.38 1.]] 1.69 
0.00 1.61 0.00 0.29 2.25 1.61 1.56 
0.00 ~ _~.OO 0.29 2.18 I.]) 1.4S 
PIlS 
I.bl 
1.11 
~ 
~ 
-
0.81 
1.00 
1.11 
....uL 
1.,0 
1. )J 
~. 
1.61 
_!..:l!... 
2.11 
--.!:lL 
~-
1.50 
1.13 
--
~ 
1.13 
~ 
1.21 
.J.J..! _ 
--
.J.:.~_ 
~. 
1.61 
l.JJ 
I-' 
1.0 
I-' 
TABLE A9.!i ProfllB ot Hood Stotes Re'pons •• [Subject 5 (VWll 
PII",. I ,IH 6) 
Wed. Ooy r'lI~ ((.Impuled Respons.e Rdot IIIQS 
Ont: 011150 
1--'=-t-="-+=~I---'Vc:.I:::.G_~1 I con tnl £LA I AnO ~ 
2.88 I 0.00 O.S/ 2.00 2.11 3.19 I 2.11 
121,50 0.13 I 0.00 I 0.00 1.1l I 0.00 I 0.14 I 3.11 I 2.63 3.11 2.83 
I- I 191050 I I I I I I I I I 011150 0.11 0.00 ~ 2.25 I 0.00 I ~.29 I 2./S 2 ~~-J..-.U!!. 
1
191050 0.11 0.00. 0.00 2.75 0.00 0.14 2.25 2.81 
011,50 0.00 0.00 0.00 2.63 0.00 0.51 3.00 2.83 2.05 2.83 
I--- 191050 0.00 0.13 0.00 1.50 0./1 0.43 2.11 2.11 0.36 2.03 
011150 0.11 0.00 0.00 2.38 0.00 0.14 2.63 2.n 2.]4 2.ll 
2.12J-lJ!!-
121,50 0.000.000.00 2.1l 0.00 0.29 2.252.001.842.00 
. ___ +_~I 191150 0.11 0.20 0.00 1.38 0.29 0.41 1.15 1.83 0.11 '~I 
Iwo , 
ftn-clt! 
0/1150 0.11 0.00 0.00 1.88 0.00 0.29 2.50 2.50 2./0 ~, 
I 0.11 0.00 0.00 2.15 0.00 0.14 1.00 1.83 2.11 2.63 121150 
,. 1%50 0.11 0.00 0.00 2.18 0.00 0.29 2.38 2.50 2.20 2.50 
I 0lh50 0.11 O.OO.~ 2.13 0.00 0.14 1.15 2.ll 2.09 2.31 
I 19h50 0.11 0.00 0.11 1.]8 0.00 0.29 1.88 2.00 1.10 2.00 
0.00 1-~12.i6 2.17 
12h50 _~~ 2.61 2.bl 
IYh50 0.00 0.00 
0.00 
_~~ 0.00 
0.00 11~~.!U.L~L.~1L\--L!!Lt~~ U3 
0.00 .L!.W_O.22.....1~1....L.!l...~ 1.32 -1.Jl... 
0.00 ~I~~ 0.00 1.6'1 2.lll 
__ ~~~~ 0.11 11.20 I 0.17 I.....'!.~~ 1.00 1.50 ·0.4 
tour ~ ~/-!U!-l. 2 .11 .Ll.!..j. 
.~=O-..ji-=0.::.O::;:.O _I_!.l..:!!!!~~ ~I 
-·---J.--..'.-·-l~!!.·+--I--I----f--J--I I -1--+---+---1 
HVij I- 011150 0.22 ~I~I~+~~~ 1.]3 I 0.12 ~I 
J{n50 o.n 
___ ~I 191150 0.11 
~!Q.l![ AIIIIII[Vl.1!IOIIU!ili!: 
Alii. Allx"!!,, 
U[P Ocp('ess IOu 
AUG A"9or 
VIG IJlguuf 
fAl fot iguc 
(0,. (ol1liJ~ioll 
fRJ frlemJI illc:,~ 
U A f ~Q t lOCI 
AAO AI oU~<l1 
POS I'o::.illvc MUIJlI 
0.00 I 0.00 1.11 I 0.14 I 0.£9 I 2.00 I 1.00 I 0.92 I 2.00 
0.00 ~.00J..U5 I 0.00 I 0.14 2.86 I 2.50 I 2.n 2.50 J 
PII ... l ,I" A) 
Wed, Oay lime 
AlIX 
OliO I 0lh50 0.11 
121150 0.11 
191150 
2 07h50 0.11 
191150 0.11 
3 0lh50 0.11 
191050 0.11 
4 011150 0.11 
12h50 0.11 
I 191150 0.11 
Iwo I 0]1150 0.11 
121150 0.11 
191150 0.11 
--
2 071150 0.11 
19h50 0.11 
3 0lh50 0.11 
191150 0.00 
4 0ln50 0.11 
1211,0 0.56 
I 191150 0.11 
'hrce 4 0lh50 0.11 
-_. ~- 0.11 
I 191,50 0.11 
four 4 071150 0.11 
121150 0.11 
f---- I 191050 0.11 
f Hit! 4 011150 0.11 
12h50 0.11 
I 191150 
Kfl 10 rilE AUURfVIAIiOHS USfO: 
AIU AnXh:lY 
OfP UCPfl!SS Ion 
Af~G Anqcr 
VIG VIgour 
fAI fdllguo 
(ON Confusion 
fRI Fr'efltJllIlt!~~ 
EtA tld[IOn 
AnO Arou~il.' 
PUS Pos Illvo Muou 
OlP 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.20 
0.00 
0.00 
0.00 
0.00 
0.20 
(OlI41llletJ RcsJ.lou~C RdtiluJs 
AUG VIG fAT CON fRI [LA AUG POS 
0.00 1.00 0.00 0.14 1.00 2.50 2.9/ 2.50 
0.00 2.75 0.00 0.14 3.00 2.50 2.n 2.50 
0.00 3.00 0.00 0.14 2.63 2.50 2.91 ~! 
0.00 2.63 0.00 0.14 1.00 2.50 1.59 2.50 I 
0.00 3.00 
..J!J!.IL. 0.14 2.61 2.50 2.91 2.50 , 
0.00 2.63 0.00 0.14 1.00 2.50 2.59 2.50 j 
0.00 2.63 0.00 0.14 3.00 I-~ .....u! r-U!!.! 
0.00 1.00 0.00 
-
0.14 3.00 2.50 2.91 
...L:2Q..J 
0.00 1.61 0.00 0.14 1.00 U,O 2.59 2.50 1 
. ~ 0.00 ~ ~- O.H 1.00 2.50 2.59 
0.00 2.50 0.00 ~ ~ 2.33 2.41 2.n I 
--
-;:;;;l 0.00 2.50 0.00 0.29 ~ 2.00 2.ll 
0.00 ~- 0.00 0.14 2.63 2.50 2.41 2.50 ! 
~- 1.50 2.14 0.14 1.1l 1.50 ·0./ I. SO 
0.00 3.00 0.00 
....!!..:.!.4 1.00 2.31 2.97 1.3j ! 
-·1 
0.11 1.15 l.H 0.29 1.88 1.11 ·0.6 1.11 
0.00 
.J..:2!. ....!:.!!!!- 0.29 2.15 181 2.20 ~i 
....!:.!l0 ~~- 1.ll ....!:.~- 1.50 0.67 ·2.2 0.61 -~ 
O.O~_ f~ 1.14 0.41 3.00 1.31 ·0.6 r-Ul~ 
o.n 0.66 
..l.:.i.L .!!..:£.. 3.00 0.61 ·1.9 ...!.l..:!!L ~ 
, 
O.H 0.63 j·1L. 0.41 1.00 1.50 ·1.1 1.50 
0.00 2.38 ~ I-!.l..:~ 1.25 --"-- 2.1/ 2.06 ~-. 1.91 
0.00 3.25 O.Otl 
. ...!!.:.!.L ~ ._L~L ~ ~-
0.00 2.63 O.tlO 0.14 1.00 2.50 ~ 2.50 
0.00 3.00 0.00 ~.!.'!..... ~. 2.61 2.91 2.61 
0.00 3.15 0.00 0.14 3.11 1. SO l.n 2.50 , 
1--'--1 
0.00 3.00 0.00 0.14 3.00 2.50 2.9/ 2.30 j 
1 
'---- _____ l-.. ___ L...-... __ '--._ '------., 
~ 
lD 
N 
TABLE A9.6 Prof II. of Hood Shte. lIo.pon ••• (Subject 6 (1I) 1 
PI,.," I (1M 6) 
...-
Het:k o.y 
0"" 
Till.: (OlillUled R&:sponst! Rd t lugs 
011150 
NIX Ofp AIIG I VIC ~ (011 POS 
0.44 0.011 0.00 1.11 I 0.14 I 0.29 1.50 
I 
12h50 0.22 0.00 ~_ 1.50 0.00 0.29 2.IJ I.B 1.44 1.1.!. 
._ . 191,;0 0.44 0.00 0.08 1.00 0.57 0.51 1.75 1.11 0.30 1.11 I 
011150 0.33 0.00 0.06 t.25 -.!hlL~ ~~ ~~. 
~~. 0.22 0.00 0.08 0.15 0.00 0.43 1.63 0.83 0.54 0.83 
) 011,50 0.33 0.00 0.08 1.25 
1.00 
I 
19h50 0.22 0.00 0.08 
011150 0.22 0.00 I 0.11 t.25 I 0.00 I 0.43 
1-121,50 0.44 0.00 0.06 0.66 0.00 0.43 1.25 0.61 0.69 0.61 I 
19h50 0.33 0.00 0.00 0.50 0.29 0.57 1.00 0.33 ~ ~ 
Iwo 011150 0.33 0.00 0.08 1.00 0.00 0.41 1.50 1.00 0.91 1.00 I 
-""'- -""-c,,"OO c""'-8-" · .. ._n...'dL'" 
1%50 0.33 0.00 0.06 Ol!.. 0.00 ~!... 0.66 O . .:.JJ'--II-'=~ 
0/1150 0.33 0.00 0.08 0.66 0.00 0.43 1.63 ~~ 
- __ • 1%'0 I U.J3 I 0.00 I 0.08 I 0.15 I 0.00 I 0.;; I 0.15 I 0.3J I 0.661-'!..2L 
I 011,50 I 0.33 l~~~I~I-.~W-£-~!.,-.!l.J~J-'!.~1 0.50 
___ +_19115~~_~~_~1 0.00_~t_~"~I-0.50 I O.bb ~J!2!!. 
011.50 0.44 O.OO.~~. 0.00 0.43 1.00 1-0.11 0.39 0.11 
/--_. 121150 ~ ~~_ 0.66 0.00 0.4j I~ ~~ .O.bl 
I 191150 0.33 0.01_ ~ ~~.~l. 0.88 0.17 ·0.1 0.10 
IlIrel;: I 011150 ~.~_~.~~..J!.:.!L 1.36 0.50 0.89 0.5~ 
__ .• ~~ 0.)) 0.00 0.08.0.63 0.00 0.29 1.00 0.61 O.bl 0.01 
191150 I 0.61 I 0.40 I~~~~~LI 0.00 I ·0.3 I ·0.4 
, uur _..Q~~ 0':'::4 ~ 008 g.38 0.14 o.41J..!.:!ili0.J.!..... 0.25. 0.11 
____ ~ 0.44 ~ ~ 0.50 0.00 0.43...l~ ~ 0.S2 0.50 
I 191,SO O.ll 0.00 006 0.,0 0.00 0.43 1.00 0.33 0.41 O.lJ 
I iv"-r-~-+ 0111,0 - 0.33 --;;-:;;;- .-;; OH .0.63 0.00 0.4;- _~.E!!!._ - O.~ O.S] _ o~ 
12h!lO 0.44 0.00 I 0.00 0.63 0.00 0.4] 
...!.2!'.~~!L~.00 0.08 0.63 o."~ 0.4J 
t!.L!!U!1. AUHIUV!~!!!~: 
AltX Allxldy 
OfP Ucpre:i~ 'on 
AhG Auger 
VIG V igOUf 
fAr fcj( l(juc 
COli {on' U~ ivu 
fRI fricntJlluc:.::. 
iLA ltd! 10,. 
AHO; AfOU~J I 
POS; jJu~itivt.' Mood 
1.00 O. jj 0.64 O. )) 
.~~LL~.::'.u~ 
Ph.,. 2 (III AI 
Ucttk U·Y lime COII~ted Rt!~ponst! Rat ings 
1---1 1 ~ OfP AliG VIG fAI COli fRI flA AIlO POS 
Olle OIMO ~ 0.00 0.08 0.38 0.\4 0.41 1.13 0.3] 0.21 O.H 
121,50 I 0.33 0.00 ~ ~~ 0.43 1.00 O.SO 0.28 Q 
0.00 0.00 0.25 ~4 0.43 0.88 ~ 0.12 0.33 1911;0 0.44 
~I~~~_~ 0.13 0.14 0.43 0.66 0.1/ 0.00 0.11 
19h50 
0.17 I~J--Ul 0.33 0.0Il~_ 
1.00 0.17 0.25 I 0.17 
I ~ 0.44 I 0.00 I 0.08 _1. 0 . 11 
191t,0 .0.44 0.00 0.08 I 0.38 ~W,~ 
071150 0.44 0.00 I 0.08 I 0.38 I 0.00 1-~J-.!.:.!l-/-!U4~~ 
I--:--I~SO 0.44 0.00 0.08 0.50 0.14 ~ 1.00 0.11 0.2] 0.11 I 
1 ___ ~50 0.56 0.00 0.08 ~!l..~ ~.!!...~ O.ll 0.11 0.]3 
T.o 011150 0.56 0.00 ~ 0.50 0.14 0.;7 1.00 O.H 0.34 0.33 
121150 0.6/ 0.00 . ~ 0.38 0.00 0.41 1.00 0.00 0.61 0.00 
r 191150 0.61 0.00 0.11 0.50 O.ll 0.43 1.13 . ~~. ~ 
011150 0.61 0.00 0.11 0.38 0.14 __ ~~ .. 1.13 0.11 0.41 0.1i. 
191150 0.56 0.00 0.1/ 0.50 ~_~:.!!_.r...!.1L~_0.40 ~ 
011150 0.18 0.00 .!olL ~~_ ~ .~!L .~L _JUL !L!!L _!olL 
I--- 19h5O r--- . ___________________ -__ 
011150 0.6/ ~ ...!:!L_!UL,..Q:OU .!l.:.!l. _~_.~.~:!.. 0.,0 
12hSO ~~ ~ ~ ~~. _~ ..L!!. _~ ~E.. ~ .• 
~_!_+_~(...Q:!L ~. ~~ ...QOO __ 0.41 1.50 0.61 _!2L ~._ 
0111,,0 1G,33 ~!l0 .~.~ __ !oQ'!. ~ . .!.:~,..Q,81 0.53 0.83 lhree 
121150 J 0.33 0.00 0.06 ~ _~~ _~il..~5 0.61 0.26 0.61 
J----.-.1-I-I~I~~I·~I~~I~\_!!~~~~ 
fUllr 
f ivt: 
_7_ ---.!~ ~!.. ~ 0.17 0.50 O,!!. ..Q:.:!.!..t;o.88 O.5~. O.:JL _~_ 
011&50 0.44 0.00 0.11 0,63 ~ _~"~ 1.!.l. 0.)] O.;0..Q.:J~ 
121150 O.lJ 0.00 0.00 0.50 0.00 0.43 1.13 0.50 0.41 0.50 
------
1 ___ L_~_L~I_~~t~~~ 
~t !.J.Q . .!"E AOIIII£VIAI lO~i.USHl: 
AHX Aux let)' 
Off O~pr~ss 'on 
Af.G AflgCI' 
VaG Vigour 
fAr rdt .que 
lON (olll U':i ion 
fRI fl'll:,jdl illt:~~ 
UA 1I4tion 
AAO Aruli~,J I 
PUS Posit i .... c Hood 
0.00 0.41 1.00 _~2L~~J~ 
...... 
I.D 
W 
TABLE A9.7 Profile 01 IIood St.t .. no.pon ••• (Subject 1 (EG)) 
PII .. " I (1M A) r==-'- . 
Het::k O.y JIII~ 
AHX 
Gnu I OIIl~O 0.22 
1211~0 0,33 
191,~0 0,11 
2 011000 0.22 
1911~0 0.22 
J 01/100 0,22 
191150 0.22 
--
4 011150 0,22 
121150 0,31 
--
/ 191050 
------
----
I.u I 011150 ~ 
121150 0.33 
~?O 0,33 
--
2 0lh50 O,J} 
--
19ti50 r----~ 
J ~ Ulh~O 0.22 
.--
~ ~L 
i OJt.~O O,H 
12h!.O 0,33 
----f---' 19hbO 0,22 
lhrt:t 4 0lh50 0.22 
--' -~ ~ 
1 191150 0.33 
,--
fOUl" 4 OlhSO 
---
~. 1-
7 -l~ 
------
fhlt! 4 011150 
W,50 
---. 
1 1911~0 
----
tLU!L!!!L ~~!llit~!lliQ!!i..!!SI 0, 
AI'A. AUAiI!1Y 
OlP Ocpress IOU 
AIIG AIl<Jcr 
VIG Vigour 
fAI IdIl9". 
(ON (oni U~ 1011 
fill fflt:nJljllc~~ 
UA E 14t lull 
AAO ArOU)41 
I'OS h.l~ltlvc MuvJ 
OEY 
0.00 
0.00 
0.00 
0.00 
0,00 
0,00 
0.00 
0.00 
0.00 
r--
0.00 
0,00 
0,00 
0,00 
0.00 
0,00 
~-
0.00 
0.00 
0.00 
0,00 
~ 
0.00 
---
---
COII~uted Res.ponse Ral lugs 
MG VIG fA! (ON fRI [LA ~ POS 
0.00 1.13 0.00 0.5/ 2.00 I.J} 0,/6 I.]] 
0.00 0.63 0.00 0,4] 1.88 0.6/ 0,,3 0.6/ 
0,00 0,88 0,00 0,29 2.00 I.]] 0,10 I.J3 
0,00 I,!l!!..., 0,00 0,19 1./0 1.3J 0.94 1.33 
0,00 0./5 0.00 O.U 1.50 1.11 0,54 1.1/ 
0,00 0,88 0,00 0,5} 1.63 1.00 0,53 1.00 
0,00 0,63 0,00 0,43 2.00 1.00 0.42 1.00 
I~' 0, }5 0.00 0,51 1.50 1.00 0,40 1.00 
0.00 -~ 0.00 0.43 I. 50 0.50 0.5J 0,50 
---- --- ---
0.00 0.6J 0.00 0,43 1.30 0.50 0,53 0.50 
0.00 0,50 ~ ....IUL 1.63 0.83 0,41 0.83 
0,00 0./5 0,00 0.43 1.38 1.11 0.66 1.11 
0,00 0.63 0,00 0,5/ 
.....u!. 0.8' 0.,9 0.83 
0,00 0.63 0,00 0.43 I. 50 0,61 0.5) O,bl 
0,00 0,/5 0.00 0,5/ 1.13 0,63 0.40 0.63 
0.00 0.25 0,00 0.5/ I.Jd 0.6/ ~ o .bl 
0,00 0.,8 0,00 0.41 1.63 1.00 0.28 1.00 
0,00 0.36 0.00 0,4] 1.25 0.50 0,28 0,50 
. ....i:.!l!!.... 0./5 0.00 0,43 1.25 ~ 0.54 O,SJ 
0,00 0,03 0.00 0,4] I. 50 0.50 0.41 0.;0 
0.00 
.!:.50 0,00 0.43 1.63 0.67 ~ 0.67 
0.00 -~ 0.00 ~ 1.50 ~ 0.53 ~-
--- --- ---
i-----
---
. __ . f---- ---
--- r----
_.0-
--'---- ._-'----'----
Phase 2 (III 8) 
Wetk nay II .... Computed Jiesponse Rdl ings 
AHX Off MIG VIG fAr CON fltl [LA AIlO POS 
One ~ 
121150 
0,11 0.41 
0.22 O.ll 
U!..I~ 
1.61 ~-!-=-'--If-"-= 
I 19h50 ~I 0,00 I 0.00 ~P~~I 1.15 I 0,61 I 0,42 I 0.6/, 
011150 0.22 0.00 ~1_1!2LI...!!:!l!!....I~~~1 0.54 10,67-1 
0.00 0.00 0.75 0,00 0.43 I.~ uw-~~~ 
1-~~-I.~.!.O.....f....~O:::.O~O~,~ 0.5~ 0.00 .!!: . .:4~3+.!I.::,0:.::·l,-+--"'=_J-.=:'::"'~ 
191150 0.00 0.00 0.75 ~ 0.43:-I-....!.;1.c::5::.0_1-=:::..J-...=~j.....:=~ 
071150 0.33 0.00 0.00 0,63 0.00 0.5/ 1.75 0,61 
± 
121150 0,33 0.00 0.00 O.tiJ 0,00 0.11 1.63 0.83 0,53 0.83 
I _,_ ~,5~_ O,H 0,00 0.00 e-~~ ~~L '!.J!...~_...!.:.!.L 
rwu I OMO 0,33 0,00 0,00 .f.-..'!~~ ~ _.!.:.!!!L.I~ 0.66 __ ~ 
~50 0,22 0,00 0.00 I 0.63 0,00. ~-J--l:!L ~~ ~ 
19050 O.ll 0.00 0.00 0,50 0,00 -I....IUL 1.50 0.83 0.41 0.83 
0lh50 O,ll 0,00 0,00 0.63 O,OO.~ . ..!..J!LI~ ~ __ ~ 
I--- 19h50 0,22 0,00 0.00 0,ti3 0.00 0.51~. 0,83 0,20 0.83 
~~I..!:lLf~~...!!~1 0,00 WW-\--!2!!.-~!:.iq...!!.!!L 
1--~+---I--I-----I---/---!--~--+--'I---1---
~,50 I 0,)3 I 0.00 I 0,00 I 0.63 ~_I-~q.~_~I_~~_ 
[heee 
121150 
191150 
0/1150 
121150 
O,ll I 0.00 ~_I 0.50 I 0.00 0,0 I~L~.~.1~lJ!.:.~_ 
O.ll 0.00 0.00 I~I O,OO+!L:!.L~_t"'!!:J!LI-!:.!LWJ!L 
O.)j_/--2.:!l!!....~~ I 0.00 I 0.41 1.63 I 0.81 I 0.41 I O.Oj 
~~~19=h5:.::0-t~~_~~~~ ~J~l~- 0.50 
fOUl" 0/h50 O,ll 
I--~~. 3 ~ 0.00 0,63 O.O~. ~_ ...!.:H...~'Q!_ ~ ~.I 
0,22 O,OO...!!:.I!!!... 0.6J_,..!!.00 _~ ~ O~L .!!.:.!l._ 0.6' 
~ 0.00 0,00 0,50.J!JI!!......!!.!1 ~ ~ ~ 0.6/ 
o,n 0.00 0.00 0.)8 0.00 043 I 50 0.50 0,20 0,50 
---------
0.l3 0,00 0,00 0.38 0.00 0.5/ I 15 0.,0 0 14 0.50 
-- - ------
191150 
f Ivo I I 01h50_ 
121150 
L-...-l 191050 
0,00 I 0,00 I O.JlI I 0,00 I-~~J....!.!!l.-I 0,20 I 0.8J 
~U_l!L!!~\'!g~!!; 
AUJ( An)!. lely 
OfP Depress 1011 
AHG Allger 
VIG Vigour 
fAT f4ligue 
CON (antus ioo 
fRJ friemjlint:ss 
HA E 101'011 
AAO Afousa I 
,JOS Pus. it I lie Huod 
.... 
\.0 
-t;o. 
TABLE A9.8 Protll. at Hood Slot •• Rc>po/lll •• (SubJ.,t 8 (ev)) 
Ph.,. I (1M A) 
Wct:k lliJy filiI! 
AAX 
---
OUI! I ~~ ~ 
121150 0.22 
191150 0.6/ 
- .. 
2 0111'>0 0.44 
J9hflO 1.00 
] 01h50 O.B 
1~1I50 0.89 
4 011150 0.22 
111150 0.22 
1--- f-.I 191150 
I ... I 0lh50 0.22 
121150 0.09 
1--- 1911'>0 0./8 
2 01,,50 0.44 
~. - 191150 O. ]] 
j 011050 
f-19li50 0.22 
---
4 0/1050 0.44 
121,50 0.56 
I 1!l1I50 0.22 
---
Ihret: 4 011,50 0.11 
llli!lO 0.22 
----
I Hill50 0.25 
---
four 4 0111,0 0.22 
111150 1.22 
.. --
I~ 191150 0.]] 
---
f '\Ie 4 011150 ~ 
121150 I~ 
--
I 19h~O 0.22 
---
HlJO lilt AUIlI,rVIAllOl;S US[o: 
AJU.~ Alill. h:ty 
Off»: Ot!(,JreS'illOn 
Aid;; AUlJer 
VIG; Vlgouf 
fAI: follgo" 
(Ou: COli' u~ lull 
flU: frit!II(jIIlIC~~ 
[LA; lldllOI\ 
AkO: Arow.,j I 
JlOS: JllIS" i .... 1..! NUlJd 
COO4)utcli Res ome Rot Ings 
UEP AAG VIG fAI CON fHI 
0.00 0.00 1.25 0.86 0.51 2. j] 
0.00 0.00 2.00 0.00 0.2~ 2.00 
0.00 0.00 0.50 0.51 0.4] 1.6] 
0.00 0.00 0.15 0.00 0.51 1.6] 
0.00 0.00 0.00 0.29 0.11 1.00 
0.00 0.00 1.50 0.00 0.51 2.00 
0.00 0.00 0.6] 0.29 0.11 1.50 
0.00 0.00 2.00 0.00 0.41 ~ 
0.00 0.00 1.50 0.00 0.51 1.15 
0.00 0.00 1.50 0.29 0.51 2.00 
0.1l 0.00 0.13 0.86 0.86 0.6J 
0.01 0.00 0.]8 0.51 0.4] 1.6. 
0.01 0.08 0.15 0.14 0.5/ 1. ]8 
0.00 0.00 0.15 0.00 0.41 1.6] 
0.3] 1.15 0.00 1.15 
0.00 0.00 0.88 0.00 0.29 ~ 
0.00 0.00 1.50 0.00 0.29 1./'> 
0.13 0.08 ~ 0.14 0.5/ 2.00 
0.00 0.00 0.6] 0.00 0.4] 2.00 
0.00 0.00 1.00 0.00 0.14 , .13 
0.00 0.00 1.00 0.00 0.29 2.25 
-
0.14 0.00 1.63 0.00 0.5/ 2.2, 
0.00 0.00 ~ 0.00 ~ -LI!L 
0.13 0.50 2. J3 0.29 0.41 1.25 
0.00 0.00 I-l15 0.00 o.n 2.00 
0.00 I~ 2.00 0.00 0.14 2.]8 
0.00 0.00 1.15 0.00 0.14 2.13 
0.00 0.00 1.6] 0.00 0.14 2.25 
, 
£LA AHD ~ 
1.00 O. ]ij ~i 
1.00 1.~4 1.00 ! 
--, 
0.6/ 0.11 0.61 j 
0.8] 0.62 0.8] j 
0.11 0.00 
, 
0.11 i 
I. I I 1.26 
.--U1J 
0.50 0.51 ~ 
2.00 1.19 2.00 i 
I 
0.83 1.15 0.8] I 
i 
1.11 0.61 1.11 1 
I 
0.11 -0.1 0.01 ! 
0.50 0.15 0.4] J 
0.50 0.48 0.4] I 
0.50 0.66 0.,0 i 
I.]] I. IS 
1.00 ~ 
-I 
~' 
1.11 1.66 ~ 
0.50 0.91 O. ]1 
0.61 0.42 0.61 
1.83 0.9/ 1.83 
I.:~ ~ ~. 
1.1/ 1.]0 1.02 
.!!J!.L I~ 0.8] 
0.50 2.6] -;;;-1 
1.50 1.16 l.50 I 
1.6] 2.]0 1.83 
2.0U 1.12 2.00 1 
1.8] 1.62 1.8ll 
~lIas. 2 (I" 0) 
llt:ek Oay Ti"", (OIlllut~(J Itcsponse Rdt logs 
AAX OfP AJiG VIG fAT con ~ -ill..... ~ pus --, 
0 ... I 0lh50 0.89 0.5] 0.11 1.0U O. I~ 0.4] 1.88 0.]] 1.]2 
-0.2 : 
1 
121150 1.00 0.11 0.00 0.88 0.14 
_....UL I.U 0.11 1.16 -0.2 , 
I 
I---- f-}91150 0.]] 0.20 0.08 0.50 0.14 0.4] 1.00 0.50 0.26 0.30 
2 011150 0.61 0.13 j-QR- .-!!..:li.... ~ ,~ .-!.:..!!L ~ ~ .J!.JL.I 
191150 1---. - . i 
] 011150 0.56 O. I] 0.11 1.00 0.00 ~ I-} .25 0.33 1.1] 0.20 
191150 
4 011150 0.44 0.01 0.06 O.JO 0.00 0.51 1.25 o.n 0.25 0.21 
_. 
121150 0.22 0.00 0.00 1.]6 0.00 .~ 2.00 0.6/ 1.11 0.6/ 
r----- I 191150 
Iwo 1 011150 D.]} 0.01 0.00 0.88 0.14 0.4J 1.1] 0.]] 0.64 0.21 l 
121150 0.44 I~ ~ ~ ~ 0.4] I.IJ 0.11 0.01 0.0) I 
191150 0.18 0.41 0.08 1.00 0.86 0.11 1.6] 0.50 0.21 0.0] i 
2 011150 I 
~- I 
--
I--
-----
I---
--
1---- .--
--- --
--I 
1 011150 1---- I--
--I 
191,50 1----1- ---, 
4 011,50 1-. 1-----f--- ! --- i 121150 
---I--- --' ---I- i 
I--- 1 ~ --I-- ---I-- '-- ---- -- --- .-- -----j ~ 
Hlree 4 ~ 
.--- .-- ---I-----l 
1---~~ I--- ----I--- --- ---- I-
I- I 191150 -- ---I---- 1--------
four 4 0lh50 
'----
I----~ I--- --- ---I---1---_. -_. -- --I----- ---' 
I 191150 
. _--
--
I--. 
f ave 4 ~~ I--
--I--- --- --- I---
--~ '-- ---. ---- ---- ._--- --1---1----
I 1~I,50 _____ L--. ___ L--I 
HL!!Ll!!UJ!Il!l!..'lW!!J!!LI!'jill : 
AtU; Anxiely 
Off; Ocpress Ion 
AUG: Amjtf 
VIG: Vigour 
fAT: fdllgo" 
(0,.: (on/us iun 
fRI: fnelldllllc>s 
EtA: tld"OIl 
MO. Arousal 
POS: ~os i t i.e /1000 
t-' 
I.D 
Ln 
196 
POHS Weeks Tl! A • SEM MRT F P I Tl1B.SEM F P Scale 
Anxiety 1 0.25 • 0.04 0.42 • 0.07 4.00' 0.0477 
2 0.29 • 0.03 0.32 • 0.04 
3 Q.29 • 0.04 0.34 0.8510 0.29 • 0.05 1.06 0.3768 
4 0.35 • 0.10 0.42 .O.ll 
5 0.28 • 0.05 0.27 • 0.03 
Depress 10n 1 0.06 • 0.05 . 0.29 • 0.09 4.79 0.0313 
2 0.02 • 0.01 . 0.15 • 0.05 
3 0.23 • 0.14 . 2.77; 0.0288 0.12 • 0.06 1.38 0.2417 
4 0.33 • 0.18 0.19 • 0.13 
5 0.13 • 0.12 . 0.00 • 0.00 
Anger 1 0.18.0.06 0.31 • 0.09 1.54 0.2171 
2 0.10 • 0.02 0.19 • 0.06 
3 0.26 • O.ll 0.95 0.4383 0.10.0.05 1.59 0.1786 
4 0.24 • 0.09 0.12 • 0.06 
5 0.17 • 0.09 0.04 • 0.02 
Vigour 1 1.65 • 0.14 1.57 • 0.12 0.17 0.6845 
2 1.49 • 0.12 1.29. 0.10 
3 1.22 • 0.21 0.92 0.4559 1.26 • 0.19 1.37 0.2471 
4 1.73 • 0.28 1.18 • 0.19 
5 1.71 • 0.27 1.24 • 0.16 
Fatigue 1 0.24 • 0.07 0.18 • 0.04 0.62 0.4395 
2 0.16 • 0.06 0.13 • 0.04 
3 0.46 • 0.23 1.73 0.1452 0.28 • 0.14 1.14 0.3395 
4 0.07 • 0.04 0.12 • 0.06 
5 0.04 • 0.04 0.06 • 0.03 
Confus ion 1 0.37 • 0.04 0.53 • 0.06 4.51' 0.0356 
2 0.36 • 0.03 0.47 • 0.05 
3 0.43 • 0.08 0.78 0.5405 0.47 • 0.08 0.52 0.7202 
4 0.50 • 0.13 0.54 • 0.10 
5 0.40. 0.09 0.39 • 0.03 
Friendl iness 1 2.01 • 0.12 1.95 • 0.09 0.22 0.6474 
2 1.90. 0.11 1.79 • 0.09 
3 1.90 • 0.19 0.15 0.9608 1.83 • 0.19 0.62 0.6525 
4 1.93 • 0.24 1.71 • 0.14 
5 2.01 • 0.24 1.77 .0.14 
Elation 1 1.57 • 0.13 1.52 • 0.11 0.07 0.1975 
2 1.38 • 0.12 1.25 • 0.08 
3 1.17 • 0.20 0.72 0.5787 1.25 • 0.16 1.64 0.1670 
4 1.48 • 0.28 1.15 • 0.18 
5 1.49 , 0.26 1.24 • 0.16 
Arousa 1 1 1.30 • 0.18 1.28 , 0.16 0.01 0.9465 
2 1.26 • 0.15 1.01 , 0.13 
3 0.62 • 0.37 1.49 0.2079 0.79 • 0.31 0.97 0.4262 
4 1.51 • 0.33 0.94 • 0.21 
5 1.55 • 0.31 1.05 • 0.17 
I'os ltive 1 1.50 • 0.14 1.23 • 0.17 0.154 0.2178 
Hood 2 1.36 • 0.12 1.09 • 0.11 
3 0.94 • 0.27 1.12 0.3492 1.13 • 0.19 0.33 0.8567 
4 1.15 • 0.38 0.96 , 0.26 
5 1.36 • 0.30 1.24 • 0.16 
The rr:ean responses to each of the POMS seales for we~ 1 for both treatltents are given in the body of the 
table. For week 1. n • 61 for each phase. df • 1.120. Bold italiCised F ratios and P values indicate 
s ign1ficance for weexs 1. 
For the co""arison of the treatn:ent weeks (2·5) with week 1. n • 177 for each phase, df • 4,172. 
The ir's in the MRT column indicates where the differences in the weeks occurred. 
§ indicates a P value of bebeen 0.015 and 0.05 
TABlE A9.Z.1 Average Week ly Responses to the 10 Sea les of the I'CIIS Questionnaire (Hean Va lues for 7 
Subjects) 
Subject TM A t SEM TM 8 7 SfM F P i I 
1 0.07 • 0.01 0.11 • 0.00 8.73' 0.0058 I 
2 0.59 • 0.08 0.83 t 0.14 2.15 0.1528 
3 0.20 • 0.03 0.27 • 0.02 0.37 0.5561 
4 0.19 • 0.01 0.20 • 0.03 0.32 0.5802 
5 0.14 • 1.02 0.12 t 0.03 0.12 0.7315 
6 0.49 • 0.04 0.38 t 0.02 6.121 0.0186 
n· 16 for each Test Hedlcatlon Phase for Subject 5, df • 1,30 
n • 17 for each Test Medication Phase for Subjects I, 2, and 4, df • 1,32 
n· 18 for each Test Medication Phase for Subjects 3 and 6, df • 1,34 
§ Indicates a P value of between 0.015 and 0.05 
, Indicates a P value of less than 0.01 
TABLE A9.2.2 Average -Anxiety· Response for each Test Hedicat10n Phase per Volunteer 
Subject THA.SfH 1M 8 • SEM F P 
I 0.00 • 0.00 0.01 t 0.01 1.00 0.3248 
2 0.78 t 0.21 0.82 t 0.16 0.02 0.8971 
3 0.00 • 0.00 0.01 t 0.01 1.89 0.1778 
4 0.00 t 0.00 0.02 • 0.02 0.91 0.3564 
5 0.02 t 0.02 0.07 t 0.07 0.42 0.5270 
6 0.00 • 0.00 0.03 , 0.02 1.35 0.1531 
n • 16 for each Test Medication Phase for Subject 5, df • 1,30 
n • 17 for each Test Medication Phase for Subjects 1. 2, and 4, df " 1,32 
n " 18 for each Test Medication Phase for Subjects 3 and 6, df " 1,34 
TABLE A9.2.3 Average "Depression" Response for each Test Medication Phase per Volunteer 
Subject TMA.SEM TM 8 • SEH F P 
1 0.29 • 0.01 0.22 • 0.03 5.531 0.0250 
2 0.60 • 0.15 0.63 • 0.11 0.01 0.9122 
3 0.00 t 0.00 0.01 • 0.01 11.89 0.1786 
4 0.00 • 0.00 0.06 • 0.05 1.45 0.2376 
5 0.05 • O.Ol 0.03 • 0.02 0.37 0.5531 
-~--~.ll~ 0.09 • 0.01 6,761 0.0137 
n • 16 for each Test Hedlcatlon Phase for Subject 5, ,df • 1,30 
n " 17 for each Test Medication Phase for Subjects r, 2, and 4, df • 1,32 
n • 18 for each Test Hedlcatlon Phase for Subjects 3 and 6, df " I.l4 
§ Indicates a P value of between 0.015 and 0.05 
TABLE A9.2.4 Average -Anger- Response for each Test Medication Phase per Volunteer 
Subject THA,SEM TMBtSEM F P 
1 3.22 • 0.07 2.40 • 0.14 46.8' 0.0000 
2 0.90 • 0.13 0.49 • 0.08 7.30' 0.0109 
3 1.12 • 0.08 1.55 • 0.10 12.0' 0.0015 I 
I 
4 1.67 , 0.05 1.48 • 0.11 2.55 0.1198 I 
5 2.12 • 0.23 1.85, 0.16 0.94 0.3491 
6 0.47 • 0.02 0.60 • 0.07 2.94 0.0957 
n " 16 for each Test Medication Phase for Subject 5, df " 1,30 
n " 17 for each Test Medication Phase for Subjects I. 2, and 4, df • l,l2 
n· 18 for each Test Medication Phase for Subjects 3 and 6, df " 1.34 
§ IndIcates a P va lue of between 0.015 and 0.05 
, indicates a P value of less than 0.01 
TABLE A9.2.S Ave .... age -Vigour- Response for each Test Medication Phase per Voluntee .... 
Subject TMA.SEM THB.SEM F P 
1 O.ll • 0.07 0.01 • 0.01 1.99 0.1676 
2 0.31 • 0.11 0.59 • 0.17 1.89 0.1785 
3 0.01 , 0.01 0.06 • 0.04 1.35 0.2535 
4 0.00 ,0.00 0.03 , 0.01 4.861 0.0344 
5 0.78 • 0.29 0.30 • 0.12 2.27 0.1409 I 
6 0.06 , 0.02 O.O~ .0.02 ~- .~ 
n " 16 for each Test Medication Phase for Subject 5, df • l,lO 
n - 17 for each Test Medication Phase for Subjects I, 2, and 4, df " I.l2 
n - 18 for each Test Medication Phase for Subjects 3 and 6, df - I.l4 
§ indicates a P va lue of between 0.015 and 0.05 
TABLE A9.2.6 Average -Fatigue- Response for each Test Medication Phase per Volunteer 
Subject n~A.SEH TM 8 , SEM F P 
1 O.ll • 0.01 0.32 t 0.04 19.0' 0.0001 
2 0.89 • 0.14 1.11 • 0.16 1.09 0.3047 
3 0.35 • 0.04 0.32 t O.Ol 0.42 0.5267 
4 0.28 • 0.01 0.l9 t 0.05 5.69' 0.0228 
5 0.25 • 0.04 0.29 • 0.05 0.22 0.6482 
6 0.45 • 0.01 0.43 • 0.01 1.89 0.1780 
-
--"-- -.~-. 
n • 16 for each Test Medication Phase for Subject 5, df " 1.30 
n. 17 for each Test Hedlcatlon Phase for Subjects I, 2, and 4, df - 1,32 
n. 18 for each Test Hedlcation Phase for Subjects 3 and 6, df • 1,34 
§ indicates a P value of between 0.015 and 0.05 
, Indicates a P value of less than 0.01 
TABLE A9.2.7 Average -Confusion- Response for each Test Hedication Phase per Volunteer 
...... 
lD 
....... 
Sub ject 1M A , SEH IH B , SEM F P 
1 3.1B , 0.08 2.77 , 0.07 25.5' 0.0000 
2 1.10,0.09 1.17 t 0.11 0.25 0.6251 
3 1.15 , 0.06 1.33 t 0.09 2.75 0.1069 
4 2.25 , 0.02 2.03 t 0.11 4.19' 0.0486 
5 1.81 , 0.11 1.53 , 0.14 1.47 0.1154 
6 1.10 t 0.0·\ 1.04 ± O.OB 0.51 0.4883 
n .. 16 for each Test Medication Phase for Subject 5, df .. 1.30 
n. 17 for each Test Hedlcatlon Phase for Subjects I, 2, and 4, df • 1.32 
n • 18 for each Test Medication Phase for Subjects 3 and 6, df • 1.34 
§ indicates a P va lue of between 0.015 and 0.05 
, indicates a P va lue of less than 0.01 
TNllE A9.1.8 Average "Fr1endliness" Response for each Test Medication Phase per Volunteer 
Subject 1M A , SEH Hi 8 , SEM F P 
1 3.14 • 0.06 1.90 , 0.05 124' 0.0000 
1 0.79 • 0.10 0.78 ± 0.14 0.00 0.9530 
3 0.76 • 0.07 1.14 • 0.10 14.8' 0.0005 
4 1.45 , 0.06 1.48 • 0.12 0.04 0.8376 
5 1.98 • 0.16 2.09 , 0.17 0.31 0.5904 
6 0.39 , 0.05 0.39 , 0.05 0.00 0.9987 
n. 16 for each Test Medication Phase for Subject 5, df • 1,30 
n. 17 for each Test Medication Phase for Subjects I, 1, and 4, df • 1.32 
n'" 18 for each Test Medication Phase for Subjects 3 and 6, df ... 1,34 
I Indicates a P value of less than 0.01 
TMlE A9.2.9 Average "Elation" Response for each Test Medication Phase per Volunteer 
Subject TMA,SEM IM8.SEM F P 
1 3.05 , 0.11 2.19 • 0.17 18.3' 0.0001 
1 0.19 , 0.26 -0.38 , 0.15 3.l1 0.0757 
3 1.06 • 0.09 1.45 • 0.14 5.72' 0.0228 
4 1.58 • 0.05 1.26 • 0.13 5.59' 0.0239 
5 1.12 • 0.53 1.38 • 0.30 0.07 .' 0.7939 
6 0.45 , 0.03 0.52 • 0.08 0.70 0.4181 
n ... 16 for each Test Medication Phase for Subject 5. df .. 1,30 
n .. 17 for each Test Medication Phase for Subjects 1. 2. and 4, df .. 1,32 
n .. 18 for each Test Medication Phase for Subjects 3 and 6, df .. 1,34 
§ indicates a P value of between 0.015 and 0.05 
, Indicates a P value of less than 0.01 
TAHI E A9.2.10 Average "Arousal" Response for each Test Medication Phase per Volunteer 
Subject TM A • SEM 1M B , SEM F P 
1 3.14 • 0.06 1.89 • 0.05 228' 0.0000 
2 0.10 • 0.27 -0.04 • 0.26 0.01 0.9068 
3 0.76 • 0.07 1.22 • 0.10 13.6' 0.0008 
4 1.45 • 0.06 1.46 , 0.13 0.01 0.9190 
5 1.96 • 0.15 2.03 • 0.17 0.08 0.7793 
6 0.39 • 0.05 0.36 • 0.06 0.11 0.7474 
n· 16 for each Test Medication Phase for Subject 5, df • 1.30 
n· 17 for each Test Medication Phase for Subjects 1. 2, and 4, df • 1,32 
n .. 18 for each Test Medication Phase for Subjects 3 and 6, df .. 1,34 
, Indicates a P value of less than 0.01 
TADlE A9.2.11 Average "Positive Hood" Response for each Test Medication Phase per Voluntt-er 
f-' 
lD 
OJ 
IAtilt AIO_I Visual Aflillogue Scales (SobjeCl I (SS)) 
PIIase 2 (III 8) 
... -- . ... ... 
Ucek Day II.., Response ratings (,on) Wc!li!k Oay rillle Response Rat In95 ('1111) 
STiM III Gil AHX S£O 001111 HUll 51111 tliGH AHX 5£0 DOliN HUN 
Oue I 011150 10 2 2 2 I 0 One I 0lh50 4 2 I 2 I 0 
12h~0 13 13 12 10 12 12 
Illl50 9 ti 10 5 -~ ___ 4 ___ 
191150 19h50 
2 011150 1 :, 5 4 5 4 
2 011150 4 5 4 4 5 4 
191150 1M II 16 14 15 15 
191150 8 I 1 4 I 4 
) 011150 ) 2 ) 2 ) 2 3 011150 8 5 6 5 I S -
19h50 0 0 0 0 0 0 191150 5 4 2 5 5 to 
4 011150 2 0 I I 2 ) 4 ~!II50 I b _!Q- ti 8 10 
121150 0 0 0 0 0 19 
121150 2 2 I 0._ 2 2 
I 191150 I 191150 5 5 
] 6 4 5 
< 
1 .. 0 I 011150 2 I I 2 I I 
, .. 0 I ~!50 4 4 6 J 6 6 » (/) 
1211~0 0 0 0 0 0 12 
191150 ) 1 ) 2 I 2 
2 011150 2 0 ) 2 J 0 
19h50 2 1 2 1 J J 
3 011150 1 0 I 2 J 2 
121150 2 0 I c--!!- 2 15 
191150 4 4 I J 4 6 
2 011150 J 3 5 5 2 6 
191150 6 5 5 2 I 5 
--
3 OIIiSO 1 0 I 
-1.-- 4 2 
» 
;;U ""0 I-' 
M ""0 ~ (/) ...., ~ 
-U :z 
0 0 
Z H 
(/) >< 
M 
l~h,O 1 I I 2 
_L- 2 
4 0lh50 I I 2 13 0 3 
191150 4 3 r--! 4 5 I) '---
4 0lh50 1 9 9 !~ 9 9 
.... 
0 0 
» 
...... 
12h50 J 2 3 
121150 
J ) 51 
6 6 9 4 30 )0 » 
I 19h50 I 2 ) 2 4 3 
I 19h50 2 2 4 __ 2___ 1 6 
Jhfee 4 011150 2 2 4 2 4 2 U'fee 
4 011.50 4 2 2 4 15 1 
12h50 3 2 2 0 0 56 
121,50 6 1 8 -~- II 8 
I 191.50 2 2 2 2 2 J I 191150 II IJ 7 - 6 I 9 
four 4 0lh50 2 2 2 2 1 4 
fOUl" 4 0lh50 9 4 9 5 8 3 
121150 II 3 J 5 6 41 121150 10 5 6 5 II '--!.-. 
I 191150 6 2 2 2 3 b 
------
I 19h50 4 r--o_2_ ~- 6 r---2--c-~----
f I\lt: 4 Olh~O 2 3 4 4 4 4 
f lv~ 4 ~~-- i--.!.- 2 I--~- 6 5 09 
-'--'---
121150 2 -~ 5 4 ) 012 121.50 6 1 2 4 5 5 -----r-----
1 19h50 j J J 3 2 2 
-----'-------
I 1%50 
------ ----- -'----------
lASH A10_2 Vlsu.1 AtI4l09ue SCdles (Subject 2 (CA)1 
Ph,),. I (III AI 
Wed. nay 111110 Respolise Rat lngs (nlll) 
SliM 11I~1t AHX SW OOWN ttUN 
aue 1 0lb50 H )0 61 41 til 51 
121150 50 54 41 44 12 60 
191.50 
2 011150 60 14 58 59 I ~ 191150 5 B I 21 0 J 071150 28 21 28 20 0 o ' 
191150 28 46 51 32 II 0 I 
4 07n50 45 J9 24 21 0 0 I 
i 
12h50 44 16 B 1I 1 19 
7 191150 0 0 0 0 61 0 1 
'.0 I 011150 21 22 9 B 0 16 
121150 26 55 10 52 09 B 
191150 14 ,. 2 30 0 ~ 
2 071150 9 12 10 8 56 20 , 
191150 16 16 15 II 39 0 
1 011150 14 45 8 8 0 0 
191150 
4 071150 31 32 39 II 18 8 
121150 30 II 16 44 0 90 
-----
__ I 191150 42 39 5 28 0 52 
Ihn~c 4 0lh50 I 62 39 4 85 26 
121150 25 22 '5 18 14 14 
---
I 191150 5 4 60 ]0 15 0 
four 4 011150 12 II II 9 85 0 
12h50 16 II 39 14 82 22 
-----
I 191150 9 8 I 6 64 20 
f .v~ 4 011150 2 0 64 
" 
92 21 
121150 0 0 0 0 0 0 i 
I 191150 "---I ----
Plld'. 2 (III 8) 
Week Ddy II" .. 
5 JIll III Gil 
Ond I 011150 20 19 
12h50 20 18 
191150 6 I 
2 0lb50 6 8 
191.50 I 20 
3 0lh50 II 9 
191150 10 9 
4 011.50 6 2 
121150 Il 10 
I 191150 14 12 
1.0 I 071150 0 0 
121150 9 9 
19h50 52 II 
2 0lh50 54 66 
191150 I 5] 
1 011l~0 6 9 
1%50 ~ 1----_6_1_ 
4 0lh50 42 46 
121150 IJ 32 
I 191150 0 0 
Ihrc:e 4 011150 30 44 
W.50 II 35 
1--.- 7 191150 I I 
fuur 4 011.50 24 24 
----~~- 0 0 
1------ 1 191150 52 58 
f lvtl 4 ~- IJ 16 
121150 ~ n --------
I 191150 
Response Rdt Ing~ (IUB) 
ANX 5£0 !lOWN IIUN 
16 14 15 ~ 
11 16 90 100 
II II 92 0 
12 II 92 0 
65 J 9ti 4 
15 5 98 ~ 
64 II 16 23 
-
19 IJ 93 2 
80 II 94 19 
12 9 66 56 
16 0 81 0 
80 20 89 100 
-
60 21 8U 0 
11 66 5 0 
-
5 4 J 0 
I ~- 55 ~-
1 I 46 ~-
9 0 0 ~; 
0 19 0 IJ f-----'-~-, 
72 __ 0 39 ~ 
10 
-1_J_ 0 ~-
7 4 0 69 
---, 
5 48 8 38 
---- ---- ---I 
60 4 18 ~ 
/I 0 99 6 
i 
25 21 -~ __ 36_-_: 
1---_1- IJ 0 11 
---j 
0 10 0 5J 
----- ---- ----, 
I 
_______ ------L--... ___ : 
N 
a 
a 
IABLE Al0.3 Visual Analogue Scales [Subject 3 (lO] 
PII .. e 1 (TN B) 
Week Day Time Response Rat Ings (UJIl) 
SIIH HIGH AIlX SED DOUN 
One 1 071150 
12h50 20 20 20 17 16 
19h50 25 J 3 5 6 
2 071150 
191150 
3 07h50 20 1 3 3 3 
19h50 24 17 7 3 3 
4 071150 19 9 J 3 3 
121150 13 13 4 3 5 
I 19h50 
Iwo 1 071150 13 1 4 3 5 
12h50 I 2 3 2 5 
191150 6 5 4 4 4 
2 071150 4 5 6 2 3 
191150 3 1 2 3 0 
3 071150 6 2 5 3 4 
191150 5 1 3 2 4 
4 07h50 7 6 3 4 4 
12h50 6 4 3 4 4 
I 19h50 18 5 5 3 J 
Ihree 4 071150 5 7 5 9 6 
12h50 8 5 5 5 I 
7 191150 8 4 2 5 3 
Four 4 07h50 9 7 9 7 6 
12h50 16 4 3 4 3 
I 19h50 8 7 5 4 4 
FIve 4 07h50 4 1 4 4 4 
12h50 10 6 7 5 4 
L .... L L .. ~9115o.. 7 0 8 1 7 
- -- --
.. 
Phase 2 (TM A) 
Ileok Oay Time 
IIUN SliM 
One 1 07h50 13 
38 12h50 10 
7 191150 a 
2 071150 8 
19h50 6 
4 3 071150 10 
13 191150 6 
8 4 07h50 10 
33 121150 10 
7 191150 9 
19 Two I 071150 7 
11 12h50 II 
2 191150 9 
2 2 071150 9 
2 191150 15 
5 3 071150 4 
0 19h50 10 
3 4 071150 9 
4 12h53 7 
4 7 191150 6 
5 Three 4 011150 8 
42 121150 9 
3 7 191150 13 
4 four 4 07h50 14 
33 121150 9 
3 1 191150 9 
2 five 4 071150 9 
73 121150 11 
8 1 191150 13 
Response Rat ings (UJll) 
ItiGH ANX SED 
7 7 6 
a 6 9 
5 5 5 
5 5 4 
5 4 3 
7 5 4 
6 5 3 
7 5 4 
9 9 8 
6 6 4 
7 6 6 
8 9 7 
7 7 6 
8 7 1 
11 7 7 
4 7 6 
11 6 6 
7 6 5 
6 5 6 
6 4 3 
9 8 1 
7 9 8 
9 10 6 
9 8 8 
5 8 1 
4 7 5 
8 9 7 
9 7 I 
8 9 4 
DDUN 
4 
7 
4 
4 
3 
4 
3 
20 
10 
6 
6 
5 
6 
8 
9 
5 
5 
5 
5 
4 
6 
7 
5 
1 
10 
3 
9 
1 
5 
HUN 
3 
45 
4 
3 
2 
3 
2 
3 
43 
5 
5 
48 
4 
6 
1 
6 
2 
1 
26 
3 
6 
35 
4 
1 
44 
3 
8 
40 
5 
N 
a 
....... 
TABLE AI0.4 Visual Analogue Scales [Subject 4 (EA)] 
Phase 1 (TN B) Phase 2 (iii A) 
Week Oay Time Response Ra t i figs ( .. n) Week 
STiM HIGH ANX SED DOWN HUN 
One I 0lh50 II 12 42 46 45 61 One 
12h50 66 61 31 24 4 46 
19h50 30 28 16 54 23 70 
2 07h50 69 70 46 45 23 14 
19h50 41 21 19 18 18 10 
3 07h50 39 33 48 32 32 18 ! 
19h50 33 30 27 28 27 11 
4 07h50 33 33 40 31 25 6 
12h50 34 33 31 33 33 50 
I 19h50 
Two I 07h50 39 33 31 29 30 30 Two 
12h50 46 30 30 28 28 41 
19h50 33 30 32 30 31 4 
2 0lh50 33 31 30 29 38 24 
19h50 30 13 13 g I 7 
3 07h50 24 18 14 12 11 7 
19h50 
4 07h50 24 19 16 13 17 14 
12h50 24 19 20 18 1) )9 
) 19h50 50 34 36 34 34 46 
Three 4 0lh50 13 10 IS 4 4 4 lhree 
12h50 22 13 12 10 12 22 
) 191150 16 11 12 10 9 9 
four 4 07h50 11 7 8 7 5 5 four 
12h50 20 12 11 10 10 59 
7 19h50 10 6 5 5 4 3 
five 4 07h50 14 10 II 9 8 9 Five 
,2h50 17 11 13 II 12 10 
7 19h50 11 6 6 5 6 5 
Day Time 
STIM HIGH 
1 07h50 10 6 
12h50 16 12 
19h50 17 II 
2 0lh50 13 11 
19h50 
3 07h50 18 13 
19h50 12 11 
4 07h50 9 6 
12h50 13 7 
7 19h50 11 6 
1 07h50 11 6 
12h50 14 12 
19h50 10 5 
2 0lh50 8 3 
19h50 4 1 
3 07h50 6 2 
19h50 I 4 
4 0lh50 I I 
12h50 2 2 
I 19h50 7 3 
4 0lh50 5 2 
12h50 I 3 
I 19h50 6 3 
4 0lh50 3 2 
12h50 
7 19h50 4 I 
4 07h50 5 2 
12h50 6 3 
I 19h50 6 2 
Response Ratings (om) 
ANX SED 
8 6 
12 12 
15 16 
9 8 
12 8 
10 10 
6 6 
8 8 
6 5 
8 9 
12 11 
6 6 
3 3 
I 0 
2 3 
5 4 
1 2 
I I 
4 3 
2 3 
2 3 
2 2 
2 2 
2 2 
2 1 
3 3 
3 2 
DOWN 
4 
12 
12 
7 
8 
10 
6 
8 
5 
6 
11 
6 
4 
0 
2 
3 
2 
2 
3 
2 
4 
2 
3 
2 
2 
2 
3 
HUN 
4 
10 
16 
5 
6 
8 
5 
15 
5 
6 
20 
6 
6 
0 
2 
2 
3 
5 
3 
I 
I 
4 
2 
0 
1 
I 
2 
J 
I 
I 
! 
I 
I 
I 
I 
I 
I 
I 
I 
, 
I 
I 
i 
. 
! 
N 
a 
N 
TAUlf AIO.5 
Phase I (1M B) 
Week 
On. 
Two 
Three 
four 
five 
Day 
I 
2 
3 
4 
I 
I 
2 
3 
4 
I 
4 
7 
4 
7 
4 
7 
Visual Analogue Scales (Subject 5 (VH)] 
Time Response Ratings (nrn) 
STiM HIGH AHX SED 
011150 70 69 3 6 
121150 66 61 31 29 
19h50 
011150 64 55 2 0 
19h50 92 15 3 3 
011150 84 84 9 8 
19h50 32 41 3 2 
0lh50 58 53 3 2 
12h50 69 56 4 3 
191150 44 32 I 0 
0lh50 61 10 I 2 
12h50 81 63 2 2 
19h50 51 49 0 I 
0lh50 46 29 2 I 
191150 35 30 2 3 
071150 24 \3 3 I 
191150 32 10 6 6 
011150 70 66 0 3 
121150 82 81 4 4 
19h50 28 2 2 3 
07h50 21 19 5 2 
12h50 1 9 9 2 
19h50 2 2 4 I 
07h50 3) 3 4 2 
12h5O 43 19 19 17 
191150 
07h50 28 24 1 0 
121150 31 4 2 1 
191150 32 47 3 0 
Phase 2 (TM A) 
Week 
DOHN HUN 
3 II One 
30 98 
0 9 
I 94 
8 2 
3 0 
I 2 
3 96 
2 I 
2 I Two 
I 96 
I 12 
2 2 
2 3 
2 2 
6 6 
2 0 
3 97 
2 4 
0 2 Three 
I 94 
0 0 
3 3 four 
20 63 
I 0 five 
I 28 
2 1 
Day Time 
STIH HIGH 
1 07h50 32 30 
121150 35 33 
19h50 
2 071150 8 24 
19h50 14 14 
3 07h50 28 27 
19h50 4 3 
4 071150 7 2 
12h50 19 10 
7 19h50 27 3 
1 071150 12 4 
12h50 14 2 
191150 6 3 
2 07h50 I 23 
19h50 4 0 
3 071150 5 13 
19h50 I 4 
4 0lh50 4 4 
12h50 2 2 
7 191150 3 2 
4 071150 0 0 
12h50 4 4 
7 19h50 I 2 
4 0lh50 2 I 
121150 5 6 
7 19h50 2 5 
4 071150 4 5 
121.50 2 3 
7 19h50 
-~ 
-
Response Rat ings (nrn) 
ANX SED 
2 0 
2 1 
4 2 
I 0 
0 2 
2 3 
2 2 
11 ') 
2 2 
4 3 
0 I 
3 3 
7 5 
0 0 
3 3 
0 0 
4 2 
2 2 
0 2 
0 2 
3 3 
I 2 
3 I 
5 6 
3 2 
,I 3 
5 5 
DOWN 
0 
1 
2 
0 
3 
3 
1 
1 
1 
I 
I 
3 
4 
2 
3 
31 
3 
62 
2 
2 
3 
2 
3 
7 
4 
3 
ti 
HUN 
3 
53 
3 
I 
4 
4 
0 
25 
2 
1 
2 
I 
4 
I 
3 
3 
3 
2 
15 
3 
42 
2 
3 
23 
3 
26 
I 
I 
i 
J 
I 
i 
N 
o 
w 
TABlE AI0.6 V isual Analogue Sca les (Subject 6 (L1) I 
Phase I (1M B) 
Week Day Time Response Rat ings (001) 
STiM HIGH ANX SED DO~N HUN 
One 1 07h50 41 5 13 2 2 21 
12h50 49 4 5 4 10 63 
19h50 59 58 6 5 11 65 
2 Dlh50 48 39 11 5 4 29 
19h50 26 5 3 4 5 4 
3 07h50 29 15 21 3 4 6 
19h50 32 25 2 3 2 ] 
4 07h50 ]0 5 5 2 ] 4 
l1h5D 15 8 7 6 5 78 
I 19h50 8 6 5 5 7 7 
Two 1 D7h50 8 I I 7 9 27 
12h50 5 6 5 5 6 33 
19h50 5 6 5 6 6 9 
2 07h50 8 8 9 9 10 19 
19h50 6 6 5 5 5 6 
3 D7h5D 8 8 6 7 7 7 
19h50 5 4 6 5 4 5 
4 07h50 7 5 6 8 7 7 
12h50 4 3 6 4 5 31 
7 19h50 6 5 16 3 27 13 
Three 4 07h5D 6 5 5 4 25 16 
12h50 4 4 5 4 13 49 
7 19h50 5 4 33 5 35 6 
four 4 07h50 5 5 15 I 16 18 
12h50 8 5 21 3 6 48 
7 19h50 7 5 6 7 9 9 
Five 4 07h50 7 7 7 5 8 9 
12h50 3 5 6 6 7 44 
/ 19h50 ?--- 5 4 5 5 5 ~-
Phase 2 (1M A) 
! Week Day Time 
I STIH HIGH 
i One 1 07h50 5 4 
I 12h50 6 6 
19h50 5 6 
j 2 07h50 5 6 
I 19h50 6 6 
! 3 07h50 4 4 
I 19h50 5 4 
4 07h50 5 5 
I 12h50 6 5 
7 19h50 9 5 
T ... ,o 1 07h50 5 4 
12h50 6 7 
19h50 6 5 
2 07h50 6 5 
19h50 5 4 
, 
J D7h50 7 6 
19h50 
4 07h50 6 6 
12h50 4 5 
7 19h50 5 3 
Three 4 O/h50 8 7 
12h50 6 4 
7 19h50 5 4 
Four 4 07h50 6 J 
12h50 6 5 
/ 19h50 I 5 
five 4 011150 4 4 
12h50 6 3 
L ... 7 19h50 4 6 
Response Ratillgs (mn) 
ANX SED 
5 4 
15 5 
2 6 
20 6 
22 5 
16 4 
15 5 
18 4 
21 5 
32 5 
26 4 
28 4 
22 5 
19 5 
30 4 
22 4 
6 6 
6 5 
3 4 
7 6 
4 3 
4 3 
4 4 
4 4 
18 3 
5 6 
5 4 
7 5 
OO~N 
6 
18 
23 
23 
24 
19 
9 
IS 
15 
20 
11 
23 
18 
22 
21 
10 
5 
5 
5 
8 
3 
5 
6 
4 
6 
7 
I 
6 
HUN 
7 
36 
18 
18 
29 
23 
6 
20 
45 
5 
3 
34 
5 
11 
8 
6 
7 
51 
6 
31 
33 
6 
I 
15 
6 
~ 
36 
I 
I 
! 
I 
i 
i 
I 
I 
I 
I 
I 
, 
I 
J 
N 
a 
.t:> 
TABLE A10.7 Visual Analogue Scales [Subject 7 ([G)l 
..-UQ:ll> , \ ,.-. ,.., 
Week Day Time Response Ratings (11m) 
STIM HIGH ANX SED DOWN 
One 1 071150 29 26 3 0 2 
121150 15 15 16 16 17 
191150 18 15 14 12 11 
2 071150 18 23 0 1 0 
19h50 6 11 10 8 7 
3 07h50 8 6 6 5 5 
19h50 5 to 9 10 9 
4 07h50 11 9 9 7 7 
12h50 14 14 9 6 13 
7 19h50 
Two 1 07h50 5 4 5 4 5 
12h50 20 15 17 to 8 
19h50 12 12 11 7 6 
2 07h50 8 6 8 7 6 
19h50 10 11 10 10 10 
3 07h50 II II 8 8 6 
19h50 14 14 12 II 7 
4 07h50 13 5 2 1 2 
12h50 17 6 0 0 0 
7 19h50 17 5 4 0 0 
Three 4 07h50 21 10 1 0 1 
12h50 9 11 2 3 4 
7 19h50 5 14 0 0 0 
four 4 07h50 
12h50 
7 191150 
five 4 07h50 
12h50 
I 191150 
Phase 2 (1M 8) 
Week Oay Time 
HUN 
STiH 
3 One I 071150 21 
12 12h50 21 
14 
19h50 16 
2 
2 07h50 22 
10 
19h50 19 
7 3 07h50 21 
4 
19h50 33 
I 
4 07h50 17 
32 
12h50 24 
I 1 191150 22 
5 Two I 07h50 20 
25 12h50 26 
5 i 
19h50 25 
10 I 
II I 2 07h50 27 1%50 19 
3 j 07h50 25 
7 
19h50 16 
4 4 07h50 20 
2 
121150 21 
3 7 191150 17 
2 Three 4 07h50 22 
34 12h50 28 
0 7 191150 28 
four 4 07h50 21 
121150 18 
7 19h50 20 
five 4 071150 17 
121050 24 
7 1%50 25 
Resoons. Ratinos ( .. H) 
HIGH ANX SED 
17 8 2 
23 4 0 
12 3 2 
11 6 3 
5 3 0 
13 2 0 
21 8 4 
10 6 0 
17 5 I 
10 7 3 
!3 7 3 
12 7 3 
12 8 4 
II 7 4 
II 8 3 
12 B 4 
10 4 I 
10 6 5 
15 11 7 
7 4 2 
15 7 6 
14 7 4 
16 13 7 
14 8 4 
II 9 3 
13 9 5 
14 7 3 
16 9 4 
19 16 1 
DOWN 
4 
3 
2 
2 
0 
2 
4 
I 
6 
2 
2 
2 
3 
2 
2 
5 
2 
2 
6 
4 
4 
4 
5 
0 
3 
3 
0 
7 
11 
HUH 
12 
35 
5 
8 
7 
5 
10 
5 
29 
8 
6 
31 
5 
4 
7 
6 
7 
7 
27 
4 
10 
41 
8 
5 
13 
II 
5 
26 
13 
N 
o 
tTl 
TABLE A10.6 Visual Analogue Scales [Subject 6 (ev)] 
t'nase 1 tIM 1'01 
Week Day Time Response Ratil19s (11m) 
STIM HIGH ANX SED 
One I 07h50 62 65 19 16 
121150 64 74 15 14 
19h50 35 30 18 25 
2 071150 45 44 24 29 
191150 30 15 41 21 
3 0)1150 70 64 22 II 
191150 48 42 56 20 
4 071150 78 76 10 5 
121150 
7 19h50 
Iwo I 071150 45 18 60 16 
12h50 28 18 65 64 
191150 21 18 62 43 
2 0)1150 43 43 23 5 
19h50 45 51 6 5 
3 07h50 61 60 52 7 
191150 45 45 5 16 
4 071150 66 II 4 3 
121150 64 44 56 16 
7 191150 46 54 8 10 
Three 4 07h50 74 73 5 3 
121150 76 II 6 7 
7 191150 71 70 9 II 
four 4 071150 69 57 9 9 
121150 II 13 65 14 
7 19h50 64 35 9 4 
f1ve 4 071150 75 76 8 6 
121150 70 69 12 8 
'-~- I 191150 45 43 13 13 
55 
Pllase 2 (1M 6) 
Week Day 
DOWN HUN 
19 70 One I 
15 71 
31 25 
21 29 2 
18 17 
15 12 3 
3D 12 
3 48 4 
I 
46 15 
6) 54 I 
Two I 
61 12 ! 
58 18 2 
6 11 
23 2 3 
4 6 
4 16 4 
26 43 
10 26 7 
4 5 Three 4 
6 70 
10 22 7 
10 14 four 4 
50 43 
4 42 1 
7 15 five 4 
21 69 
15 22 7 
Tire 
STlH HIGH 
071150 50 47 
121150 75 50 
191150 25 '22 
071150 
191150 62 26 
07h50 63 27 
19h50 
Olh50 56 46 
12h50 76 68 
19h50 
071150 54 46 
12h50 34 23 
19h50 38 27 
07h50 
19h50 
07h50 
191150 
07h50 
121150 
191150 
011150 
121150 
191150 
071150 
12h50 
191150 
011150 
121150 
191150 
Response Ratings (",n) 
AnX SED 
62 II 
58 7 
30 10 
14 5 
68 10 
24 6 
48 6 
15 3 
39 7 
34 10 
OOWN 
59 
61 
29 
3 
60 
49 
21 
12 
40 
30 
IIUN 
43 
72 
13 
15 
12 
43 
76 
13 
24 
42 
, 
, 
I 
N 
a 
0'1 
207 
VAS Weeks TMA.SEM MRT F ? iMB.SEM MRT I F ? Sea ie 
StinuJated 1 15.10 : 1.76 
· 
30.02 • 3.0B . 17.11' 0.0001 
2 9.58 • 1.00 . 21.12 • 2.45 . 
3 6.90 : 1.36 
· 
5.75' 0.0002 13.14 • 1.96 . 3.85' 0.0051 
" 
7.56 : 1.04 
· 
15.69 • 3.69 . 
5 5.13 • 0.94 
· 
18.87 : 5.42 . 
Hiqn 1 13.78 • 1.90 
· 
23.43 • 3.10 7.0l' 0.0090 
2 9.31 • 1.45 
· 
17.28 • 2.47 
3 7.JJ • 1.68 . 3.53' 0.0085 11.95 .2.26 2.07 0.0866 
4 5.25 • 0.80 
· 
10.38 • 3.54 
5 4.20.0.74 
· 
16.93.6.i3 
Anxious 1 12.17 • 1.30 18.33 • 3.04 3.04 0.0842 
2 7.60 • 0.97 12.15 • 2.11 
3 10.00 • 3.62 1.22 0.3048 9.14 • 1.49 2.29 0.0617 
4 7.88 • 2.32 17.19.5.07 
5 8.87 • 3.99 5.40 • 1.00 I 
Sedated 1 9.62 • 1.59 9.95 • 1.65 0.02 0.8883 
2 8.00 • 1.62 8.07 • 1.32 
3 5.19 • 1.50 0.78 0.5411 7.76.2.ll 0.58 0.6798 
4 8.56 • 3.59 6.59 • 1.36 
5 5.20 • 1.24 6.47 • 0.90 
Down 1 10.43 • 1.96 20.83 • l.98 5.511 0.0207 
2 9.22 • 1.75 12.28 • 2.38 
J 14.14 : 5.86 0.96 0.4330 8.76 • 1.98 2.27 0.0642 
4 18.56 • 7.34 17.69.7.09 
5 10.50 • 5.84 5.20 • 0.85 
Hungry 1 13.93 • 2.34 23.71 • 3.79 4.BO' 0.0304 
2 12.09 • 2.35 15.90 • 2.89 
3 14.71 • 3.74 0.14 0.9676 21.47 • 5.53 0.83 0.5111 
4 13.38 • 3.56 16.81 • 4.65 
5 14.27 • 3.99 19.53 • 5.61 
The rr.ean responses to each of the VAS sea les for week 1 for both treatlr.ents are given in the boOY of the 
table. For ·~eek. 1. n ,. 58 for eac" phase. df ,. 1.114. Sold italicised F rat~os and P values indicate 
significance for weeleS l. 
For the corr.oartson of the treatrr.ent '>'leeks {2 .. 5} with ""eek 1, n ,. 177 for each phase. df ,. 4.177. 
The "'s in the AAT column inclicates ',mere the differences in the weexs occurred. 
§ indicates a P value of bet~een 0.015 and 0.05 
, indicates a ? value of less than 0.01 
TABlE AlO.l.1 Average Weelcly Responses to the 5 Scales of the VAS Questionnaire (Mean Values for 7 
Subjects) 
Subject TM A • SEM TM 8 • SfM F P 
1 1.61 • 0.57 5.39 • 0.63 10.2' 0.0030 
2 11.17 • 2.99 26.35 • 5.85 1.95 0.1121 
3 9.63 • 0.61 8.32 • 0.91 1.43 0.2398 
4 6.82 • 0.73 24.44 • 2.91 34.0' 0.0000 
5 4.11 , 0.94 40.J5 • 5.69 J8.2' 0.0000 
6 5.61 • 0.26 6.39 • 0.31 1.56 0.1187 
n" 16 for each Test Medication Phase for Subject 5. df .. 1.30 
n" 11 for each Test Medication Phase for Subjects 1. 2, and 4. df • 1.32 
n" 18 for each Test Medication Phase for Subjects 3 and 6, df • 1.34 
, indicates a P va lue of less than 0.01 
TABLE AIO.2.2 Average "StiOl.lJation" Response for each Test Medication Phase per Volunteer 
Subject TM A , S£M 1M B , SEM F P 
1 1.61 , 0.29 4.28 • 0.14 10.1' 0.0025 
2 23.24 • 4.23 32.41 • 6.43 1.42 0.2422 I 
3 1.14 • 0.46 5.32 • 0.54 11.8' 0.0015 
4 3.41 • 0.61 18.06 • 2.46 33.2' 0.0000 I 
5 4.76 • 1.41 30.59 • 6.89 13.5' 0.0009 
6 4.78 • 0.30 5.94 • 0.35 6.50' 0.0155 I 
n' 16 for each Test Medication Phase for Subject 5, df " 1.30 
n· 17 for each Test f1edication Phase for Subjects 1. 2, and 4, df • 1,32 
n " 18 for each Test Medication Phase for Subjects 3 and 6, df " 1.34 
§ indicates a P va lue of between 0.015 and 0.05 
I ind1cates a P va lue of less than 0.01 
TABlE AIO.2.3 Average "High" Response for each Test Medication Phase per Volunteer 
Subject TM A • SEM TM B • SEM f P . 
23.6' 
I 
1 2.39 • 0.29 5.61 • 0.59 0.0000 i 
2 22.35 • 5.03 30.18.7.61 0.74 0.4068 
3 7.53.0.33 4.84 • 0.43 24.8' 0.0000 
4 3.53 • 0.69 IB.41 • 2.43 34.7' 0.0000 
5 2.76 • 0.54 4.12. 1.08 1.25 0.2122 
6 12.33 • 2.34 9.56 % 1.78 0.89 0.3616 
n' 16 for each Test Medication Phase for Subject 5, df • 1,30 
n· 17 for each Test Medication Phase for Subjects 1. I, and 4, df • 1,32 
n· 18 for each Test Medication Phase for Subjects 3 and 6, df • 1.34 
I indicates a P value of less than 0.01 
TABLE AIO.2.4 Average "Anxious" Response for each Test Kedication Phase per Volunteer 
Subject TM A • SEM TM B • 5EM F P 
1 2.78.0.67 4.44 • 0.51 3.61 0.0660 
2 25.94 • 5.59 14.88.4.35 2.44 0.1283 
3 6.37 • 0.28 4.63 • 0.43 11.6' 0.0016 
4 3.53 • 0.68 15.71 • 2.51 21.9' 0.0000 
5 2.65 • 0.40 3.47 • 0.98 0.61 0.4501 
6 4.39 • 0.2~ 5.89 • 0.37 11.9' 0.0015 
----- ---
n. 16 tor each Test Medication Phase for Subject 5, df • 1,30 
n • 17 for each Test Medication Phase for Subjects 1. 2, and 4, df • 1,32 
n • 18 for each Test Medication Phase for Subjects 3 and 6. df • 1.34 
t indicates a P va lue of less than 0.01 
TADLE AIO.2.S Average "Sedated" Response for each Test licdication Phase per Volunteer 
Subject TM A , SfM TM8.5EM F P I 
1 2.44 • 0.39 3.11 • 1.63 11. 4' 0.0019 
2 44.71 ,8.96 31.94 • 9.60 0.95 0.3486 
J 6.47 • 0.43 4.58 • 0.39 10.6' 0.0024 
4 3.76 • 0.64 16.29.2.75 19.7' 0.0001 
5 8.19 • 3.75 3.35. 1.15 1.58 0.2172 
6 9.89 • 1.62 11.89. 2.07 0.58 0.4600 
n • 16 for each Test Medication Phase for Subject 5, df • 1.30 
n • 17 for each Test Medication Phase for Subjects 1. 2, and 4, df • 1,32 
n • 18 for each Test Medication Phase for Subjects 3 and 6, df • 1,34 
lind lea tes a P va lue of less than 0.01 
TABlE AlO.2.6 Average "Down" Response for each Test /\edieation Phase per Volunteer 
I 
Subject TMA.SEM TM8.SEM F P 
1 16.50 , 5.60 7.61 • 1.48 2.36 0.1340 
2 21.35 • 6.59 25.53.7.71 0.17 0.6878 
3 14.26 • 3.59 12.47 • 4.27 0.10 0.7537 
4 4.00 • 1.11 19.12 .4.92 9.0' 0.0052 
5 8.41 • 2.86 24.59 • 9.07 2.89 0.0987 
6 16.11 • 3.44 20.009 .3.55 0.62 0.4457 
n" 16 for each Test Medication Phase for Subject 5, df • 1,30 
n. 17 for each Test Medication Phase for Subjects I, 2, and 4, df " 1,32 
n • 18 for each Test Medication Phase for Subjects 3 and 6, df • 1.34 
1 Indicates a P value of less than 0.01 
TAlliE AlO.2.7 Average "Hungry" Response for each Test Ht.'<.Iieation Phase per Volunteer 
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five 66 II 12 35 34 22 
-.--~------
PM •• 2 (Tit A) 
Ue~ponse Hat hll ~ !lllll) on sg 
ileek Ooy 
Question 2 Quest Ion 1 Qut!stlon 1 Qu~st IOU 4 Quest Ion 5 Question 6 
00. I 68 Il 14 44 41 22 
4 ,] 20 20 15 15 24 
I.u I II 18 15 f--_ 31 12 31 
4 51 18 16 39 36 20 
lhre~ 4 60 19 16 18 29 39 
four 4 58 19 19 40 41 22 
f ille 4 65 11 14 11 II 26 
!M!lLllid..! POll-ileal S4Uoty Qu •• tlcnnolre. (SIll 04t. [Subject 4 (fAll 
Ph ••• I (Tit 8) 
UespOll5,e Itat 1m S (11111) on 5Q 
Week Day 
Quest iou 5 
----
Qu~st ion 1 Ques( Ion 2 Quest 1011 j ~.lon4 Quest ion 6 
0"" I 41 31 32 }4 35 42 -
4 12 ] 6 31 ]6 ]4 
Iwo 1 61 n j] 32 35 41 
4 56 21 35 /0 69 29 
~~ -~ H ]} 29 58 62 4] 
four 4 51 29 21 59 60 29 
five 4 21 12 U 50 56 21 
Pha,. ~~ A) 
u.s oflse Rill 'T~.JIIIII) Oil ~ _____ _ ___ _ 
Heek Oay ---~-r Questioll I Questioll 2 Qu.~~~ Qu.stl~L(luestIOIlJ (juestloll 6 
60 16 O,jC 
64 I-~I 24 
___ ~~ -41--/----i!-- _ 20 
51 
5J 57 26 
rwo 1----l----1 __ J6__ ~-26-~--2b-I--4/-__I-5-0--I--~ 
- ~'I 15 ~2 ~ ~Jl 4~ gu <:~:. f : . __ H__ I~-- - IL  =~~o__ _lJ --: - / = 
---- --- .----- - - j 
5 14 2H 6 
----- -~--- ----
f iv._L __ ~_~ _ 
N 
I-' 
o 
TABLE Al!.!.5 Pre-Heal Hunger and Appettt. Que.tlo_lres (AHQ) Dat. [Subject 5 (VII)] TABLE Al!'Z.5 
Phase 1 (TM 8) Phase I (TM 8) 
Response Rat tl S {11m} on AHQ I 
Week Day Week Day 
Question 1 QuestIon 2 Question 3 Quest Ion 4 
One 1 10 19 81 72 One I 
4 87 89 91 19 4 
Twu 1 58 59 35 61 Iwo 1 
4 52 63 66 69 4 
Three 4 91 98 96 98 Three 4 
four 4 42 47 49 49 Four 4 
five 4 20 22 20 18 Five 4 
---
Phase 2 (TM A) Phase 2 (IM A) 
Response Ra t i s llIJIll on AHO 
Week Day Week Oay 
Question 1 Question 2 Quest Ion 3 Quest ion 4 
One 1 55 51 58 53 One 1 
4 18 19 20 18 4 
Two 1 26 26 28 25 Two I 
4 4 
Thrt:e 4 33 35 41 45 Three 4 
four 4 12 10 11 9 four 4 
_!~~ ___ I 4 L _____ ~1_6_._ 16 18 15 five 4 
TABLE AIl.1.6 Pre-Ileal Hunger and Appetite Questionnaires (AHQ) Data [Subject 6 Ill)] TABLE AIl.Z.S 
Ph.,. 1 (TM 8) Pt.dse 1 (1M H) 
Response Ratln s ( ... \ on AHO 
Week Day 
Question 1 Quest ion 2 Question 3 Quest lOn 4 
Week Oay 
One 1 16 65 63 62 One I 
4 55 56 61 63 4 
Two 1 10 19 19 19 Iwo I 
4 34 30 31 29 4 
Three 4 32 39 45 49 Three 4 
four 4 41 48 25 25 four 4 
five 4 30 28 23 l8 
~ 
f_!~e_ 4 
Phase 2 (1M A) Phase 2 (TM A) 
Response Ratin s (nln) on AHQ 
Week Oay Ueek Day 
Question 1 Question 2 Quest ion 3 Quest ion 4 
One 1 36 38 41 41 One 1 
4 36 42 41 50 4 
Iwo 1 25 35 40 45 Iwo I 
4 48 51 55 52 4 
Three 4 48 51 55 52 Three 4 
four 4 18 16 19 20 four 4 
five 4 26 30 28 29 Five 4 
----
Post-Ileal Satiety Questionnaires (SQ) Datil [Subject 5 (VII)] 
Resnonse Rat in 5 (Ifln) on SQ 
Ques t ion 1 Question 2 Question 3 Question 4 Quest iOIl 5 Quest 100 6 
74 2 6 62 64 I 
12 2 2 60 58 2 
15 2 I 0 0 0 
80 1 0 74 72 0 
90 0 3 18 30 2 
77 1 0 30 28 3 
67 2 0 34 34 --~~.-
ReSDonse Ratln s (mil) on SO 
Question I Question 2 Question 3 Question 4 Question 5 Quest ion 6 
)4 4 6 38 38 2 
99 I 0 II 24 2 
75 4 0 26 45 2 
72 2 2 0 0 2 
88 2 2 21 L-_JO_ J 
Post-Ileal Satiety Questionnaires (SQ) Dat. [Subject S (1I)] 
Response Rat II s (lao) on SQ 
Question 1 Quest ion 2 Question 3 Question 4 Question 5 Quest Ion 6 
53 ZI 21 29 50 80 
48 22 9 II 40 33 
38 ZI 18 4 30 29 
47 13 II 12 14 31 
62 25 18 23 41 46 
57 22 21 35 54 50 
51 17 II 50 40 45 
Response Rat In S (filII) on SQ 
Quest ion 1 Quest10n 2 Question 3 Ques t ion 4 Quest ion 5 Quest ion 6 
62 24 17 SO 50 29 
51 31 24 38 48 82 
42 26 32 31 40 71 
29 22 27 50 52 77 
47 18 II 31 38 51 
52 18 16 11 32 56 
50 24 12 56 52 52 
N 
....... 
....... 
TABLE Alt.l.' P .... -Heal Ilul>;jor .nd Appettte Qu •• ttonllllt ..... (AHQ) DIIt. [Subject 7 (EG)] TABLE All.2.7 
Ph.se I (1M A) Phase 1 (TM A) 
Resoonse Rat In S (11m) on AHQ 
Week Oay 
Question 1 Quest ion 2 Quest ion 3 Quest ion 4 
Week Day 
One 1 24 29 25 35 One I 
4 60 49 31 35 4 
Iwo 1 25 11 16 23 Two 1 
4 J8 39 30 36 4 
Three 4 46 41 34 49 Three 4 
Four 4 four 4 
five 4 five 4 
Phase 2 (1M B) Phase 2 (TM 8) 
Response Rat in s (am) on AHQ 
Wet::k Day 
Quest ion 1 Question 2 Question J Question" 
Week Day 
0 .. 1 50 46 27 45 One 1 
4 35 28 22 36 4 
fwo 1 30 32 27 32 Iwo 1 
4 32 30 25 27 4 
Three 4 45 41 34 48 Three 4 
four 4 27 29 24 33 four 4 
~.~ve 4 26 30 12 
--
26 
---------
five 4 
TAIllE AI1.1.8 Pre-lleol Hunger and Appetite Questionnaire. (A1IQ) Data [Subje<:t 8 (ev)] TABlE AI1.2.8 
Pha,. I (1M A) Phase 1 (TM A) 
Response Ratin s (11m) on AHQ 
Ueek. Day Question 1 Question 2 Quest ion 3 Quest ion 4 Week Day 
One 1 51 42 30 38 One I 
4 59 69 71 11 4 
Iwo I 26 22 28 45 1.0 1 
4 35 36 29 40 4 
Three 4 55 66 67 66 Three 4 
Four 4 60 57 62 58 Four 4 
five 4 59 60 55 60 five 4 
Phd,e 2 (1M B) Phase 1 (1M B) 
Response Ra t i ngs (am) on AHQ 
week Day 
Question 1 Quest Ion 2 Question 3 QuestIon 4 Week Day 
One 1 75 64 66 63 One I 
4 63 41 49 65 4 
Iwo 1 34 31 33 35 Two 1 
4 4 
Three 4 lhr~e 4 
Four 4 Four ~ 
L-_f ive 4 Five 4 
Po.t-lleol Sattety Questtonlllltre. (SQl Dat. [Subject' (EG)] 
Response Rat in 5 (OlD) on SO 
Quest ion 1 Question 2 Question 3 Question 4 Quest ion 5 Ou~st ion 6 
14 2 3 12 21 14 
65 10 19 35 29 6 
85 18 12 16 24 13 
3 5 2 41 39 6 
60 10 0 40 36 10 
- - ---------
Response Rat in s (,"u) on SQ I 
Quest ion 1 Quest ion 2 Quest ion 3 Question 01 Quest ion 5 Ques t ion 6 
64 15 9 21 30 26 
71 20 12 30 39 5 
28 12 5 18 26 10 
42 19 14 31 31 18 
46 26 12 21 2B 12 
44 22 14 21 25 19 
49 42 28 29 34 15 
Post-Heal Satiety Questionnaires (SQ) Oat. (Subject 8 (CV)] 
Response Rat in s ("",) on SQ 
Question 1 Question 2 Question 3 Quest Ion 4 Question 5 Question 6 
66 18 15 14 14 15 
19 44 26 68 BO 51 
68 19 11 18 80 20 
62 21 18 39 40 31 
70 15 16 10 70 11 
64 12 15 19 16 21 
I 68 20 21 ~- .. - 70 69 24 
----
--
Response Ratio S (11m) on SQ 
Ques t 10n I Quest ion 2 Quest 10n 3 Question 4 Quest Ion 5 Qu~stion 6 
0;4 II 11 68 66 35 
75 20 15 15 82 54 
70 26 17 31 41 18 
______ 1 __ -
N 
...... 
N 
TAIllE All.1.9 Bodi ly Sensations Quest ionna ire (BSQ) data [Subject I (55)] 
PHASE ONE (1M A) PIIASE TWO (TM B) 
WEEK I 2 3 4 5 I 2 3 4 5 
DAY I 4 I 4 4 4 4 I 4 I 4 4 4 4 
GASTRIC 
1. feeling of ell'41tiness 
· · · · 2. runi> lIng 
3. ache 
4. pain 
5. tenseness 
6. nausea 
7. no gastr1c sensations 
· · · · 
HOUTH AND THROAT 
1. e~tiness 
2. dryness . 
3. salivation 
· · · · · 
. 
· 4. unpleasant taste/sensation 
5. pleasant 
· · · 6. tightness 
CEREBRAL 
1. headache 
2. dizziness 
3. fa intness 
<1. spots before the eyes 
5. ringing in the ears 
GENERAL 
1. weakness 
2. tiredness 
3. rest lessness 
4. cold . 
· · · 5. warmth 
· · · · · 
. 
· 6. muscular spasms 
MOOO WHEN HUNGRY 
1. nervous 
2. irritable 
3. tense 
4. depressed 
5. apathetic 
6. cheerful 
· 7. excited 
8. Cd 1m 
· 9. relaxed . 
· · 
. 
· · 
. 
· · 10. contented 
· 
TADIE AI1.2.9 Food Preference Questionnaire (fPQ) Oata [Subject 1 (55)] 
Nuuber of I terns Chosen on fPQ 
Tata I Nurftler Chosen High Protein High Carbohydrate 
WEEK Day Phi (TM A) Ph2 (1M B) Phi (TM A) Ph2 (1M B) Phi (TM A) Ph2 (TH B) 
One I 13 7 . 6 
4 13 6 7 2 6 4 
lwo I 10 6 6 3 4 J 
4 11 5 6 2 5 3 
Three 4 10 5 6 2 4 J 
four 4 9 5 4 J 5 2 
five , 4 10 5 5 2 5 J 
-
TAIllE All.I.IO Bodi Jy Sensat ions Qoest ionna ire (OSQ) data [Subject 2 (CAll 
PIIASE ONE (TM A) PHASE T~O (1M B) 
WEEK I 2 J 4 5 I 2 J 
DAY I 4 I 4 4 4 4 I 4 I 4 4 
GASTRIC 
I. feeling of e""tiness 
· · · 
. 
2. runi>ling 
· · · 
0 
3. ache 
· 4. pain 
· 5. tenseness 
6. nausea 
7. no gastric sensations 
· · 
HOUTH AND TlIROAT 
1. eq>t lness 
· · 2. dryness 0 
· · 3. sa Iivation 
· 4. unpleasant taste/sensation 
· 
0 
· · 
0 
· 5. pleasant 
· · 6. tightness 0 
CEREBRAL 
1. headache 
· · · 2. dizziness 
3. faintness 
4. spots before the eyes 
5. ringing in the edrs 
· 
GENERAL 
1. weakness 
2. tiredness 
· · · 3. rest lessness 
4. cold 
· 
0 
· 5. warmth 
6. muscular spasms 
HOOD WHEN HUNGRY 
1. nervous 
2. Irritable 
3. tense 
4. depressed 
5. apathet ie 
6. cheerful 
· · 7. excited 0 
· 8. calm 
· · · 
. 
· 9. re laxed 
· · · 
0 
10. contented 
· 
. 
· · · 
TABLE Al1.2.10 food Preference Questionnaire (fPQ) Oata [Subject 2 (CAll 
Nunber of Items Chosen on FPQ 
Tota 1 Nurmer Chosen High Protein High Carbohydrate 
WEEK Day Phi (TM A) Ph2 (TM 0) Phi (TM A) Ph2 (TM 8) Phl (TM A) Ph2 (TM B) 
One I 9 3 6 
4 11 0 4 0 7 0 
Two I II 6 4 I 7 5 
4 12 2 5 0 7 2 
Three 4 14 7 6 5 B 2 
Four 4 12 5 5 2 7 3 
Five 4 4 I J 
--
4 
4 
· 
· 
0 
· 
5 
4 
· 
· 
· 
· 
· 
· 
N 
I-' 
W 
fABlE AI1.1.11 Bodily Sen.atlons Questionnaire (DSQ) data [Subject l (LEI] 
PHASE ONE (TM B) PHASE TWO (TN A) 
WEEK I 1 3 4 5 I 2 3 4 5 
DAY 1 4 I 4 4 4 4 I 4 I 4 4 4 4 
GASTRIC 
1. fee ling of e~t ioess 
· · · · · · · · 2. runbling 
3. ache 
4. pain 
S. tenseness 
6. nausea 
· · 7. no gastric sensations 
HOUTH AND THROAT 
1. erf4ltiness 
· · 2. dryness 
· · · 
. 
· · 3. sa) ivat ion 
4. unpleasant taste/sensation 
5. pleasant 
6. tightness 
CEREBRAL 
1. headache 
· · 2. dizziness . 
3. fa intness 
4. spots before the eyes 
5. ringing In the ears 
GENERAL 
1. weakness 
2. tiredness 
3. rest lessness 
· · · 4. cold 
· 
. 
· · 5. warmth 
6. rruJscu Jar spasms 
MOOD WHEN HUNGRY 
1. nervous 
2. irritable 
), tense 
4. depressed 
5. apathet Ic 
6. cheerful 
· 7. excited 
8. calm 
· · · · 
. 
· 
. 
9. relaxed 
· 
. . 
· · · 10. contentE!d 
TABLE AI1.2.11 food Preference Questionnaire (fPQ) Data [Subject 3 (LEll 
NUlooer of I tems Chosen on FPQ 
Tota I Nuntler Chosen High Protein High Carbohydra te 
WEEK Day Phi (TM B) Ph2 (TM A) Phi (1M B) Ph2 (TM A) Phi (TM B) Ph2 (TM A) 
. 
One 1 14 8 I 5 I 3 
4 10 I 5 5 5 2 
Two 1 9 I 5 5 4 2 
4 9 6 5 5 4 I 
Three 4 9 5 6 5 3 0 
Four 4 9 6 6 4 3 2 
five 4 8 1 6 2 2 0 
.. 
TABI E Al1.1.12 Bodlly Sensation. Quest ionna ire (BSQ) data [Subject 4 (EAll 
PHASE ONE (m B) PHASE TWO (TM A) 
WEEK 1 2 3 4 5 1 2 3 
DAY I 4 I 4 4 4 4 I 4 I 4 4 
GASTRIC 
I. feeling of e,,,,tiness . 
· · 
. 
· · 
. 
2. runbllng 
3. ache 
4. pain 
S. tenseness 
6. nausea 
7. no gastric sensations . 
· 
MOUTH AND THROAT 
1. eu~t i ness 
2. dryness . 
· · · 3. salivation . 
4. unpleasant taste/sensation 
5. pleasant 
· 
. 
· 
. 
6. tightness 
CEREBRAL 
1. headache 
2. dizziness 
3. fa intness 
4. spots before the eyes 
5. ringing in the ears 
GENERAL 
1. weakness 
2. ti redoes s 
3. res t lessness 
4. cold 
5. warmth 
6. museu lar spasms 
MOOD WHEN HUNGRY 
1. nervous 
2. irritable 
3. tense 
4. depressed 
5. apathet ic 
6. cheerfu I 
7. excited 
8. calm 
9. relaxed . . 
· · · · · 
. 
to. contented . 
TABLE AII.2.ll food Preference Questionnaire (fPQ) Data [Subject 4 (EAl] 
Number of Items Chosen on FPQ 
Total Nunber Chosen High Protein High Carbohydrate 
WEEK Day Phi (TM B) Ph2 (TM A) Ph! (TM 8) Ph2 (TM A) Phi (TM B) Ph2 (TM A) 
One 1 12 I 5 
4 14 8 6 
Two 1 13 13 8 I 5 6 
4 14 14 8 8 6 6 
Three 4 14 0 8 0 6 0 
Four 4 15 8 I 
five 4 0 15 0 8 0 I 
I 
4 5 I 
4 4 
· 
· I 
I 
, 
, 
I 
I 
I 
I 
I 
, 
· 
N 
........ 
.p. 
fABlE All .1.13 Bodily Sensations Questionnaire (BSQ) data [Subject 5 (VII)] 
PHASE ONE (TM B) PHASE fHO (TM A) 
WEEK 1 2 1 4 5 1 2 J 4 
DAY 1 4 1 4 4 4 4 1 4 1 4 4 4 
GASTRIC 
1. fee 110g of eflf)t lness 
· · · · · · · 2. rullblilllJ 
3. ache 
4. pain 
· 5. tenseness 
6. nallsea 
7. no gdstric sensations . . 
MOUTH AND THROAT 
1. ellipt loess 
· · 2. dryness 
· · 3. sal ivation 
· · · 4. unpleasant taste/sensation 
· · · · 5. pleasant 
6. tlQhtness 
CEREBRAL 
1. headache 
· 2. dizzinE:ss 
3. faintness 
· 4. spots before the eyes 
5. ringing in the ears 
GENERAl 
1. w~dkness 
2. tiredness 
3. rest lessness 
· 4. cold 
· · · 5. warmth 
· · · · 6. muscular spasms 
MOOD WHEN HUNGRY 
1. nervous 
2. Irritable 
· 3. tense 
4. depressed 
5. apathetic 
6. cheerful 
· 7. excited 
8. calm 
· · · 9. re laxed 
· · · · · 
. 
10. contented 
fABlE AI1.2.13 food Preference Questionnaire (fPQ) Data [Subject 5 (VII)] 
Number of I tems Chosen on FPQ I 
Tota I Number Chosen High Protein High Carbohydra te 
WEEK Day Phi (TM 0) Ph2 (TN A) Phi (TM 0) I Ph2 (TM A) Phi (TH 0) Ph2 (TM A) 
One I 10 6 . 4 I 
4 II 5 6 
, 
6 5 9 I 
Two I II 15 6 6 5 9 
4 12 6 6 
Three 4 H 15 7 4 I 11 
Four 4 14 16 6 6 8 10 
five 4 18 II I 5 II 
. 
12 
TABLE AI 1.1.14 Bodily Sensations QuestlolUlaire (BSQ) data [Subject 6 (L1)] 
PHASE OUE (TM B) PHASE T~O (TM A) 
5 ~EEK I 2 J 4 5 1 2 3 
4 DAY 1 4 I 4 4 4 4 I 4 I 4 4 
GASTRIC 
I. tee ling of empt iness 
2. rumbling 
· 
. . . . . 
3. ache . 
4. pain 
S. tensenes s 
· 
6. nausea 
· · 7. no gastriC sensations 
· · 
MOUTH AND THROAT 
1. en~t iness 
2. dryness 
· 
. . 
3. sa 1 ivat lon 
· 
· 4. unp leasant taste/sensat ton · · 5. pleasant 
6. tightness 
CEREBRAL 
1. headache 
· 2. d izz tness 
3. faintness 
4. spots before the eyes 
5. ringing in the edrs 
GENERAL 
1. weakness 
· 2. tiredness 
· · 3. rest lessness 
4. cold 
5. warmth 
6. IJIUscular spasms 
MOOD WHEN HUNGRY 
1. nervous 
2. irritable 
3. tense 
4. depressed 
5. apathetic 
6. cheerful . 
· 
. . 
I. excited 
· 8. calm · · 
. . 
· · 9. relaxed 
· 10. contented 
· 
TABlE A11.2.14 food Preference Questionnaire (fPQ) nata [Subject 6 (ll)] 
Nuuber of I tems Chosen on FPQ 
iota I NutMer Chosen High Protein High Carbohydrate 
~EEK Oay Ph! (TM 8) Ph2 (TM A) PhI (TM B) Ph2 (TH A) Ph! (lM B) Ph2 (TM A) 
One I 17 II LO 5 7 6 
4 14 10 8 5 6 5 
Two I 12 9 6 5 6 4 
4 13 2 6 0 I 2 
Three 4 3 0 1 0 2 0 
Four 4 4 J 0 0 4 3 
Five 4 4 J I 0 3 J 
4 
4 
. 
. 
5 
4 
. 
I 
I 
i 
I 
N 
i-' 
U1 
TABLE All. LIS Bodi Iy Sensat ions Questionna Ire (OSQ) data [Subject 1 (EG)] 
PHASE ONE (T11 A) PHASE TWO (TM B) 
WEEK I 1 J 4 5 I 1 J 4 5 
DAY I 4 I 4 4 4 4 I 4 I 4 4 4 4 
GASTRIC . 
1. fee i jog of empt 'ness . . 
· 
. . . . 
· 
. 
2. runbllng . 
· · 3. ache 
4. pain 
5. tenseness 
6. nausea 
7. no~stric sensations 
MOUIH AND IHROAT 
1. e~[iness 
2. dryness . 
3. salivation 
4. unpleasant taste/sensation 
5. pleasant 
6. tightness 
CEREBRAL 
1. headache 
2. dizziness 
3. faintness 
4. spots before the eyes 
5. ringing in the ears 
GENERAl 
1. weakness 
2. tiredness 
3. rest lessoes'S 
4. cold 
5. warmth 
6. rtlJSCu jar spasms 
MOOD WHEN HUNGRY 
1. nervous 
2. irritable 
3. tense 
4. depressed 
5. apathet Ie 
6. cheerful 
7. exel ted 
8. Cd 1m . 
· 
. . . . . 
· 
. . 
9. re laxed 
10. contented 
-~-.. -.--.~-
TABLE Al1.2.15 food Preference QuestiolUldire (f~Q) Data [Subject 7 (EG)] 
Number of I terns Chosen on FPQ 
Tota I Nunber Chosen High Protein High Carbohydrate 
WEEK Day Phi (TM A) Ph2 (TM B) Phi (1M A) Ph2 (TH B) Phi (1M A) Ph2 (1M B) 
One I 19 19 9 . 10 10 9 
4 10 IB 10 9 10 9 
Iwo 1 10 19 10 9 10 10 
4 16 19 9 9 9 10 
Three 4 16 19 6 9 10 10 
Four 4 18 9 9 
five 4 II 9 8 
-
IABLE AIl.I.16 Bodily Sensations Questionnaire (BSQ) data [Subject 8 (ev)] 
PHASE ONE (TM A) PHASE IWO (1M B) 
WEEK I 2 ] 4 5 1 2 J 
DAY 1 ~ I 4 4 4 4 I 4 I 4 4 
GASTRIC 
1. fee ling of empt iness 
· · · · · · · 2. rURilling 
· 3. ache 
· 4. pain 
5. tenseness 
6. nausea 
7. no qastric sensat ions 
MOUTH AND IHROAT 
1. eflllt 1ness 
2. dryness 
· 3. salivation 
· · 
. 
· · · · 4. unpleasant taste/sensation 
5. pleasant 
· 6. tightness 
CERE6RAl 
1. headache 
2. dizziness 
3. fa intness 
4. spots before the eyes 
5. ringing in the ears 
GENERAL 
1. weakness 
2. tiredness 
· J. restlessness 
· · 4. cold 
· 5. warmth 
6. ruscuiar spasms 
MODO WHElI HUNGRY 
1. nervous 
2. irritable 
· 
. 
3. tense 
· · · 4. depressed 
· · 5. apathetic 
· 6. cheerfu I 
· · · 7. exe ited 
· · · 8. calm 
· · 9. re laxed 
· 10. contented 
· 
TABLE AIl.2.16 Food Preference Questionnaire (FPQ) Data [Subject 8 (CV)] 
Number ot !terRS Chosen on FPQ 
Tota I Nunber Chosen High Protein High Carbohydra te 
WEEK Day Phi (1M A) Ph1 (1M B) Phi (TM A) Ph2 (1M B) Phi (1M A) Ph2 (TM 8) 
One I i4 3 6 I 6 2 
4 11 I I 0 4 I 
Iwo I J 0 2 0 I 0 
4 4 3 2 
Thre~ 4 1 I 0 
Four 4 I 0 I 
five 4 I 0 I 
4 5 
4 4 
i 
! 
, 
, 
N 
I-' 
Q) 
217 
TASlE AI!.3.1 Average Responses to the 8SQ (mean 6 subjects) 
~o of Suo jeets 1./0 of Tii'OOS 
Sensations I I TM A rna ~M A TM 8 
€:Ttlty (stomach) I 5 ; II 12 
,untll ing 2 I 2 3 ; 
Pain ! 0 , 0 
Nausea 2 0 4 0 
, I ~o sensations ; 5 3 !1 
ElIVty (ltOuth) I 1 I 1 ! 
Ory 4 5 9 9 
Sa 1 ivation 1 2 2 5 
uno leasant 2 I 2 5 5 
PJeasnat 2 2 2 J 
!-feadache ! 3 1 5 
OiZZlness 1 0 1 0 
Fa intness 1 0 i 1 0 
Ringing in ears 0 I I 0 I 
Tiredness 2 I , J 2 
Rest iessness 0 2 0 I 3 
Cold , 4 3 I 7 7 
'.Iarmth 1 
, 
I 4 2 
Irritable 0 ! a I I 
Cheerful 1 2 I I 2 
Excited 1 0 1 I 0 
Calm 4 J 9 10 
Re laxed 5 5 16 15 
Contented 2 I 4 2 
TABLE A12.1.1 
Phase I (TH A) 
~eek Day 
I I 
q 
2 1 
Q 
3 4 
Q 4 
5 4 
Ph 2 (TH B) ~-- - , ... -,
Week Day 
I 1 
4 
2 I 
4 
3 4 
4 4 
5 4 
Quantity of Each Food Conm::I(.Hty Presented. Remaining and faten (g) at the Test 
Meals (Subject 1 (55)] 
Measure (g) Meat Potato Veqetab Ie Gravy Bradd Margar ioe 
Amt Presented 99.20 197.qO 128.10 60.00 17.80 
Amt Rema.ining 44.30 192.qO 19.60 0.00 8.30 
Amt Eaten 5q.90 5.00 108.50 60.00 9.50 
Amt Presented 76.50 97.20 108.50 QQ.50 60.00 19.80 
Amt Remaining 18.70 83.70 0.20 18.30 0.00 9.QO 
Amt Eaten 57.80 13.50 108.30 26.20 60.00 10.40 
runt PI"esented 93.90 125.80 115.30 20.00 60.00 22.80 
Amt Relllaining 37.70 123.QO 18.00 2.40 30.00 15.70 
Amt Eaten 56.20 2.40 97.30 17.60 30.00 7.10 
Amt Presented 104.50 238.80 110.60 22.80 60.00 31.10 
Alut Rema ioing 13.70 105.80 22.20 3.90 30.00 22.30 
Amt Eaten 90.80 133.00 88.40 18.90 30.00 8.80 
Amt Presented 105.90 216.30 111.50 18.20 60.00 20.50 
Amt RelIldining 18.40 94.60 1.00 Q.20 15.00 7.50 
Amt Eaten 87.50 121.70 110.50 13.90 45.00 13.00 
Amt Presented 101.90 220.00 91.20 20.70 60.00 18.60 
Amt Remaining 30.00 62.00 8.30 3.QO 30.00 8.30 
Amt Eaten 11.90 158.00 88.90 17.30 30.00 10.30 
Amt Presented 96.70 224.10 108.90 19.40 60.00 22.80 
Amt Rema 10109 36.60 95.50 10.20 3.20 30.00 4.90 I Amt Eaten 60.10 129.20 98.70 16.20 30.00 17.90 
Measure (9) Meat Potato Vegetable Gravy Bread Margarine 
AlDt Presented 111.10 193.90 94.20 24.00 60.00 11.90 
Amt Remaining 4.30 18.90 15.10 2.10 7.50 3.90 
Amt Eaten 105.80 115.00 19.10 21.90 52.50 14.00 
AD'lt Presented 119.40 231.60 112.20 25.60 60.00 21.80 
Amt Rema ining 40.60 30.70 l.80 2.90 lO.OO 10.20 
Amt Eaten 18.80 200.90 108.40 22.70 30.00 11.60 
Amt Presented 109.10 152.10 107.40 36.60 60.00 19.10 i Amt Remaining 32.00 43.80 3.40 5.10 1.50 8.30 
Amt faten 77.10 108.90 104.00 31.50 52.50 11.00 
Amt Presented 91.70 234.50 98.60 13.50 60.00 25.50 
I 
Amt Aema ining 27.80 40.40 9.30 5.40 15.00 14.90 
Amt Eaten 69.90 194.10 89.30 8.10 45.00 10.60 
Amt Presented 101.60 200.00 85.60 26.60 60.00 16.60 
Amt Remaining 49.50 35.20 5.20 3.10 15.00 8.50 
Amt faten 58.10 64.80 80.40 23.50 45.00 8.10 
Amt Presented 105.70 241.20 102.10 34.20 60.00 19.10 
Amt Rema ining 31.90 66.30 29.80 11.50 7.50 10.10 
Amt faten 73.80 180.90 72.90 22.70 52.50 9.00 
AlDt Presented 100.50 226.40 95.00 31.60 60.00 22.80 
Amt Remaining 20.50 12 .20' 3.00 4.60 0.00 10.90 
AiRt faten 
-
80.00 L 154.20 92.00 33.00 60.00 11.90 
IABLE AI2.2.1 Total Food Intake and Macro-Nutrient Consufl\ltion for lest Meals [5ubject 1 (55)] 
Phase I (TM A) 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Day 1 Day 4 Day I Day 4 Day 4 Day Q Day 4 
Iota I food Presented (9) 502.50 Q06.50 437.80 561.80 532.40 518.40 532.50 
Iota I Food Ren .. inlnq (q) 264 .60 130.l0 227.20 191.90 140.80 142.00 180.40 
lotal Food Intake (9) 237.90 276.20 210.60 369.90 391.60 376.40 352.10 
Total Food Intake (kJ) 2040.39 2324.31 1730.57 2824.59 3060.50 2125.88 2702.63 
Corrected (kJ) 2048.51 2331. 72 1731.63 2832.19 3068.73 2138.02 2708.00 
Total Protein Intake (g) 22.05 23.40 19.67 31.11 31.87 26.95 23.61 
lotal Protein Intake (kJ) 370.44 393.12 330.46 522.65 535.42 452.16 396.65 
Total Carboh~rate Intake (g) 48.99 51.47 32.01 63.65 11.84 69.99 64.32 
Tota I Carbohydrate Intake (KJ) 823.03 846.10 531.71 1069.32 1206.91 1115.83 1080.58 
Tota I Fat Intake (9) 22.62 28.41 23.00 32.81 35.09 29.35 32.56 
Iota I Fat Intake (kJ) 855.04 1073.90 869.40 1240.22 1326.40 1l09.43 1230.71 
Protein Energy % 18.08 16.86 19.02 18.45 11.45 16.54 14.65 H 
Carbohydrate Energy % 40.18 37.08 30.95 37.76 39.33 42.94 39.90 
Fat Energy % 41.14 46.06 50.03 43.19 43.22 40.52 45.45 
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Phase 1 (TM 8) 0 
» 
~teasure Week I Week 2 Week 3 Week 4 Week 5 ~ 
» 
Day I Day 4 Day 1 Day 4 Day 4 Day 4 Day 4 
Total Food Presented (9) 500.10 510.60 485.10 529.80 496.40 568.90 524.30 
Total Food Remaining (g) 51.80 118.20 110.10 112.80 116.50 151.10 111.20 ' 
Tala I Food Intake (9) 448.30 452.40 385.00 417.00 379.90 411.80 431.10 ! 
Tota I Food Intake (kJ) 3624.64 3151.42 2989.17 2975.60 2688.45 3054.05 3320.99 I 
Correc ted (k J) 3623.50 3110.18 2999.43 2991.54 2705.26 3065.29 3330.98 i 
lotal Protein Intake (g) 31.63 30.29 29.80 28.46 24.91 29.63 31.96 
lotal Protein Intake (kJ) 632.18 508.81 500.64 418.13 418.49 491.18 536.93 
Total Carbohydrate Intake (9) 84.23 84.13 71.90 86.45 78.09 84.12 85.20 
Tota I Carbohydrate Intake (kJ) 1415.06 1413.36 1201.92 145.86 1311. 91 1423.30 1431.36 
Total Fat Intake (g) 41.10 33.03 34.15 28.01 25.19 30.21 36.05 
Tota I Fat Intake (kJ) 1576.26 1248.53 1290.87 1061.05 914.86 1144.21 1362.69 
Protein Energy % 17.45 16.05 16.69 15.98 15.41 16.24 16.12 
Carbohydrate Energy % 39.05 44.58 40.21 48.55 48.49 46.43 42.97 
I 
L--____ !~_~Ilerg~_~ ________ 43.50 39.38 43.04 35.47 36.04 31.33 40.91 
TABLE A12.1.2 
Phase 1 (TM A) 
Week Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Phase 2 1M B) 
Week Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
QuantHy of Each food Conruldlty Presented, Remaining and Eaten (g) at the Test 
Meals [Subject 2 (CAll 
Measure (Q) Meat Potato VeQetab Ie Gravy Bread MarQarine ! 
Amt Presented IOD.IO 185.60 130.90 60.00 15.10 
Amt Remaining 12.40 1.80 4.20 0.00 4.60 
Amt Eaten 88.30 183.80 126.10 60.00 IUD 
Amt Presented 90.00 113.50 122.10 28.20 60.00 23.40 
Amt Remaining 4.80 0.40 6.80 12.80 0.00 11.00 
Amt Eaten 85.20 1l3.10 115.30 15.40 60.00 12.40 
Amt Presented 92.20 125.60 111.10 14.90 60.00 24.50 
Amt Remaining 1.60 8.80 20.90 0.20 0.00 ll.OO 
Amt Eaten 84.60 116.80 90.80 14.70 60.00 11.50 
Amt Presented 91.70 272.10 114.00 27 .90 60.00 24.00 
Amt Ren .. lnlng 0.50 4.50 29.40 3.40 0.00 4.40 
Amt faten 91.20 268.20 84.60 24.50 60.00 19.60 
Amt Presented 95.10 119.10 IlS.40 17.20 60.00 22.80 
Amt Ren"l in i ng 7.90 2.50 115.30 5.30 0.00 6.10 
Amt Eaten 87.80 197.20 3.10 11.90 60.00 16.70 
Amt Presented 114.40 219.90 70.10 26.30 60.00 IS.IO 
Amt Remaining 18.50 11.70 8.20 4.10 30.00 2.90 
Amt Eaten 95.90 108.20 61.90 22.10 30.00 15.20 
Amt Presented 
Amt Remaining 
Amt Eaten 
Measure (q) Meat Potdto Vegetab Ie Gravy Bread Margarine 
AIDt Presented 103.90 222.80 88.90 31.20 60.00 19.30 
Amt Remaining 4.00 14.40 20.00 4.90 0.00 0.40 
Amt Eaten 99.90 208.40 68.90 26.30 60.00 18.90 
Amt Presented 105.60 199.40 81.60 32.60 60.00 22.20 
Amt Rema 101ng 0.10 3.70 ~ .90 6.10 7.50 0.80 
Amt Eaten 105.50 195.10 76.70 26.50 52.50 21.40 
Amt Presented 108.60 204.90 96.60 29.30 60.00 22.40 
Amt Remaining 17.60 3.80 9.40 5.90 0.00 2.00 
Amt Eaten 91.00 201.10 87.20 23.40 60.00 20.40 
Amt Presented 101.50 245.00 99.20 21.10 60.00 21.30 I 
Amt Remaining 30.60 5.20 8.50 3.50 0.00 0.40 
Amt Eaten 10.90 239.80 90.70 17.60 60.00 20.90 
Amt Presented 100.00 239.8 86.10 34.90 60.00 20.10 
Amt Rema inlng 13.00 31.80 13.80 4.80 0.00 3.80 
Amt Eaten 81.00 208.00 12.30 30.10 60.00 16.90 
Amt Presented 100.50 241.80 96.60 53.40 60.00 23.40 
Amt RelJlalning 28.60 39.40 53.60 10.70 0.00 9.40 
Amt Eaten 71.90 208.40 43.00 42.10 60.00 14.00 
Amt Presented 98./0 261.1 102.80 36.10 60.00 20.40 
Amt Rema ining 51.30 13.411 56.10 5.90 0.00 1.80 
Amt Eaten 41.40 248.30 46.70 30.20 60.00 18.60 
TABLE AI2.2.2 
Phase 1 (TM A) 
Toted food Intake and Macro-Nutrient Consulfl)tion for Test Heals [Subject 2 (CAl] 
Meusure Week 1 Week 2 Week 3 Week 4 Week 5 
Dot_ 1 Dal 4 Oat 1 Day_ 4 Day 4 Oat 4 Day 4 
Iota I Food Presented (g) 492.90 437.20 428.90 590.30 513.80 508.80 I 
Total food ReOlOlnln9 (9) 13.00 35.80 153.50 42.40 137.10 75.40 I 
Total food Intake (g) 469.90 401.40 270.40 548.10 376.70 433.40 
lotal food Intake (kJ) 3234.69 3055.49 2563.96 4153.20 3358.14 3384.22 
Corrected (kJ) 3250.59 3062.43 2557.59 4159.06 3336.90 3381.88 
Total Protein Intake (g) 33.S9 31.90 29.31 37.01 32.08 33.46 
Iota I Protein Intake (kJ) 569.35 535.92 492.41 621.17 538.94 562.13 
Tota I Carbohydrate Intake (g) 87.11 72.20 41.35 112.52 81.00 78.45 
Tota 1 Carbohydrate Intake (kJ) 1473.53 1212.96 195.48 1890.34 1360.80 1317.96 
Total fat Intake (g) 31.95 34.75 33.59 43.51 38.02 39.73 
Tota I fat Intake (kJ) 1201.11 1313.55 1269.10 1646.95 1437.16 1501. 79 
Protein Energy % 17.52 11.50 19.25 14.95 16.15 16.62 
Carbohydrate Energy % 45.33 39.61 31.10 45.45 40.18 38.97 
fat Energy % 37.15 42.89 49.64 39.60 43.07 44.41 
Phase 1 (TM 8) 
Measure Heek 1 Ueek 2 Week 3 Week 4 Heek 5 
Day 1 Day 4 Day I Day 4 Day 4 Day 4 Day 4 
Tota I food Presented (g) 526.10 501.40 521.80 548.10 541.50 581. 70 579.10 
lotal food R .... lnlng (g) 43.10 23.10 38.10 48.20 67.20 141.10 128.50 
Total food Intake (9) 482.40 478.30 483.10 499.90 474.30 440.00 451.20 i 
Total food Intake (kJ) 3939.44 3977 .42 3870.13 3765.03 3739.66 3450.40 3376.50 
Corrected (kJ) 3933.72 3968.16 386S.71 3712.56 3740.39 3449.92 3380.81 
Total Pr'oteln Intake (q) 37.41 38.05 35.46 31.33 34.33 30.03 24./2 
Tota: Protein Intake (kJ) 628.49 639.24 595.13 526.34 576.14 504.50 415.30 
Total Carbohydrate Intake (g) 94.95 89.25 96.00 106.13 95.50 91.24 101. 53 
Total Carbohydrate Intake (kJ) 1595.16 1499.40 1612.80 1182.98 1604.40 1532.83 1705.10 , 
Total Fat Intake (g) 45.24 48.40 43.92 38.11 41.25 37.37 33.33 i 
Iota 1 fat Intake (kJ) 1110.01 1829.52 1660.18 1463.24 1559.25 1412.59 1259.87 
PI'otein Energy % 15.98 16.11 15.40 13.95 15.42 14.62 12.28 , 
, 
Carbohydrate Energy % 40.55 37.79 41.69 41.26 42.89 44.43 50.45 
. --
~f.t Energy % 43.47 ~.I~ _.i2.-~ 38.79 41.69 40.95 ~~ 
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TABlE A12.1.3 
PI.ase I (TM B) 
Week Oay 
I 1 
4 
2 I 
4 
3 4 
4 4 
5 4 
Phase 2 (TM A) 
Week Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Quantity of Each food Comoodity Presented, Remaining and Eaten (g) at the lest 
Heals (Subject 3 (LE)] 
MedSure (g) Heat Potato Vegetab Ie Gravy Bread Hargar ioe I 
Amt Presented 95.20 181.30 130.20 60.00 19.60 I Amt Rema inilUj 34.70 85.80 21.90 30.00 15.00 
Amt Eaten 60.50 95.50 108.30 30.00 4.60 i 
Amt Presented 94.50 123.40 113.2 35.00 60.00 19.40 
I Amt Remaining 19.70 60.70 0.40 18.00 30.00 15.30 
Amt Eaten 74.80 62.70 112.80 16.90 30.00 4.10 
Amt Presented 109.40 133.90 122.00 24.30 60.00 20.70 
Amt Reo\aining 8.60 23.90 88.50 11.80 30.00 16.10 
Amt Eaten 100.80 110.00 33.50 12.50 30.00 4.60 
Amt Presented 99.30 182.70 126.10 15.20 60.00 16.30 
Amt Remaining 0.00 75.20 71.70 3.70 30.00 9.00 
Amt Eaten 99.30 107.50 54.40 11.50 30.00 7.30 
Amt Presented 103.BO 209.50 130.90 14.30 60.00 23.10 
Am! Remaining 8.50 65.10 39.80 3.60 30.00 10.20 
Amt Eaten 95.30 144.40 91.10 10.70 30.00 12.90 
Amt Presented 101.50 216.90 104.80 16.90 60.00 19.10 
Amt Rema i n i ng 14.40 96.20 76.30 2.60 30.00 10.60 
Amt Eaten 87.10 120.70 28.50 16.10 30.00 8.50 
Amt Presented 112.40 257.00 102.60 24.20 60.00 20.40 
Allit Remaining 0.70 54.40 1.20 2.90 60.00 9.00 
Alot Eaten Ill. 70 202.60 101.40 21.30 0.00 11.40 
Med$ure «() Meat Potato Veqetab Ie Gravy Bread Margarine ! 
Amt Presented 110.10 134.10 122.70 20.40 60.00 22.30 I 
Amt Rema.ining 29.80 17.20 24.80 4.10 30.00 14.10 \ Amt Eaten 80.40 116.90 97.90 16.30 30.00 8.20 
Allit Presented 109.60 234.20 98.00 33.20 60.00 20.10 , 
Amt Remaining 6.20 78.10 14.90 3.90 30.00 10.60 
Alllt Eaten 103.40 156.10 83.10 29.30 30.00 9.50 
Amt Presented 110.80 234.10 96.10 32.90 60.00 20.10 
AmI Remaining 34.10 98.90 17.90 4.80 60.00 12.10 
Amt Eacen 76.70 135.30 78.20 28.10 0.00 8.60 
Amt Presented 101.20 242.80 94.40 36.80 60.00 10.00 
Amt Remaining 30.70 112.20 32.20 3.00 60.00 10.00 
Amt Eaten 70.50 130.60 61.20 33.80 0.00 10.00 
Afllt Presented 98.80 125.50 88.50 39.50 60.00 18.00 
Amt Remaining 15.60 105.50 11.60 5.70 60.00 11.50 
Amt Eaten 83.20 120.00 76.90 33.80 0.00 6.50 
Amt Presented 100.30 262.60 108.30 38.90 60.00 26.70 
Amt Remaining 11.80 142.40 10.40 4.80 60.00 16.00 
Amt Eaten 87.50 110.20 97.90 34.10 0.00 10.70 
Amt Presented 99.20 267.50 114.00 48.50 60.00 15.70 
Amt Relnaining 21.50 157.70 9.30 5.20 60.00 4.90 
Amt Eaten 77.70 109.80' 104.70 n.30 0.00 10.80 ~-----
TABlE All.2.3 Totd I food Intake dnd Macro-Nutrient ConslJUlltion for TeSI Hea Is (Subject 3 (I.E)] 
Phase I (1M B) 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Day I Oa~ 4 Day I Day 4 Day 4 Oay 4 Day 4 
Tota 1 food Presented (9) 486.30 445.50 470.30 499.60 541.60 521.20 576.60 
Total food Remaining (9) 187.40 144.20 178.90 189.60 151.20 130.30 128.20 
Tota 1 food Intake (9) 298.90 301.30 291.40 310.00 384 .40 290.90 448.40 
Tala I food Intake (kJ) 1951.32 2140.45 1403.19 2618.75 3017.16 2510.76 3234.77 
Corrected (kJ) 1970.21 2155.90 2391.53 2612.78 3019.39 2500.51 2886.83 
Tota I Protein Intake (9) 22.28 25.75 30.79 31.51 32.41 28.24 35.63 
Tota 1 Protein Intake (kJ) 374.30 432.60 511.21 530.38 544.49 474.43 598.58 
Tota I Carbohydrate Intake (9) 51.84 46.53 43.02 51.48 66.12 50.16 68.21 
Tota I Carbohydrate intake (kJ) 870.91 781.70 722.14 864.86 1120.90 852.77 1145.93 
Total rat Intake (9) 19.18 24.91 30.49 32.21 35.62 31.04 30.22 
Tot a I fat Intake (kJ) 725.00 941.60 1152.52 1217.54 1354.00 1I11.31 1142.32 
Prate in Energy .. 19.00 20.01 11.62 20.30 18.03 18.91 20.73 
Carbohydra te Energy % 44.20 36.26 30.21 33.10 37.12 34.10 39.70 
Fat Energy % 36.80 43.68 48.11 46.60 44.84 46.92 39.57 
Phase I (1M A) 
Measure Week I Week 1 Week 3 Week 4 Week 5 
Day I Day 4 Day I Oay 4 Day 4 Oay 4 Day 4 
Total food Presented (g) 469.70 555.10 554.70 555.20 530.30 596.80 604.90 
Total food Remaining (9) 120.00 143.70 227 .60 248.10 209.90 246.40 258.60 
Total Food Intakel!!) 349.70 411.40 326.90 307.10 320.40 350.40 346.30 
, 
Total food Intake (kJ) 2603.85 3177.73 2343.87 2177.71 2319.65 2587.15 2498.72 
Corrected (kJ) 1648.39 3181.38 23,2.08 2280.43 2337.42 1594.41 2509.50 
Tota I Protein Intake (g) 30.33 34.83 24.87 22.89 26.21 27 .86 25.55 
lotal Protein Intake (kJ) 509.54 585.14 417.82 384 .55 440.33 468.05 429.24 
Tota I Carbohydrate Intake (g) 61.05 68.94 47.68 44.09 43.78 41.26 46.02 
Total Carbohydrate Intake (U) 1025.64 1158.19 801.02 740.71 735.50 793.97 773.14 
Iota I fat Intake (9) 29.45 38.07 29.98 30.56 30.73 35.25 34.58 
Total fat Intake (kJ) 1113.21 1439.05 1133.24 1155.17 1161. 59 1331.45 1301.12 
Protein Energy % 19.24 18.39 17.76 16.86 18.84 18.04 17.10 
Carbohydrate Energy % 38./3 36.39 34.06 32.48 31.47 10.60 30.81 
~ __ ~~~ Energy % 42.03 45.22 48~ -~ 49.70 ~.36._ L_~'O~ 
N 
N 
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TABLE A12.1.4 
Phase 1 (TM B) 
Week Oay 
1 1 
4 
2 1 
4 
3 4 
4 4 
5 4 
t'1I4se (. \ 1M J\ 
Hl!ek Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Quantity of Each food COlnoodlty Presented, Reoaining and Eaten (g) at the Jest 
Mea Is [Subject 4 (EA) 1 
Measure (q) Heat Potato Vegetab Ie Gravy Bread Margarine 
Amt Presented 107.00 179.10 122.10 60.00 19.80 
Amt Remaining 41.40 101.30 0.00 30.00 17.50 
Amt faten 65.60 )) .80 122.10 30.00 2.30 
Amt Presented 102.40 114.50 117.60 40.40 60.00 21.30 
Amt Rcma tRing 44.30 60.70 25.80 10.30 60.00 21.30 
Amt faten 58.10 53.80 91.80 30.10 0.00 0.00 
Amt Presented 94.90 123.30 118.20 12.10 60.00 14.90 
Amt Rema Inlng 1.10 91.00 41.70 1.90 60.00 14.90 
Amt Eaten 93.80 31.30 75.50 9.10 0.00 0.00 
Amt Presented 101.20 247.00 139.50 18.70 60.00 25.20 
I 
I 
Amt Remaining 27.40 137 .80 63.40 4.00 60.00 25.20 
Amt Eaten 73.80 109.10 76.10 24.70 0.00 0.00 
Amt Presented 99.10 232.20 133.20 16.10 60.00 17.80 
Ami Remaining 10.60 192.70 0.00 3.20 60.00 17.80 
Amt faten 68.50 38.50 131.20 12.90 0.00 0.00 
Amt Presented 102.20 209.20 100.00 23.60 60.00 16.10 
Amt Rema iRing 44.90 106.60 18.10 3.40 60.00 16.10 
Amt Eaten 57.30 48.60 81.90 10.20 0.00 0.00 
Amt Presented 105.00 210.50 90.10 31.00 60.00 10.60 
Amt Remaining 19.70 138.10 8.50 2.70 60.00 20.60 
Amt Eaten 85.10 72 .40 81.70 28.30 0.00 0.00 
Measure (a) Heat Potato Veaetable Gravy Bread Haraar ine 
Amt Presented 110.10 207.30 98.20 31.20 60.00 22.70 
Amt Remaining 24.30 101.00 1.00 1.80 60.00 22.70 
AmI Ea ten 85.BO 106.30 9) .20 29.40 0.00 0.00 
Amt Presented 101.40 237.)0 B7.50 27.10 60.00 22.40 
AJut Remaining 36.20 \38.00 14.60 5.30 60.00 22.40 
Amt faten 6) .20 99. )0 12.90 21.80 0.00 0.00 
Amt Presented 109.50 157.30 91.70 26.40 60.00 20.00 I 
AmI Remaining 45.90 99.80 31.60 6.)0 60.00 20.00 
AmI Eaten 63.60 57.50 60.10 19.70 0.00 0.00 
Amt Presented 102.20 224.90 98.50 12.00 60.00 20.20 
Amt Remaining 32.00 220.90 0.00 3.10 60.00 20.20 
Amt Eaten 70.20 4.00 9B.50 8.90 0.00 0.00 
Amt Presented 92.10 225.00 114.70 30.80 60.00 18.00 
Amt Remaining 42.10 208.70 28.50 4.90 60.00 18.00 
Amt Eaten 50.00 16.30 86.20 25.90 0.00 0.00 
Amt Presented 
Amt Remaining 
AJilt Eaten 
Am( Presented 99.20 273. ]0 83.20 32.70 60.00 15.70 I 
Amt Remaining 34.50 213.00' 3.70 4.70 60.00 15.70 
Amt Eaten 64.70 0.30 79.50 28.00 0.00 0.00 
-
TA8LE A12.2 .4 
Phase I (lM B) 
Total food Intake and Macro-Nutrient Consun~tjon for T~st Meals [Subject 4 (fA)] 
Measure Week 1 Week 2 Week 3 Week 4 Week 5 
Oay 1 Oay 4 Oay 1 Oil}' 4 Oay 4 Oa}'4 Oa,. 4 
Total FoO<J Presented (9) 488.00 456.20 433.40 601.60 558.40 511.10 517.30 
Total FoO<J Remaining (9) 190.20 222.40 223.60 317.80 305.30 303.10 249.60 
Total FoO<J Intake (9) 297.80 233.80 209.80 283.80 253.10 208.00 267.70 
Tata I Food Intake (kJ) 1922.75 1454.00 1648.97 1880.68 1574.68 1370.69 1907.85 
Corrected (kJ) 1945.98 1412.52 1651. 73 1897.10 1602.30 1387.00 1920.12 
Total Protein Intake (9) 23.63 18.43 26.10 23.41 21.80 17.98 25.66 
Tota I Protein Intake (kJ) 396.98 309.62 438.48 391.29 366.24 302.06 431.09 
Tota I Carbohydrate Intake (g) 50.51 26.56 18.78 40.62 31.68 26.15 32.36 
Tota I Carbohydrate Intake (kJ) 84B.57 446.21 315.50 682.42 532.22 439.32 543.65 
Total fat Intake (g) 18.53 18.96 23.75 21.73 18.62 11.08 25.01 
Total Fat Intake !kJ) 700.43 716.69 897.75 821.39 703.84 645.62 945.38 
Prate in £ne~y % 20.40 21.03 26.55 20.73 22.86 21.78 22.45 
Cdrbohydrate Energy % 43.61 30.30 19.10 35.91 32.22 31.67 28.31 
Fat Energy % 36.00 48.67 54.35 43.30 43.93 46.55 49.24 
Phase 1 (1M A) 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Day 1 Oay 4 Oay 1 Oay 4 Oay 4 Day 4 Day 4 
Tota I Food Presented (g) 529.50 538.10 464.90 511.80 540.60 564.10 
Total Food Remaining (g) 210.80 276.50 264.00 336.20 362.20 391.60 
Tota I food Intake (g} 318.70 26\.60 200.90 18\.60 178.40 172.50 
Iota I Food Intake (kJ) 2123.26 1719.56 1426.13 1307.68 1119.98 1297.01 
Corrected (kJ) 2143.\3 1735/27 1434.93 1321.24 1196.46 1l06.45 
Total Protein Intake (g) 26.99 21.40 19.15 20.40 15.65 18.80 
Tota I Proteill Intake (kJ) 453.43 359.52 321. 72 342.72 262.92 315.84 
Tota I Carbohydrate I ntake (g) 43.45 37.61 24.84 17.25 18.87 13.83 
Total Carbohydrate Intake (kJ) 729.96 631.85 417.31 289.80 317.02 232.34 
lola I Fat Intake (9) 25.39 19.68 18.41 18.22 16.31 20.06 
Tota I Fat Intake (kJ) 959.74 743.90 695.90 688.72 616.52 758.27 
Prote in Energy % 21.16 20.72 22.42 25.94 21.97 24.18 
Carbohydrate Energy % 34.06 36.41 29.08 21.93 26.50 17.78 
_______ ~_~_ EnerlJY~ _________ 44.78 42.87 48.50 52.13 51.~ 58.04 
--.. ------
N 
N 
....... 
TABLE A12.1.5 
Phase I (TH B) 
Yeek Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
--------------"-
Phase 2 (TH A) 
Week Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
----
Quantity of fach food COlllllOdlty Presented. Remaining and faten (g) at the Test 
Hea Is [Subject 5 (VW) 1 
Heasure (0) Meat Potato Veoetab Ie Gravy Bread HarQarine 
Amt Presented 97.70 115.80 150.10 60.00 15.00 
AlDt Rema Inin9 0.00 0.00 0.00 0.00 1.00 
Amt Eaten 97.70 155.80 151.10 60.00 14.00 
Amt Presented 110.90 112.10 130.80 45.50 60.00 20.50 
Amt Remaining 0.00 0.00 11.40 8.00 60.00 20.50 i 
AfIlt Eaten 110.90 112.10 119.40 37.50 0.00 0.00 
Amt Presented 94.60 122.20 119.30 19.10 60.00 26.30 
Amt Rema ini09 i5.60 24.10 11.60 7.50 0.00 14.70 ! 
Amt faten 79.00 98.10 107.]0 11.60 60.00 11.60 
Am! Presented 98.50 249.70 12] .80 30.80 60.00 24.10 
Amt Remaining 5.80 108.10 33.20 7.20 30.00 14.10 
Amt Eaten 92.]0 141.60 94.60 23.60 30.00 10.00 
Amt Presented 93.70 21B.60 105.30 15.90 60.00 26.40 
Amt Remaining 33.00 81.50 0.00 12.10 0.00 9.60 
Amt faten 60.70 13] .10 105.30 3.80 60.00 16.60 
Amt Presented 108.20 215.40 102.10 22.70 60.00 17.40 
Amt Remaining 33.40 119.70 22.60 4.80 15.00 0.40 
Amt Eaten 74.80 95.70 79.50 17.90 45.00 17.00 
Amt Presented 106.60 188.90 95.90 22.60 60.00 19.30 
Amt Rema ioing 48.40 154.40 13.60 3.10 30.00 2.90 
Alnt faten 58.20 34.50 82.30 19.50 30.00 16.40 
---.-.---~--
Heasure (g) Meat Potato Vegetab Ie Gravy Bread Margar ine 
Amt Presented 105.10 199.10 97.30 28.00 60.00 19.30 
Amt Remaining 4.30 18.90 15.10 2.10 30.00 3.70 
Amt faten 100.80 180.20 62.20 25.90 30.00 15.60 
Amt Presentt:d 119.60 241.20 97.30 40.80 60.00 21.50 
Amt Remaining 21.20 194.40 21.20 3.70 30.00 5.90 
Amt faten 98.60 46.80 76.00 37.10 30.00 15.60 
Amt Presented 108.70 150.00 87.50 36.10 60.00 22.40 
Amt Rema in 109 30.50 107.50 18.90 5.30 0.00 7.80 
Amt Eaten 78.20 42.50 68.60 30.80 60.00 14.80 
Amt Presented 
Amt Relfl1lining 
Amt Eaten 
Amt Presented 109.60 215.50 89.20 35.00 60.00 19.80 
Alllt Ren13ining 64.80 170.10 23.50 7.70 30.00 8.50 
AlRt Eaten 45.20 45.40 85.70 27 .30 30.00 11.10 
Amt Presented 106.40 216.10 91.90 40.30 80.00 25.60 
Am! Remaining 70.80 185.30 36.40 8.10 30.00 18.00 
Amt Eaten 35.80 32.80 55.50 32.20 30.00 7.80 
Amt Pres~oted 100.00 274.10 109.60 41.50 60.00 24.60 
Amt Remdining 73.60 254.70 ' 53.60 8.50 30.00 11.30 
Amt Ealen ,---26.~_ 19.40 55.80 33.00 30.00 L ___ 7~ 
~- --- -
TABLE A12. 2.5 
Phase I (TH 8) 
Total food Intake and Hacro-Nutrient Consulll'tion for Test Meals [Subject 5 (VW)] 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Day I Day 4 Oay I Day 4 Oay 4 Day 4 Day 4 
Tota I food Presented (9) 478.60 479.80 441.50 590.90 519.90 525.80 493.30 
Total food Relndining (9) 1.00 99.90 73.50 198.40 136.40 195.90 252.40 
Tota I food Intake (g) 4/1.60 379.90 368.00 392.50 383.50 329.90 240.90 
Total food Intake (kJ) 3421.12 2500.33 2843.68 2979.41 2969.18 2831.20 2172.05 
Corrected (kJ) 3436.40 2518.32 2850.24 2986.96 29/8.64 2831.94 2165.46 
Total Protein Intake (9) 36.40 33.45 29.83 32.03 26.55 27 .36 20.57 
Total Protein Intake (kJ) 611.52 561.96 501.44 538.10 446.04 459.65 345.58 
Total Carbohydrate Intake {g) 85.91 42.92 67.85 66.97 82.17 60.41 31.88 
Tot a I Carbohydrate Intake (kJ) 1443.29 721.06 1139.88 1125.10 1360.46 1014.89 636.38 
Total Fat Intake (g) 36.55 32.68 31.99 35.02 30.48 35.91 31.31 
Tota I fat Intake (kJ) 1381.59 235.30 1209.22 1323.76 1152.14 1357.40 1183.52 
Protein fnergy % 17.80 22.31 17.58 16.01 14.97 16.23 15.96 
Carbohydrate Ene~y % 42.00 28.63 39.99 37.67 46.34 35.84 29.39 
Fat fnergy % 40.20 49.05 42.43 44.32 38.68 47.93 54.65 
Phase 2 (TH A) 
Measure Week 1 Week 2 Week 3 Week 4 Week 5 
Day I Oay 4 Oay I Oay 4 Oay 4 Oay 4 Oay 4 
Tota I Food Presented (a) 508.80 580.50 464.70 528.90 542.50 609.80 
Total food Remaining (g) 74.10 2/6.40 170.00 304.20 348.40 437.90 
Total food Intake (a) 434.70 304.10 294.70 224.70 194.10 111.90 
Total food Intake (kJ) 3421.42 2845.12 2/88.52 1885.54 1602.15 1406.89 
Corrected (kJ) 3420.90 2830.38 2/16.96 1885.85 1604.86 1411.12 
Total Protein Intake to) 34.65 31.08 28.26 17 .27 14.46 11.84 
Total Protein Intake (kJ) 582.12 522.14 474.77 290.14 242.93 198.91 
Total Carbohydrate intake (a) 74.79 40.51 53.20 18.17 33.48 30.17 
Total Carbohydrate intake (kJ) 1256.47 680.57 893.76 641.26 562.46 506.86 
Tota I fat intake (q) 41.86 43.06 37.26 25.25 21.15 18.66 
Tota I Fat Intake (kJ) 1582.31 1627.67 1408.43 954.45 799.47 705.35 
Prate in Enerqy % 17.02 18.45 11.10 15.39 15.14 14.10 
Carbohydrate Energy % 36.73 24.05 32.18 34.00 35.05 35.92 
Fat Energy % 46.25 51.51 50. /2 50.61 49.82 50.00 
--
N 
N 
N 
TABLE AI2.1.6 
Phase I (1M 0) 
Heek Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
. ,,~ ........ \ '" " 
I1I~d, --~ 
I I 
-_.-
4 
---
--
1 I 
4 
3 4 
4 4 
5 4 
Quantity of Each Food COlnoodity Presented. Remaining and Eaten (g) at the Test 
Mea Is [Subject 6 (1I)] 
Measure (q) Meat Potdto Vegetab Ie Gravy Bread Marr.lar ine 
Amt Presented 56.30 191.10 130.30 13.90 60.00 19.20 Amt Rema ining 5.70 1.40 122.50 2.60 30.00 0.20 Amt Eaten 50.60 189.70 7.80 11.30 30.00 19.00 
Amt Presented 108.10 224.30 108.80 34.00 60.00 23.40 Amt Reffia ining 25.50 89.00 39.40 4.20 30.00 8.30 Amt Ea ten 83.20 135.30 69.40 29.80 30.00 15.10 
Amt Presented 105.60 242.50 93.30 11.10 60.00 20.80 
I 
Amt Remaining 18.20 110.30 80.90 4.10 30.00 7.70 Amt Eaten 27.40 132.20 12.40 7.00 30.00 13.10 
Am! Presented 111.30 246.20 94.00 35.40 60.00 19.60 Amt Rema ining 106.10 24.30 55.10 13.00 60.00 0.40 Aml Eaten 11.20 221.90 38.30 22.40 0.00 19.20 
Amt Presented 102.00 186.10 \05.60 31.50 60.00 28.20 Amt Rema ining 33.80 62.70 5.00 3.90 30.00 7.60 Arne faten 68.20 123.40 100.60 27.60 30.00 20.60 
Amt Presented 112.00 218.90 98.80 16.60 60.00 19.10 Amt Remaining 35.50 53.60 51.20 2.00 30.00 0.40 Amt Eaten 76.50 165.30 47.60 14.60 30.00 18.10 
Am[ Presented 106.70 225.30 96.40 29.00 60.00 22.00 Amt Remaining 38.00 78.90 5.30 4.20 30.00 0.40 Amt Ealen 68.70 146.40 91.10 24.80 30.00 21.60 
Ml'd~ure (q) Meal Potiltu veoetJIJ Ie GrJvy Urecld MJrqdf"lf1e 
Amt Pn~..:erlkd 102.?U 252.:)0 e3.00 2~.tJO ()(i.OO 1Il.50 i'Jllt kCl1lo1inlng 10. JO 62.10 4~.GO , .10 60.00 0.·\0 Ann futen --~ 190. JO 33,·10 13.\0 I). t)Q 1d.40 
A.mt Preseflted ~8.IO 158.,0 90.40 28.20 60.00 18.90 }\flit R~nld Inlng 16.10 118.60 B6.ID 3.10 60.00 6. ,0 AfIll Eaten 71.40 139.60 3.70 15. JO 0.00 12.40 
Amt Presented 100.00 100.00 97.80 34.10 60.00 10.40 Amt Rcn~iniflg 64.30 33.10 90.60 4.10 60.00 9.90 Amt Eaten 35.70 174.90 1.20 29.60 0.00 10.50 
Amt Presented 112.10 220.70 91.90 38.40 60.00 19.30 Amt Remaining 33.50 179.50 3.30 3.00 60.00 13.90 Amt Eaten 78.60 41.20 88.60 35.40 0.00 5.40 
Amt Presented 101.00 264.10 87.40 36.20 60.00 24.70 Amt Rem in ing 101. 00 122.00 1.20 36.20 60.00 9.50 Amt Eaten 0.00 142.10 86.20 0.00 0.00 15.20 
Amt Presented 99.20 245.30 90.00 38.60 60.00 15.30 Amt RemB ining 71.00 124.40 28.00 11.20 60.00 2.20 Amt Eaten 28.20 120.90 62.00 27.40 0.00 13.10 
Amt 11rest!l1ted 98.90 229.60 104.70 43.10 (,0.00 18.20 Amt Henldining 73.90 113.20 • 11.70 5.70 45.00 0.50 Ana Ea ten 25.00 116.40 93.00 38.00 15.00 17.70 
TABLE AII.2 .6 
Phase I (TM 8) 
Total food Intake and Macro·Hutrient Consu~tlon for Test Meals (Subject 6 (LI)] 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Oay I Day 4 Oay 1 Oay 4 Oay 4 Day 4 Day 4 
Total food Presented (g) 470.80 559.20 533.30 572.50 513.40 525.40 539.40 
Total food Remaining (g) 162.40 196.40 .J11.20 259.5 143.00 172 .70 156.50 
Tota I food Intake (g) 308.40 362.80 222.10 313.00 370.40 352.70 382.60 
Total food Intake (kJ) 2580.97 1956.62 1805.25 2048.89 2956.91 2946.30 3052.11 
Corrected (kJ) 1505.86 2951.86 1798.90 2055.31 1957.60 2935.42 3050.93 
Total Protein Intake (g) 20.09 28.97 13.02 9.39 25.77 21.13 26.12 
-
Total Protein Intake (kJ) 337.51 486.70 218.74 151.75 432.94 455.IB 438.82 
Tota I Carbohydrate Intake (g) 64.69 61.52 50.79 62.91 63.54 65.09 67.11 
Tota I Carbohydrate Intake (kJ) 1086.79 1033.54 853.27 1056.89 10b7.41 1093.51 1131.53 
Tota I Fat Intake (g) 30.20 37.90 19.23 22.24 38.55 36.61 39.01 
Tota I Fat Intake (kJ) 1141.56 1432.62 726.89 840.67 1457.19 1286.13 1474.58 
Prate in Energy % 13.15 16.48 12.16 7.68 14.64 15.53 14.38 
Carbohydrate Energy % 42.36 35.00 47.43 51.42 36.09 37.25 37.28 
fat Energy % 44.49 48.52 40.41 40.90 49.27 47.22 48.33 • 
Phase 1 (1M A) 
--'-. 
-
~Iejsurc I-l~ck 1 -.---..l:I~"U_ WerA 3 Week 4 ~~~. 
(--. O.1y 1 Day 4 D<lY 1 Day -1 lJ.jy ·1 DJY 4 ~-:~-
futal Food Pre~ented {y} 541.80 »3.80 520. :W 542.40 513. 40 548.40 55,.10 
Iota I foou Renu Hlillg (g) 204.50 )01.60 262.40 293.20 329.90 296.80 250.00 i 
Total Food Intake (0) 337.30 252.20 151.90 249.20 243.50 251.60 305.10 
Tota I food Intake (kJ) 2616.96 1170.63 1839.56 1920.65 1293.12 1725.18 2143.91 
Corrected (kJ) 1665.19 1153.13 1837.22 1926.20 1412.50 1733.34 2156.81 
Total Protein Intake 101 23.66 11.59 13.68 23.59 5.63 12.02 13.52 
Total Protein Intake (kJ) 397.49 362.11 229.82 396.31 94.58 201.94 227.14 
Total Carbohydrate Intake (9) 54.14 36.62 46.12 25.86 49.85 41.43 53.26 
Tota I Carbohydrate Intake (kJ) 909.55 615.22 776.50 434.45 837.48 696.02 894.77 
Total fat Intake (0) 35.93 31.09 21.99 28.98 12.11 22.10 27.38 
Tota I fat Intake (kJ) 1358.15 1175.20 831.22 1095.44 480.44 835.38 1034.96 
Protein Energy %, 14.91 16.85 12.51 20.51 6.70 11.65 10.53 
Carbohydra te f nergy % 34.13 2B.57 42.16 22 .55 59.29 40.15 41.48 
Fat Energy ~ 50.96 54.58 45.24 56.87 34.01 48.19 47.98 
N 
N 
W 
TABL[ AL2.1.7 
Phase I (TM A) 
Week Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
Phase 2 IH H) 
Week Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
--------
--
Quantity of Each food Conrnodity Presented, Remaining and Eaten (9) at the Jest 
Mea Is (Subject 7 (EG)] 
Measure (g) Meat Potato Vegetab Ie Gravy Bread Haraarlne 
Amt Presented 123.10 182.90 150.50 60.00 22.20 I 
AJOt Rema '"tng 101.10 182.90 78.00 60.00 15.00 
Amt faten 22.00 0.00 72 .50 0.00 7.20 
Arnt Presented 74.70 112.90 99.50 38.00 60.00 19.40 i 
Amt Remaining 38.90 110.70 23.00 16.40 30.00 15.90 
Amt Eaten 35.80 2.20 76.50 21.60 30.00 3.50 
Amt Presented 97.60 131.10 124.20 32.20 60.00 19.90 
Amt Remaining 41.40 )) .50 51.20 8.50 30.00 15.10 
Amt Eaten 56.20 53.60 73.00 23.70 30.00 4.80 
Amt Presented 100.40 165.10 120.20 13.90 60.00 20.60 
Amt Remaining 29.00 113.50 40.50 2.10 30:00 14.90 
Amt [aten 71.41 51.60 79.70 11.80 30.00 5.70 
Amt Presented 103.80 164.40 146.10 16.80 60.00 20.80 
Amt Remaining 72.00 105.50 49.10 7.60 30.00 15.70 
Amt Eaten 31.80 58.90 97.00 9.80 30.00 5.10 
Amt Presented 
Afllt Remaining 
Amt Ealen 
Amt Pres~nted 
Amt Rema Ining 
Amt Eaten 
MedSure (9) Meat Potato Vegetab Ie Gravy Bread Maraar ine 
AJllt Presented 100.50 164.10 107.00 21.00 60.00 23.10 
I 
Amt Relnaining 39.10 70.00 34.60 1.80 30.00 9.90 I Alllt faten 61.40 94.10 72 .40 19.20 30.00 13.20 
Amt Presented 117.50 209.80 92.00 44.80 60.00 24.80 
I Amt Remaining 60.30 105.40 24.70 5.50 60.00 14.40 
Amt Eaten 57.20 104.40 67.30 39.30 0.00 10.40 I 
Amt Presented 119.20 222.60 84.20 34.50 60.00 20.SO ! 
Amt Remaining 70.60 130.90 22.30 9.30 30.00 13.00 i 
Amt Eaten 48.60 91.70 61.90 25.20 30.00 7.80 
Amt Presented 96.60 227.40 102.40 36.00 60.00 18.90 
Amt Remaining 51.80 126.10 20.30 4.40 30.00 8.50 
Amt Eaten 44.80 101. 30 82.10 31.60 30.00 10.40 
Amt Presented 106.50 245.70 97.70 35.40 60.00 25.40 
Amt Remaining 51.50 152.20 17.10 4.30 30.00 6.70 
AJnt faten 55.00 93.50 SO.60 31.10 30.00 18.70 
Amt Presented 98.90 244.10 84.40 33.80 60.00 23.20 
Amt Remaining 34.10 165.00 4.70 3.70 30.00 13.90 
Amt Eaten 64.SO 79.10 79.70 30.10 30.00 9.30 
Amt Presented 209.90 259.10 96.20 36.30 60.00 18.60 
Alut R~lllaining 49.10 139.20' 10.60 8.20 30.00 7.20 
Amt Eaten 60.80 119.90 85.60 28.10 30.00 1.40 
IA8LE AI2.2.7 
Phase 1 (TH A) 
Total food Intake and Macro-Nutrient CansuII"tlon for Test Heals (Subject 7 (£G)] 
Measure Week 1 Week 2 Week 3 Week 4 Week 5 
Day 1 Day 4 Day 1 Day 4 Day 4 Day 4 Day 4 
lata I Food Presented (g) 538.70 404.50 465.00 480.20 511. 90 
Total Food Remaining (q) 337.00 234.90 223.70 230.00 279.90 
lotal Food Intake (g) 161.70 169.60 241. 30 250.20 232.00 
Total Food Intake (kJ) 1404.52 1310.24 1B12.58 2020.33 1542.00 
Corrected (kJ) 1412.12 1321. 74 1819.35 2025.16 1526.94 
lotd I Protein Intake (g) 12.78 14.11 20.00 24.02 14.74 
lotal Protein Intake (kJ) 214.87 237.05 336.00 403.54 247.63 
Iota 1 Carbohydrate Intake (9) 42.15 28.70 38.48 41.49 46.05 
lata I Carbohydrate Intake (kJ) 708.12 482.16 646.46 697.03 173.64 
Tota I Fat Intake (g) 12.94 15.94 22.14 24.46 14.33 
Iota I Fat Intake (kJ) 489.13 602.53 836.89 924.59 541.67 
Protein Energy % 15.22 17.93 18.47 19.93 15.84 
Carbohydrate Energy % 50.15 36.48 35.53 34.42 49.50 
fat Energy ~ 34.46 45.59 46.00 45.66 34.66 
Phase 1 (1M 8) 
Measure Week 1 Week 2 Week 3 Week 4 Week 5 
Day 1 Day 4 Day 1 Day 4 Day 4 Day 4 Day 4 
Tota I Food P,'esented J_ill 475.70 548.90 541.30 541. 30 570.70 544.40 580.10 
Total food Relllaining (g) 185.40 270.30 276.10 241.10 261.80 251.40 244.30 
lata I food Intake (q) 290.30 278.60 265.20 300.20 208.90 293.00 335.80 
Tota I food Intake (kJ) 2352.16 2048.95 2009.87 2192.40 2549.73 2303.51 2507.07 
Corrected (kJ) 1352.21 2052.87 2016.88 2230.99 2546.92 2308.63 2516.13 
lotal Protein Intake (g) 22.46 19.23 19.05 19.00 21.33 23.37 23.B 
lotal Protein Intake (kJ) 377.33 323.06 320.04 319.20 358.34 392.62 393.62 
Tota I Carbohydrate Intake (g) 51.29 34.48 49.14 55.04 52.85 49.00 60.19 
lata I Carbohydrate Intake (kJ) 861.67 646.46 825.55 924.67 887.88 823.20 1011.19 
lotal Fat Intake (9) 29.45 22.86 23.05 25.40 34.41 28.91 29.40 
lotal fat Intake (kJ) 1113.21 1983.35 871.29 960.12 1300.70 1092.80 111.32 
Prote in Energy % 16.04 15.74 15.87 14.48 14.07 17.01 15.64 
Carbohydrate Energy % 36.63 31.49 40.93 41.95 34.86 35.66 40.19 
--
fa!..Energy \ 47.33 52.71 43.20 43.56 51.07 47.34 44.17 
I 
, 
, 
i 
! 
N 
N 
.t:> 
.... 
TABLE AIl.I.B 
Phase I (Tli A) 
Week Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
Phase 2 (TM B) 
Week ! D"y I 
Quantity of Each food COfllllOdlty Presented, Remaining and Eaten (g) at the Test 
Meals (Subject 8 (CV)] 
Measure (g) Heat Potato Veqetab I. Gravy Bread 
Amt Presented 104.20 221.20 112.20 16.30 60.00 
AlRt ReOldlning 11.60 24.00 1.20 3.80 60.00 
AlRt Eaten 86.60 187.20 111.00 12.50 0.00 
Amt Presented 102.20 191.10 143.20 16.00 60.00 
AI"t Remaining 4.90 21.20 1.30 3.60 60.00 
Amt [aten 91.30 176.50 135.90 12.40 0.00 
Amt Presented 114.60 210.60 109.90 17.60 60.00 
Amt Remaining 49.30 135.00 0.00 1.20 30.00 
Amt Eaten 65.30 15.60 109.90 16.40 30.00 
Amt Presented 108.70 229.00 96.60 20.70 60.00 
AlRt ReOld inlng 29.30 141.70 5.80 4.10 30.00 
Amt faten 79.40 88.10 90.80 16.60 30.00 
Amt Presented 105.60 284.90 98.70 18.90 60.00 
Amt Reina inil1<J 5.60 207.50 6.30 3.30 0.00 
AlRt Eaten 100.00 77.40 92.40 15.60 60.00 
Amt Presented 104.10 241.80 94.10 23.40 60.00 
Amt Rema ining 2.40 209.10 5.00 3.10 15.00 
Amt faten 101. 70 38.70 89.10 20.30 45.00 
Amt Presented 110.80 215.40 93.60 33.80 60.00 
Amt Remaining 27.60 152.10 3.70 5.80 30.00 
AlRt Eaten 83.20 63.30 '-- 8~.90_ 28.00 30.00 
Measure ( ) Potato eqetab Ie Gravy BI'ead 
Amt P,'esellted 233.00 107.40 30.70 60.00 
Amt Rema lOing 62.00 49.60 3.10 30.00 
Amt fau~n 171.00 57.S0 21.60 30.00 
99.10 34.10 60.00 
5.00 6.10 0.00 
9·1.}0 21.·10 tiO.OI) 
Am! preSell!~'d 9~.10 1113.90 
AJut HtJflJ.inlng B.OO 122.·10 
,'"jat t..ltt"11 91.10 IOl.~O 
~---- ------.---~ 
101.80 JI.OO CJO.UO 
/\m( kt.:!u~dniny 40.10 102.70 1.00 l.70 JO.OO 
Q~ .'In ?7.3D JO.OO 
--
Amt Pres~!ited UtoO.110 I Z)U.SO 
;~rnt [Jter! 51.~Q ___ --...!36.ilO -~.-t--"""'-j--
Allit Presented 
,/\,Jut Kenld Inlrlg 
Margarine 
22.30 
11.60 
4.10 
22.10 
10.60 
11.50 
22.80 
11.30 
11.50 
21.40 
10.10 
11.30 
24.20 
8.10 
16.10 
21.10 
9.00 
12.10 
20.30 
12.20 
8.10 
Ma~r1ne 
19.80 
13.10 
6.70 
24. /0 
IJ.80 
10. 'jO 
18.40 
10. JO 
f--...!!.:.IO 
f---t-- Am! ,,,e,, 
Amt Presented 
Alllt Rellla in ing 
Amt Ea [en 
Amt Presented 
AlIIt Remaining 
Allit Eaten 
Amt Presented 
AlRt ReOia Iniog 
AlRt Eaten 
TABLE AI2.Z.B Total food Intake and Macro-Nutrient ConswJ4)tlon for Test Heals (Subject 8 (CV)] 
(1M A) .. 
Measure Week I Week 2 Week 3 Week 4 Week 5 
Day I Day 4 Day I Day 4 Day 4 Oay 4 Day 4 
Total food Presented (g) 526.20 541.20 535.50 537.20 592.30 550.50 533.90 
Total food ReOldlning (g) 124.20 101.60 226.80 221.00 230.80 243.60 231.40 
Total food Intake (g) 402.00 433.60 308.70 316.20 361.50 306.90 302.50 
Tota I food Intake (kJ) 2574.10 2958.64 2357.34 2539.36 3241.50 2823.23 2452.77 
Corrected (kJ) 2602.82 2988.15 2376.96 2550.62 3251. 77 2B24.12 2462.84 
Total Proteill Intake (9) 29.12 32.22 23.97 27.26 34.85 33.04 27 .83 
Total Protein Intake (kJ) 489.22 541.30 402.70 451.91 585.48 555.07 467.54 
Tota I Carbohydrate Intake (g) 65.61 61.46 53.12 53.17 66.12 48.19 46.97 
Total Carbohydrate Intake (kJ) 1105.10 il33.33 892.42 893.26 1110.82 B09.59 789.10 
Total fat Intake (9) 26.68 34.15 28.62 31.73 41.15 38.61 31.91 
Total fat Intake (kJ) 1008.50 1313.55 1081.84 1199.39 1555.47 1459.46 1205.20 
Protein Energy % 18.80 18.11 16.94 17.96 18.00 19.65 18.98 
I 
Carbohydrate Energy % 42.46 31.93 31.54 35.02 34.16 28.67 32.04 i 
-
fatEne"'l~ "-_ 
--
38.75 43.96 45.51 47 .02 47.83 51.68 ,--4S __ !)8 __ 
Phase I (1M B) 
Measure Week Week Week 3 Week 4 We~k 5 
Day I Oay 4 OJY 1 Day 4 Day 4 D"y 4 Day 4 
fota I food PreSented J..lll 550.130 \41.50 ~~ 
t-_...!~{dl ~ood fh~nl.Ji~~Jg) tetl.ID 155.~O --.!.~-:~~-,-- -.-.-----... --~.- -~------
fot,,1 food Intake (kJ) 
101..11 tllnd lotakl;! (c) 3~2./O 3HI.!.60 YJ?IJU I 
- --'- ----"-,---1-----
IltiI9.~ llti4.IB lJ94.n. ~'----~l--+-__ ~ ___ _ 
Corret:ted (kJ) Zfi~5.S9 llbl.51 l415.;; 
~Protei..'.'~'1L-j lfi.02 J3.45 __ L2.!-'.'!.L_t-___ } ___ -t-__ ~ 
Tot,,1 Protein Intake (kJ) I 431.14 501.96 I 36B./b 
Total Carbohydrate Intake (g) I 68.52 72 .IS 66.55 
Total Carbohydrate Intake (kJ) I 1151.14 1212.62 1I1S.04 
Total fat Intake (q) I 21.54 36.85 24.57 
Tota I fat Intake (kJ) I 1037.61 1392.93 928.75 
Protein Enerqy % I 16.65 17.74 15.27 
Carbohydrate Energy % I 43.84 38.28 46.28 
fat Energy % 39.51 43.98 38.45 
N 
N 
U'1 
Measure Subj 
iotal Food Intake (g) 1 
2 
3 
4 
5 
6 
Tota I Food Intake (<J) 1 
2 
3 
4 
5 
6 
Tota 1 Protein Intake (g) 1 
2 
3 
4 
5 
6 
Tota I Protein Intaxe (xJ) 1 
2 
3 
4 
5 
6 
Tata 1 CarbOhydrate 1 
Intaxe (g) 2 
3 
4 
5 
6 
Tota I Caroonydrate I 
Intake (~J) 2 
3 
4 
5 
5 
Tota 1 fat Intake (g) 1 
2 
3 
4 
5 
5 
Tota 1 Fat [nta~e (~J) 1 
2 
3 
4 
5 
6 
Measure Subj 
Protein Energy % 1 
2 
3 
4 
5 
6 
Carbonydrate Energy % 1 
2 
3 
4 
5 
6 
Fat Energy % 1 
2 
3 
4 
5 
6 
n '"' 4, df .,. 1.6 for suojects 1. 3 and 6 
~ ... 3, at ... 1.4 for suojects 2 . .l and 5 
226 
THA.SEM 
372.50 • 8.18 
452.73 • 50.41 
331.05 • 10.38 
177.50.2.67 
221.35 • 26.74 
252.35 • 14.35 
2836.74 .81.73 
3625.95 • 266.87 
2430.46 • 73.21 
1274.72 _ 39.36 
1919.70 • 301.91 
1807.23 • 157.50 
28.39 • 1.92 
34.16.1.48 
15.63 • 1.03 
18.28 • 1.40 
17.96 t 3.61 
13.69 • 3.72 
476.87 • 32.33 
574.28 • 14.67 
430.54 • 17.37 
307.15 • 23.44 
301.69 • 60.63 
229.99 • 62.45 
57.45 • 2.04 
90.66 • 10.96 
45.29 • 0.82 
16.65 • 1.49 
38.75 • 5.09 
42.60 • 5.l! 
1133.16 • 34.28 
1523.03 • 184.07 
760.83 • !l.83 
279.72 • 24.96 
651.09 • 85.46 
715.58 • 102.63 
32.45 • 1.18 
40.44 • 1.64 
32.78 • 1.24 
18.20 • 1.08 
25.58 • 4.12 
22.79. 3.67 
1225.71 • 44.62 
1528.63 • 62.03 
1239.08 • ~5.90 
687.84 .40.92 
966.93 • 155.87 
861.55 • 138.66 
TMA.SEM 
15.77 • 0.81 
15.91 • 0.48 
17.71 • 0.45 
24.03 • 1.15 
14.88 • 0.39 
12.35 • 2.93 
39.98 • LOS 
41.73 • 1.93 
31.34 • 0.42 
22.07 • 2.52 
34.99 • 0.56 
40.87 • 7.05 
43.25 • 1.02 
42.35 • 1.43 
50.95 • 0.51 
53.90 • 2.08 
50.14 • 0.24 
45.75 • 4.73 
9 indicates a P value of between 0.015 and 0.05 
, indicates a P value of less than 0.01 
THS.SEM F P 
409.95 • 10.81 7.63§ 0.0328 
471.40 • 17.35 0.12 0.7474 
358.43 • 35.14 0.53 0.5015 
268.20 • 8.87 96.01 0.0006 
336.70 • 34.79 6.91§ 0.0391 
354.58 • 15.19 19.5\ 0.0045 
3023.28 • 128.64 1.50 0.2669 
3654.29 • 102.61 0.01 0.9268 
2754.88 • 119.82 5 .. 34 0.0602 
1806.51 • 102.32 23.5\ 0.0083 
2740.76 • 195.03 5.22 0.0624 
1749.82 • 132.85 11.2§ 0.0154 
28.74 • 1.47 0.02 0.8897 
31.90 • 1.27 1.38 0.3046 
31.96 • 1.52 11.9§ 0.0137 
23.62 • 1.12 8.91§ 0.0405 
25.23 • 2.35 4.05 0.0908 
22.10 • 4.24 2.22 0.1867 
482.33 • 24.68 0.02 0.8897 
535.85 • 21.39 1.38 0.~046 
536.97 • 15.51 11.3§ 0.0137 
396.87 • 18.81 8.919 0.0405 
447.34 .39.52 4.05 0.0908 
371.32 • 71.36 2.22 0.1867 
83.62 • 1.88 34.0' 0.0011 
97.62.4.13 0.35 0.5931 
59.29 • 4.73 8.51§ 0.0267 
34.89 • 2.87 31.81 0.0049 
61.86 • 9.20 4.83 0.0703 
64.81 • l.07 12.8§ 0.0116 
1404.73 • 31.54 34.0' 0.0011 
1640.07 • 74.38 0.35 0.5931 
996.12 • 79.47 8.519 0.0267 
588.10 • 48.27 31.8' 0.0049 
1039.21 • 154.57 4.83 0.0703 
1088.85 , 17.96 12.8§ 0.0116 
30.05 • 2.20 0.93 0.3821 
39.11 • 1.14 0.44 0.5485 
32.32 • 1.24 0.07 0.8053 
21.79 • 1.84 2.82 0.1685 
33.18 • 1.34 3.07 0.1302 
34.12 • 3.99 4.35 0.0817 
1135.70 • 83.19 0.93 0.3821 
1478.36 • 43.01 0.44 0.5485 
1221.79 , 45.69 0.07 0.8053 
823.54 • 59.73 2.82 0.1585 
1254.21 • 50.75 3.07 0.1302 
1289.64 • 150.88 4.35 0.0817 
THB,SEH F p 
15.95 • 0.17 0.99 0.3691 
14.56 • 0.42 3.61 0.1301 
19.51 • 0.62 5.48 0.0578 
22.01 • 0.65 2.33 0.2015 
15.72 • 0.38 2.35 0.2001 
13.06 • 1.81 0.04 0.8489 
40.61 • 1.31 15.21 ! 0.0080 I 
44.SO • 1.28 1.82 I 0.2483 36.01 • 1.50 8.97§ 0.0242 
32.50 • 2.24 9.53§ 0.0364 
37.19 .4.94 0.20 0.6854 
40.51 , 3.65 0.00 0.9677 
37.44' 1.22 13.31 0.0108 
40.48 • 0.87 1.26 0.3242 
44.48 • 1.70 13.3! 0.0108 
45.49 • 1.88 8.99§ 0.0400 
47.09 • 4.63 0.44 0.5523 
46.43 • 1.89 0.00 0.9507 
TABLE AI2.3.l Total Food Intus and the Elective Cons~tion of Macro-nutriems per Volunteer 
, 
I 
I 
I 
TABLE A13.1 
Phase 1 (1M A) 
Week. Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
Phase 2 (1M B) 
Week Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
L--__ '-- _ 
Salivation oata [Subject 1 (55)] 
Base line Mean :t SO St illl.! Ius-Induced 
Sal ivation Sa I ivat Ion 
(g/2min) (g/2min) 
1. 739 0.974 
1.423 1.543.0.172 1.266 
1.465 1.039 
1.681 0.9144 
1.004 1.469 • 0.260 1.1807 
1.722 2.0027 
1.718 0.5085 
1.027 0.994 • 0.260 1.1650 
1.236 1.0129 
0.983 3.0064 
1.122 I.lIB • 0.134 1.8880 
1.250 1.2796 
1.469 2.2016 
1.384 1.379 • 0.093 1.2873 
1.284 1.4420 
1.660 2.2480 
1.542 2.062 , 0.801 2.7620 
2.985 3.9391 
2.156 1.6230 
1.676 2.201 , 0.550 1.3753 
2./Il I. 7660 
~-
~~-
Base 1 ine Mean .t SO St ilw Ius-Induced 
S(~)~!:~)n Sf!,lvation /2n,lo) 
3.085 1.679 
2.837 2.483 • 0.238 3.247 
2.608 4.788 
2.879 3.624 
1.616 2.650 • 0.229 2.169 
3.427 4.345 
3.425 4.400 
2.572 3.498 • 0.965 2.698 
4.498 4.056 
3.163 4.107 
1.509 2.810 , 0.166 3.01! 
3.158 4.011 
4.639 3.864 
4.874 4.061 • 1.208 4.241 
2.615 5.831 
4.519 4.980 
3.200 3.934 • 0.6/2 5.243 
4.082 . 4.700 
4.136 4.344 
4.176 4.502 , 0.330 3.615 
4.594 3.978 
TABLE A13.2 Sallvatlon oat. [Subject 2 (CAll 
Phdse 1 (TM A) 
Mean % SO Week Day Base line Meao • 50 Stimo Ius-Induced Mean :t SO 
I Sa I ivat ion 5(11 ivation (g12mln) (g/2mln) 
1 I 0.841 1.184 
1.0780 • 0.131 0.988 0.782 • 0.105 0.922 1.034.0.133 i 0.782 1.011 
1.3660 • 0.570 
4 1.366 1.248 I 
1.282 1.240 • 0.122 1.170 1.238 • 0.063 I 
1.103 1.295 
0.8954 • 0.344 
2 I 0.623 1.419 ! 
1.128 0.832 , 0.264 l.281 1.117 • 0.301 I 
0.14 0.832 
2.0580 • 0.880 
4 0.999 1.583 ! 
0.910 0.861 t 0.204 1.081 1.215 ,0.322 I 
0.631 0.981 
3 4 0.913 0.642 
1.6436 • 0.490 0.570 0.615 • 0.207 0.693 0.646 • 0.046 
I 0.542 0.602 
2.9830 • 0.870 ! 
I 
4 4 1.161 0.981 
0.950 1.029 • 0.1l4 1.238 1.350 • 0.436 
0.968 1.831 
1.5880 • 0.1980 ! 5 4 
(.I) 
Phase 2 (TM 6) » r- );> 
Mean J: SD Week Day Baseline Mean i SO St iw lus-lnduc~d Mean ;t. SO 
Salivation 5f~)~~,:~)n (g/2min) 
H '"'C 
< -0 );> rrt N 
~ :z: N 
I 1 1.494 1.492 H C '-l 
3.071 , 1.313 1.639 I. 546 • 0.061 1.276 1.454 .0.162 
1.504 1.594 
a H 
:z: >< 
4 0.961 1.463 c ...... 
3.379 • 1.108 1.142 1.135. 0.110 1.820 1.631 t 0.160 
1.302 1.610 
» w 
~ 
2 I 1.699 2.344 » 
3.718,0.900 1.605 1.462 • 0.322 1.399 1.931 • 0.486 
1.083 2.069 
4 1.642 1.944 
3.752 • 0.590 1.079 I. 363 • 0.282 1.937 1.977 .0.064 
! 1.368 2.051 
3 4 0.781 1.952 
4.641 '1.041 _ 1.490 1.152 • 0.352 0.992 1.419 • 0.460 
l.l77 1.493 
I 4 4 1.381 1.856 
4.914 • 0.2/1: 1.351 1.161 • 0.360 2.404 2.121 .0.275 
0.147 2.103 
5 4 2.953 1.519 
3.919 ,0.365 I 1.210 1.149 , 1.050 1.193 1.436 , 0.212 
--
~~ 
1.023 
- ,~~ .. -~~ -_ .. __ .- ---_ .. ~~- -_ .. ---
TABlE A13.3 
(1M 6) 
.. -
- . 
Week Day 
I I 
4 
2 1 
4 
3 4 
4 4 
5 4 
Phase 2 (1M A) 
Uet:k Day 
I 1 
4 
2 I 
4 
3 4 
4 4 
5 4 
Saltvatlon nata [Subject 3 (lU)) 
8asel ine Mean :l SO 
Sa Ilvation 
(g/2min) 
0.832 
0.966 0.846 .0.114 
0.139 
0.700 
1.141 0.899 • 0.224 
0.856 
1.215 
0.952 1.000. 0.196 
0.833 
1.557 
1.142 1.179 • 0.361 
0.839 
0.974 
0.809 1.167 • 0.484 
1.118 
0.591 
0.669 0.670 • 0.081 
0.752 
1.072 
1.230 1.089 • 0.133 
0.970 
Base line Mean :t SO 
s(~)~~\~)n 
0.745 
0.595 0.630. 0.101 
0.552 
1.503 
0.485 0.923 • 0.524 
0.780 
0.740 
0.700 0.695 • 0.046 
0.645 
0.598 
0.578 0.517 .0.124 
0.374 
0.613 
0.317 0.480 t 0.150 
0.508 
LIDO 
1.021 0.940 • 0.212 
0.700 
0.624 
0.824 0.676 , 0.129 
0.581 
Stillllius-induced Mean .t SO 
Sa J ivat ion 
(g/2min) 
0.629 
0.574 0.069 • 0.030 
0.623 
0.661 
1.663 0.890 • 0.256 
0.843 
0.759 
0.882 1.108 ,0.502 : 
1.682 
1.025 
0.627 1.112 • 0.534 
1.685 
1.354 
1.156 1.125 • 0.247 
0.864 
0.796 
1.074 1.008 • 0.188 
1.154 
1.010 
1.435 1.047 t 0.415 
0.608 
Stll1l.1lus~lnauced Mean t. SO 
Sal ivat ion 
(0/21OIn) 
1.041 
1.260 1.371 • 0.335 
1.711 
1.006 
0.619 0.960 , 0.320 ! 
1.254 
, 
0.886 
0.771 0.733,0.175 
0.542 
0.701 
0.494 0.681 t 0.118 
0.848 
0.737 
0.885 0.836 • 0.086 
0.885 
1.284 
0.964 1.059 • 0.196 
0.928 
0.783 
0.938 0.746 , 0.213 
0.518 
TABLE A13.4 
Phase 1 (TM 6) 
Week Day 
1 1 
4 
2 I 
4 
J 4 
4 4 
5 4 
Phase 2 (TM A) 
Week Oay 
1 I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Saltvatlon Oat. [Subject 4 (EA)] 
6ase line Mean. SO Sti ... Ius-Induced 
Sa Ilvat Ion Salivation 
(g/201In) (g/201in) 
0.698 1.564 
0.680 0.922 • 0.202 0.625 
1.089 0.970 
0.671 0.378 
0.688 0.687 • 0.015 0.602 
0.701 0.714 
0.675 0.689 
0.587 0.533 • 0.175 0.532 
0.338 0.551 
0.587 0.567 
0.524 0.506 • 0.092 0.589 
0.407 0.601 
0.445 0.268 
0.442 0.468 • 0.041 0.770 
0.515 0.899 
0.339 0.482 
0.749 0.536 , 0.205 0.575 
0.525 0.601 
0.743 0.566 
0.308 0.529 t 0.217 0.700 
0.536 0.525 
Base line Mean. SO St imu Ius-Induced 
Sa I ivat ~)n (gl2mln salivat~)n (g/2mln 
0.473 0.766 
0.626 0.643 • 0.179 0.660 
0.830 0.539 
0.597 0.617 
0.523 0.547 • 0.043 0.735 
0.522 0.614 
0.476 0.648 
0.419 0.388 • 0.107 0.452 
0.270 0.417 
0.255 0.421 
0.395 0.305 t 0.080 0.222 
0.265 0.575 
0.349 0.461 
0.489 0.423 t 0.070 0.549 
0.430 0.843 
0.308 0.509 
0.284 0.271 • 0.045 0.352 
0.222 0.463 
~~~~. 
Hean • SO 
1.053 • 0.475 
0.565 • 0.111 
I 0.591 • 0.086 I 
0.585 • 0.017 I 
I 
0.646 • 0.333 
0.553 .0.063 
0.597 • 0.092 
Mean !c SO : 
, 
, 
I 
0.655 • 0.115 : 
I 
I 
0.655 • 0.069 
0.505 • 0.124 
I 
I 
I 
0.408 • 0.177 ' 
0.618 • 0.200 
I 
0.442 t 0.081 
N 
N 
(Xl 
TABLE All.S Salivation Data [Subject 5 (VII)] 
Ph I (TN B) --- . , .. - -, 
Week Day Sase line Mean .t SO St illu Ius-Induced Mean ;t SO , 
Si~;2:l~)n Sa J ivation (g/2mln) I 
I I 2.596 1.899 I 
2.480 2.368 • 0.302 1.442 2.097 • 0.773 I 
2.026 2.950 
4 1.595 1.226 I 
2.037 1.547 • 0.516 0.817 1.206 • 0.380 I 
1.009 1.576 
2 I 1.097 1.888 ! 
1.245 1.059 • 0.208 1.565 1.176.0.171 I 
0.835 1.826 
1.050 0.901 
I 
4 I 1.050 1.062 • 0.021 1.034 1.003 • 0.090 I 
1.081 1.073 
I 
3 4 1.271 1.595 
0.934 1.152 • 0.189 1.790 1.555 • 0.257 I 
1.252 1.280 
4 4 1.446 1.351 I 0.724 LOU. 0.382 2.060 1.443 • 0.577 
0.868 0.917 
5 4 1.244 1.809 
1.373 1.348 • 0.095 2.822 2.172 • 0.564 
1.429 ~_ ,-__ !-88~ 
Phase 2 (TN A) 
i 
Week Oay Base) ioe Hean % SO St I .... Ius-Induced Hean :t SO 
S(~,IVatiOn 
/2mln) Si!)~~l~)n I 
I I 0.731 1.868 
2.190 • 0.289 i !.lSI 1.199 • 0.493 2.275 
1. 714 2.428 I 
4 1.423 2.274 I 
I 1.236 1.326 • 0.094 2.031 2.141 .0.124 I 
1.318 2.117 
2 I 0.938 1.309 
1.145.0.162\ 0.876 1.024 • 0.205 1.142 
1.258 0.985 
4 I 
I 
3 4 0.901 1.342 ! 0.964 0.975 • 0.079 1.812 1.700 t 0.318 I 
1.059 1.946 
4 4 1.278 1.102 
1.371 1.286 • 0.081 1.598 1.393 • 0.259 
1.209 1.479 
5 4 1.536 1.638 
2.097 1.638 • 0.417 2.067 1.814 • 0.225 
1.282 1.736 
TABlE All.6 
Phase I (TN B) 
Week Oay 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Ph 
- ~ 2 (TM A) - . 
Week Oay 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Salt.atlon Dat. [Subject 6 (1I1] 
Base line Mean ;t SO 
Salivation 
(gI2mi.) 
1.199 
1.643 1.406 • 0.223 
1.377 
1.541 
1.111 1.243 • 0.259 
1.077 
0.620 
0.149 0.626 • 0.120 
0.509 
0.739 
1.306 0.976 • 0.300 
0.856 
0.710 
0.970 0.837 • 0.130 
0.829 
1.068 
1.003 1.047 • 0.038 
1.070 
0.837 
0.508 0.980 • 0.557 
1.594 
Base line lledn i SO 
Salivation 
(gi2mln) 
1.699 
1.266 1.333 • 0.338 
1.034 
1.055 
0.579 0.829 • 0.238 
0.825 
0.566 
0.486 0.589 • 0.116 
0.714 
0.596 
0.895 0.672 .0.197 
0.524 
0.530 
1.065 0.696 • 0.320 
0.492 
0.401 
0.374 0.376 • 0.024 
0.353 
0.896 
0.958 0.743 .0.321 
0.375 
St 1Il>.Ilus-1 nduced 
Salivation 
(g/2min) 
0.700 
1.144 
1.222 
0.505 
0.667 
0.624 
0.624 
0.333 
0.609 
0.691 
0.805 
1.063 
1.035 
0.527 
1.058 
0.729 
0.719 
0.769 
0.436 
OA97 
0.556 
-- -- -----
St iru lus-Illduced S,!;vation 
12mio) 
1.283 
0.]16 
1.031 
0.722 
0.607 
1.333 
0.988 
0.855 
1.004 
0.561 
0.508 
0.513 
0.633 
0.454 
0.673 
0.677 
0.516 
1.187 
1.294 
0.492 
0.925 
Mean :t SO 
1.020 • 0.285 
I 
0.599 • 0.084 I 
! 
0.522 • 0.164 
0.853 • 0.191 
0.873 • 0.300 
0.739 • 0.026 
0.496 • 0.060 
Me.n • SO 
1.017 i 0.274 
0.881 t 0.390 
0.949 • 0.082 
0.528 • 0.030 
0.581 • 0.111 
0.860 • 0.336 
0.904 • 0.401 
----.~-.-.-.-
N 
N 
\.0 
TABLE AB.7 Salivation Dat. [Subject 7 (EG)] 
Phdse I (TM A) 
Week Day Base I lne Mean .t SO Sthrulus-lruJuced Mean :t SO 
Salivation Sa Ilvat Ion 
(a12min) (q!2mln) 
I I 3.414 2.123 
3.435 3.414 • 0.021 3.466 3.139 • 0.898 
3.393 3.827 
4 4.837 2.604 
3.965 3.893 • 0.982 3.1;78 3.141 • 0.537 
2.8/7 3.142 
2 I 3.625 2.945 
3.771 3.648 • 0.113 3./78 3.401 • 0.422 
3.548 3.481 
4 3.764 3.983 
3.533 3.655 • 0.116 2.293 3.004 • 0.876 
3.667 2.m 
3 4 3.463 2.423 
4.046 3.488 • 0.546 3.333 2.531 • 0.753 
2.955 1.839 
4 4 
5 4 
Phase 2 (1M 8) 
Week Oay Base line Mean .t SO SUmu Ius-Induced Mean .t SO S(/ ivation Sa IIvat ian (g/2mln) (a12mln) 
1 I 6.275 6.109 
4.103 • 1.669 I 2.629 4.011 • 1.976 3.416 
3.130 3.053 
4 3.671 3.450 
3.562 • 0.4691 3.069 3.388 • 0.303 4.6/7 
3.523 3.160 
2 I 2.756 3.938 
3.617 • 0.386 I 3.317 2.801 • 0.496 3.189 
2.327 3./26 I 
4 3.033 2.363 
3.116 • 0.7041 1.695 2.620 • 0.802 3.618 
3.132 3.546 
3 4 3.746 3.599 
, 
4.350 4.304 t 0.536 3.121 3.237 • 0.320 I 
4.815 2.990 
I 4 4 3.291 3.711 
3.534 t 0.164 I 3.266 3.195 • 0.lp5 3.482 
3.028 3.402 
5 4 2.301 1.983 
3.671 2.995 • 0.643 2.555 2.210 • 0.303 
2.922 2.093 
-.~----
-
TABLE AI3.8 
Phase I (TM A) 
Week Day 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Pha.e 2 (TM 8) 
Week Oay 
I I 
4 
2 I 
4 
3 4 
4 4 
5 4 
Salivation Data [Subject 8 (ev)] 
Base line Mean :t 50 
Sa Ilvat Ion 
(a/2m;n) 
1.812 
1.598 1.605 • 0.264 
1.345 
1.311 
1.220 1.236 • 0.129 
1.116 
1.016 
0.778 0.941 • 0.142 
1.029 
0.957 
1.302 1.101 • O.IBO 
1.043 
1.186 
0.741 0.838 • 0.311 
0.587 
0.912 
0.797 0.861 • 0.096 
0.815 
0.836 
0.686 0.815 t 0.119 
0.921 
Baseline Mean. SO 
Si,livation (u/2Inln) 
1.356 
1.307 1.291 • 0.075 
1.209 
1.031 
1.145 1.086 • 0.057 
1.083 
0.565 
0.908 0.860 • 0.275 
1.108 
St 1m Ius-Induced 
Salivation 
(u12min) 
1.311 
1.671 
1.354 
1.493 
1.371 
1.343 
1.247 
0.929 
1.786 
1.041 
0.B91 
1.221 
0.705 
0.544 
1.018 
0.7B2 
1.076 
1.238 
0.665 
0.838 
1.245 
Stlmu lu.-Induced 
Si!;~~\~)" 
1.191 
0.857 
1.551 
0.989 
0.852 
0.888 
0.676 
0.662 
1.022 
Mean .t SO 
1.446 • 0.197 
1.402 • 0.080 
1.321 • 0.434 
1.051 .0.165 
0.755 • 0.241 
1.032 • 0.231 
0.916 • 0.298 
Meap • SO 
i 
I 
1.191 .0.347 I 
, 
I 
0.909 • 0.01l i 
i 
0.787 • 0.204 
N 
W 
a 
~ 
Tillie 
(Hrs) 
12 
36 
48 
60 
0.0 
0.5 
1.0 
2.0 
3.0 
4.0 
5.0 
6.0 
8.0 
9.0 
10.0 
11.0 
.lli!li...LJ. 
8100d levels of PPA.HCI 
reached (Pi lot Steady-State 
lrial) 
PPA 
Concentrat ion 
(ng/mll 
61.J1 
83.20 
92.67 
81.59 
70.58 
140.82 
2/6.87 
336.52 
297.83 
228.39 
117.48 
168.48 
115.87 
104.97 
97.68 
59.98 
Steady-state 1 patient 
TABlE AI4.2.1 
WEEK 
Two 
Thr.e 
Four 
five 
DAV 
I 
2 
3 
4 
7 
4 
7 
4 
I 
4 
I 
Peak alld Trough 8100d levels 
of PPA.HCI reached during Hultlple 
Oos Ing (Subject I. Phase I. [55]) 
SERUM PPA.HCl 
TIME CONCENTRATION 
(ng/ml) 
07050 0.00 
12050 174.18 
, 
19h50 72.93 
07h50 J1S.29 
19h50 118.73 
07h50 138.06 
19h5O 120.79 
07hSO 147.38 
11050 282.33 
191\50 128.59 
011\50 129.52 
12h50 263.65 
191\50 144.16 
011\50 
12h50 248.25 
19h50 149.42 
0lh50 135.11 
121\50 239.J1 
191\50 123.05 
TABLE AI4.2.2 
WEEK DAV 
Two 1 
2 
3 
4 
I 
Three 4 
7 
four 4 
7 
five 4 
7 
Peak and Trough 8100d Levels 
of PPA.HCI reached during Hultiele 
Dosing (Subject 2. Phase 1. (CAll 
SERUM PPA.IICL 
TIME CONCENTRATION 
(ng/ml) 
0lh50 0.00 
12h50 161.53 
19h50 56.01 
0lh50 81. I! 
19050 63.14 
07050 66.90 
19h5O 68.IS 
071\50 95.18 
12h50 204.66 
19h50 80.7S 
07hSO 90.22 
12h50 190.54 
19h5O 19.78 
0lh50 80.82 
121\50 217.96 
19h50 106.86 
011\50 117.86 
12050 39S.45 
19h5O 
to 
r-
0 » 0 
0 
" 
" r- m N ,.., Z W 
<:: 0 ....... 
m ...... 
r- >< 
0 ...... 
» ,J:::. 
-I 
» 
TAlliE AI4.2.3 
WEEK DAY 
Two I 
2 
3 
4 
7 
Three 4 
7 
four 4 
7 
F iv~ 4 
7 
Peak and Trough Blood Levels 
of PPA.IICI reached during /1ulti~le 
Ilosing (Subject J, Phase 2, [LE]) 
SERUM PPA.HCL 
TIME CONCENTRATION 
(ng/ml) 
07h50 0.00 
12h50 215.19 
19h50 131.96 
07h50 127 .16 
19h50 150.06 
07h50 112.49 
19h50 130.46 
07h50 134.87 
12h50 277.72 ! 
19h50 150.76 I 
07h50 138.59 
12h50 269.74 
19h50 180.14 
07h50 
12h50 363.86 
19h50 I I 
07h50 49.88 i 
12h50 284.09 I 
I 
19h50 169.61 
- -"---_._.- -----
I 
TAilLE A14.2 .4 
WEEK DAY 
Two 1 
2 
3 
4 
7 
Three 4 
7 
Four 4 
7 
five 4 
7 
Peak and Trough Blood Levels 
of PPA.IICI reached during /1ultiele 
Ilosing (Subject 4, Phase 2, (EA]) 
SERUM PPA.HCL 
I TIME CONCENTRATION (ng/mll 
07h50 0.00 I 
12h50 150.20 i 
19h50 57.27 I 
07h50 86.77 
19h50 69.63 
07h50 97.29 
19h50 86.57 
07h50 89.35 
12h50 236.57 
19h50 )) .13 
07h50 96.64 ! 
121150 216.27 , 
19h50 75.41 
, 
07h50 85.05 
12h50 : 
191150 84.11 I 
071150 94.47 
121150 242.05 
191150 89.98 
TAillE A14.2.5 
WEEK 
Two 
Three 
Four 
five 
DAY 
I 
2 
3 
4 
7 
4 
7 
4 
7 
4 
7 
Peak and Trough Blood leve Is 
of PPA.HCI reached during /1ultiel. 
Ilosing (Subject 5, Phase 2, (Vllj) 
SERUM PPA. HCL 
TIME CONCENTRATION 
( ng/ml) 
071150 0.00 
121150 154.76 
19h50 48.07 
07h50 74.34 
19h50 53.14 ! 
07h50 91.05 I 
19h50 60.21 I 
071150 107.28 i 
12h50 187.93 
19h50 
07h50 18.13 
I 
12h50 136.52 ! 
I 
19h50 18.19 ! 
071150 188.03 
12h50 J28.50 
19h50 0.00 
07h50 0.00 
12h50 168.02 
19h50 59.45 I 
N 
w 
N 
TABLE A14.2 .6 
~EEK DAY 
Two I 
2 
3 
4 
7 
Three 4 
7 
four 4 
7 
Five 4 
Peak and Trough Blond levels 
of PPA.IICI reached during Hultiele 
Dosing (Subject 6, Pha .. 2, (ll]) 
SERUM PPA.HCl 
TIME CONCENTRATION 
(ng/ml) 
07h50 0.00 
12hSO 192.76 
19h50 81.99 
07hSO 98.2S ! 
19h5O 88.38 
07hSO lIS.08 
19h50 
07hSO 
11h50 
19h50 101.46 
07h50 111.36 
11h50 147.79 
19h50 116.18 
07h50 IS2.34 
12h50 350. S9 
19h50 232.16 
07h50 197.12 
12h50 311.73 
~_ ~ __ 2.........~50 182.84 
TABlE Al4.1.7 
~EEK DAY 
Two I 
2 
3 
4 
I 
Three 4 
I 
four 4 
7 
Five 4 
7 
Peak and Trough Blond levels 
of PPA.HCI reached during Hulti~le 
Dos ing (Subject 7, Phase I, (EGIl 
SERUM PPA. Hel 
TIME CONCENTRATION 
(ng/ml) 
07h50 0.00 
11h50 18S.33 
19h50 66.93 
07h50 72.55 
19h50 109.14 
07h50 99.97 
19h50 75.26 
0lh50 104.23 
12h50 329.48 
19h50 91.,2 
07h50 113.55 
12h50 132.50 
19h50 68.21 
07h50 
!2h50 
19h50 
0lh50 
11h50 
19h50 
TABLE AI4.1.B 
WEEK 
Two 
Three 
Four 
Five 
DAY 
I 
1 
3 
4 
7 
4 
I 
4 
I 
4 
I 
Peak and Trough Blond leve Is 
of PPA.IICI reached during HuHiele 
Dosing (Subject 8, Phase I, (evil 
SERUM PPA.HCl 
TIME CONCENTRATION 
(ng/mn 
07h50 0.00 
12h50 178.41 
19h50 118.26 
07h50 160.94 
19h50 184.96 
07hSO 218.57 
19h50 198.40 
07hSO 219.10 
12h50 344.89 
19h50 177 .01 
0lh50 173.67 
11h50 344.26 
19h50 183.31 
07h50 188.88 
11h50 330.02 
19h50 204.10 
07h50 106.14 
11hSO 374.61 
19h50 14S.78 
N 
W 
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SilllJlated vs Observed Steady-state Profile [Subject 4 (EA)] 
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Simulated vs Observed Steady-state Profile [Subject 8 (CV)] 
It 
600 
Week 5 
660 700 
N 
.p. 
..... 
'fABLE A15. 1 Fraction PPA.HCl Dissolved (Product LE) TABU AIS.2 fraction PPA.IICI Dissolved (Product 00) 
Fraction PPA.HCI Dissolved Fraction PPA.HCI Dissolved 
Till~ Replicate Capsule Numbers Mean : SD Time Rep I kate Capsu le Nulltlers Mean • SD I 
(Hrs) I 2 3 4 5 6 (Hrs) I 2 3 4 5 6 , 
0.011 0.000 0.000 0.000 0.000 0.000 0.000 0.000 , 0.000 0.011 0.000 0.000 0.000 0.000 0.000 0.000 0.000 • 0.000 
0.033 0.000 0.000 0.000 0.000 0.000 0.000 0.000 , 0.000 0.033 0.000 0.000 0.000 0.000 0.000 0.000 0.000 , 0.000 
0.067 0.002 0.039 0.066 0.032 0.064 0.107 0.052 , 0.033 0.061 0.000 0.000 0.000 0.000 0.000 0.000 0.000 • 0.000 
0.100 0.052 0.111 0.140 0.093 0.183 0.111 0.116 : 0.040 0.100 0.013 0.019 0.001 0.000 0.035 0.000 0.012 , 0.012 C 1-1 
0.133 0.090 0.163 0.206 0.141 0.231 0.134 0.163 , 0.048 
0.161 0.112 0.215 0.244 0.201 0.282 0.113 0.204 , 0.054 
0.208 0.163 0.266 0.218 0.249 0.317 0.201 0.246 • 0.051 
0.250 0.195 0.307 0.301 0.268 0.352 0.224 0.279 , 0.053 I 
O. JJ3 0.238 0.354 0.368 0.339 0.410 0.262 0.328 : 0.060 
0.133 0.055 0.064 0.019 0.000 0.058 0.034 0.038 , 0.023 
0.161 0.060 0.018 0.030 0.024 0.014 0.085 0.058 , 0.024 
0.208 0.081 0.081 0.031 0.036 0.073 0.098 0.068 , 0.026 
0.250 0.098 0.102 0.043 0.041 0.085 0.111 0.081 • 0.027 
0.333 0.110 0.111 0.011 0.0601 0.109 0.1222 0.091 • 0.023 
CJ1 
CJ1 » 
0 "'0 ,... "'0 
c::: m 
-I z 
N 
1-1 C 
-t:> 
0 1-1 
N 
:z: >< 
0.417 0.287 0.386 0.391 0.385 0.463 0.342 0.316 , 0.053 
0.500 0.312 0.424 0.422 0.436 0.493 0.334 0.403 , 0.062 
0.750 0.386 0.492 0.472 0.517 0.563 0.404 0.472 : 0.061 
O.~II 0.143 0.121 0.106 0.01l 0.121 0.133 0.117 • 0.023 
0.500 0.1122 0.14B 0.111 0.085 0.121 0.147 0.131 • 0.031 
0.750 0.192 0.181 0.141 0.110 0.161 0.184 0.162 , 0.029 
0 ..... 
» 
(.)1 
-I 
» 
1.000 0.448 0.555 0.529 0.576 0.617 0.463 0.531 , 0.059 1.000 
. 
0.228 0.2018 0.185 0.136 0.184 0.221 0.194 , 0.030 
I. 500 0.529 0.630 0.600 0.652 0.680 0.546 0.606 , 0.054 1.500 0.291 0.261 0.239 0.194 0.186 0.258 0.240 • 0.040 
2.000 0.592 0.693 0.676 0.715 0.138 0.633 0.674 , 0.049 2.000 0.369 0.342 0.309 0.255 0.323 0.369 0.328 • 0.039 
3.000 0.684 0.781 0.753 0.828 0.829 0.103 0.163 • 0.056 3.000 0.493 0.449 0.416 0.369 0.418 0.473 0.436 o 0.041 
4.000 0.741 0.850 0.816 0.888 0.868 0.116 0.824 , 0.050 4.000 0.589 0.538 0.505 0.448 0.498 0.548 0.521 • 0.044 
5.0UO 0.188 0.916 0.858 0.9J4 0.915 0.829 0.813 , 0.53 5.000 0.642 0.592 0.510 0.523 0.535 0.613 0.579 • 0.042 
6.000 0.844 0.941 0.819 0.959 0.951 0.855 0.901 • 0.049 6.000 0.691 0.646 0.620 0.585 0.608 0.665 0.631 
, 0.037 
7.000 0.876 0.949 0.891 0.983 0.941 0.888 0.923 • 0.039 1.000 0.152 0.697 0.661 0.632 0.665 0.118 0.687 • 0.040 
8.000 0.894 0.961 0.9J5 0.994 0.911 0.901 0.943 • 0.036 8.000 0.184 OJ31 0.123 0.669 0.105 0.798 0.1l6 
, 0.044 
9.000 0.901 0.985 0.931 1.006 0.982 0.912 0.954 • 0.039 9.000 0.828 0.790 0.168 0.114 0.142 0.803 0.714 
, 0.038 
10.00 0.913 0.996 0.960 1.018 1.006 0.924 0.910 , 0.040 10.00 0.858 0.833 0.195 0.142 0.181 0.821 0.806 • 0.038 
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